effect	"Tablet If a patient receiving  DRUG1  is also taking  DRUG2 , the effect of  DRUGOTHER  may be reduced, thus necessitating an increase in dosage."	clonidine hydrochloride	tricyclic antidepressants	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Tablet If a patient receiving  DRUG1  is also taking  DRUGOTHER , the effect of  DRUG2  may be reduced, thus necessitating an increase in dosage."	clonidine hydrochloride	clonidine	ClC1=CC=CC(Cl)=C1NC1=NCCN1	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	"Tablet If a patient receiving  DRUGOTHER  is also taking  DRUG1 , the effect of  DRUG2  may be reduced, thus necessitating an increase in dosage."	tricyclic antidepressants	clonidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC=CC(Cl)=C1NC1=NCCN1
effect	" DRUG1  may enhance the CNS-depressive effects of  DRUG2 ,  DRUGOTHER  or other  DRUGOTHER ."	Clonidine hydrochloride	alcohol	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	" DRUG1  may enhance the CNS-depressive effects of  DRUGOTHER ,  DRUG2  or other  DRUGOTHER ."	Clonidine hydrochloride	barbiturates	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
effect	" DRUG1  may enhance the CNS-depressive effects of  DRUGOTHER ,  DRUGOTHER  or other  DRUG2 ."	Clonidine hydrochloride	sedatives	ClC1=CC=CC(Cl)=C1NC1=NCCN1	
other	" DRUGOTHER  may enhance the CNS-depressive effects of  DRUG1 ,  DRUG2  or other  DRUGOTHER ."	alcohol	barbiturates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  may enhance the CNS-depressive effects of  DRUG1 ,  DRUGOTHER  or other  DRUG2 ."	alcohol	sedatives	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUGOTHER  may enhance the CNS-depressive effects of  DRUGOTHER ,  DRUG1  or other  DRUG2 ."	barbiturates	sedatives	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	
effect	" DRUG1  in combination with  DRUG2  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER ."	Amitriptyline	clonidine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	" DRUG1  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUG2  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER ."	Amitriptyline	Clonidine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	" DRUG1  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUG2 ,  DRUGOTHER  or other  DRUGOTHER ."	Amitriptyline	alcohol	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUG2  or other  DRUGOTHER ."	Amitriptyline	barbiturates	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUG1  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUGOTHER  or other  DRUG2 ."	Amitriptyline	sedating drugs	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER  in combination with  DRUG1  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUG2  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER ."	clonidine	Clonidine	ClC1=CC=CC(Cl)=C1NC1=NCCN1	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	" DRUGOTHER  in combination with  DRUG1  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUG2 ,  DRUGOTHER  or other  DRUGOTHER ."	clonidine	alcohol	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  in combination with  DRUG1  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUG2  or other  DRUGOTHER ."	clonidine	barbiturates	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  in combination with  DRUG1  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUGOTHER  or other  DRUG2 ."	clonidine	sedating drugs	ClC1=CC=CC(Cl)=C1NC1=NCCN1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
effect	" DRUGOTHER  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUG1  may potentiate the CNS-depressive effect of  DRUG2 ,  DRUGOTHER  or other  DRUGOTHER ."	Clonidine	alcohol	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	" DRUGOTHER  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUG1  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUG2  or other  DRUGOTHER ."	Clonidine	barbiturates	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
effect	" DRUGOTHER  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUG1  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUGOTHER  or other  DRUG2 ."	Clonidine	sedating drugs	ClC1=CC=CC(Cl)=C1NC1=NCCN1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUG1 ,  DRUG2  or other  DRUGOTHER ."	alcohol	barbiturates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUG1 ,  DRUGOTHER  or other  DRUG2 ."	alcohol	sedating drugs	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER  in combination with  DRUGOTHER  enhances the manifestation of corneal lesions in rats Epidural Injection  DRUGOTHER  may potentiate the CNS-depressive effect of  DRUGOTHER ,  DRUG1  or other  DRUG2 ."	barbiturates	sedating drugs	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
effect	 DRUG1  may potentiate the hypotensive effects of  DRUG2 .	Narcotic analgesics	clonidine	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	ClC1=CC=CC(Cl)=C1NC1=NCCN1
effect	 DRUG1  may antagonize the hypotensive effects of  DRUG2 .	Tricyclic antidepressants	clonidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	The effects of  DRUG1  on  DRUG2 s analgesic actions are not known.	tricyclic antidepressants	clonidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC=CC(Cl)=C1NC1=NCCN1
effect	 DRUG1  may exacerbate the hypertensive response seen with  DRUG2  withdrawl.	Beta blockers	clonidine		ClC1=CC=CC(Cl)=C1NC1=NCCN1
advise	"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving  DRUG1  with agents known to affect sinus node function or AV nodal conduction (e.g.,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .)"	clonidine	digitalis	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
advise	"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving  DRUG1  with agents known to affect sinus node function or AV nodal conduction (e.g.,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .)"	clonidine	calcium channel blockers	ClC1=CC=CC(Cl)=C1NC1=NCCN1	[Ca]
advise	"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving  DRUG1  with agents known to affect sinus node function or AV nodal conduction (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .)"	clonidine	beta-blockers	ClC1=CC=CC(Cl)=C1NC1=NCCN1	
other	"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving  DRUGOTHER  with agents known to affect sinus node function or AV nodal conduction (e.g.,  DRUG1 ,  DRUG2 , and  DRUGOTHER .)"	digitalis	calcium channel blockers	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[Ca]
other	"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving  DRUGOTHER  with agents known to affect sinus node function or AV nodal conduction (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUG2 .)"	digitalis	beta-blockers	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving  DRUGOTHER  with agents known to affect sinus node function or AV nodal conduction (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUG2 .)"	calcium channel blockers	beta-blockers	[Ca]	
effect	There is one reported case of a patient with acute delirium associated with the simultaneous use of  DRUG1  and oral  DRUG2 .	fluphenazine	clonidine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	Symptoms resolved when  DRUG1  was withdrawn and recurred when the patient was rechallenged with  DRUG2 .	clonidine	clonidine	ClC1=CC=CC(Cl)=C1NC1=NCCN1	ClC1=CC=CC(Cl)=C1NC1=NCCN1
effect	"Epidural  DRUG1  may prolong the duration of pharmacologic effects of epidural local  DRUG2 , including both sensory and motor blockade."	clonidine	anesthetics	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CCOC(=O)C1=CC=C(N)C=C1
effect	"Hypotension: Patients on Diuretic Therapy: Patients on  DRUG1  and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with  DRUG2  or  DRUGOTHER ."	diuretics	enalapril	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
effect	"Hypotension: Patients on Diuretic Therapy: Patients on  DRUG1  and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with  DRUGOTHER  or  DRUG2 ."	diuretics	enalaprilat	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Hypotension: Patients on Diuretic Therapy: Patients on  DRUGOTHER  and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with  DRUG1  or  DRUG2 ."	enalapril	enalaprilat	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	The possibility of hypotensive effects with  DRUG1  or  DRUG2  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake prior to initiation of treatment with  DRUGOTHER  or  DRUGOTHER .	enalapril	enalaprilat	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
effect	The possibility of hypotensive effects with  DRUG1  or  DRUGOTHER  can be minimized by either discontinuing the  DRUG2  or increasing the salt intake prior to initiation of treatment with  DRUGOTHER  or  DRUGOTHER .	enalapril	diuretic	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	The possibility of hypotensive effects with  DRUG1  or  DRUGOTHER  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake prior to initiation of treatment with  DRUG2  or  DRUGOTHER .	enalapril	enalapril	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	The possibility of hypotensive effects with  DRUG1  or  DRUGOTHER  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake prior to initiation of treatment with  DRUGOTHER  or  DRUG2 .	enalapril	enalaprilat	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
effect	The possibility of hypotensive effects with  DRUGOTHER  or  DRUG1  can be minimized by either discontinuing the  DRUG2  or increasing the salt intake prior to initiation of treatment with  DRUGOTHER  or  DRUGOTHER .	enalaprilat	diuretic	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	The possibility of hypotensive effects with  DRUGOTHER  or  DRUG1  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake prior to initiation of treatment with  DRUG2  or  DRUGOTHER .	enalaprilat	enalapril	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	The possibility of hypotensive effects with  DRUGOTHER  or  DRUG1  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake prior to initiation of treatment with  DRUGOTHER  or  DRUG2 .	enalaprilat	enalaprilat	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	The possibility of hypotensive effects with  DRUGOTHER  or  DRUGOTHER  can be minimized by either discontinuing the  DRUG1  or increasing the salt intake prior to initiation of treatment with  DRUG2  or  DRUGOTHER .	diuretic	enalapril	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	The possibility of hypotensive effects with  DRUGOTHER  or  DRUGOTHER  can be minimized by either discontinuing the  DRUG1  or increasing the salt intake prior to initiation of treatment with  DRUGOTHER  or  DRUG2 .	diuretic	enalaprilat	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	The possibility of hypotensive effects with  DRUGOTHER  or  DRUGOTHER  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake prior to initiation of treatment with  DRUG1  or  DRUG2 .	enalapril	enalaprilat	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents Causing Renin Release: The antihypertensive effect of  DRUG1  and  DRUG2  IV is augmented by  DRUGOTHER  that cause renin release (e.g.,  DRUGOTHER )."	enalapril	enalapril	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
effect	"Agents Causing Renin Release: The antihypertensive effect of  DRUG1  and  DRUGOTHER  IV is augmented by  DRUG2  that cause renin release (e.g.,  DRUGOTHER )."	enalapril	antihypertensive agents	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"Agents Causing Renin Release: The antihypertensive effect of  DRUG1  and  DRUGOTHER  IV is augmented by  DRUGOTHER  that cause renin release (e.g.,  DRUG2 )."	enalapril	diuretics	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
effect	"Agents Causing Renin Release: The antihypertensive effect of  DRUGOTHER  and  DRUG1  IV is augmented by  DRUG2  that cause renin release (e.g.,  DRUGOTHER )."	enalapril	antihypertensive agents	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"Agents Causing Renin Release: The antihypertensive effect of  DRUGOTHER  and  DRUG1  IV is augmented by  DRUGOTHER  that cause renin release (e.g.,  DRUG2 )."	enalapril	diuretics	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Agents Causing Renin Release: The antihypertensive effect of  DRUGOTHER  and  DRUGOTHER  IV is augmented by  DRUG1  that cause renin release (e.g.,  DRUG2 )."	antihypertensive agents	diuretics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	" DRUG1 : In some patients with compromised renal function who are being treated with  DRUG2 , the co-administration of  DRUGOTHER  may result in a further deterioration of renal function."	Non-steroidal Anti-inflammatory Agents	nonsteroidal anti-inflammatory drugs	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1 : In some patients with compromised renal function who are being treated with  DRUGOTHER , the co-administration of  DRUG2  may result in a further deterioration of renal function."	Non-steroidal Anti-inflammatory Agents	enalapril	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
effect	" DRUGOTHER : In some patients with compromised renal function who are being treated with  DRUG1 , the co-administration of  DRUG2  may result in a further deterioration of renal function."	nonsteroidal anti-inflammatory drugs	enalapril	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"In a clinical pharmacology study,  DRUG1  or  DRUG2  was administered to hypertensive patients receiving  DRUGOTHER ."	indomethacin	sulindac	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O
other	"In a clinical pharmacology study,  DRUG1  or  DRUGOTHER  was administered to hypertensive patients receiving  DRUG2 ."	indomethacin	VASOTEC	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
other	"In a clinical pharmacology study,  DRUGOTHER  or  DRUG1  was administered to hypertensive patients receiving  DRUG2 ."	sulindac	VASOTEC	CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
effect	"However, reports suggest that  DRUG1  may diminish the antihypertensive effect of  DRUG2 ."	NSAIDs	ACE inhibitors		
advise	This interaction should be given consideration in patients taking  DRUG1  concomitantly with  DRUG2 .	NSAIDs	ACE inhibitors		
other	"Other Cardiovascular Agents:  DRUG1  and  DRUG2  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	Enalapril	enalapril	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Other Cardiovascular Agents:  DRUG1  and  DRUGOTHER  IV have been used concomitantly with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	Enalapril	beta adrenergic-blocking agents	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Other Cardiovascular Agents:  DRUG1  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	Enalapril	methyldopa	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	"Other Cardiovascular Agents:  DRUG1  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	Enalapril	nitrates	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[O-]N(=O)=O
other	"Other Cardiovascular Agents:  DRUG1  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	Enalapril	calcium-blocking agents	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[Ca]
other	"Other Cardiovascular Agents:  DRUG1  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	Enalapril	hydralazine	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	NN=C1NNC(=NN)C2=CC=CC=C12
other	"Other Cardiovascular Agents:  DRUG1  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	Enalapril	prazosin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
other	"Other Cardiovascular Agents:  DRUG1  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  without evidence of clinically significant adverse interactions."	Enalapril	digoxin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUG1  IV have been used concomitantly with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	enalapril	beta adrenergic-blocking agents	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUG1  IV have been used concomitantly with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	enalapril	methyldopa	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUG1  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	enalapril	nitrates	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[O-]N(=O)=O
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUG1  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	enalapril	calcium-blocking agents	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[Ca]
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUG1  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	enalapril	hydralazine	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	NN=C1NNC(=NN)C2=CC=CC=C12
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUG1  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	enalapril	prazosin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUG1  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  without evidence of clinically significant adverse interactions."	enalapril	digoxin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	beta adrenergic-blocking agents	methyldopa	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	beta adrenergic-blocking agents	nitrates	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[O-]N(=O)=O
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	beta adrenergic-blocking agents	calcium-blocking agents	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[Ca]
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	beta adrenergic-blocking agents	hydralazine	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	NN=C1NNC(=NN)C2=CC=CC=C12
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	beta adrenergic-blocking agents	prazosin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  without evidence of clinically significant adverse interactions."	beta adrenergic-blocking agents	digoxin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	methyldopa	nitrates	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	[O-]N(=O)=O
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	methyldopa	calcium-blocking agents	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	[Ca]
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	methyldopa	hydralazine	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	NN=C1NNC(=NN)C2=CC=CC=C12
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	methyldopa	prazosin	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  without evidence of clinically significant adverse interactions."	methyldopa	digoxin	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	nitrates	calcium-blocking agents	[O-]N(=O)=O	[Ca]
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	nitrates	hydralazine	[O-]N(=O)=O	NN=C1NNC(=NN)C2=CC=CC=C12
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	nitrates	prazosin	[O-]N(=O)=O	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  without evidence of clinically significant adverse interactions."	nitrates	digoxin	[O-]N(=O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	calcium-blocking agents	hydralazine	[Ca]	NN=C1NNC(=NN)C2=CC=CC=C12
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	calcium-blocking agents	prazosin	[Ca]	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  without evidence of clinically significant adverse interactions."	calcium-blocking agents	digoxin	[Ca]	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER  without evidence of clinically significant adverse interactions."	hydralazine	prazosin	NN=C1NNC(=NN)C2=CC=CC=C12	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2  without evidence of clinically significant adverse interactions."	hydralazine	digoxin	NN=C1NNC(=NN)C2=CC=CC=C12	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other Cardiovascular Agents:  DRUGOTHER  and  DRUGOTHER  IV have been used concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2  without evidence of clinically significant adverse interactions."	prazosin	digoxin	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUG1  IV has been used concomitantly with  DRUG2  without evidence of clinically significant adverse reactions.	Enalapril	digitalis	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	Agents Increasing Serum Potassium:  DRUG1  and  DRUG2  IV attenuate potassium loss caused by  DRUGOTHER .	Enalapril	enalapril	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
effect	Agents Increasing Serum Potassium:  DRUG1  and  DRUGOTHER  IV attenuate potassium loss caused by  DRUG2 .	Enalapril	thiazide-type diuretics	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	
effect	Agents Increasing Serum Potassium:  DRUGOTHER  and  DRUG1  IV attenuate potassium loss caused by  DRUG2 .	enalapril	thiazide-type diuretics	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	
other	" DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ),  DRUGOTHER  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	Potassium-sparing diuretics	spironolactone	[KH]	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
other	" DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ),  DRUGOTHER  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	Potassium-sparing diuretics	triamterene	[KH]	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
other	" DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ),  DRUGOTHER  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	Potassium-sparing diuretics	amiloride	[KH]	OC(=O)CCCCCCCC(O)=O
other	" DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ),  DRUG2  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	Potassium-sparing diuretics	potassium	[KH]	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ),  DRUGOTHER  supplements, or  DRUG2 -containing salt substitutes may lead to significant increases in serum potassium."	Potassium-sparing diuretics	potassium	[KH]	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 , or  DRUGOTHER ),  DRUGOTHER  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	spironolactone	triamterene	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
other	" DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , or  DRUG2 ),  DRUGOTHER  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	spironolactone	amiloride	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , or  DRUGOTHER ),  DRUG2  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	spironolactone	potassium	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , or  DRUGOTHER ),  DRUGOTHER  supplements, or  DRUG2 -containing salt substitutes may lead to significant increases in serum potassium."	spironolactone	potassium	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , or  DRUG2 ),  DRUGOTHER  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	triamterene	amiloride	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , or  DRUGOTHER ),  DRUG2  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	triamterene	potassium	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , or  DRUGOTHER ),  DRUGOTHER  supplements, or  DRUG2 -containing salt substitutes may lead to significant increases in serum potassium."	triamterene	potassium	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUG1 ),  DRUG2  supplements, or  DRUGOTHER -containing salt substitutes may lead to significant increases in serum potassium."	amiloride	potassium	OC(=O)CCCCCCCC(O)=O	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUG1 ),  DRUGOTHER  supplements, or  DRUG2 -containing salt substitutes may lead to significant increases in serum potassium."	amiloride	potassium	OC(=O)CCCCCCCC(O)=O	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ),  DRUG1  supplements, or  DRUG2 -containing salt substitutes may lead to significant increases in serum potassium."	potassium	potassium	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUG1 :  DRUG2  toxicity has been reported in patients receiving  DRUGOTHER  concomitantly with drugs which cause elimination of sodium, including  DRUGOTHER ."	Lithium	Lithium	[Li+]	[Li+]
other	" DRUG1 :  DRUGOTHER  toxicity has been reported in patients receiving  DRUG2  concomitantly with drugs which cause elimination of sodium, including  DRUGOTHER ."	Lithium	lithium	[Li+]	[Li+]
other	" DRUG1 :  DRUGOTHER  toxicity has been reported in patients receiving  DRUGOTHER  concomitantly with drugs which cause elimination of sodium, including  DRUG2 ."	Lithium	ACE inhibitors	[Li+]	
other	" DRUGOTHER :  DRUG1  toxicity has been reported in patients receiving  DRUG2  concomitantly with drugs which cause elimination of sodium, including  DRUGOTHER ."	Lithium	lithium	[Li+]	[Li+]
other	" DRUGOTHER :  DRUG1  toxicity has been reported in patients receiving  DRUGOTHER  concomitantly with drugs which cause elimination of sodium, including  DRUG2 ."	Lithium	ACE inhibitors	[Li+]	
effect	" DRUGOTHER :  DRUGOTHER  toxicity has been reported in patients receiving  DRUG1  concomitantly with drugs which cause elimination of sodium, including  DRUG2 ."	lithium	ACE inhibitors	[Li+]	
other	It is recommended that serum  DRUG1  levels be monitored frequently if  DRUG2  is administered concomitantly with  DRUGOTHER .	lithium	enalapril	[Li+]	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	It is recommended that serum  DRUG1  levels be monitored frequently if  DRUGOTHER  is administered concomitantly with  DRUG2 .	lithium	lithium	[Li+]	[Li+]
advise	It is recommended that serum  DRUGOTHER  levels be monitored frequently if  DRUG1  is administered concomitantly with  DRUG2 .	enalapril	lithium	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[Li+]
effect	"Since  DRUG1  may raise the serum uric acid level, dosage adjustment of  DRUG2  may be necessary"	hydroxyurea	uricosuric medication	NC(=O)NO	
effect	There have been isolated reports of patients experiencing increases in their prothrombin times when  DRUG1  was added to  DRUG2  therapy.	etidronate	warfarin	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"The risk of using  DRUG1  in combination with other drugs has not been systematically evaluated, but  DRUG2  may potentiate the side effects of  DRUGOTHER ."	bromocriptine mesylate	alcohol	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"The risk of using  DRUG1  in combination with other drugs has not been systematically evaluated, but  DRUGOTHER  may potentiate the side effects of  DRUG2 ."	bromocriptine mesylate	bromocriptine mesylate	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
effect	"The risk of using  DRUGOTHER  in combination with other drugs has not been systematically evaluated, but  DRUG1  may potentiate the side effects of  DRUG2 ."	alcohol	bromocriptine mesylate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
int	" DRUG1  may interact with  DRUG2 ,  DRUGOTHER , and certain other agents."	Bromocriptine mesylate	dopamine antagonists	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	NCCC1=CC(O)=C(O)C=C1
int	" DRUG1  may interact with  DRUGOTHER ,  DRUG2 , and certain other agents."	Bromocriptine mesylate	butyrophenones	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	
other	" DRUGOTHER  may interact with  DRUG1 ,  DRUG2 , and certain other agents."	dopamine antagonists	butyrophenones	NCCC1=CC(O)=C(O)C=C1	
effect	"Compounds in these categories result in a decreased efficacy of  DRUG1 :  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	bromocriptine mesylate	phenothiazines	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	N1C2=CC=CC=C2SC2=CC=CC=C12
effect	"Compounds in these categories result in a decreased efficacy of  DRUG1 :  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	bromocriptine mesylate	haloperidol	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
effect	"Compounds in these categories result in a decreased efficacy of  DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	bromocriptine mesylate	metoclopramide	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	OC(=O)CCCCCCCC(O)=O
effect	"Compounds in these categories result in a decreased efficacy of  DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	bromocriptine mesylate	pimozide	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Compounds in these categories result in a decreased efficacy of  DRUGOTHER :  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	phenothiazines	haloperidol	N1C2=CC=CC=C2SC2=CC=CC=C12	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Compounds in these categories result in a decreased efficacy of  DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	phenothiazines	metoclopramide	N1C2=CC=CC=C2SC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
other	"Compounds in these categories result in a decreased efficacy of  DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	phenothiazines	pimozide	N1C2=CC=CC=C2SC2=CC=CC=C12	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Compounds in these categories result in a decreased efficacy of  DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ."	haloperidol	metoclopramide	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Compounds in these categories result in a decreased efficacy of  DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ."	haloperidol	pimozide	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Compounds in these categories result in a decreased efficacy of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ."	metoclopramide	pimozide	OC(=O)CCCCCCCC(O)=O	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
advise	Concomitant use of  DRUG1  with other  DRUG2  is not recommended.	bromocriptine mesylate	ergot alkaloids	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	Poor metabolizers have higher than expected plasma concentrations of  DRUG1  ( DRUG2 ) when given usual doses.	tricyclic antidepressants	TCAs	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUG2 ,  DRUGOTHER , and the Type 1C antiarrhythrnics propatenone and  DRUGOTHER )."	cimetidine	antidepressants	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG2 , and the Type 1C antiarrhythrnics propatenone and  DRUGOTHER )."	cimetidine	phenothiazines	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the Type 1C antiarrhythrnics propatenone and  DRUG2 )."	cimetidine	flecainide	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUG2 , and the Type 1C antiarrhythrnics propatenone and  DRUGOTHER )."	antidepressants	phenothiazines	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUGOTHER , and the Type 1C antiarrhythrnics propatenone and  DRUG2 )."	antidepressants	flecainide	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG1 , and the Type 1C antiarrhythrnics propatenone and  DRUG2 )."	phenothiazines	flecainide	N1C2=CC=CC=C2SC2=CC=CC=C12	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"While all the  DRUG1  ( DRUG2 ), e.g.,  DRUGOTHER , seriraline, and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	SSRIs	NCCC1=CNC2=CC=C(O)C=C12	
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUG2 , seriraline, and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	fluoxetine	NCCC1=CNC2=CC=C(O)C=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUGOTHER , seriraline, and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	paroxetine	NCCC1=CNC2=CC=C(O)C=C12	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUG2 , seriraline, and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	fluoxetine		CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUGOTHER , seriraline, and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	paroxetine		FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUG1 , seriraline, and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	fluoxetine	paroxetine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
int	The extent to which  DRUG1 - DRUG2  interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUGOTHER  involved.	SSRI	TCA		[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	The extent to which  DRUG1 - DRUGOTHER  interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUG2  involved.	SSRI	SSRI		
other	The extent to which  DRUGOTHER - DRUG1  interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUG2  involved.	TCA	SSRI	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	
advise	"Nevertheless, caution is indicated in the co-administration of  DRUG1  with any of the  DRUG2  and also in switching from one class to the other."	T.A.	SSRIs	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	
other	Concomitant use of  DRUG1  with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the  DRUG2  or the other drug.	tricyclic antidepressants	tricyclic antidepressant	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	It is desirable to monitor  DRUG1  plasma levels whenever a  DRUG2  is going to be co-administered with another drug known to be an inhibitor of P450 2D6.	TCA	TCA	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with  DRUG1  or  DRUG2 .	anticholinergic	sympathomimetic drugs	C[N+](C)(C)CCO	
effect	"If  DRUG1  is to be combined with other  DRUG2  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	desipramine hydrochloride	psychotropic agents	CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"If  DRUG1  is to be combined with other  DRUGOTHER  such as  DRUG2  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	desipramine hydrochloride	tranquilizers	CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
effect	"If  DRUG1  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUG2 / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	desipramine hydrochloride	sedative	CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
effect	"If  DRUG1  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUG2 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	desipramine hydrochloride	hypnotics	CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	"If  DRUG1  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUG2  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	desipramine hydrochloride	desipramine	CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"If  DRUG1  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUG2  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	desipramine hydrochloride	benzodiazepines	CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12	N1N=CC=CC2=CC=CC=C12
other	"If  DRUG1  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUG2  or  DRUGOTHER ) are additive."	desipramine hydrochloride	chlordiazepoxide	CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"If  DRUG1  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUG2 ) are additive."	desipramine hydrochloride	diazepam	CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"If  DRUGOTHER  is to be combined with other  DRUG1  such as  DRUG2  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	psychotropic agents	tranquilizers	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"If  DRUGOTHER  is to be combined with other  DRUG1  such as  DRUGOTHER  or  DRUG2 / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	psychotropic agents	sedative	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	"If  DRUGOTHER  is to be combined with other  DRUG1  such as  DRUGOTHER  or  DRUGOTHER / DRUG2 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	psychotropic agents	hypnotics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	"If  DRUGOTHER  is to be combined with other  DRUG1  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUG2  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	psychotropic agents	desipramine	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"If  DRUGOTHER  is to be combined with other  DRUG1  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUG2  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	psychotropic agents	benzodiazepines	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	N1N=CC=CC2=CC=CC=C12
other	"If  DRUGOTHER  is to be combined with other  DRUG1  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUG2  or  DRUGOTHER ) are additive."	psychotropic agents	chlordiazepoxide	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"If  DRUGOTHER  is to be combined with other  DRUG1  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUG2 ) are additive."	psychotropic agents	diazepam	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUG1  or  DRUG2 / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	tranquilizers	sedative	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUG1  or  DRUGOTHER / DRUG2 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	tranquilizers	hypnotics	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUG1  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUG2  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	tranquilizers	desipramine	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUG1  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUG2  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	tranquilizers	benzodiazepines	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	N1N=CC=CC2=CC=CC=C12
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUG1  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUG2  or  DRUGOTHER ) are additive."	tranquilizers	chlordiazepoxide	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUG1  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUG2 ) are additive."	tranquilizers	diazepam	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUG1 / DRUG2 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	sedative	hypnotics		
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUG1 / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUG2  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	sedative	desipramine		CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUG1 / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUG2  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	sedative	benzodiazepines		N1N=CC=CC2=CC=CC=C12
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUG1 / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUG2  or  DRUGOTHER ) are additive."	sedative	chlordiazepoxide		CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUG1 / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUG2 ) are additive."	sedative	diazepam		CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUG1 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUG2  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	hypnotics	desipramine		CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUG1 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUG2  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	hypnotics	benzodiazepines		N1N=CC=CC2=CC=CC=C12
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUG1 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUG2  or  DRUGOTHER ) are additive."	hypnotics	chlordiazepoxide		CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUG1 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUG2 ) are additive."	hypnotics	diazepam		CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
effect	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUG1  and  DRUG2  (e.g.,  DRUGOTHER  or  DRUGOTHER ) are additive."	desipramine	benzodiazepines	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	N1N=CC=CC2=CC=CC=C12
effect	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUG1  and  DRUGOTHER  (e.g.,  DRUG2  or  DRUGOTHER ) are additive."	desipramine	chlordiazepoxide	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
effect	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUG1  and  DRUGOTHER  (e.g.,  DRUGOTHER  or  DRUG2 ) are additive."	desipramine	diazepam	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUG1  (e.g.,  DRUG2  or  DRUGOTHER ) are additive."	benzodiazepines	chlordiazepoxide	N1N=CC=CC2=CC=CC=C12	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUG1  (e.g.,  DRUGOTHER  or  DRUG2 ) are additive."	benzodiazepines	diazepam	N1N=CC=CC2=CC=CC=C12	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"If  DRUGOTHER  is to be combined with other  DRUGOTHER  such as  DRUGOTHER  or  DRUGOTHER / DRUGOTHER , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUG1  or  DRUG2 ) are additive."	chlordiazepoxide	diazepam	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
effect	Both the sedative and anticholinergic effects of the  DRUG1  are also additive to those of  DRUG2 .	major tranquilizers	desipramine	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
mechanism	Concurrent administration of  DRUG1  and  DRUG2  can produce clinically significant increases in the plasma levels of the  DRUGOTHER .	cimetidine	tricyclic antidepressants	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	Concurrent administration of  DRUG1  and  DRUGOTHER  can produce clinically significant increases in the plasma levels of the  DRUG2 .	cimetidine	tricyclic antidepressants	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	Concurrent administration of  DRUGOTHER  and  DRUG1  can produce clinically significant increases in the plasma levels of the  DRUG2 .	tricyclic antidepressants	tricyclic antidepressants	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
mechanism	"Conversely, decreases in plasma levels of the  DRUG1  have been reported upon discontinuation of  DRUG2  which may result in the loss of the therapeutic efficacy of the  DRUGOTHER  6."	tricyclic antidepressants	cimetidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Conversely, decreases in plasma levels of the  DRUG1  have been reported upon discontinuation of  DRUGOTHER  which may result in the loss of the therapeutic efficacy of the  DRUG2  6."	tricyclic antidepressants	tricyclic antidepressant	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Conversely, decreases in plasma levels of the  DRUGOTHER  have been reported upon discontinuation of  DRUG1  which may result in the loss of the therapeutic efficacy of the  DRUG2  6."	cimetidine	tricyclic antidepressant	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
mechanism	There have been greater than two-fold increases of previously stable plasma levels of  DRUG1  when  DRUG2  has been administered in combination with these agents.	tricyclic antidepressants	fluoxetine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
effect	 DRUG1  may interfere with the anti-glaucoma action of  DRUG2  or  DRUGOTHER ;	Cyclopentolate	carbachol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	C[N+](C)(C)CCOC(N)=O
effect	 DRUG1  may interfere with the anti-glaucoma action of  DRUGOTHER  or  DRUG2 ;	Cyclopentolate	pilocarpine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
other	 DRUGOTHER  may interfere with the anti-glaucoma action of  DRUG1  or  DRUG2 ;	carbachol	pilocarpine	C[N+](C)(C)CCOC(N)=O	CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUG2 , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sulfonylureas	nonsteroidal anti-inflammatory agents	NC(N)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUGOTHER , some  DRUG2  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sulfonylureas	azoles	NC(N)=O	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sulfonylureas	salicylates	NC(N)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sulfonylureas	sulfonamides	NC(N)=O	OC(=O)CCCCCCCC(O)=O
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sulfonylureas	chloramphenicol	NC(N)=O	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sulfonylureas	probenecid	NC(N)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	sulfonylureas	coumarins	NC(N)=O	O=C1OC2=CC=CC=C2C=C1
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	sulfonylureas	monoamine oxidase inhibitors	NC(N)=O	OC(=O)CCCCCCCC(O)=O
effect	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUG1  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	sulfonylureas	beta adrenergic blocking agents	NC(N)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUG1 , some  DRUG2  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	azoles	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUG1 , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	salicylates	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUG1 , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	sulfonamides	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUG1 , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	chloramphenicol	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUG1 , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	probenecid	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUG1 , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	coumarins	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	O=C1OC2=CC=CC=C2C=C1
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUG1 , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	monoamine oxidase inhibitors	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUG1 , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	nonsteroidal anti-inflammatory agents	beta adrenergic blocking agents	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUG1  and other drugs that are highly protein bound,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	azoles	salicylates	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUG1  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	azoles	sulfonamides	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUG1  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	azoles	chloramphenicol	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUG1  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	azoles	probenecid	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUG1  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	azoles	coumarins	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	O=C1OC2=CC=CC=C2C=C1
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUG1  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	azoles	monoamine oxidase inhibitors	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUG1  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	azoles	beta adrenergic blocking agents	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	salicylates	sulfonamides	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	salicylates	chloramphenicol	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	salicylates	probenecid	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	salicylates	coumarins	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	O=C1OC2=CC=CC=C2C=C1
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	salicylates	monoamine oxidase inhibitors	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	salicylates	beta adrenergic blocking agents	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sulfonamides	chloramphenicol	OC(=O)CCCCCCCC(O)=O	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sulfonamides	probenecid	OC(=O)CCCCCCCC(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	sulfonamides	coumarins	OC(=O)CCCCCCCC(O)=O	O=C1OC2=CC=CC=C2C=C1
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	sulfonamides	monoamine oxidase inhibitors	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	sulfonamides	beta adrenergic blocking agents	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	chloramphenicol	probenecid	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	chloramphenicol	coumarins	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	O=C1OC2=CC=CC=C2C=C1
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	chloramphenicol	monoamine oxidase inhibitors	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	chloramphenicol	beta adrenergic blocking agents	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	probenecid	coumarins	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	O=C1OC2=CC=CC=C2C=C1
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	probenecid	monoamine oxidase inhibitors	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	probenecid	beta adrenergic blocking agents	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	coumarins	monoamine oxidase inhibitors	O=C1OC2=CC=CC=C2C=C1	OC(=O)CCCCCCCC(O)=O
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	coumarins	beta adrenergic blocking agents	O=C1OC2=CC=CC=C2C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Immediate and Extended Release Tablets The hypoglycemic action of  DRUGOTHER  may be potentiated by certain drugs including  DRUGOTHER , some  DRUGOTHER  and other drugs that are highly protein bound,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	monoamine oxidase inhibitors	beta adrenergic blocking agents	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	In vitro binding studies with human serum proteins indicate that  DRUG1  binds differently than  DRUG2  and does not interact with  DRUGOTHER  or  DRUGOTHER .	glipizide	tolbutamide	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	
other	In vitro binding studies with human serum proteins indicate that  DRUG1  binds differently than  DRUGOTHER  and does not interact with  DRUG2  or  DRUGOTHER .	glipizide	salicylate	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	In vitro binding studies with human serum proteins indicate that  DRUG1  binds differently than  DRUGOTHER  and does not interact with  DRUGOTHER  or  DRUG2 .	glipizide	dicumarol	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	In vitro binding studies with human serum proteins indicate that  DRUGOTHER  binds differently than  DRUG1  and does not interact with  DRUG2  or  DRUGOTHER .	tolbutamide	salicylate		CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	In vitro binding studies with human serum proteins indicate that  DRUGOTHER  binds differently than  DRUG1  and does not interact with  DRUGOTHER  or  DRUG2 .	tolbutamide	dicumarol		OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	In vitro binding studies with human serum proteins indicate that  DRUGOTHER  binds differently than  DRUGOTHER  and does not interact with  DRUG1  or  DRUG2 .	salicylate	dicumarol	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"These drugs include the  DRUG1  and other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	diuretics	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	corticosteroids	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	phenothiazines	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	thyroid products	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	estrogens	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	contraceptives	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	phenytoin	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	nicotinic acid	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	sympathomimetics	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	thiazides	calcium channel blocking drugs	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[Ca]
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	thiazides	isoniazid	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	corticosteroids	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	phenothiazines	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	thyroid products	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	estrogens	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	contraceptives	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	phenytoin	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	nicotinic acid	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	sympathomimetics	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	diuretics	calcium channel blocking drugs	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	diuretics	isoniazid	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	phenothiazines	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	thyroid products	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	estrogens	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	contraceptives	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	phenytoin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	nicotinic acid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	sympathomimetics	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	corticosteroids	calcium channel blocking drugs	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	corticosteroids	isoniazid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	thyroid products	N1C2=CC=CC=C2SC2=CC=CC=C12	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	estrogens	N1C2=CC=CC=C2SC2=CC=CC=C12	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	contraceptives	N1C2=CC=CC=C2SC2=CC=CC=C12	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	phenytoin	N1C2=CC=CC=C2SC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	nicotinic acid	N1C2=CC=CC=C2SC2=CC=CC=C12	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	sympathomimetics	N1C2=CC=CC=C2SC2=CC=CC=C12	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	phenothiazines	calcium channel blocking drugs	N1C2=CC=CC=C2SC2=CC=CC=C12	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	phenothiazines	isoniazid	N1C2=CC=CC=C2SC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	estrogens		C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	contraceptives		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	nicotinic acid		OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	sympathomimetics		
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	thyroid products	calcium channel blocking drugs		[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	thyroid products	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	estrogens	contraceptives	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	estrogens	phenytoin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	estrogens	nicotinic acid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	estrogens	sympathomimetics	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	estrogens	calcium channel blocking drugs	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	estrogens	isoniazid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	phenytoin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	nicotinic acid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	sympathomimetics	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	contraceptives	calcium channel blocking drugs	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	contraceptives	isoniazid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenytoin	nicotinic acid	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	phenytoin	sympathomimetics	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	phenytoin	calcium channel blocking drugs	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	phenytoin	isoniazid	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	nicotinic acid	sympathomimetics	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	nicotinic acid	calcium channel blocking drugs	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	nicotinic acid	isoniazid	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	sympathomimetics	calcium channel blocking drugs		[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	sympathomimetics	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	calcium channel blocking drugs	isoniazid	[Ca]	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
int	A potential interaction between oral  DRUG1  and oral  DRUG2  leading to severe hypoglycemia has been reported.	miconazole	hypoglycemic agents	CC(C)N1CCN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2OC[C@@](CN3C=NC=N3)(O2)C2=CC=C(F)C=C2F)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
int	The effect of concomitant administration of  DRUG1  and  DRUG2  has been demonstrated in a placebo-controlled crossover study in normal volunteers.	fluconazole	glipizide	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	All subjects received  DRUG1  alone and following treatment with 100 mg of  DRUG2  as a single daily oral dose for seven days.	glipizide	fluconazole	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mechanism	The mean percentage increase in the  DRUG1  AUC after  DRUG2  administration was 56.9% (range: 35 to 81).	glipizide	fluconazole	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mechanism	 DRUG1  generally should not be given with  DRUG2  because they reduce its renal clearance and add a high risk of  DRUGOTHER  toxicity.	Lithium	diuretics	[Li+]	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	 DRUG1  generally should not be given with  DRUGOTHER  because they reduce its renal clearance and add a high risk of  DRUG2  toxicity.	Lithium	lithium	[Li+]	[Li+]
other	 DRUGOTHER  generally should not be given with  DRUG1  because they reduce its renal clearance and add a high risk of  DRUG2  toxicity.	diuretics	lithium	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[Li+]
effect	 DRUG1  may increase the ototoxic potential of other drugs such as  DRUG2  and some  DRUGOTHER .	EDECRIN	aminoglycoside	CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1	OC(=O)CCCCCCCC(O)=O
effect	 DRUG1  may increase the ototoxic potential of other drugs such as  DRUGOTHER  and some  DRUG2 .	EDECRIN	cephalosporin antibiotics	CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	 DRUGOTHER  may increase the ototoxic potential of other drugs such as  DRUG1  and some  DRUG2 .	aminoglycoside	cephalosporin antibiotics	OC(=O)CCCCCCCC(O)=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
mechanism	"A number of drugs, including  DRUG1 , have been shown to displace  DRUG2  from plasma protein;"	ethacrynic acid	warfarin	CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
effect	"In some patients, the administration of a  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ."	non- steroidal antiinflammatory agent	loop diuretics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
effect	"In some patients, the administration of a  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUG2  and  DRUGOTHER ."	non- steroidal antiinflammatory agent	potassium- sparing diuretics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[KH]
effect	"In some patients, the administration of a  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ."	non- steroidal antiinflammatory agent	thiazide diuretics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	"In some patients, the administration of a  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG1 ,  DRUG2  and  DRUGOTHER ."	loop diuretics	potassium- sparing diuretics		[KH]
other	"In some patients, the administration of a  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG1 ,  DRUGOTHER  and  DRUG2 ."	loop diuretics	thiazide diuretics		
other	"In some patients, the administration of a  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUG1  and  DRUG2 ."	potassium- sparing diuretics	thiazide diuretics	[KH]	
effect	"Therefore, when  DRUG1  and  DRUG2  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUGOTHER  is obtained."	EDECRIN	non- steroidal anti- inflammatory agents	CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Therefore, when  DRUG1  and  DRUGOTHER  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUG2  is obtained."	EDECRIN	diuretic	CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Therefore, when  DRUGOTHER  and  DRUG1  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUG2  is obtained."	non- steroidal anti- inflammatory agents	diuretic	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
int	Clinical implications of  DRUG1  interactions with five  DRUG2 .	warfarin	sedatives	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
other	"The intensity, uniformity and time course of  DRUG1  interference by  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	anticoagulant	phenobarbital	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"The intensity, uniformity and time course of  DRUG1  interference by  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	anticoagulant	secobarbital	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
other	"The intensity, uniformity and time course of  DRUG1  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	anticoagulant	glutethimide	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
other	"The intensity, uniformity and time course of  DRUG1  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	anticoagulant	chloral hydrate	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"The intensity, uniformity and time course of  DRUG1  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	anticoagulant	methaqualone	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
other	"The intensity, uniformity and time course of  DRUG1  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUG2  therapy."	anticoagulant	coumarin	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	O=C1OC2=CC=CC=C2C=C1
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	phenobarbital	secobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	phenobarbital	glutethimide	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	phenobarbital	chloral hydrate	CCC1(CC)C(=O)NC(=O)NC1=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	phenobarbital	methaqualone	CCC1(CC)C(=O)NC(=O)NC1=O	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUG2  therapy."	phenobarbital	coumarin	CCC1(CC)C(=O)NC(=O)NC1=O	O=C1OC2=CC=CC=C2C=C1
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	secobarbital	glutethimide	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	secobarbital	chloral hydrate	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	secobarbital	methaqualone	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUG2  therapy."	secobarbital	coumarin	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	O=C1OC2=CC=CC=C2C=C1
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	glutethimide	chloral hydrate	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	glutethimide	methaqualone	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUG2  therapy."	glutethimide	coumarin	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1	O=C1OC2=CC=CC=C2C=C1
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2  were systematically investigated in 16 patients receiving  DRUGOTHER  therapy."	chloral hydrate	methaqualone	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER  were systematically investigated in 16 patients receiving  DRUG2  therapy."	chloral hydrate	coumarin	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	O=C1OC2=CC=CC=C2C=C1
other	"The intensity, uniformity and time course of  DRUGOTHER  interference by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1  were systematically investigated in 16 patients receiving  DRUG2  therapy."	methaqualone	coumarin	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O	O=C1OC2=CC=CC=C2C=C1
other	"Anticoagulant inhibition was observed during the administration of  DRUG1 ,  DRUG2  and  DRUGOTHER ;"	phenobarbital	secobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
other	"Anticoagulant inhibition was observed during the administration of  DRUG1 ,  DRUGOTHER  and  DRUG2 ;"	phenobarbital	glutethimide	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
other	"Anticoagulant inhibition was observed during the administration of  DRUGOTHER ,  DRUG1  and  DRUG2 ;"	secobarbital	glutethimide	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
other	there was no significant change in prothrombin test results during the trials of  DRUG1  and  DRUG2 .	chloral hydrate	methaqualone	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
other	 DRUG1  and  DRUG2  should not be administered to patients receiving  DRUGOTHER .	Barbiturates	glutethimide	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
advise	 DRUG1  and  DRUGOTHER  should not be administered to patients receiving  DRUG2 .	Barbiturates	coumarin drugs	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	O=C1OC2=CC=CC=C2C=C1
other	" DRUG1  and  DRUG2  interact pharmacologically with orally administered  DRUGOTHER , but the effect is not clinically significant."	Chloral hydrate	methaqualone	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
int	" DRUG1  and  DRUGOTHER  interact pharmacologically with orally administered  DRUG2 , but the effect is not clinically significant."	Chloral hydrate	anticoagulant agents	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	It is concluded that  DRUG1  and  DRUG2  may be administered safely without additional caution in prothrombin test monitoring during oral  DRUGOTHER  therapy.	chloral hydrate	methaqualone	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
other	It is concluded that  DRUG1  and  DRUGOTHER  may be administered safely without additional caution in prothrombin test monitoring during oral  DRUG2  therapy.	chloral hydrate	anticoagulant	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	It is concluded that  DRUGOTHER  and  DRUG1  may be administered safely without additional caution in prothrombin test monitoring during oral  DRUG2  therapy.	methaqualone	anticoagulant	CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	"After multiple dosing,  DRUG1  ( DRUG2   30 mcg IM once weekly) reduced  DRUGOTHER   clearance by approximately 30%."	interferon beta-1a	AVONEX		O
mechanism	"After multiple dosing,  DRUG1  ( DRUGOTHER   30 mcg IM once weekly) reduced  DRUG2   clearance by approximately 30%."	interferon beta-1a	TYSABRI		
mechanism	"After multiple dosing,  DRUGOTHER  ( DRUG1   30 mcg IM once weekly) reduced  DRUG2   clearance by approximately 30%."	AVONEX	TYSABRI	O	
other	"The similarity of the  DRUG1  -associated adverse event profile between Study 1 (without co-administered  DRUG2  ) and Study 2 (with co-administered  DRUGOTHER  ) indicates that this alteration in clearance does not necessitate reduction of the  DRUGOTHER   dose to maintain safety, General)."	TYSABRI	AVONEX		O
other	"The similarity of the  DRUG1  -associated adverse event profile between Study 1 (without co-administered  DRUGOTHER  ) and Study 2 (with co-administered  DRUG2  ) indicates that this alteration in clearance does not necessitate reduction of the  DRUGOTHER   dose to maintain safety, General)."	TYSABRI	AVONEX		O
other	"The similarity of the  DRUG1  -associated adverse event profile between Study 1 (without co-administered  DRUGOTHER  ) and Study 2 (with co-administered  DRUGOTHER  ) indicates that this alteration in clearance does not necessitate reduction of the  DRUG2   dose to maintain safety, General)."	TYSABRI	TYSABRI		
other	"The similarity of the  DRUGOTHER  -associated adverse event profile between Study 1 (without co-administered  DRUG1  ) and Study 2 (with co-administered  DRUG2  ) indicates that this alteration in clearance does not necessitate reduction of the  DRUGOTHER   dose to maintain safety, General)."	AVONEX	AVONEX	O	O
other	"The similarity of the  DRUGOTHER  -associated adverse event profile between Study 1 (without co-administered  DRUG1  ) and Study 2 (with co-administered  DRUGOTHER  ) indicates that this alteration in clearance does not necessitate reduction of the  DRUG2   dose to maintain safety, General)."	AVONEX	TYSABRI	O	
other	"The similarity of the  DRUGOTHER  -associated adverse event profile between Study 1 (without co-administered  DRUGOTHER  ) and Study 2 (with co-administered  DRUG1  ) indicates that this alteration in clearance does not necessitate reduction of the  DRUG2   dose to maintain safety, General)."	AVONEX	TYSABRI	O	
other	Results of studies in multiple sclerosis patients taking  DRUG1   and concomitant  DRUG2  ( DRUGOTHER   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUGOTHER .	TYSABRI	interferon beta-1a		
other	Results of studies in multiple sclerosis patients taking  DRUG1   and concomitant  DRUGOTHER  ( DRUG2   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUGOTHER .	TYSABRI	AVONEX		O
other	Results of studies in multiple sclerosis patients taking  DRUG1   and concomitant  DRUGOTHER  ( DRUGOTHER   30 mcg IM once weekly) or  DRUG2  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUGOTHER .	TYSABRI	glatiramer acetate		
other	Results of studies in multiple sclerosis patients taking  DRUG1   and concomitant  DRUGOTHER  ( DRUGOTHER   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUG2  or  DRUGOTHER .	TYSABRI	beta-interferon		
other	Results of studies in multiple sclerosis patients taking  DRUG1   and concomitant  DRUGOTHER  ( DRUGOTHER   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUG2 .	TYSABRI	glatiramer acetate		
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUG1  ( DRUG2   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUGOTHER .	interferon beta-1a	AVONEX		O
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUG1  ( DRUGOTHER   30 mcg IM once weekly) or  DRUG2  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUGOTHER .	interferon beta-1a	glatiramer acetate		
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUG1  ( DRUGOTHER   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUG2  or  DRUGOTHER .	interferon beta-1a	beta-interferon		
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUG1  ( DRUGOTHER   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUG2 .	interferon beta-1a	glatiramer acetate		
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUGOTHER  ( DRUG1   30 mcg IM once weekly) or  DRUG2  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUGOTHER .	AVONEX	glatiramer acetate	O	
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUGOTHER  ( DRUG1   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUG2  or  DRUGOTHER .	AVONEX	beta-interferon	O	
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUGOTHER  ( DRUG1   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUG2 .	AVONEX	glatiramer acetate	O	
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUGOTHER  ( DRUGOTHER   30 mcg IM once weekly) or  DRUG1  were inconclusive with regard to the need for dose adjustment of the  DRUG2  or  DRUGOTHER .	glatiramer acetate	beta-interferon		
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUGOTHER  ( DRUGOTHER   30 mcg IM once weekly) or  DRUG1  were inconclusive with regard to the need for dose adjustment of the  DRUGOTHER  or  DRUG2 .	glatiramer acetate	glatiramer acetate		
other	Results of studies in multiple sclerosis patients taking  DRUGOTHER   and concomitant  DRUGOTHER  ( DRUGOTHER   30 mcg IM once weekly) or  DRUGOTHER  were inconclusive with regard to the need for dose adjustment of the  DRUG1  or  DRUG2 .	beta-interferon	glatiramer acetate		
effect	"There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of  DRUG1  and  DRUG2 ."	loxapine	lorazepam	CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	 DRUG1 : Several short-term controlled studies failed to wshow that  DRUG2  significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on  DRUGOTHER .	Coumarin-Type Anticoagulants	ibuprofen	O=C1OC2=CC=CC=C2C=C1	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	 DRUG1 : Several short-term controlled studies failed to wshow that  DRUGOTHER  significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on  DRUG2 .	Coumarin-Type Anticoagulants	coumarin-type anticoagulants	O=C1OC2=CC=CC=C2C=C1	O=C1OC2=CC=CC=C2C=C1
other	 DRUGOTHER : Several short-term controlled studies failed to wshow that  DRUG1  significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on  DRUG2 .	ibuprofen	coumarin-type anticoagulants	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	O=C1OC2=CC=CC=C2C=C1
other	"However, because bleeding has been reported when  DRUG1  and other  DRUG2  have been administered to patients on  DRUGOTHER , the physician should be cautious when administering  DRUGOTHER  to patients on  DRUGOTHER ."	ibuprofen	nonsteroidal anti-inflammatory agents	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"However, because bleeding has been reported when  DRUG1  and other  DRUGOTHER  have been administered to patients on  DRUG2 , the physician should be cautious when administering  DRUGOTHER  to patients on  DRUGOTHER ."	ibuprofen	coumarin-type anticoagulants	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	O=C1OC2=CC=CC=C2C=C1
other	"However, because bleeding has been reported when  DRUG1  and other  DRUGOTHER  have been administered to patients on  DRUGOTHER , the physician should be cautious when administering  DRUG2  to patients on  DRUGOTHER ."	ibuprofen	ibuprofen	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"However, because bleeding has been reported when  DRUG1  and other  DRUGOTHER  have been administered to patients on  DRUGOTHER , the physician should be cautious when administering  DRUGOTHER  to patients on  DRUG2 ."	ibuprofen	anticoagulants	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	
effect	"However, because bleeding has been reported when  DRUGOTHER  and other  DRUG1  have been administered to patients on  DRUG2 , the physician should be cautious when administering  DRUGOTHER  to patients on  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	coumarin-type anticoagulants	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	O=C1OC2=CC=CC=C2C=C1
other	"However, because bleeding has been reported when  DRUGOTHER  and other  DRUG1  have been administered to patients on  DRUGOTHER , the physician should be cautious when administering  DRUG2  to patients on  DRUGOTHER ."	nonsteroidal anti-inflammatory agents	ibuprofen	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"However, because bleeding has been reported when  DRUGOTHER  and other  DRUG1  have been administered to patients on  DRUGOTHER , the physician should be cautious when administering  DRUGOTHER  to patients on  DRUG2 ."	nonsteroidal anti-inflammatory agents	anticoagulants	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	"However, because bleeding has been reported when  DRUGOTHER  and other  DRUGOTHER  have been administered to patients on  DRUG1 , the physician should be cautious when administering  DRUG2  to patients on  DRUGOTHER ."	coumarin-type anticoagulants	ibuprofen	O=C1OC2=CC=CC=C2C=C1	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"However, because bleeding has been reported when  DRUGOTHER  and other  DRUGOTHER  have been administered to patients on  DRUG1 , the physician should be cautious when administering  DRUGOTHER  to patients on  DRUG2 ."	coumarin-type anticoagulants	anticoagulants	O=C1OC2=CC=CC=C2C=C1	
advise	"However, because bleeding has been reported when  DRUGOTHER  and other  DRUGOTHER  have been administered to patients on  DRUGOTHER , the physician should be cautious when administering  DRUG1  to patients on  DRUG2 ."	ibuprofen	anticoagulants	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	
other	" DRUG1 : Animal studies wshow that  DRUG2  given with  DRUGOTHER , including  DRUGOTHER , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."	Aspirin	aspirin	CC(=O)OC1=CC=CC=C1C(O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	" DRUG1 : Animal studies wshow that  DRUGOTHER  given with  DRUG2 , including  DRUGOTHER , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."	Aspirin	nonsteroidal anti-inflammatory agents	CC(=O)OC1=CC=CC=C1C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUG1 : Animal studies wshow that  DRUGOTHER  given with  DRUGOTHER , including  DRUG2 , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."	Aspirin	ibuprofen	CC(=O)OC1=CC=CC=C1C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
effect	" DRUGOTHER : Animal studies wshow that  DRUG1  given with  DRUG2 , including  DRUGOTHER , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."	aspirin	nonsteroidal anti-inflammatory agents	CC(=O)OC1=CC=CC=C1C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	" DRUGOTHER : Animal studies wshow that  DRUG1  given with  DRUGOTHER , including  DRUG2 , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."	aspirin	ibuprofen	CC(=O)OC1=CC=CC=C1C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUGOTHER : Animal studies wshow that  DRUGOTHER  given with  DRUG1 , including  DRUG2 , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."	nonsteroidal anti-inflammatory agents	ibuprofen	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	Single dose bioavailability studies in normal volunteers have failed to wshow an effect of  DRUG1  on  DRUG2  blood levels.	aspirin	ibuprofen	CC(=O)OC1=CC=CC=C1C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUG1 :  DRUG2 , as well as other  DRUGOTHER , probably reduces the tubular secretion of  DRUGOTHER  based on in vitro studies in rabbit kidney slices."	Methotrexate	Ibuprofen	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUG1 :  DRUGOTHER , as well as other  DRUG2 , probably reduces the tubular secretion of  DRUGOTHER  based on in vitro studies in rabbit kidney slices."	Methotrexate	nonsteroidal anti-inflammatory drugs	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1 :  DRUGOTHER , as well as other  DRUGOTHER , probably reduces the tubular secretion of  DRUG2  based on in vitro studies in rabbit kidney slices."	Methotrexate	methotrexate	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER :  DRUG1 , as well as other  DRUG2 , probably reduces the tubular secretion of  DRUGOTHER  based on in vitro studies in rabbit kidney slices."	Ibuprofen	nonsteroidal anti-inflammatory drugs	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	" DRUGOTHER :  DRUG1 , as well as other  DRUGOTHER , probably reduces the tubular secretion of  DRUG2  based on in vitro studies in rabbit kidney slices."	Ibuprofen	methotrexate	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mechanism	" DRUGOTHER :  DRUGOTHER , as well as other  DRUG1 , probably reduces the tubular secretion of  DRUG2  based on in vitro studies in rabbit kidney slices."	nonsteroidal anti-inflammatory drugs	methotrexate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
effect	This may indicate that  DRUG1  could enhance the toxicity of  DRUG2 .	ibuprofen	methotrexate	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
advise	Caution should be used if  DRUG1  is administered concomitantly with  DRUG2 .	ibuprofen	methotrexate	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	"H-2 Antagonists: In studies with human volunteers, co-administration of  DRUG1  or  DRUG2  with  DRUGOTHER  had no substantive effect on  DRUGOTHER  serum concentrations."	cimetidine	ranitidine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"H-2 Antagonists: In studies with human volunteers, co-administration of  DRUG1  or  DRUGOTHER  with  DRUG2  had no substantive effect on  DRUGOTHER  serum concentrations."	cimetidine	ibuprofen	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"H-2 Antagonists: In studies with human volunteers, co-administration of  DRUG1  or  DRUGOTHER  with  DRUGOTHER  had no substantive effect on  DRUG2  serum concentrations."	cimetidine	ibuprofen	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"H-2 Antagonists: In studies with human volunteers, co-administration of  DRUGOTHER  or  DRUG1  with  DRUG2  had no substantive effect on  DRUGOTHER  serum concentrations."	ranitidine	ibuprofen	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"H-2 Antagonists: In studies with human volunteers, co-administration of  DRUGOTHER  or  DRUG1  with  DRUGOTHER  had no substantive effect on  DRUG2  serum concentrations."	ranitidine	ibuprofen	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"H-2 Antagonists: In studies with human volunteers, co-administration of  DRUGOTHER  or  DRUGOTHER  with  DRUG1  had no substantive effect on  DRUG2  serum concentrations."	ibuprofen	ibuprofen	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUG1 : Clinical studies, as well as random observations, have shown that  DRUG2  can reduce the natriuretic effect of  DRUGOTHER  and  DRUGOTHER  in some patients."	Furosemide	ibuprofen	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUG1 : Clinical studies, as well as random observations, have shown that  DRUGOTHER  can reduce the natriuretic effect of  DRUG2  and  DRUGOTHER  in some patients."	Furosemide	furosemide	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUG1 : Clinical studies, as well as random observations, have shown that  DRUGOTHER  can reduce the natriuretic effect of  DRUGOTHER  and  DRUG2  in some patients."	Furosemide	thiazides	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
effect	" DRUGOTHER : Clinical studies, as well as random observations, have shown that  DRUG1  can reduce the natriuretic effect of  DRUG2  and  DRUGOTHER  in some patients."	ibuprofen	furosemide	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
effect	" DRUGOTHER : Clinical studies, as well as random observations, have shown that  DRUG1  can reduce the natriuretic effect of  DRUGOTHER  and  DRUG2  in some patients."	ibuprofen	thiazides	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	" DRUGOTHER : Clinical studies, as well as random observations, have shown that  DRUGOTHER  can reduce the natriuretic effect of  DRUG1  and  DRUG2  in some patients."	furosemide	thiazides	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"During concomitant therapy with  DRUG1 , the patient should be observed closely for signs of renal failure, as well as to assure  DRUG2  efficacy."	ibuprofen	diuretic	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	 DRUG1 :  DRUG2  produced an elevation of plasma  DRUGOTHER  levels and a reduction in renal  DRUGOTHER  clearance in a study of eleven normal volunteers.	Lithium	Ibuprofen	[Li+]	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	 DRUG1 :  DRUGOTHER  produced an elevation of plasma  DRUG2  levels and a reduction in renal  DRUGOTHER  clearance in a study of eleven normal volunteers.	Lithium	lithium	[Li+]	[Li+]
other	 DRUG1 :  DRUGOTHER  produced an elevation of plasma  DRUGOTHER  levels and a reduction in renal  DRUG2  clearance in a study of eleven normal volunteers.	Lithium	lithium	[Li+]	[Li+]
mechanism	 DRUGOTHER :  DRUG1  produced an elevation of plasma  DRUG2  levels and a reduction in renal  DRUGOTHER  clearance in a study of eleven normal volunteers.	Ibuprofen	lithium	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	[Li+]
other	 DRUGOTHER :  DRUG1  produced an elevation of plasma  DRUGOTHER  levels and a reduction in renal  DRUG2  clearance in a study of eleven normal volunteers.	Ibuprofen	lithium	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	[Li+]
other	 DRUGOTHER :  DRUGOTHER  produced an elevation of plasma  DRUG1  levels and a reduction in renal  DRUG2  clearance in a study of eleven normal volunteers.	lithium	lithium	[Li+]	[Li+]
other	The mean minimum  DRUG1  concentration increased 15% and the renal clearance of  DRUG2  was decreased by 19% during this period of concomitant drug administration.	lithium	lithium	[Li+]	[Li+]
advise	"Thus, when  DRUG1  and  DRUG2  are administered concurrently, subjects should be observed carefully for signs of  DRUGOTHER  toxicity."	ibuprofen	lithium	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	[Li+]
other	"Thus, when  DRUG1  and  DRUGOTHER  are administered concurrently, subjects should be observed carefully for signs of  DRUG2  toxicity."	ibuprofen	lithium	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	[Li+]
other	"Thus, when  DRUGOTHER  and  DRUG1  are administered concurrently, subjects should be observed carefully for signs of  DRUG2  toxicity."	lithium	lithium	[Li+]	[Li+]
other	"In patients receiving a potent CYP3A4 inducer such as  DRUG1  or  DRUG2 , a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections)."	rifampicin	phenytoin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
effect	International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking  DRUG1  while on  DRUG2  therapy.	warfarin	IRESSA	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
other	"Substances that are potent inhibitors of CYP3A4 activity (eg,  DRUG1  and  DRUG2 ) decrease  DRUGOTHER  metabolism and increase  DRUGOTHER  plasma concentrations."	ketoconazole	itraconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mechanism	"Substances that are potent inhibitors of CYP3A4 activity (eg,  DRUG1  and  DRUGOTHER ) decrease  DRUG2  metabolism and increase  DRUGOTHER  plasma concentrations."	ketoconazole	gefitinib	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
mechanism	"Substances that are potent inhibitors of CYP3A4 activity (eg,  DRUG1  and  DRUGOTHER ) decrease  DRUGOTHER  metabolism and increase  DRUG2  plasma concentrations."	ketoconazole	gefitinib	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
mechanism	"Substances that are potent inhibitors of CYP3A4 activity (eg,  DRUGOTHER  and  DRUG1 ) decrease  DRUG2  metabolism and increase  DRUGOTHER  plasma concentrations."	itraconazole	gefitinib	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
mechanism	"Substances that are potent inhibitors of CYP3A4 activity (eg,  DRUGOTHER  and  DRUG1 ) decrease  DRUGOTHER  metabolism and increase  DRUG2  plasma concentrations."	itraconazole	gefitinib	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
other	"Substances that are potent inhibitors of CYP3A4 activity (eg,  DRUGOTHER  and  DRUGOTHER ) decrease  DRUG1  metabolism and increase  DRUG2  plasma concentrations."	gefitinib	gefitinib	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
other	Drugs that cause significant sustained elevation in gastric pH ( DRUG1  such as  DRUG2  or  DRUGOTHER ) may reduce plasma concentrations of  DRUGOTHER  and therefore potentially may reduce efficacy.	histamine H2-receptor antagonists	ranitidine	NCCC1=CNC=N1	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	Drugs that cause significant sustained elevation in gastric pH ( DRUG1  such as  DRUGOTHER  or  DRUG2 ) may reduce plasma concentrations of  DRUGOTHER  and therefore potentially may reduce efficacy.	histamine H2-receptor antagonists	cimetidine	NCCC1=CNC=N1	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
mechanism	Drugs that cause significant sustained elevation in gastric pH ( DRUG1  such as  DRUGOTHER  or  DRUGOTHER ) may reduce plasma concentrations of  DRUG2  and therefore potentially may reduce efficacy.	histamine H2-receptor antagonists	IRESSA	NCCC1=CNC=N1	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
other	Drugs that cause significant sustained elevation in gastric pH ( DRUGOTHER  such as  DRUG1  or  DRUG2 ) may reduce plasma concentrations of  DRUGOTHER  and therefore potentially may reduce efficacy.	ranitidine	cimetidine	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
mechanism	Drugs that cause significant sustained elevation in gastric pH ( DRUGOTHER  such as  DRUG1  or  DRUGOTHER ) may reduce plasma concentrations of  DRUG2  and therefore potentially may reduce efficacy.	ranitidine	IRESSA	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
mechanism	Drugs that cause significant sustained elevation in gastric pH ( DRUGOTHER  such as  DRUGOTHER  or  DRUG1 ) may reduce plasma concentrations of  DRUG2  and therefore potentially may reduce efficacy.	cimetidine	IRESSA	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
other	"Phase II clinical trial data, where  DRUG1  and  DRUG2  have been used concomitantly, indicate that  DRUGOTHER  may exacerbate the neutropenic effect of  DRUGOTHER ."	IRESSA	vinorelbine	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
other	"Phase II clinical trial data, where  DRUG1  and  DRUGOTHER  have been used concomitantly, indicate that  DRUG2  may exacerbate the neutropenic effect of  DRUGOTHER ."	IRESSA	IRESSA	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
other	"Phase II clinical trial data, where  DRUG1  and  DRUGOTHER  have been used concomitantly, indicate that  DRUGOTHER  may exacerbate the neutropenic effect of  DRUG2 ."	IRESSA	vinorelbine	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
other	"Phase II clinical trial data, where  DRUGOTHER  and  DRUG1  have been used concomitantly, indicate that  DRUG2  may exacerbate the neutropenic effect of  DRUGOTHER ."	vinorelbine	IRESSA	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
other	"Phase II clinical trial data, where  DRUGOTHER  and  DRUG1  have been used concomitantly, indicate that  DRUGOTHER  may exacerbate the neutropenic effect of  DRUG2 ."	vinorelbine	vinorelbine	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
effect	"Phase II clinical trial data, where  DRUGOTHER  and  DRUGOTHER  have been used concomitantly, indicate that  DRUG1  may exacerbate the neutropenic effect of  DRUG2 ."	IRESSA	vinorelbine	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
mechanism	 DRUG1  is inhibited by  DRUG2 .	Colchicine	acidifying agents	COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
mechanism	The action of  DRUG1  is potentiated by  DRUG2 .	colchicine	alkalinizing agents	COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	 DRUG1  may increase sensitivity to the  DRUG2 .	Colchicine	CNS depressants	COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
effect	Response to  DRUG1  may be enhanced by  DRUG2 .	sympathomimetic agents	colchicine	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
effect	"The adverse effects of  DRUG1 , such as myelosuppression and diarrhea, would be expected to be exacerbated by other  DRUG2  having similar adverse effects."	CAMPTOSAR	antineoplastic agents	CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"Lymphocytopenia has been reported in patients receiving  DRUG1 , and it is possible that the administration of  DRUG2  as antiemetic prophylaxis may have enhanced the likelihood of this effect."	CAMPTOSAR	dexamethasone	CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
effect	"The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when  DRUG1  was administered on the same day as  DRUG2  than when these drugs were given on separate days (1.3%, 1/80 patients)."	prochlorperazine	CAMPTOSAR	CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1	CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O
effect	"It would be expected that  DRUG1  use during therapy with  DRUG2  would worsen the incidence or severity of diarrhea, but this has not been studied."	laxative	CAMPTOSAR	CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1	CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O
other	"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by  DRUG1 , the physician may wish to withhold  DRUG2  during dosing with  DRUGOTHER  and, certainly, during periods of active vomiting or diarrhea."	CAMPTOSAR	diuretics	CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by  DRUG1 , the physician may wish to withhold  DRUGOTHER  during dosing with  DRUG2  and, certainly, during periods of active vomiting or diarrhea."	CAMPTOSAR	CAMPTOSAR	CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O	CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O
effect	"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by  DRUGOTHER , the physician may wish to withhold  DRUG1  during dosing with  DRUG2  and, certainly, during periods of active vomiting or diarrhea."	diuretics	CAMPTOSAR	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O
other	" DRUG1  is the first  DRUG2  to be approved for clinical use, and has been studied extensively in humans since 1986."	Fluvastatin	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12	CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCS
other	"It is structurally distinct from the other currently available  DRUG1  ( DRUG2 ,  DRUGOTHER , and  DRUGOTHER ), leading to unique biopharmaceutical properties relative to the other agents of this class."	HMGCoA reductase inhibitors	lovastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"It is structurally distinct from the other currently available  DRUG1  ( DRUGOTHER ,  DRUG2 , and  DRUGOTHER ), leading to unique biopharmaceutical properties relative to the other agents of this class."	HMGCoA reductase inhibitors	simvastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
other	"It is structurally distinct from the other currently available  DRUG1  ( DRUGOTHER ,  DRUGOTHER , and  DRUG2 ), leading to unique biopharmaceutical properties relative to the other agents of this class."	HMGCoA reductase inhibitors	pravastatin		[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
other	"It is structurally distinct from the other currently available  DRUGOTHER  ( DRUG1 ,  DRUG2 , and  DRUGOTHER ), leading to unique biopharmaceutical properties relative to the other agents of this class."	lovastatin	simvastatin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
other	"It is structurally distinct from the other currently available  DRUGOTHER  ( DRUG1 ,  DRUGOTHER , and  DRUG2 ), leading to unique biopharmaceutical properties relative to the other agents of this class."	lovastatin	pravastatin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
other	"It is structurally distinct from the other currently available  DRUGOTHER  ( DRUGOTHER ,  DRUG1 , and  DRUG2 ), leading to unique biopharmaceutical properties relative to the other agents of this class."	simvastatin	pravastatin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC	[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
mechanism	" DRUG1 , an anionic-binding resin, has a considerable effect in lowering the rate and extent of  DRUG2  bioavailability."	Cholestyramine	fluvastatin	NCCC1=CC=C(O)C=C1	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
effect	"Although this effect was noted even when  DRUG1  was given 4 hours prior to  DRUG2 , this regimen did not result in diminished efficacy."	cholestyramine	fluvastatin	NCCC1=CC=C(O)C=C1	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
other	"Further, no effects on either  DRUG1  levels or prothrombin times were observed in a study involving concomitant administration of  DRUG2  and  DRUGOTHER ."	warfarin	warfarin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Further, no effects on either  DRUG1  levels or prothrombin times were observed in a study involving concomitant administration of  DRUGOTHER  and  DRUG2 ."	warfarin	fluvastatin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
other	"Further, no effects on either  DRUGOTHER  levels or prothrombin times were observed in a study involving concomitant administration of  DRUG1  and  DRUG2 ."	warfarin	fluvastatin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
other	"Moreover, additional interaction studies with  DRUG1  and  DRUG2  have not demonstrated any effect on  DRUGOTHER  plasma levels, and administration to a patient population chronically receiving  DRUGOTHER  resulted in no difference in the extent of bioavailability of  DRUGOTHER  relative to control data."	niacin	propranolol	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"Moreover, additional interaction studies with  DRUG1  and  DRUGOTHER  have not demonstrated any effect on  DRUG2  plasma levels, and administration to a patient population chronically receiving  DRUGOTHER  resulted in no difference in the extent of bioavailability of  DRUGOTHER  relative to control data."	niacin	fluvastatin	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
other	"Moreover, additional interaction studies with  DRUG1  and  DRUGOTHER  have not demonstrated any effect on  DRUGOTHER  plasma levels, and administration to a patient population chronically receiving  DRUG2  resulted in no difference in the extent of bioavailability of  DRUGOTHER  relative to control data."	niacin	digoxin	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Moreover, additional interaction studies with  DRUG1  and  DRUGOTHER  have not demonstrated any effect on  DRUGOTHER  plasma levels, and administration to a patient population chronically receiving  DRUGOTHER  resulted in no difference in the extent of bioavailability of  DRUG2  relative to control data."	niacin	digoxin	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Moreover, additional interaction studies with  DRUGOTHER  and  DRUG1  have not demonstrated any effect on  DRUG2  plasma levels, and administration to a patient population chronically receiving  DRUGOTHER  resulted in no difference in the extent of bioavailability of  DRUGOTHER  relative to control data."	propranolol	fluvastatin	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
other	"Moreover, additional interaction studies with  DRUGOTHER  and  DRUG1  have not demonstrated any effect on  DRUGOTHER  plasma levels, and administration to a patient population chronically receiving  DRUG2  resulted in no difference in the extent of bioavailability of  DRUGOTHER  relative to control data."	propranolol	digoxin	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Moreover, additional interaction studies with  DRUGOTHER  and  DRUG1  have not demonstrated any effect on  DRUGOTHER  plasma levels, and administration to a patient population chronically receiving  DRUGOTHER  resulted in no difference in the extent of bioavailability of  DRUG2  relative to control data."	propranolol	digoxin	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Moreover, additional interaction studies with  DRUGOTHER  and  DRUGOTHER  have not demonstrated any effect on  DRUG1  plasma levels, and administration to a patient population chronically receiving  DRUG2  resulted in no difference in the extent of bioavailability of  DRUGOTHER  relative to control data."	fluvastatin	digoxin	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Moreover, additional interaction studies with  DRUGOTHER  and  DRUGOTHER  have not demonstrated any effect on  DRUG1  plasma levels, and administration to a patient population chronically receiving  DRUGOTHER  resulted in no difference in the extent of bioavailability of  DRUG2  relative to control data."	fluvastatin	digoxin	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Moreover, additional interaction studies with  DRUGOTHER  and  DRUGOTHER  have not demonstrated any effect on  DRUGOTHER  plasma levels, and administration to a patient population chronically receiving  DRUG1  resulted in no difference in the extent of bioavailability of  DRUG2  relative to control data."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
advise	 DRUG1  should not be used with  DRUG2 .	Anafranil	MAO inhibitors	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	CN(CC#C)CC1=CC=CC=C1
advise	Close supervision and careful adjustment of dosage are required when  DRUG1  is administered with  DRUG2  or  DRUGOTHER .	Anafranil	anticholinergic	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	C[N+](C)(C)CCO
advise	Close supervision and careful adjustment of dosage are required when  DRUG1  is administered with  DRUGOTHER  or  DRUG2 .	Anafranil	sympathomimetic drugs	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	
other	Close supervision and careful adjustment of dosage are required when  DRUGOTHER  is administered with  DRUG1  or  DRUG2 .	anticholinergic	sympathomimetic drugs	C[N+](C)(C)CCO	
effect	"Several  DRUG1  have been reported to block the pharmacologic effects of  DRUG2 ,  DRUGOTHER , or similar agents, and such an effect may be anticipated with  DRUGOTHER  because of its structural similarity to other  DRUGOTHER ."	tricyclic antidepressants	guanethidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	NC(N)=NCCN1CCCCCCC1
effect	"Several  DRUG1  have been reported to block the pharmacologic effects of  DRUGOTHER ,  DRUG2 , or similar agents, and such an effect may be anticipated with  DRUGOTHER  because of its structural similarity to other  DRUGOTHER ."	tricyclic antidepressants	clonidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC=CC(Cl)=C1NC1=NCCN1
effect	"Several  DRUG1  have been reported to block the pharmacologic effects of  DRUGOTHER ,  DRUGOTHER , or similar agents, and such an effect may be anticipated with  DRUG2  because of its structural similarity to other  DRUGOTHER ."	tricyclic antidepressants	CMI	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
effect	"Several  DRUG1  have been reported to block the pharmacologic effects of  DRUGOTHER ,  DRUGOTHER , or similar agents, and such an effect may be anticipated with  DRUGOTHER  because of its structural similarity to other  DRUG2 ."	tricyclic antidepressants	tricyclic antidepressants	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Several  DRUGOTHER  have been reported to block the pharmacologic effects of  DRUG1 ,  DRUG2 , or similar agents, and such an effect may be anticipated with  DRUGOTHER  because of its structural similarity to other  DRUGOTHER ."	guanethidine	clonidine	NC(N)=NCCN1CCCCCCC1	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	"Several  DRUGOTHER  have been reported to block the pharmacologic effects of  DRUG1 ,  DRUGOTHER , or similar agents, and such an effect may be anticipated with  DRUG2  because of its structural similarity to other  DRUGOTHER ."	guanethidine	CMI	NC(N)=NCCN1CCCCCCC1	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
other	"Several  DRUGOTHER  have been reported to block the pharmacologic effects of  DRUG1 ,  DRUGOTHER , or similar agents, and such an effect may be anticipated with  DRUGOTHER  because of its structural similarity to other  DRUG2 ."	guanethidine	tricyclic antidepressants	NC(N)=NCCN1CCCCCCC1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Several  DRUGOTHER  have been reported to block the pharmacologic effects of  DRUGOTHER ,  DRUG1 , or similar agents, and such an effect may be anticipated with  DRUG2  because of its structural similarity to other  DRUGOTHER ."	clonidine	CMI	ClC1=CC=CC(Cl)=C1NC1=NCCN1	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
other	"Several  DRUGOTHER  have been reported to block the pharmacologic effects of  DRUGOTHER ,  DRUG1 , or similar agents, and such an effect may be anticipated with  DRUGOTHER  because of its structural similarity to other  DRUG2 ."	clonidine	tricyclic antidepressants	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Several  DRUGOTHER  have been reported to block the pharmacologic effects of  DRUGOTHER ,  DRUGOTHER , or similar agents, and such an effect may be anticipated with  DRUG1  because of its structural similarity to other  DRUG2 ."	CMI	tricyclic antidepressants	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
mechanism	The plasma concentration of  DRUG1  has been reported to be increased by the concomitant administration of  DRUG2 ;	CMI	haloperidol	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
mechanism	"plasma levels of several closely related  DRUG1  have been reported to be increased by the concomitant administration of  DRUG2  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	tricyclic antidepressants	methylphenidate	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	OC1=CC=CC=C1C(=O)OC1=CC=CC=C1
mechanism	"plasma levels of several closely related  DRUG1  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUG2 ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	tricyclic antidepressants	cimetidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
mechanism	"plasma levels of several closely related  DRUG1  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUG2 ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	tricyclic antidepressants	fluoxetine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
mechanism	"plasma levels of several closely related  DRUG1  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUG2 ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	tricyclic antidepressants	barbiturates	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
mechanism	"plasma levels of several closely related  DRUG1  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUG2 ), and such an effect may be anticipated with  DRUGOTHER  as well."	tricyclic antidepressants	phenytoin	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"plasma levels of several closely related  DRUG1  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUG2  as well."	tricyclic antidepressants	CMI	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUG1  or hepatic enzyme inhibitors (e.g.,  DRUG2 ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	methylphenidate	cimetidine	OC1=CC=CC=C1C(=O)OC1=CC=CC=C1	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUG1  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUG2 ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	methylphenidate	fluoxetine	OC1=CC=CC=C1C(=O)OC1=CC=CC=C1	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUG1  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUG2 ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	methylphenidate	barbiturates	OC1=CC=CC=C1C(=O)OC1=CC=CC=C1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUG1  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUG2 ), and such an effect may be anticipated with  DRUGOTHER  as well."	methylphenidate	phenytoin	OC1=CC=CC=C1C(=O)OC1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUG1  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUG2  as well."	methylphenidate	CMI	OC1=CC=CC=C1C(=O)OC1=CC=CC=C1	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUG1 ,  DRUG2 ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	cimetidine	fluoxetine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUG1 ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUG2 ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	cimetidine	barbiturates	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUG1 ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUG2 ), and such an effect may be anticipated with  DRUGOTHER  as well."	cimetidine	phenytoin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUG1 ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUG2  as well."	cimetidine	CMI	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUG1 ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUG2 ,  DRUGOTHER ), and such an effect may be anticipated with  DRUGOTHER  as well."	fluoxetine	barbiturates	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUG1 ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUG2 ), and such an effect may be anticipated with  DRUGOTHER  as well."	fluoxetine	phenytoin	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUG1 ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUGOTHER ), and such an effect may be anticipated with  DRUG2  as well."	fluoxetine	CMI	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
other	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUG1 ,  DRUG2 ), and such an effect may be anticipated with  DRUGOTHER  as well."	barbiturates	phenytoin	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUG1 ,  DRUGOTHER ), and such an effect may be anticipated with  DRUG2  as well."	barbiturates	CMI	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
mechanism	"plasma levels of several closely related  DRUGOTHER  have been reported to be increased by the concomitant administration of  DRUGOTHER  or hepatic enzyme inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  DRUGOTHER ,  DRUG1 ), and such an effect may be anticipated with  DRUG2  as well."	phenytoin	CMI	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
mechanism	"Administration of  DRUG1  has been reported to increase the plasma levels of  DRUG2 , if given concomitantly."	CMI	phenobarbital	[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	Poor metabolizers have higher than expected lasma concentrations of  DRUG1  ( DRUG2 ) when given usual doses.	tricyclic antidepressants	TCAs	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUG2 ,  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER  and  DRUGOTHER )."	cimetidine	antidepressants	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG2 , and the  DRUGOTHER   DRUGOTHER  and  DRUGOTHER )."	cimetidine	phenothiazines	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUG2   DRUGOTHER  and  DRUGOTHER )."	cimetidine	Type 1C antiarrhythmics	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUGOTHER   DRUG2  and  DRUGOTHER )."	cimetidine	propafenone	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER  and  DRUG2 )."	cimetidine	flecainide	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUG2 , and the  DRUGOTHER   DRUGOTHER  and  DRUGOTHER )."	antidepressants	phenothiazines	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUGOTHER , and the  DRUG2   DRUGOTHER  and  DRUGOTHER )."	antidepressants	Type 1C antiarrhythmics	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUGOTHER , and the  DRUGOTHER   DRUG2  and  DRUGOTHER )."	antidepressants	propafenone	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER  and  DRUG2 )."	antidepressants	flecainide	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG1 , and the  DRUG2   DRUGOTHER  and  DRUGOTHER )."	phenothiazines	Type 1C antiarrhythmics	N1C2=CC=CC=C2SC2=CC=CC=C12	
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG1 , and the  DRUGOTHER   DRUG2  and  DRUGOTHER )."	phenothiazines	propafenone	N1C2=CC=CC=C2SC2=CC=CC=C12	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG1 , and the  DRUGOTHER   DRUGOTHER  and  DRUG2 )."	phenothiazines	flecainide	N1C2=CC=CC=C2SC2=CC=CC=C12	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUG1   DRUG2  and  DRUGOTHER )."	Type 1C antiarrhythmics	propafenone		CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUG1   DRUGOTHER  and  DRUG2 )."	Type 1C antiarrhythmics	flecainide		FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUGOTHER   DRUG1  and  DRUG2 )."	propafenone	flecainide	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"While all the  DRUG1  ( DRUG2 ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	SSRIs	NCCC1=CNC2=CC=C(O)C=C12	
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	fluoxetine	NCCC1=CNC2=CC=C(O)C=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	sertraline	NCCC1=CNC2=CC=C(O)C=C12	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	paroxetine	NCCC1=CNC2=CC=C(O)C=C12	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	fluvoxamine	NCCC1=CNC2=CC=C(O)C=C12	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	fluoxetine		CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	sertraline		C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	paroxetine		FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	fluvoxamine		ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	fluoxetine	sertraline	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	fluoxetine	paroxetine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	fluoxetine	fluvoxamine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	sertraline	paroxetine	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	sertraline	fluvoxamine	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	paroxetine	fluvoxamine	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
mechanism	" DRUG1  has also been shown to inhibit P450 1A2, an isoform also involved in  DRUG2 metabolism."	Fluvoxamine	TCA	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
int	The extent to which  DRUG1 - DRUG2 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUGOTHER  involved.	SSRI	TCA		[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	The extent to which  DRUG1 - DRUGOTHER interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUG2  involved.	SSRI	SSRI		
other	The extent to which  DRUGOTHER - DRUG1 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUG2  involved.	TCA	SSRI	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	
advise	"Nevertheless, caution is indicated in the co-administration of  DRUG1  with any of the  DRUG2  and also in switching from one class to the other."	TCAs	SSRIs		
advise	"Of particular importance, sufficient time must elapse before initiating  DRUG1 treatment in a patient being withdrawn from  DRUG2 , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary)."	TCA	fluoxetine	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	Concomitant use of agents in the  DRUG1  (which includes  DRUG2 ) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the  DRUGOTHER  or the other drug.	tricyclic antidepressant class	Anafranil	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
other	Concomitant use of agents in the  DRUG1  (which includes  DRUGOTHER ) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the  DRUG2  or the other drug.	tricyclic antidepressant class	tricyclic antidepressant agent	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	Concomitant use of agents in the  DRUGOTHER  (which includes  DRUG1 ) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the  DRUG2  or the other drug.	Anafranil	tricyclic antidepressant agent	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	It is desirable to monitor  DRUG1 plasma levels whenever an agent of the  DRUG2  including  DRUGOTHER  is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).	TCA	tricyclic antidepressant class	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	It is desirable to monitor  DRUG1 plasma levels whenever an agent of the  DRUGOTHER  including  DRUG2  is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).	TCA	Anafranil	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
other	It is desirable to monitor  DRUGOTHER plasma levels whenever an agent of the  DRUG1  including  DRUG2  is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).	tricyclic antidepressant class	Anafranil	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
other	"Because  DRUG1  is highly bound to serum protein, the administration of  DRUG2  to patients taking other drugs that are highly bound to protein (e.g.,  DRUGOTHER ,  DRUGOTHER ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."	Anafranil	Anafranil	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
other	"Because  DRUG1  is highly bound to serum protein, the administration of  DRUGOTHER  to patients taking other drugs that are highly bound to protein (e.g.,  DRUG2 ,  DRUGOTHER ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."	Anafranil	warfarin	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Because  DRUG1  is highly bound to serum protein, the administration of  DRUGOTHER  to patients taking other drugs that are highly bound to protein (e.g.,  DRUGOTHER ,  DRUG2 ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."	Anafranil	digoxin	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	"Because  DRUGOTHER  is highly bound to serum protein, the administration of  DRUG1  to patients taking other drugs that are highly bound to protein (e.g.,  DRUG2 ,  DRUGOTHER ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."	Anafranil	warfarin	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
mechanism	"Because  DRUGOTHER  is highly bound to serum protein, the administration of  DRUG1  to patients taking other drugs that are highly bound to protein (e.g.,  DRUGOTHER ,  DRUG2 ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."	Anafranil	digoxin	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Because  DRUGOTHER  is highly bound to serum protein, the administration of  DRUGOTHER  to patients taking other drugs that are highly bound to protein (e.g.,  DRUG1 ,  DRUG2 ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."	warfarin	digoxin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  DRUG1  and either  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ."	iloprost	nifedipine	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  DRUG1  and either  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ."	iloprost	diltiazem	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	
other	"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  DRUG1  and either  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ."	iloprost	captopril	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  DRUGOTHER  and either  DRUG1 ,  DRUG2 , or  DRUGOTHER ."	nifedipine	diltiazem	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  DRUGOTHER  and either  DRUG1 ,  DRUGOTHER , or  DRUG2 ."	nifedipine	captopril	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  DRUGOTHER  and either  DRUGOTHER ,  DRUG1 , or  DRUG2 ."	diltiazem	captopril		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
effect	"However,  DRUG1  has the potential to increase the hypotensive effect of  DRUG2  and  DRUGOTHER ."	iloprost	vasodilators	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	
effect	"However,  DRUG1  has the potential to increase the hypotensive effect of  DRUGOTHER  and  DRUG2 ."	iloprost	antihypertensive agents	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"However,  DRUGOTHER  has the potential to increase the hypotensive effect of  DRUG1  and  DRUG2 ."	vasodilators	antihypertensive agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"Since  DRUG1  inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on  DRUG2 ."	iloprost	anticoagulants	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	
other	"During clinical trials,  DRUG1  was used concurrently with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	iloprost	anticoagulants	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	
other	"During clinical trials,  DRUG1  was used concurrently with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	iloprost	diuretics	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"During clinical trials,  DRUG1  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	iloprost	cardiac glycosides	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	
other	"During clinical trials,  DRUG1  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	iloprost	calcium channel blockers	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	[Ca]
other	"During clinical trials,  DRUG1  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	iloprost	analgesics	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"During clinical trials,  DRUG1  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other medications."	iloprost	antipyretics	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	
other	"During clinical trials,  DRUG1  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other medications."	iloprost	nonsteroidal antiinflammatories	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"During clinical trials,  DRUG1  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other medications."	iloprost	corticosteroids	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	anticoagulants	diuretics		COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	anticoagulants	cardiac glycosides		
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	anticoagulants	calcium channel blockers		[Ca]
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	anticoagulants	analgesics		OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other medications."	anticoagulants	antipyretics		
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other medications."	anticoagulants	nonsteroidal antiinflammatories		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other medications."	anticoagulants	corticosteroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	diuretics	cardiac glycosides	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	diuretics	calcium channel blockers	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[Ca]
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	diuretics	analgesics	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other medications."	diuretics	antipyretics	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other medications."	diuretics	nonsteroidal antiinflammatories	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other medications."	diuretics	corticosteroids	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	cardiac glycosides	calcium channel blockers		[Ca]
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	cardiac glycosides	analgesics		OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other medications."	cardiac glycosides	antipyretics		
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other medications."	cardiac glycosides	nonsteroidal antiinflammatories		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other medications."	cardiac glycosides	corticosteroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other medications."	calcium channel blockers	analgesics	[Ca]	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other medications."	calcium channel blockers	antipyretics	[Ca]	
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other medications."	calcium channel blockers	nonsteroidal antiinflammatories	[Ca]	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other medications."	calcium channel blockers	corticosteroids	[Ca]	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other medications."	analgesics	antipyretics	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other medications."	analgesics	nonsteroidal antiinflammatories	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other medications."	analgesics	corticosteroids	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and other medications."	antipyretics	nonsteroidal antiinflammatories		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and other medications."	antipyretics	corticosteroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"During clinical trials,  DRUGOTHER  was used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and other medications."	nonsteroidal antiinflammatories	corticosteroids	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	Intravenous infusion of  DRUG1  had no effect on the pharmacokinetics of  DRUG2 .	iloprost	digoxin	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUG1  did not alter the clearance (pharmacokinetics) of  DRUG2 .	Acetylsalicylic acid	iloprost	CC(=O)OC1=CC=CC=C1C(O)=O	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O
other	Influence of coadministration of  DRUG1  on  DRUG2  pharmacokinetics and QTc intervals in healthy volunteers.	fluoxetine	cisapride	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	STUDY OBJECTIVE: To evaluate the effect of  DRUG1  on the pharmacokinetics and cardiovascular safety of  DRUG2  at steady state in healthy men.	fluoxetine	cisapride	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	and phase 3 (days 45-52):  DRUG1  10 mg 4 times/day (days 45-51) plus  DRUG2  20 mg/day (days 45-52).	cisapride	fluoxetine	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
mechanism	Coadministration of  DRUG1  significantly decreased  DRUG2  plasma concentrations.	fluoxetine	cisapride	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	There were no clinically significant changes in corrected QT intervals during administration of  DRUG1  alone or with  DRUG2 .	cisapride	fluoxetine	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	 DRUG1  was well tolerated when administered alone or with  DRUG2 .	Cisapride	fluoxetine	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	CONCLUSION:  DRUG1  can be administered safely to patients receiving low therapeutic dosages of  DRUG2 .	Cisapride	fluoxetine	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"[Dose-time effects of competitive displacement of  DRUG1  by  DRUG2  following oral and intravenous administration] The effect of various doses of  DRUGOTHER  in several dose fractions on the extent and the time scale of displacement of  DRUGOTHER , in dependence on application mode, was studied."	radiopertechnetate	sodium perchlorate		[O-][Cl](=O)(=O)=O
other	"[Dose-time effects of competitive displacement of  DRUG1  by  DRUGOTHER  following oral and intravenous administration] The effect of various doses of  DRUG2  in several dose fractions on the extent and the time scale of displacement of  DRUGOTHER , in dependence on application mode, was studied."	radiopertechnetate	sodium perchlorate		[O-][Cl](=O)(=O)=O
other	"[Dose-time effects of competitive displacement of  DRUG1  by  DRUGOTHER  following oral and intravenous administration] The effect of various doses of  DRUGOTHER  in several dose fractions on the extent and the time scale of displacement of  DRUG2 , in dependence on application mode, was studied."	radiopertechnetate	radiopertechnetate		
other	"[Dose-time effects of competitive displacement of  DRUGOTHER  by  DRUG1  following oral and intravenous administration] The effect of various doses of  DRUG2  in several dose fractions on the extent and the time scale of displacement of  DRUGOTHER , in dependence on application mode, was studied."	sodium perchlorate	sodium perchlorate	[O-][Cl](=O)(=O)=O	[O-][Cl](=O)(=O)=O
other	"[Dose-time effects of competitive displacement of  DRUGOTHER  by  DRUG1  following oral and intravenous administration] The effect of various doses of  DRUGOTHER  in several dose fractions on the extent and the time scale of displacement of  DRUG2 , in dependence on application mode, was studied."	sodium perchlorate	radiopertechnetate	[O-][Cl](=O)(=O)=O	
other	"[Dose-time effects of competitive displacement of  DRUGOTHER  by  DRUGOTHER  following oral and intravenous administration] The effect of various doses of  DRUG1  in several dose fractions on the extent and the time scale of displacement of  DRUG2 , in dependence on application mode, was studied."	sodium perchlorate	radiopertechnetate	[O-][Cl](=O)(=O)=O	
other	An intravenous dose of 50 mg  DRUG1  was in respect of competitive suppression of organs actively concentrating  DRUG2  as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of  DRUGOTHER .	perchlorate	pertechnetate	[O-][Cl](=O)(=O)=O	O.O.O.O.[98Tc-]
other	An intravenous dose of 50 mg  DRUG1  was in respect of competitive suppression of organs actively concentrating  DRUGOTHER  as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of  DRUG2 .	perchlorate	radiopertechnetate	[O-][Cl](=O)(=O)=O	
other	An intravenous dose of 50 mg  DRUGOTHER  was in respect of competitive suppression of organs actively concentrating  DRUG1  as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of  DRUG2 .	pertechnetate	radiopertechnetate	O.O.O.O.[98Tc-]	
mechanism	"An intravenous injection of  DRUG1  given later also produces a complete and immediately beginning depletion of  DRUG2  already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels."	perchlorate	pertechnetate	[O-][Cl](=O)(=O)=O	O.O.O.O.[98Tc-]
other	Studies on the mechanism of action of  DRUG1 : effect of  DRUG2  on respiration and cell permeability of Candida albicans.	miconazole	miconazole	CC(C)N1CCN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2OC[C@@](CN3C=NC=N3)(O2)C2=CC=C(F)C=C2F)C=C1	CC(C)N1CCN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2OC[C@@](CN3C=NC=N3)(O2)C2=CC=C(F)C=C2F)C=C1
other	"The  DRUG1 ,  DRUG2 , inhibits the growth of several species of Candida."	antifungal drug	miconazole nitrate	OC(=O)CCCCCCCCC=C	[O-]N(=O)=O
mechanism	" DRUG1  may decrease the amount of  DRUG2  ( DRUGOTHER ,  DRUGOTHER ) that gets absorbed into your body."	Aminosalicylic acid	digoxin	NC1=CC(O)=C(C=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	" DRUG1  may decrease the amount of  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ) that gets absorbed into your body."	Aminosalicylic acid	Lanoxin	NC1=CC(O)=C(C=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  may decrease the amount of  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ) that gets absorbed into your body."	Aminosalicylic acid	Lanoxicaps	NC1=CC(O)=C(C=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may decrease the amount of  DRUG1  ( DRUG2 ,  DRUGOTHER ) that gets absorbed into your body."	digoxin	Lanoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may decrease the amount of  DRUG1  ( DRUGOTHER ,  DRUG2 ) that gets absorbed into your body."	digoxin	Lanoxicaps	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may decrease the amount of  DRUGOTHER  ( DRUG1 ,  DRUG2 ) that gets absorbed into your body."	Lanoxin	Lanoxicaps	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
advise	"In the case that you are taking  DRUG1  while taking  DRUG2 , higher doses of  DRUGOTHER  may be needed."	digoxin	aminosalicylic acid	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	NC1=CC(O)=C(C=C1)C(O)=O
other	"In the case that you are taking  DRUG1  while taking  DRUGOTHER , higher doses of  DRUG2  may be needed."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In the case that you are taking  DRUGOTHER  while taking  DRUG1 , higher doses of  DRUG2  may be needed."	aminosalicylic acid	digoxin	NC1=CC(O)=C(C=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	" DRUG1  may also decrease the absorption of  DRUG2 , which can lead to a deficiency."	Aminosalicylic acid	vitamin B12	NC1=CC(O)=C(C=C1)C(O)=O	CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
advise	Therefore you may need to take a  DRUG1  supplement while taking  DRUG2 .	vitamin B12	aminosalicylic acid	CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N	NC1=CC(O)=C(C=C1)C(O)=O
other	"In vitro data in human plasma indicate that  DRUG1  has no effect on protein binding of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	doxazosin mesylate	digoxin	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In vitro data in human plasma indicate that  DRUG1  has no effect on protein binding of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	doxazosin mesylate	warfarin	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In vitro data in human plasma indicate that  DRUG1  has no effect on protein binding of  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	doxazosin mesylate	phenytoin	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"In vitro data in human plasma indicate that  DRUG1  has no effect on protein binding of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	doxazosin mesylate	indomethacin	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"In vitro data in human plasma indicate that  DRUGOTHER  has no effect on protein binding of  DRUG1 ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	digoxin	warfarin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In vitro data in human plasma indicate that  DRUGOTHER  has no effect on protein binding of  DRUG1 ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	digoxin	phenytoin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"In vitro data in human plasma indicate that  DRUGOTHER  has no effect on protein binding of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	digoxin	indomethacin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"In vitro data in human plasma indicate that  DRUGOTHER  has no effect on protein binding of  DRUGOTHER ,  DRUG1 ,  DRUG2  or  DRUGOTHER ."	warfarin	phenytoin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"In vitro data in human plasma indicate that  DRUGOTHER  has no effect on protein binding of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUG2 ."	warfarin	indomethacin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"In vitro data in human plasma indicate that  DRUGOTHER  has no effect on protein binding of  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUG2 ."	phenytoin	indomethacin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUG1  has been administered without any evidence of an adverse drug interaction to patients receiving  DRUG2 ,  DRUGOTHER s, and  DRUGOTHER ."	Doxazosin mesylate	thiazide diuretics	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	
other	" DRUG1  has been administered without any evidence of an adverse drug interaction to patients receiving  DRUGOTHER ,  DRUG2 s, and  DRUGOTHER ."	Doxazosin mesylate	beta-blocking agent	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUG1  has been administered without any evidence of an adverse drug interaction to patients receiving  DRUGOTHER ,  DRUGOTHER s, and  DRUG2 ."	Doxazosin mesylate	nonsteroidal anti-inflammatory drugs	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  has been administered without any evidence of an adverse drug interaction to patients receiving  DRUG1 ,  DRUG2 s, and  DRUGOTHER ."	thiazide diuretics	beta-blocking agent		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUGOTHER  has been administered without any evidence of an adverse drug interaction to patients receiving  DRUG1 ,  DRUGOTHER s, and  DRUG2 ."	thiazide diuretics	nonsteroidal anti-inflammatory drugs		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  has been administered without any evidence of an adverse drug interaction to patients receiving  DRUGOTHER ,  DRUG1 s, and  DRUG2 ."	beta-blocking agent	nonsteroidal anti-inflammatory drugs	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of  DRUG1  on day 1 of a four-day regimen of oral  DRUG2  (400 mg twice daily) resulted in a 10% increase in mean AUC of  DRUGOTHER  (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of  DRUGOTHER ."	doxazosin	cimetidine	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of  DRUG1  on day 1 of a four-day regimen of oral  DRUGOTHER  (400 mg twice daily) resulted in a 10% increase in mean AUC of  DRUG2  (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of  DRUGOTHER ."	doxazosin	doxazosin	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
other	"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of  DRUG1  on day 1 of a four-day regimen of oral  DRUGOTHER  (400 mg twice daily) resulted in a 10% increase in mean AUC of  DRUGOTHER  (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of  DRUG2 ."	doxazosin	doxazosin	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
other	"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of  DRUGOTHER  on day 1 of a four-day regimen of oral  DRUG1  (400 mg twice daily) resulted in a 10% increase in mean AUC of  DRUG2  (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of  DRUGOTHER ."	cimetidine	doxazosin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
other	"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of  DRUGOTHER  on day 1 of a four-day regimen of oral  DRUG1  (400 mg twice daily) resulted in a 10% increase in mean AUC of  DRUGOTHER  (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of  DRUG2 ."	cimetidine	doxazosin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
other	"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of  DRUGOTHER  on day 1 of a four-day regimen of oral  DRUGOTHER  (400 mg twice daily) resulted in a 10% increase in mean AUC of  DRUG1  (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of  DRUG2 ."	doxazosin	doxazosin	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
other	" DRUG1 / DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	Analgesic	anti-inflammatory	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUG1 / DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	Analgesic	acetaminophen	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CCCCCCCC(O)=O
other	" DRUG1 / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	Analgesic	aspirin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(=O)OC1=CC=CC=C1C(O)=O
other	" DRUG1 / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	Analgesic	codeine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUG1 / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  combinations,  DRUGOTHER ,  DRUGOTHER )."	Analgesic	codeine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUG1 / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUG2 ,  DRUGOTHER )."	Analgesic	ibuprofen	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUG1 / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUG2 )."	Analgesic	indomethacin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER / DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	anti-inflammatory	acetaminophen	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER / DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	anti-inflammatory	aspirin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(=O)OC1=CC=CC=C1C(O)=O
other	" DRUGOTHER / DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	anti-inflammatory	codeine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	" DRUGOTHER / DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  combinations,  DRUGOTHER ,  DRUGOTHER )."	anti-inflammatory	codeine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	" DRUGOTHER / DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUG2 ,  DRUGOTHER )."	anti-inflammatory	ibuprofen	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUGOTHER / DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUG2 )."	anti-inflammatory	indomethacin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	acetaminophen	aspirin	OC(=O)CCCCCCCC(O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	acetaminophen	codeine	OC(=O)CCCCCCCC(O)=O	
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  combinations,  DRUGOTHER ,  DRUGOTHER )."	acetaminophen	codeine	OC(=O)CCCCCCCC(O)=O	
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUG2 ,  DRUGOTHER )."	acetaminophen	ibuprofen	OC(=O)CCCCCCCC(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUG2 )."	acetaminophen	indomethacin	OC(=O)CCCCCCCC(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUGOTHER )."	aspirin	codeine	CC(=O)OC1=CC=CC=C1C(O)=O	
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2  combinations,  DRUGOTHER ,  DRUGOTHER )."	aspirin	codeine	CC(=O)OC1=CC=CC=C1C(O)=O	
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUG2 ,  DRUGOTHER )."	aspirin	ibuprofen	CC(=O)OC1=CC=CC=C1C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUG2 )."	aspirin	indomethacin	CC(=O)OC1=CC=CC=C1C(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2  combinations,  DRUGOTHER ,  DRUGOTHER )."	codeine	codeine		
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER  combinations,  DRUG2 ,  DRUGOTHER )."	codeine	ibuprofen		CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER  combinations,  DRUGOTHER ,  DRUG2 )."	codeine	indomethacin		COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1  combinations,  DRUG2 ,  DRUGOTHER )."	codeine	ibuprofen		CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1  combinations,  DRUGOTHER ,  DRUG2 )."	codeine	indomethacin		COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER / DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  combinations,  DRUG1 ,  DRUG2 )."	ibuprofen	indomethacin	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER )."	Antibiotics	erythromycin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUG1  (e.g.,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER )."	Antibiotics	trimethoprim	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1
other	" DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER )."	Antibiotics	sulfamethoxazole	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 )."	Antibiotics	amoxicillin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
other	" DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER )."	erythromycin	trimethoprim	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1
other	" DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER )."	erythromycin	sulfamethoxazole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 )."	erythromycin	amoxicillin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1  and  DRUG2 ,  DRUGOTHER )."	trimethoprim	sulfamethoxazole	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUG2 )."	trimethoprim	amoxicillin	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
other	" DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUG2 )."	sulfamethoxazole	amoxicillin	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
other	" DRUG1  (e.g.,  DRUG2 )."	Antihistamines	chlorpheniramine	NCCC1=CNC=N1	CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
other	"Cardiovascular agents (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER )."	atenolol	hydrochlorothiazide	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Cardiovascular agents (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 )."	atenolol	propranolol	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"Cardiovascular agents (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 )."	hydrochlorothiazide	propranolol	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	" DRUG1  and  DRUG2  (e.g.,  DRUGOTHER )."	Sedatives	tranquilizers		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUG1  and  DRUGOTHER  (e.g.,  DRUG2 )."	Sedatives	diazepam		CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	" DRUGOTHER  and  DRUG1  (e.g.,  DRUG2 )."	tranquilizers	diazepam	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	The behavioral effects of the stereoisomers of  DRUG1  ( DRUG2 ) were compared with those of  DRUGOTHER  ( DRUGOTHER ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	N-allylnormetazocine	NANM	[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O	
other	The behavioral effects of the stereoisomers of  DRUG1  ( DRUGOTHER ) were compared with those of  DRUG2  ( DRUGOTHER ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	N-allylnormetazocine	phencyclidine	[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O	C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
other	The behavioral effects of the stereoisomers of  DRUG1  ( DRUGOTHER ) were compared with those of  DRUGOTHER  ( DRUG2 ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	N-allylnormetazocine	PCP	[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	The behavioral effects of the stereoisomers of  DRUGOTHER  ( DRUG1 ) were compared with those of  DRUG2  ( DRUGOTHER ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	NANM	phencyclidine		C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
other	The behavioral effects of the stereoisomers of  DRUGOTHER  ( DRUG1 ) were compared with those of  DRUGOTHER  ( DRUG2 ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	NANM	PCP		[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	The behavioral effects of the stereoisomers of  DRUGOTHER  ( DRUGOTHER ) were compared with those of  DRUG1  ( DRUG2 ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	phencyclidine	PCP	C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	Intermediate doses of  DRUG1  or  DRUG2  produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;	(+)-NANM	PCP		[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	"In monkeys,  DRUG1  was about 10 times more potent than  DRUG2  in decreasing responding, whereas in pigeons  DRUGOTHER  was about equipotent with  DRUGOTHER ."	(-)-NANM	(+)-NANM		
other	"In monkeys,  DRUG1  was about 10 times more potent than  DRUGOTHER  in decreasing responding, whereas in pigeons  DRUG2  was about equipotent with  DRUGOTHER ."	(-)-NANM	(-)-NANM		
other	"In monkeys,  DRUG1  was about 10 times more potent than  DRUGOTHER  in decreasing responding, whereas in pigeons  DRUGOTHER  was about equipotent with  DRUG2 ."	(-)-NANM	(+)-NANM		
other	"In monkeys,  DRUGOTHER  was about 10 times more potent than  DRUG1  in decreasing responding, whereas in pigeons  DRUG2  was about equipotent with  DRUGOTHER ."	(+)-NANM	(-)-NANM		
other	"In monkeys,  DRUGOTHER  was about 10 times more potent than  DRUG1  in decreasing responding, whereas in pigeons  DRUGOTHER  was about equipotent with  DRUG2 ."	(+)-NANM	(+)-NANM		
other	"In monkeys,  DRUGOTHER  was about 10 times more potent than  DRUGOTHER  in decreasing responding, whereas in pigeons  DRUG1  was about equipotent with  DRUG2 ."	(-)-NANM	(+)-NANM		
other	"In both species,  DRUG1 , but not  DRUG2 , antagonized the rate-decreasing effects of  DRUGOTHER  on FI and FR responding."	(-)-NANM	(+)-NANM		
effect	"In both species,  DRUG1 , but not  DRUGOTHER , antagonized the rate-decreasing effects of  DRUG2  on FI and FR responding."	(-)-NANM	morphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"In both species,  DRUGOTHER , but not  DRUG1 , antagonized the rate-decreasing effects of  DRUG2  on FI and FR responding."	(+)-NANM	morphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"In monkeys, the effects of  DRUG1 , but not  DRUG2  or  DRUGOTHER , were antagonized by  DRUGOTHER ;"	(-)-NANM	(+)-NANM		
other	"In monkeys, the effects of  DRUG1 , but not  DRUGOTHER  or  DRUG2 , were antagonized by  DRUGOTHER ;"	(-)-NANM	PCP		[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
effect	"In monkeys, the effects of  DRUG1 , but not  DRUGOTHER  or  DRUGOTHER , were antagonized by  DRUG2 ;"	(-)-NANM	naloxone		CC1=NC=C(N1CCO)[N+]([O-])=O
other	"In monkeys, the effects of  DRUGOTHER , but not  DRUG1  or  DRUG2 , were antagonized by  DRUGOTHER ;"	(+)-NANM	PCP		[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	"In monkeys, the effects of  DRUGOTHER , but not  DRUG1  or  DRUGOTHER , were antagonized by  DRUG2 ;"	(+)-NANM	naloxone		CC1=NC=C(N1CCO)[N+]([O-])=O
other	"In monkeys, the effects of  DRUGOTHER , but not  DRUGOTHER  or  DRUG1 , were antagonized by  DRUG2 ;"	PCP	naloxone	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O	CC1=NC=C(N1CCO)[N+]([O-])=O
effect	the doses of  DRUG1  required to antagonize the effects of  DRUG2  were more than 100 times higher than those required to antagonize the effects of  DRUGOTHER .	naloxone	(-)-NANM	CC1=NC=C(N1CCO)[N+]([O-])=O	
effect	the doses of  DRUG1  required to antagonize the effects of  DRUGOTHER  were more than 100 times higher than those required to antagonize the effects of  DRUG2 .	naloxone	morphine	CC1=NC=C(N1CCO)[N+]([O-])=O	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	the doses of  DRUGOTHER  required to antagonize the effects of  DRUG1  were more than 100 times higher than those required to antagonize the effects of  DRUG2 .	(-)-NANM	morphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"In pigeons,  DRUG1  did not systematically alter the effects of  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	naloxone	(-)-NANM	CC1=NC=C(N1CCO)[N+]([O-])=O	
other	"In pigeons,  DRUG1  did not systematically alter the effects of  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	naloxone	(+)-NANM	CC1=NC=C(N1CCO)[N+]([O-])=O	
other	"In pigeons,  DRUG1  did not systematically alter the effects of  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	naloxone	PCP	CC1=NC=C(N1CCO)[N+]([O-])=O	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	"In pigeons,  DRUGOTHER  did not systematically alter the effects of  DRUG1 ,  DRUG2  or  DRUGOTHER ."	(-)-NANM	(+)-NANM		
other	"In pigeons,  DRUGOTHER  did not systematically alter the effects of  DRUG1 ,  DRUGOTHER  or  DRUG2 ."	(-)-NANM	PCP		[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	"In pigeons,  DRUGOTHER  did not systematically alter the effects of  DRUGOTHER ,  DRUG1  or  DRUG2 ."	(+)-NANM	PCP		[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
effect	" DRUG1  reduced or eliminated the increases in FI responding produced by intermediate doses of either  DRUG2  or  DRUGOTHER  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  DRUGOTHER ."	Haloperidol	(+)-NANM	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	
effect	" DRUG1  reduced or eliminated the increases in FI responding produced by intermediate doses of either  DRUGOTHER  or  DRUG2  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  DRUGOTHER ."	Haloperidol	PCP	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	" DRUG1  reduced or eliminated the increases in FI responding produced by intermediate doses of either  DRUGOTHER  or  DRUGOTHER  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  DRUG2 ."	Haloperidol	NANM	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	
other	" DRUGOTHER  reduced or eliminated the increases in FI responding produced by intermediate doses of either  DRUG1  or  DRUG2  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  DRUGOTHER ."	(+)-NANM	PCP		[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	" DRUGOTHER  reduced or eliminated the increases in FI responding produced by intermediate doses of either  DRUG1  or  DRUGOTHER  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  DRUG2 ."	(+)-NANM	NANM		
other	" DRUGOTHER  reduced or eliminated the increases in FI responding produced by intermediate doses of either  DRUGOTHER  or  DRUG1  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  DRUG2 ."	PCP	NANM	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O	
advise	"Caution should be observed when  DRUG1  is coadministered with other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , as these agents may increase respiratory and circulatory depression."	anileridine	opioids	CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1	
advise	"Caution should be observed when  DRUG1  is coadministered with other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , as these agents may increase respiratory and circulatory depression."	anileridine	sedatives	CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1	
advise	"Caution should be observed when  DRUG1  is coadministered with other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , as these agents may increase respiratory and circulatory depression."	anileridine	phenothiazines	CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1	N1C2=CC=CC=C2SC2=CC=CC=C12
advise	"Caution should be observed when  DRUG1  is coadministered with other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , as these agents may increase respiratory and circulatory depression."	anileridine	anesthetics	CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1	CCOC(=O)C1=CC=C(N)C=C1
other	"Caution should be observed when  DRUGOTHER  is coadministered with other  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , as these agents may increase respiratory and circulatory depression."	opioids	sedatives		
other	"Caution should be observed when  DRUGOTHER  is coadministered with other  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , as these agents may increase respiratory and circulatory depression."	opioids	phenothiazines		N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Caution should be observed when  DRUGOTHER  is coadministered with other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , as these agents may increase respiratory and circulatory depression."	opioids	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	"Caution should be observed when  DRUGOTHER  is coadministered with other  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER , as these agents may increase respiratory and circulatory depression."	sedatives	phenothiazines		N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Caution should be observed when  DRUGOTHER  is coadministered with other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 , as these agents may increase respiratory and circulatory depression."	sedatives	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	"Caution should be observed when  DRUGOTHER  is coadministered with other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 , as these agents may increase respiratory and circulatory depression."	phenothiazines	anesthetics	N1C2=CC=CC=C2SC2=CC=CC=C12	CCOC(=O)C1=CC=C(N)C=C1
other	"Since  DRUG1  is primarily eliminated by the kidneys, coadministration of  DRUG2  with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either  DRUGOTHER  or the coadministered drug."	entecavir	BARACLUDE	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C
other	"Since  DRUG1  is primarily eliminated by the kidneys, coadministration of  DRUGOTHER  with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either  DRUG2  or the coadministered drug."	entecavir	entecavir	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C
other	"Since  DRUGOTHER  is primarily eliminated by the kidneys, coadministration of  DRUG1  with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either  DRUG2  or the coadministered drug."	BARACLUDE	entecavir	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C
other	"Coadministration of  DRUG1  with  DRUG2 ,  DRUGOTHER ,or  DRUGOTHER  did not result in significant drug interactions."	entecavir	lamivudine	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C	OC(=O)CCCCCCCC(O)=O
other	"Coadministration of  DRUG1  with  DRUGOTHER ,  DRUG2 ,or  DRUGOTHER  did not result in significant drug interactions."	entecavir	adefovir dipivoxil	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C	CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
other	"Coadministration of  DRUG1  with  DRUGOTHER ,  DRUGOTHER ,or  DRUG2  did not result in significant drug interactions."	entecavir	tenofovir disoproxil fumarate	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C	[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
other	"Coadministration of  DRUGOTHER  with  DRUG1 ,  DRUG2 ,or  DRUGOTHER  did not result in significant drug interactions."	lamivudine	adefovir dipivoxil	OC(=O)CCCCCCCC(O)=O	CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
other	"Coadministration of  DRUGOTHER  with  DRUG1 ,  DRUGOTHER ,or  DRUG2  did not result in significant drug interactions."	lamivudine	tenofovir disoproxil fumarate	OC(=O)CCCCCCCC(O)=O	[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
other	"Coadministration of  DRUGOTHER  with  DRUGOTHER ,  DRUG1 ,or  DRUG2  did not result in significant drug interactions."	adefovir dipivoxil	tenofovir disoproxil fumarate	CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C	[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
other	"The effects of coadministration of  DRUG1  with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when  DRUG2  is coadministered with such drugs."	BARACLUDE	BARACLUDE	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C	NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C
other	Behavioral responses to repeated  DRUG1  exposure in mice selectively bred for differential sensitivity to  DRUG2 .	cocaine	pentobarbital	CCOC(=O)C1=CC=C(N)C=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Mice from the 20th generation of three lines divergently selected for response to  DRUG1 -induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study  DRUG2 -induced behavioral sensitization."	pentobarbital	cocaine	CCC1(CC)C(=O)NC(=O)NC1=O	CCOC(=O)C1=CC=C(N)C=C1
effect	"When  DRUG1  HCl is administered concomitantly with an  DRUG2 , the risk of hyperkalemia may be increased."	amiloride	angiotensin-converting enzyme inhibitor	OC(=O)CCCCCCCC(O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
advise	 DRUG1  generally should not be given with  DRUG2  because they reduce its renal clearance and add a high risk of lithium toxicity.	Lithium	diuretics	[Li+]	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
effect	"In some patients, the administration of a  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ."	non-steroidal anti-inflammatory agent	loop diuretics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
effect	"In some patients, the administration of a  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUG2  and  DRUGOTHER ."	non-steroidal anti-inflammatory agent	potassium-sparing diuretics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[KH]
effect	"In some patients, the administration of a  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ."	non-steroidal anti-inflammatory agent	thiazide diuretics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	"In some patients, the administration of a  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG1 ,  DRUG2  and  DRUGOTHER ."	loop diuretics	potassium-sparing diuretics		[KH]
other	"In some patients, the administration of a  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG1 ,  DRUGOTHER  and  DRUG2 ."	loop diuretics	thiazide diuretics		
other	"In some patients, the administration of a  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUG1  and  DRUG2 ."	potassium-sparing diuretics	thiazide diuretics	[KH]	
advise	"Therefore, when  DRUG1  and  DRUG2  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUGOTHER  is obtained."	MIDAMOR	non-steroidal anti-inflammatory agents	NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Therefore, when  DRUG1  and  DRUGOTHER  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUG2  is obtained."	MIDAMOR	diuretic	NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Therefore, when  DRUGOTHER  and  DRUG1  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUG2  is obtained."	non-steroidal anti-inflammatory agents	diuretic	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
effect	"Since  DRUG1  and  DRUG2 , including  DRUGOTHER , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently."	indomethacin	potassium-sparing diuretics	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[KH]
effect	"Since  DRUG1  and  DRUGOTHER , including  DRUG2 , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently."	indomethacin	MIDAMOR	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1
other	"Since  DRUGOTHER  and  DRUG1 , including  DRUG2 , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently."	potassium-sparing diuretics	MIDAMOR	[KH]	NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1
mechanism	The coadministration of  DRUG1  decreases the biologic half-life of  DRUG2  because of an increase in metabolic clearance that results in a greater amount of  DRUGOTHER  in the urine.	aspirin	fenoprofen	CC(=O)OC1=CC=CC=C1C(O)=O	
other	The coadministration of  DRUG1  decreases the biologic half-life of  DRUGOTHER  because of an increase in metabolic clearance that results in a greater amount of  DRUG2  in the urine.	aspirin	hydroxylated fenoprofen	CC(=O)OC1=CC=CC=C1C(O)=O	CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1
other	The coadministration of  DRUGOTHER  decreases the biologic half-life of  DRUG1  because of an increase in metabolic clearance that results in a greater amount of  DRUG2  in the urine.	fenoprofen	hydroxylated fenoprofen		CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1
mechanism	"Although the mechanism of interaction between  DRUG1  and  DRUG2  is not totally known, enzyme induction and displacement of  DRUGOTHER  from plasma albumin binding sites are possibilities."	fenoprofen	aspirin		CC(=O)OC1=CC=CC=C1C(O)=O
other	"Although the mechanism of interaction between  DRUG1  and  DRUGOTHER  is not totally known, enzyme induction and displacement of  DRUG2  from plasma albumin binding sites are possibilities."	fenoprofen	fenoprofen		
other	"Although the mechanism of interaction between  DRUGOTHER  and  DRUG1  is not totally known, enzyme induction and displacement of  DRUG2  from plasma albumin binding sites are possibilities."	aspirin	fenoprofen	CC(=O)OC1=CC=CC=C1C(O)=O	
other	"Because  DRUG1  has not been shown to produce any additional effect beyond that obtained with  DRUG2  alone and because  DRUGOTHER  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUGOTHER  and  DRUGOTHER  is not recommended."	Nalfon	aspirin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(=O)OC1=CC=CC=C1C(O)=O
other	"Because  DRUG1  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUG2  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUGOTHER  and  DRUGOTHER  is not recommended."	Nalfon	aspirin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(=O)OC1=CC=CC=C1C(O)=O
other	"Because  DRUG1  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUGOTHER  increases the rate of excretion of  DRUG2 , the concomitant use of  DRUGOTHER  and  DRUGOTHER  is not recommended."	Nalfon	Nalfon	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Because  DRUG1  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUGOTHER  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUG2  and  DRUGOTHER  is not recommended."	Nalfon	Nalfon	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Because  DRUG1  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUGOTHER  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUGOTHER  and  DRUG2  is not recommended."	Nalfon	salicylates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUG1  alone and because  DRUG2  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUGOTHER  and  DRUGOTHER  is not recommended."	aspirin	aspirin	CC(=O)OC1=CC=CC=C1C(O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUG1  alone and because  DRUGOTHER  increases the rate of excretion of  DRUG2 , the concomitant use of  DRUGOTHER  and  DRUGOTHER  is not recommended."	aspirin	Nalfon	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUG1  alone and because  DRUGOTHER  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUG2  and  DRUGOTHER  is not recommended."	aspirin	Nalfon	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUG1  alone and because  DRUGOTHER  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUGOTHER  and  DRUG2  is not recommended."	aspirin	salicylates	CC(=O)OC1=CC=CC=C1C(O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
mechanism	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUG1  increases the rate of excretion of  DRUG2 , the concomitant use of  DRUGOTHER  and  DRUGOTHER  is not recommended."	aspirin	Nalfon	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUG1  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUG2  and  DRUGOTHER  is not recommended."	aspirin	Nalfon	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUG1  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUGOTHER  and  DRUG2  is not recommended."	aspirin	salicylates	CC(=O)OC1=CC=CC=C1C(O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUGOTHER  increases the rate of excretion of  DRUG1 , the concomitant use of  DRUG2  and  DRUGOTHER  is not recommended."	Nalfon	Nalfon	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUGOTHER  increases the rate of excretion of  DRUG1 , the concomitant use of  DRUGOTHER  and  DRUG2  is not recommended."	Nalfon	salicylates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
advise	"Because  DRUGOTHER  has not been shown to produce any additional effect beyond that obtained with  DRUGOTHER  alone and because  DRUGOTHER  increases the rate of excretion of  DRUGOTHER , the concomitant use of  DRUG1  and  DRUG2  is not recommended."	Nalfon	salicylates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
mechanism	"Chronic administration of  DRUG1 , a known enzyme inducer, may be associated with a decrease in the plasma half-life of  DRUG2 ."	phenobarbital	fenoprofen	CCC1(CC)C(=O)NC(=O)NC1=O	
advise	"When  DRUG1  is added to or withdrawn from treatment, dosage adjustment of  DRUG2  may be required."	phenobarbital	Nalfon	CCC1(CC)C(=O)NC(=O)NC1=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Patients receiving  DRUG1 ,  DRUG2 , or  DRUGOTHER  should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs."	hydantoins	sulfonamides	CC(N)COC1=C(C)C=CC=C1C	OC(=O)CCCCCCCC(O)=O
other	"Patients receiving  DRUG1 ,  DRUGOTHER , or  DRUG2  should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs."	hydantoins	sulfonylureas	CC(N)COC1=C(C)C=CC=C1C	NC(N)=O
other	"Patients receiving  DRUGOTHER ,  DRUG1 , or  DRUG2  should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs."	sulfonamides	sulfonylureas	OC(=O)CCCCCCCC(O)=O	NC(N)=O
effect	"In patients receiving  DRUG1 , the addition of  DRUG2  to therapy could prolong the prothrombin time."	coumarin-type anticoagulants	Nalfon	O=C1OC2=CC=CC=C2C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	Patients treated with  DRUG1  may be resistant to the effects of  DRUG2 .	Nalfon	loop diuretics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
advise	"In patients receiving  DRUG1  and a  DRUG2  concomitantly, any reduction in  DRUGOTHER  dosage should be gradual in order to avoid the possible complications of sudden  DRUGOTHER  withdrawal."	Nalfon	steroid	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"In patients receiving  DRUG1  and a  DRUGOTHER  concomitantly, any reduction in  DRUG2  dosage should be gradual in order to avoid the possible complications of sudden  DRUGOTHER  withdrawal."	Nalfon	steroid	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"In patients receiving  DRUG1  and a  DRUGOTHER  concomitantly, any reduction in  DRUGOTHER  dosage should be gradual in order to avoid the possible complications of sudden  DRUG2  withdrawal."	Nalfon	steroid	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"In patients receiving  DRUGOTHER  and a  DRUG1  concomitantly, any reduction in  DRUG2  dosage should be gradual in order to avoid the possible complications of sudden  DRUGOTHER  withdrawal."	steroid	steroid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"In patients receiving  DRUGOTHER  and a  DRUG1  concomitantly, any reduction in  DRUGOTHER  dosage should be gradual in order to avoid the possible complications of sudden  DRUG2  withdrawal."	steroid	steroid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"In patients receiving  DRUGOTHER  and a  DRUGOTHER  concomitantly, any reduction in  DRUG1  dosage should be gradual in order to avoid the possible complications of sudden  DRUG2  withdrawal."	steroid	steroid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
effect	The vasodilating effects of  DRUG1  may be additive with those of other  DRUG2 .	isosorbide mononitrate	vasodilators	[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H]	
effect	Marked symptomatic orthostatic hypotension has been reported when  DRUG1  and  DRUG2  were used in combination.	calcium channel blockers	organic nitrates	[Ca]	[O-]N(=O)=O
other	 DRUG1 : Elevated  DRUG2  levels have been reported in postmarketing experience when  DRUGOTHER  is administered concomitantly.	Carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUG1 : Elevated  DRUGOTHER  levels have been reported in postmarketing experience when  DRUG2  is administered concomitantly.	Carbamazepine	SUPRAX	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1
mechanism	 DRUGOTHER : Elevated  DRUG1  levels have been reported in postmarketing experience when  DRUG2  is administered concomitantly.	carbamazepine	SUPRAX	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1
other	" DRUG1  and  DRUG2 : Increased prothrombin time, with or without clinical bleeding, has been reported when  DRUGOTHER  is administered concomitantly."	Warfarin	Anticoagulants	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
effect	" DRUG1  and  DRUGOTHER : Increased prothrombin time, with or without clinical bleeding, has been reported when  DRUG2  is administered concomitantly."	Warfarin	cefixime	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O
effect	" DRUGOTHER  and  DRUG1 : Increased prothrombin time, with or without clinical bleeding, has been reported when  DRUG2  is administered concomitantly."	Anticoagulants	cefixime		[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O
other	Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using  DRUG1  but not with those using  DRUG2 .	nitroprusside	nitroferricyanide	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N
mechanism	 DRUG1  has been found to temporarily raise serum concentrations of  DRUG2 .	Trecator	isoniazid	CCC1=NC=CC(=C1)C(N)=S	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
effect	 DRUG1  may potentiate the adverse effects of other  DRUG2  administered concomitantly.	Trecator	antituberculous drugs	CCC1=NC=CC(=C1)C(N)=S	
effect	"In particular, convulsions have been reported when  DRUG1  is administered with  DRUG2  and special care should be taken when the treatment regimen includes both of these drugs."	ethionamide	cycloserine	CCC1=NC=CC(=C1)C(N)=S	N[C@@H]1CONC1=O
int	Possible drug interactions of  DRUG1  with  DRUG2  or with other  DRUGOTHER .	HUMORSOL	succinylcholine	CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C	C[N+](C)(C)CCO
other	Possible drug interactions of  DRUGOTHER  with  DRUG1  or with other  DRUG2 .	succinylcholine	anticholinesterase agents	C[N+](C)(C)CCO	C[N+](C)(C)CCO
effect	Taking a  DRUG1  while you are taking or within 2 weeks of taking  DRUG2  may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.	rauwolfia alkaloid	MAO inhibitors	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(CC#C)CC1=CC=CC=C1
effect	In vitro mixing of an  DRUG1  with beta-lactamtype  DRUG2  ( DRUGOTHER  or  DRUGOTHER ) may result in a significant mutual inactivation.	aminoglycoside	antibiotics	OC(=O)CCCCCCCC(O)=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
effect	In vitro mixing of an  DRUG1  with beta-lactamtype  DRUGOTHER  ( DRUG2  or  DRUGOTHER ) may result in a significant mutual inactivation.	aminoglycoside	penicillins	OC(=O)CCCCCCCC(O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
effect	In vitro mixing of an  DRUG1  with beta-lactamtype  DRUGOTHER  ( DRUGOTHER  or  DRUG2 ) may result in a significant mutual inactivation.	aminoglycoside	cephalosporins	OC(=O)CCCCCCCC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	In vitro mixing of an  DRUGOTHER  with beta-lactamtype  DRUG1  ( DRUG2  or  DRUGOTHER ) may result in a significant mutual inactivation.	antibiotics	penicillins	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	In vitro mixing of an  DRUGOTHER  with beta-lactamtype  DRUG1  ( DRUGOTHER  or  DRUG2 ) may result in a significant mutual inactivation.	antibiotics	cephalosporins	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	In vitro mixing of an  DRUGOTHER  with beta-lactamtype  DRUGOTHER  ( DRUG1  or  DRUG2 ) may result in a significant mutual inactivation.	penicillins	cephalosporins	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	"Even when an  DRUG1  and a  DRUG2 -type drug are administered separately by different routes, a reduction in  DRUGOTHER  serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function."	aminoglycoside	penicillin	OC(=O)CCCCCCCC(O)=O	[H][C@](N)(CCCC(O)=N[C@]1([H])C(=O)N2[C@]1([H])SC(C)(C)[C@]2([H])C(O)=O)C(O)=O
other	"Even when an  DRUG1  and a  DRUGOTHER -type drug are administered separately by different routes, a reduction in  DRUG2  serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function."	aminoglycoside	aminoglycoside	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Even when an  DRUGOTHER  and a  DRUG1 -type drug are administered separately by different routes, a reduction in  DRUG2  serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function."	penicillin	aminoglycoside	[H][C@](N)(CCCC(O)=N[C@]1([H])C(=O)N2[C@]1([H])SC(C)(C)[C@]2([H])C(O)=O)C(O)=O	OC(=O)CCCCCCCC(O)=O
effect	" DRUG1  may decrease the effectiveness of oral  DRUG2 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	Barbiturates	contraceptives	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
effect	" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	Barbiturates	antibiotics	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
effect	" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	Barbiturates	quinidine	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
effect	" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	Barbiturates	theophylline	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
effect	" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	Barbiturates	corticosteroids	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
effect	" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	Barbiturates	anticoagulants	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	
effect	" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	Barbiturates	beta blockers	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	antibiotics	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	quinidine	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	theophylline	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	corticosteroids	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	contraceptives	anticoagulants	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	contraceptives	beta blockers	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	antibiotics	quinidine	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	antibiotics	theophylline	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	antibiotics	corticosteroids	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	antibiotics	anticoagulants	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	antibiotics	beta blockers	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	quinidine	theophylline	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	quinidine	corticosteroids	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	quinidine	anticoagulants	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	quinidine	beta blockers	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	theophylline	corticosteroids	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	theophylline	anticoagulants	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	theophylline	beta blockers	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	corticosteroids	anticoagulants	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	corticosteroids	beta blockers	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
other	" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	anticoagulants	beta blockers		
other	 DRUG1  ( DRUG2 ) blood levels may be increased and prolonged by concurrent administration of  DRUGOTHER .	Geocillin	carbenicillin indanyl sodium	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC1=CC2=C(CCC2)C=C1)C1=CC=CC=C1)C(O)=O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O
mechanism	 DRUG1  ( DRUGOTHER ) blood levels may be increased and prolonged by concurrent administration of  DRUG2 .	Geocillin	probenecid	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC1=CC2=C(CCC2)C=C1)C1=CC=CC=C1)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
mechanism	 DRUGOTHER  ( DRUG1 ) blood levels may be increased and prolonged by concurrent administration of  DRUG2 .	carbenicillin indanyl sodium	probenecid	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
advise	"The daily dose of  DRUG1  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and nefazadone) ."	ENABLEX	ketoconazole	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
advise	"The daily dose of  DRUG1  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and nefazadone) ."	ENABLEX	itraconazole	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
advise	"The daily dose of  DRUG1  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and nefazadone) ."	ENABLEX	ritonavir	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
advise	"The daily dose of  DRUG1  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and nefazadone) ."	ENABLEX	nelfinavir	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
advise	"The daily dose of  DRUG1  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and nefazadone) ."	ENABLEX	clarithromycin	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and nefazadone) ."	ketoconazole	itraconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and nefazadone) ."	ketoconazole	ritonavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and nefazadone) ."	ketoconazole	nelfinavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and nefazadone) ."	ketoconazole	clarithromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and nefazadone) ."	itraconazole	ritonavir	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and nefazadone) ."	itraconazole	nelfinavir	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and nefazadone) ."	itraconazole	clarithromycin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and nefazadone) ."	ritonavir	nelfinavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and nefazadone) ."	ritonavir	clarithromycin	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"The daily dose of  DRUGOTHER  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and nefazadone) ."	nelfinavir	clarithromycin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
advise	"Caution should be taken when  DRUG1  is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  (see CLINICAL PHARMACOLOGY)."	ENABLEX	flecainide	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
advise	"Caution should be taken when  DRUG1  is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as  DRUGOTHER ,  DRUG2  and  DRUGOTHER  (see CLINICAL PHARMACOLOGY)."	ENABLEX	thioridazine	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
advise	"Caution should be taken when  DRUG1  is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as  DRUGOTHER ,  DRUGOTHER  and  DRUG2  (see CLINICAL PHARMACOLOGY)."	ENABLEX	tricyclic antidepressants	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Caution should be taken when  DRUGOTHER  is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as  DRUG1 ,  DRUG2  and  DRUGOTHER  (see CLINICAL PHARMACOLOGY)."	flecainide	thioridazine	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Caution should be taken when  DRUGOTHER  is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as  DRUG1 ,  DRUGOTHER  and  DRUG2  (see CLINICAL PHARMACOLOGY)."	flecainide	tricyclic antidepressants	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Caution should be taken when  DRUGOTHER  is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as  DRUGOTHER ,  DRUG1  and  DRUG2  (see CLINICAL PHARMACOLOGY)."	thioridazine	tricyclic antidepressants	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
effect	"The concomitant use of  DRUG1  with other  DRUG2  may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects."	ENABLEX	anticholinergic agents	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	C[N+](C)(C)CCO
advise	Patients on oral  DRUG1  receiving  DRUG2  treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their  DRUGOTHER .	antidiabetic agents	VELCADE	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
other	Patients on oral  DRUG1  receiving  DRUGOTHER  treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their  DRUG2 .	antidiabetic agents	antidiabetic medication	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	Patients on oral  DRUGOTHER  receiving  DRUG1  treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their  DRUG2 .	VELCADE	antidiabetic medication	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O	
other	Concomitant use with  DRUG1 s may result in the reduced absorption of  DRUG2 .	iron supplement	iron		
other	"By contrast,  DRUG1  (1 mM) and  DRUG2  (1 mM) had no significant effect on the translocation when added alone."	spermidine	putrescine	NCCCCNCCCN	NCCCCN
other	" DRUG1 , and to a lesser extent,  DRUG2 , enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction."	Spermine	spermidine	NCCCNCCCCNCCCN	NCCCCNCCCN
other	Molecular basis for the selective toxicity of  DRUG1  for yeast and  DRUG2  for animal cells.	amphotericin B	filipin	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Among the  DRUG1 , many, like  DRUG2 , cannot be used clinically because they are toxic;"	polyene antibiotics	filipin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	Both the toxicity of  DRUG1  and the therapeutic value of  DRUG2  can be rationalized at the cellular and molecular level by the following observations: (i) these  DRUGOTHER  showed differential effects on cells;	filipin	amphotericin B	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	Both the toxicity of  DRUG1  and the therapeutic value of  DRUGOTHER  can be rationalized at the cellular and molecular level by the following observations: (i) these  DRUG2  showed differential effects on cells;	filipin	polyene antibiotics	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	Both the toxicity of  DRUGOTHER  and the therapeutic value of  DRUG1  can be rationalized at the cellular and molecular level by the following observations: (i) these  DRUG2  showed differential effects on cells;	amphotericin B	polyene antibiotics	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	" DRUG1  was more potent in lysing human red blood cells, whereas  DRUG2  was more potent in inhibiting yeast cell growth;"	filipin	amphotericin B	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"and (ii) the effects of  DRUG1  were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of  DRUG2  were more efficiently inhibited by ergosterol, the major membrane sterol in yeast."	filipin	amphotericin B	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	" DRUG1 : Concomitant administration of  DRUG2  and  DRUGOTHER  is not recommended because  DRUGOTHER  is displaced from its binding sites during the concomitant administration of  DRUGOTHER , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	Aspirin	diclofenac	CC(=O)OC1=CC=CC=C1C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUG1 : Concomitant administration of  DRUGOTHER  and  DRUG2  is not recommended because  DRUGOTHER  is displaced from its binding sites during the concomitant administration of  DRUGOTHER , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	Aspirin	aspirin	CC(=O)OC1=CC=CC=C1C(O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	" DRUG1 : Concomitant administration of  DRUGOTHER  and  DRUGOTHER  is not recommended because  DRUG2  is displaced from its binding sites during the concomitant administration of  DRUGOTHER , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	Aspirin	diclofenac	CC(=O)OC1=CC=CC=C1C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUG1 : Concomitant administration of  DRUGOTHER  and  DRUGOTHER  is not recommended because  DRUGOTHER  is displaced from its binding sites during the concomitant administration of  DRUG2 , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	Aspirin	aspirin	CC(=O)OC1=CC=CC=C1C(O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
advise	" DRUGOTHER : Concomitant administration of  DRUG1  and  DRUG2  is not recommended because  DRUGOTHER  is displaced from its binding sites during the concomitant administration of  DRUGOTHER , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	diclofenac	aspirin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(=O)OC1=CC=CC=C1C(O)=O
other	" DRUGOTHER : Concomitant administration of  DRUG1  and  DRUGOTHER  is not recommended because  DRUG2  is displaced from its binding sites during the concomitant administration of  DRUGOTHER , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	diclofenac	diclofenac	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER : Concomitant administration of  DRUG1  and  DRUGOTHER  is not recommended because  DRUGOTHER  is displaced from its binding sites during the concomitant administration of  DRUG2 , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	diclofenac	aspirin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(=O)OC1=CC=CC=C1C(O)=O
other	" DRUGOTHER : Concomitant administration of  DRUGOTHER  and  DRUG1  is not recommended because  DRUG2  is displaced from its binding sites during the concomitant administration of  DRUGOTHER , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	aspirin	diclofenac	CC(=O)OC1=CC=CC=C1C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER : Concomitant administration of  DRUGOTHER  and  DRUG1  is not recommended because  DRUGOTHER  is displaced from its binding sites during the concomitant administration of  DRUG2 , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	aspirin	aspirin	CC(=O)OC1=CC=CC=C1C(O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
mechanism	" DRUGOTHER : Concomitant administration of  DRUGOTHER  and  DRUGOTHER  is not recommended because  DRUG1  is displaced from its binding sites during the concomitant administration of  DRUG2 , resulting in lower plasma concentrations, peak plasma levels, and AUC values."	diclofenac	aspirin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(=O)OC1=CC=CC=C1C(O)=O
other	" DRUG1 : While studies have not shown  DRUG2  to interact with  DRUGOTHER , caution should be exercised, nonetheless, since interactions have been seen with other  DRUGOTHER ."	Anticoagulants	diclofenac		OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUG1 : While studies have not shown  DRUGOTHER  to interact with  DRUG2 , caution should be exercised, nonetheless, since interactions have been seen with other  DRUGOTHER ."	Anticoagulants	anticoagulants of the warfarin type		CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
other	" DRUG1 : While studies have not shown  DRUGOTHER  to interact with  DRUGOTHER , caution should be exercised, nonetheless, since interactions have been seen with other  DRUG2 ."	Anticoagulants	NSAIDs		
other	" DRUGOTHER : While studies have not shown  DRUG1  to interact with  DRUG2 , caution should be exercised, nonetheless, since interactions have been seen with other  DRUGOTHER ."	diclofenac	anticoagulants of the warfarin type	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
advise	" DRUGOTHER : While studies have not shown  DRUG1  to interact with  DRUGOTHER , caution should be exercised, nonetheless, since interactions have been seen with other  DRUG2 ."	diclofenac	NSAIDs	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	
other	" DRUGOTHER : While studies have not shown  DRUGOTHER  to interact with  DRUG1 , caution should be exercised, nonetheless, since interactions have been seen with other  DRUG2 ."	anticoagulants of the warfarin type	NSAIDs	CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2	
other	"Because prostaglandins play an important role in hemostasis, and  DRUG1  affect platelet function as well, concurrent therapy with all  DRUG2 , including  DRUGOTHER , and  DRUGOTHER  requires close monitoring of patients to be certain that no change in their  DRUGOTHER  dosage is required."	NSAIDs	NSAIDs		
other	"Because prostaglandins play an important role in hemostasis, and  DRUG1  affect platelet function as well, concurrent therapy with all  DRUGOTHER , including  DRUG2 , and  DRUGOTHER  requires close monitoring of patients to be certain that no change in their  DRUGOTHER  dosage is required."	NSAIDs	diclofenac		OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Because prostaglandins play an important role in hemostasis, and  DRUG1  affect platelet function as well, concurrent therapy with all  DRUGOTHER , including  DRUGOTHER , and  DRUG2  requires close monitoring of patients to be certain that no change in their  DRUGOTHER  dosage is required."	NSAIDs	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Because prostaglandins play an important role in hemostasis, and  DRUG1  affect platelet function as well, concurrent therapy with all  DRUGOTHER , including  DRUGOTHER , and  DRUGOTHER  requires close monitoring of patients to be certain that no change in their  DRUG2  dosage is required."	NSAIDs	anticoagulant		[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	"Because prostaglandins play an important role in hemostasis, and  DRUGOTHER  affect platelet function as well, concurrent therapy with all  DRUG1 , including  DRUG2 , and  DRUGOTHER  requires close monitoring of patients to be certain that no change in their  DRUGOTHER  dosage is required."	NSAIDs	diclofenac		OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
advise	"Because prostaglandins play an important role in hemostasis, and  DRUGOTHER  affect platelet function as well, concurrent therapy with all  DRUG1 , including  DRUGOTHER , and  DRUG2  requires close monitoring of patients to be certain that no change in their  DRUGOTHER  dosage is required."	NSAIDs	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Because prostaglandins play an important role in hemostasis, and  DRUGOTHER  affect platelet function as well, concurrent therapy with all  DRUG1 , including  DRUGOTHER , and  DRUGOTHER  requires close monitoring of patients to be certain that no change in their  DRUG2  dosage is required."	NSAIDs	anticoagulant		[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
advise	"Because prostaglandins play an important role in hemostasis, and  DRUGOTHER  affect platelet function as well, concurrent therapy with all  DRUGOTHER , including  DRUG1 , and  DRUG2  requires close monitoring of patients to be certain that no change in their  DRUGOTHER  dosage is required."	diclofenac	warfarin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Because prostaglandins play an important role in hemostasis, and  DRUGOTHER  affect platelet function as well, concurrent therapy with all  DRUGOTHER , including  DRUG1 , and  DRUGOTHER  requires close monitoring of patients to be certain that no change in their  DRUG2  dosage is required."	diclofenac	anticoagulant	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	"Because prostaglandins play an important role in hemostasis, and  DRUGOTHER  affect platelet function as well, concurrent therapy with all  DRUGOTHER , including  DRUGOTHER , and  DRUG1  requires close monitoring of patients to be certain that no change in their  DRUG2  dosage is required."	warfarin	anticoagulant	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	" DRUG1 ,  DRUG2 ,  DRUGOTHER :  DRUGOTHER , like other  DRUGOTHER , may affect renal prostaglandins and increase the toxicity of certain drugs."	Digoxin	Methotrexate	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUG1 ,  DRUGOTHER ,  DRUG2 :  DRUGOTHER , like other  DRUGOTHER , may affect renal prostaglandins and increase the toxicity of certain drugs."	Digoxin	Cyclosporine	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER :  DRUG2 , like other  DRUGOTHER , may affect renal prostaglandins and increase the toxicity of certain drugs."	Digoxin	Diclofenac	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER :  DRUGOTHER , like other  DRUG2 , may affect renal prostaglandins and increase the toxicity of certain drugs."	Digoxin	NSAIDs	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	
other	" DRUGOTHER ,  DRUG1 ,  DRUG2 :  DRUGOTHER , like other  DRUGOTHER , may affect renal prostaglandins and increase the toxicity of certain drugs."	Methotrexate	Cyclosporine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER :  DRUG2 , like other  DRUGOTHER , may affect renal prostaglandins and increase the toxicity of certain drugs."	Methotrexate	Diclofenac	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER :  DRUGOTHER , like other  DRUG2 , may affect renal prostaglandins and increase the toxicity of certain drugs."	Methotrexate	NSAIDs	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 :  DRUG2 , like other  DRUGOTHER , may affect renal prostaglandins and increase the toxicity of certain drugs."	Cyclosporine	Diclofenac	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 :  DRUGOTHER , like other  DRUG2 , may affect renal prostaglandins and increase the toxicity of certain drugs."	Cyclosporine	NSAIDs	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER :  DRUG1 , like other  DRUG2 , may affect renal prostaglandins and increase the toxicity of certain drugs."	Diclofenac	NSAIDs	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	
mechanism	Ingestion of  DRUG1  may increase serum concentrations of  DRUG2  and  DRUGOTHER  and increase  DRUGOTHER  s nephrotoxicity.	diclofenac	digoxin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	Ingestion of  DRUG1  may increase serum concentrations of  DRUGOTHER  and  DRUG2  and increase  DRUGOTHER  s nephrotoxicity.	diclofenac	methotrexate	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
effect	Ingestion of  DRUG1  may increase serum concentrations of  DRUGOTHER  and  DRUGOTHER  and increase  DRUG2  s nephrotoxicity.	diclofenac	cyclosporine	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	Ingestion of  DRUGOTHER  may increase serum concentrations of  DRUG1  and  DRUG2  and increase  DRUGOTHER  s nephrotoxicity.	digoxin	methotrexate	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	Ingestion of  DRUGOTHER  may increase serum concentrations of  DRUG1  and  DRUGOTHER  and increase  DRUG2  s nephrotoxicity.	digoxin	cyclosporine	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	Ingestion of  DRUGOTHER  may increase serum concentrations of  DRUGOTHER  and  DRUG1  and increase  DRUG2  s nephrotoxicity.	methotrexate	cyclosporine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Patients who begin taking  DRUG1  or who increase their  DRUG2  dose or any other  DRUGOTHER  while taking  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	diclofenac	diclofenac	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Patients who begin taking  DRUG1  or who increase their  DRUGOTHER  dose or any other  DRUG2  while taking  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	diclofenac	NSAID	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
effect	"Patients who begin taking  DRUG1  or who increase their  DRUGOTHER  dose or any other  DRUGOTHER  while taking  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	diclofenac	digoxin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
effect	"Patients who begin taking  DRUG1  or who increase their  DRUGOTHER  dose or any other  DRUGOTHER  while taking  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	diclofenac	methotrexate	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
effect	"Patients who begin taking  DRUG1  or who increase their  DRUGOTHER  dose or any other  DRUGOTHER  while taking  DRUGOTHER ,  DRUGOTHER , or  DRUG2  may develop toxicity characteristics for these drugs."	diclofenac	cyclosporine	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Patients who begin taking  DRUGOTHER  or who increase their  DRUG1  dose or any other  DRUG2  while taking  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	diclofenac	NSAID	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Patients who begin taking  DRUGOTHER  or who increase their  DRUG1  dose or any other  DRUGOTHER  while taking  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	diclofenac	digoxin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Patients who begin taking  DRUGOTHER  or who increase their  DRUG1  dose or any other  DRUGOTHER  while taking  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	diclofenac	methotrexate	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	"Patients who begin taking  DRUGOTHER  or who increase their  DRUG1  dose or any other  DRUGOTHER  while taking  DRUGOTHER ,  DRUGOTHER , or  DRUG2  may develop toxicity characteristics for these drugs."	diclofenac	cyclosporine	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
effect	"Patients who begin taking  DRUGOTHER  or who increase their  DRUGOTHER  dose or any other  DRUG1  while taking  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	NSAID	digoxin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
effect	"Patients who begin taking  DRUGOTHER  or who increase their  DRUGOTHER  dose or any other  DRUG1  while taking  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	NSAID	methotrexate	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
effect	"Patients who begin taking  DRUGOTHER  or who increase their  DRUGOTHER  dose or any other  DRUG1  while taking  DRUGOTHER ,  DRUGOTHER , or  DRUG2  may develop toxicity characteristics for these drugs."	NSAID	cyclosporine	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Patients who begin taking  DRUGOTHER  or who increase their  DRUGOTHER  dose or any other  DRUGOTHER  while taking  DRUG1 ,  DRUG2 , or  DRUGOTHER  may develop toxicity characteristics for these drugs."	digoxin	methotrexate	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	"Patients who begin taking  DRUGOTHER  or who increase their  DRUGOTHER  dose or any other  DRUGOTHER  while taking  DRUG1 ,  DRUGOTHER , or  DRUG2  may develop toxicity characteristics for these drugs."	digoxin	cyclosporine	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Patients who begin taking  DRUGOTHER  or who increase their  DRUGOTHER  dose or any other  DRUGOTHER  while taking  DRUGOTHER ,  DRUG1 , or  DRUG2  may develop toxicity characteristics for these drugs."	methotrexate	cyclosporine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUG1 :  DRUG2  decreases  DRUGOTHER  renal clearance and increases  DRUGOTHER  plasma levels.	Lithium	Diclofenac	[Li+]	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	 DRUG1 :  DRUGOTHER  decreases  DRUG2  renal clearance and increases  DRUGOTHER  plasma levels.	Lithium	lithium	[Li+]	[Li+]
other	 DRUG1 :  DRUGOTHER  decreases  DRUGOTHER  renal clearance and increases  DRUG2  plasma levels.	Lithium	lithium	[Li+]	[Li+]
mechanism	 DRUGOTHER :  DRUG1  decreases  DRUG2  renal clearance and increases  DRUGOTHER  plasma levels.	Diclofenac	lithium	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[Li+]
mechanism	 DRUGOTHER :  DRUG1  decreases  DRUGOTHER  renal clearance and increases  DRUG2  plasma levels.	Diclofenac	lithium	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[Li+]
other	 DRUGOTHER :  DRUGOTHER  decreases  DRUG1  renal clearance and increases  DRUG2  plasma levels.	lithium	lithium	[Li+]	[Li+]
effect	"In patients taking  DRUG1  and  DRUG2  concomitantly,  DRUGOTHER  toxicity may develop."	diclofenac	lithium	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[Li+]
other	"In patients taking  DRUG1  and  DRUGOTHER  concomitantly,  DRUG2  toxicity may develop."	diclofenac	lithium	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[Li+]
other	"In patients taking  DRUGOTHER  and  DRUG1  concomitantly,  DRUG2  toxicity may develop."	lithium	lithium	[Li+]	[Li+]
other	Oral  DRUG1 :  DRUG2  does not alter glucose metabolism in normal subjects nor does it alter the effects of oral  DRUGOTHER .	Hypoglycemics	Diclofenac		OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	Oral  DRUG1 :  DRUGOTHER  does not alter glucose metabolism in normal subjects nor does it alter the effects of oral  DRUG2 .	Hypoglycemics	hypoglycemic agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	Oral  DRUGOTHER :  DRUG1  does not alter glucose metabolism in normal subjects nor does it alter the effects of oral  DRUG2 .	Diclofenac	hypoglycemic agents	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"There are rare reports, however, from marketing experiences, of changes in effects of  DRUG1  or oral  DRUG2  in the presence of  DRUGOTHER  that necessitated changes in the doses of such agents."	insulin	hypoglycemic agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"There are rare reports, however, from marketing experiences, of changes in effects of  DRUG1  or oral  DRUGOTHER  in the presence of  DRUG2  that necessitated changes in the doses of such agents."	insulin	diclofenac		OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
effect	"There are rare reports, however, from marketing experiences, of changes in effects of  DRUGOTHER  or oral  DRUG1  in the presence of  DRUG2  that necessitated changes in the doses of such agents."	hypoglycemic agents	diclofenac	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
effect	"A direct causal relationship has not been established, but physicians should consider the possibility that  DRUG1  may alter a diabetic patient s response to  DRUG2  or oral  DRUGOTHER ."	diclofenac	insulin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	
effect	"A direct causal relationship has not been established, but physicians should consider the possibility that  DRUG1  may alter a diabetic patient s response to  DRUGOTHER  or oral  DRUG2 ."	diclofenac	hypoglycemic agents	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"A direct causal relationship has not been established, but physicians should consider the possibility that  DRUGOTHER  may alter a diabetic patient s response to  DRUG1  or oral  DRUG2 ."	insulin	hypoglycemic agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	 DRUG1 :  DRUG2  and other  DRUGOTHER  can inhibit the activity of  DRUGOTHER .	Diuretics	Diclofenac	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	 DRUG1 :  DRUGOTHER  and other  DRUG2  can inhibit the activity of  DRUGOTHER .	Diuretics	NSAIDs	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	 DRUG1 :  DRUGOTHER  and other  DRUGOTHER  can inhibit the activity of  DRUG2 .	Diuretics	diuretics	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	 DRUGOTHER :  DRUG1  and other  DRUG2  can inhibit the activity of  DRUGOTHER .	Diclofenac	NSAIDs	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	
effect	 DRUGOTHER :  DRUG1  and other  DRUGOTHER  can inhibit the activity of  DRUG2 .	Diclofenac	diuretics	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
effect	 DRUGOTHER :  DRUGOTHER  and other  DRUG1  can inhibit the activity of  DRUG2 .	NSAIDs	diuretics		COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	azathioprine	gold	CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O	[Au]
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	azathioprine	chloroquine	CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O	CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	azathioprine	D-penicillamine	CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O	[H][C@](N)(C(O)=O)C(C)(C)S
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	azathioprine	prednisolone	CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	azathioprine	doxycycline	CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	azathioprine	digitoxin	CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUG2 ."	azathioprine	diclofenac	CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	gold	chloroquine	[Au]	CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	gold	D-penicillamine	[Au]	[H][C@](N)(C(O)=O)C(C)(C)S
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	gold	prednisolone	[Au]	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	gold	doxycycline	[Au]	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	gold	digitoxin	[Au]	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUG2 ."	gold	diclofenac	[Au]	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	chloroquine	D-penicillamine	CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1	[H][C@](N)(C(O)=O)C(C)(C)S
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	chloroquine	prednisolone	CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	chloroquine	doxycycline	CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	chloroquine	digitoxin	CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUG2 ."	chloroquine	diclofenac	CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	D-penicillamine	prednisolone	[H][C@](N)(C(O)=O)C(C)(C)S	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	D-penicillamine	doxycycline	[H][C@](N)(C(O)=O)C(C)(C)S	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	D-penicillamine	digitoxin	[H][C@](N)(C(O)=O)C(C)(C)S	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUG2 ."	D-penicillamine	diclofenac	[H][C@](N)(C(O)=O)C(C)(C)S	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	prednisolone	doxycycline	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	prednisolone	digitoxin	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUG2 ."	prednisolone	diclofenac	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2  did not significantly affect the peak levels and AUC values of  DRUGOTHER ."	doxycycline	digitoxin	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUGOTHER  did not significantly affect the peak levels and AUC values of  DRUG2 ."	doxycycline	diclofenac	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG1  did not significantly affect the peak levels and AUC values of  DRUG2 ."	digitoxin	diclofenac	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	 DRUG1  toxicity has been reported to have occurred in a patient on chronic  DRUG2  treatment following the initiation of  DRUGOTHER  therapy.	Phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	 DRUG1  toxicity has been reported to have occurred in a patient on chronic  DRUGOTHER  treatment following the initiation of  DRUG2  therapy.	Phenobarbital	diclofenac	CCC1(CC)C(=O)NC(=O)NC1=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
effect	 DRUGOTHER  toxicity has been reported to have occurred in a patient on chronic  DRUG1  treatment following the initiation of  DRUG2  therapy.	phenobarbital	diclofenac	CCC1(CC)C(=O)NC(=O)NC1=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
mechanism	"Protein Binding In vitro,  DRUG1  interferes minimally or not at all with the protein binding of  DRUG2  (20% decrease in binding),  DRUGOTHER ,  DRUGOTHER  (10% decrease in binding), or  DRUGOTHER ."	diclofenac	salicylic acid	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
mechanism	"Protein Binding In vitro,  DRUG1  interferes minimally or not at all with the protein binding of  DRUGOTHER  (20% decrease in binding),  DRUG2 ,  DRUGOTHER  (10% decrease in binding), or  DRUGOTHER ."	diclofenac	tolbutamide	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	
mechanism	"Protein Binding In vitro,  DRUG1  interferes minimally or not at all with the protein binding of  DRUGOTHER  (20% decrease in binding),  DRUGOTHER ,  DRUG2  (10% decrease in binding), or  DRUGOTHER ."	diclofenac	prednisolone	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
mechanism	"Protein Binding In vitro,  DRUG1  interferes minimally or not at all with the protein binding of  DRUGOTHER  (20% decrease in binding),  DRUGOTHER ,  DRUGOTHER  (10% decrease in binding), or  DRUG2 ."	diclofenac	warfarin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Protein Binding In vitro,  DRUGOTHER  interferes minimally or not at all with the protein binding of  DRUG1  (20% decrease in binding),  DRUG2 ,  DRUGOTHER  (10% decrease in binding), or  DRUGOTHER ."	salicylic acid	tolbutamide	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1	
other	"Protein Binding In vitro,  DRUGOTHER  interferes minimally or not at all with the protein binding of  DRUG1  (20% decrease in binding),  DRUGOTHER ,  DRUG2  (10% decrease in binding), or  DRUGOTHER ."	salicylic acid	prednisolone	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
other	"Protein Binding In vitro,  DRUGOTHER  interferes minimally or not at all with the protein binding of  DRUG1  (20% decrease in binding),  DRUGOTHER ,  DRUGOTHER  (10% decrease in binding), or  DRUG2 ."	salicylic acid	warfarin	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Protein Binding In vitro,  DRUGOTHER  interferes minimally or not at all with the protein binding of  DRUGOTHER  (20% decrease in binding),  DRUG1 ,  DRUG2  (10% decrease in binding), or  DRUGOTHER ."	tolbutamide	prednisolone		[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
other	"Protein Binding In vitro,  DRUGOTHER  interferes minimally or not at all with the protein binding of  DRUGOTHER  (20% decrease in binding),  DRUG1 ,  DRUGOTHER  (10% decrease in binding), or  DRUG2 ."	tolbutamide	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Protein Binding In vitro,  DRUGOTHER  interferes minimally or not at all with the protein binding of  DRUGOTHER  (20% decrease in binding),  DRUGOTHER ,  DRUG1  (10% decrease in binding), or  DRUG2 ."	prednisolone	warfarin	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	Benzylpenicillin	ampicillin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O
other	" DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	Benzylpenicillin	oxacillin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	Benzylpenicillin	chlortetracycline	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O	[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	Benzylpenicillin	doxycycline	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	Benzylpenicillin	cephalothin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	Benzylpenicillin	erythromycin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	Benzylpenicillin	sulfamethoxazole	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUG2  in human serum."	Benzylpenicillin	diclofenac	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	ampicillin	oxacillin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	ampicillin	chlortetracycline	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	ampicillin	doxycycline	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	ampicillin	cephalothin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	ampicillin	erythromycin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	ampicillin	sulfamethoxazole	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUG2  in human serum."	ampicillin	diclofenac	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	oxacillin	chlortetracycline	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O	[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	oxacillin	doxycycline	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	oxacillin	cephalothin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	oxacillin	erythromycin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	oxacillin	sulfamethoxazole	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUG2  in human serum."	oxacillin	diclofenac	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	chlortetracycline	doxycycline	[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	chlortetracycline	cephalothin	[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	chlortetracycline	erythromycin	[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	chlortetracycline	sulfamethoxazole	[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUG2  in human serum."	chlortetracycline	diclofenac	[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	doxycycline	cephalothin	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	doxycycline	erythromycin	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	doxycycline	sulfamethoxazole	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUG2  in human serum."	doxycycline	diclofenac	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	cephalothin	erythromycin	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	cephalothin	sulfamethoxazole	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUG2  in human serum."	cephalothin	diclofenac	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2  have no influence in vitro on the protein binding of  DRUGOTHER  in human serum."	erythromycin	sulfamethoxazole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  have no influence in vitro on the protein binding of  DRUG2  in human serum."	erythromycin	diclofenac	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1  have no influence in vitro on the protein binding of  DRUG2  in human serum."	sulfamethoxazole	diclofenac	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
effect	"Catecholamine-depleting drugs (eg,  DRUG1 ) may have an additive effect when given with  DRUG2 s."	reserpine	beta-blocking agent	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	 DRUG1  may also have an additive effect when given with  DRUG2  .	Calcium channel blockers	TENORMIN	[Ca]	CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
effect	 DRUG1  may exacerbate the rebound hypertension which can follow the withdrawal of  DRUG2 .	Beta blockers	clonidine		ClC1=CC=CC(Cl)=C1NC1=NCCN1
advise	"If the two drugs are coadministered, the  DRUG1  should be withdrawn several days before the gradual withdrawal of  DRUG2 ."	beta blocker	clonidine		ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	"If replacing  DRUG1  by  DRUG2  therapy, the introduction of  DRUGOTHER  should be delayed for several days after  DRUGOTHER  administration has stopped."	clonidine	beta-blocker	ClC1=CC=CC(Cl)=C1NC1=NCCN1	
other	"If replacing  DRUG1  by  DRUGOTHER  therapy, the introduction of  DRUG2  should be delayed for several days after  DRUGOTHER  administration has stopped."	clonidine	beta blockers	ClC1=CC=CC(Cl)=C1NC1=NCCN1	
other	"If replacing  DRUG1  by  DRUGOTHER  therapy, the introduction of  DRUGOTHER  should be delayed for several days after  DRUG2  administration has stopped."	clonidine	clonidine	ClC1=CC=CC(Cl)=C1NC1=NCCN1	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	"If replacing  DRUGOTHER  by  DRUG1  therapy, the introduction of  DRUG2  should be delayed for several days after  DRUGOTHER  administration has stopped."	beta-blocker	beta blockers		
other	"If replacing  DRUGOTHER  by  DRUG1  therapy, the introduction of  DRUGOTHER  should be delayed for several days after  DRUG2  administration has stopped."	beta-blocker	clonidine		ClC1=CC=CC(Cl)=C1NC1=NCCN1
advise	"If replacing  DRUGOTHER  by  DRUGOTHER  therapy, the introduction of  DRUG1  should be delayed for several days after  DRUG2  administration has stopped."	beta blockers	clonidine		ClC1=CC=CC(Cl)=C1NC1=NCCN1
effect	"Concomitant use of prostaglandin synthase inhibiting drugs, eg,  DRUG1 , may decrease the hypotensive effects of  DRUG2 ."	indomethacin	beta blockers	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	
other	Information on concurrent usage of  DRUG1  and  DRUG2  is limited.	atenolol	aspirin	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	CC(=O)OC1=CC=CC=C1C(O)=O
other	"Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between  DRUG1  and  DRUG2  in the acute myocardial infarction setting."	aspirin	beta blockers	CC(=O)OC1=CC=CC=C1C(O)=O	
other	"Concomitant use with other  DRUG1 -containing medicines (including  DRUG2 ) may cause too much  DRUGOTHER  in the blood or urine, which may increase the chance of side effects."	calcium	antacids	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Concomitant use with other  DRUG1 -containing medicines (including  DRUGOTHER ) may cause too much  DRUG2  in the blood or urine, which may increase the chance of side effects."	calcium	calcium	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Concomitant use with other  DRUGOTHER -containing medicines (including  DRUG1 ) may cause too much  DRUG2  in the blood or urine, which may increase the chance of side effects."	antacids	calcium		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	"Using  DRUG1  with  DRUG2  (heart medicine) may cause hypercalcemia (too much  DRUGOTHER  in the blood), which could increase the chance of developing an irregular heartbeat."	calcium acetate	digitalis glycosides	[Ca]	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Using  DRUG1  with  DRUGOTHER  (heart medicine) may cause hypercalcemia (too much  DRUG2  in the blood), which could increase the chance of developing an irregular heartbeat."	calcium acetate	calcium	[Ca]	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Using  DRUGOTHER  with  DRUG1  (heart medicine) may cause hypercalcemia (too much  DRUG2  in the blood), which could increase the chance of developing an irregular heartbeat."	digitalis glycosides	calcium	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"[Stimulation by  DRUG1 --an analog of the octapeptide cholecystokinin--of  DRUG2  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	cerulein	3H-spiroperidol	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	
other	"[Stimulation by  DRUG1 --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUG2 ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	cerulein	neuroleptics	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	
other	"[Stimulation by  DRUG1 --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUG2  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	cerulein	haloperidol	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"[Stimulation by  DRUG1 --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUG2  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	cerulein	pyreneperone	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"[Stimulation by  DRUG1 --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUG2  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	cerulein	3H-spiroperidol	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	
other	"[Stimulation by  DRUG1 --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUG2  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	cerulein	apomorphine	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"[Stimulation by  DRUG1 --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUG2  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	cerulein	3H-spiroperidol	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	
other	"[Stimulation by  DRUG1 --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUG2  increased both in the frontal cortex and subcortical structures of the forebrain."	cerulein	apomorphine	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUG1  binding after the long-term administration of  DRUG2 ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	3H-spiroperidol	neuroleptics		
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUG1  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUG2  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	3H-spiroperidol	haloperidol		OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUG1  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUG2  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	3H-spiroperidol	pyreneperone		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUG1  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUG2  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	3H-spiroperidol	3H-spiroperidol		
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUG1  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUG2  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	3H-spiroperidol	apomorphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUG1  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUG2  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	3H-spiroperidol	3H-spiroperidol		
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUG1  binding after the long-term administration of  DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUG2  increased both in the frontal cortex and subcortical structures of the forebrain."	3H-spiroperidol	apomorphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUG1 ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUG2  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	neuroleptics	haloperidol		OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUG1 ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUG2  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	neuroleptics	pyreneperone		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUG1 ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUG2  and low affinity binding sites for  DRUGOTHER  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	neuroleptics	3H-spiroperidol		
other	"[Stimulation by  DRUGOTHER --an analog of the octapeptide cholecystokinin--of  DRUGOTHER  binding after the long-term administration of  DRUG1 ] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  DRUGOTHER  (0.25 mg/kg) and  DRUGOTHER  (0.25 mg/kg) resulted in the reduced interaction between  DRUGOTHER  and low affinity binding sites for  DRUG2  in subcortical structures, whereas  DRUGOTHER  binding with high affinity binding sites for  DRUGOTHER  increased both in the frontal cortex and subcortical structures of the forebrain."	neuroleptics	apomorphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"After prolonged administration of  DRUG1  the displacing effect of  DRUG2 , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on  DRUGOTHER  binding."	neuroleptics	cerulein		[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
other	"After prolonged administration of  DRUG1  the displacing effect of  DRUGOTHER , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on  DRUG2  binding."	neuroleptics	3H-spiroperidol		
other	"After prolonged administration of  DRUGOTHER  the displacing effect of  DRUG1 , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on  DRUG2  binding."	cerulein	3H-spiroperidol	[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	
other	It is assumed that increased interaction between  DRUG1  and high affinity binding sites for  DRUG2  on dopamine2- and serotonin2-receptors underlies the antipsychotic action of  DRUGOTHER  after their prolonged administration.	3H-spiroperidol	apomorphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	It is assumed that increased interaction between  DRUG1  and high affinity binding sites for  DRUGOTHER  on dopamine2- and serotonin2-receptors underlies the antipsychotic action of  DRUG2  after their prolonged administration.	3H-spiroperidol	neuroleptics		
other	It is assumed that increased interaction between  DRUGOTHER  and high affinity binding sites for  DRUG1  on dopamine2- and serotonin2-receptors underlies the antipsychotic action of  DRUG2  after their prolonged administration.	apomorphine	neuroleptics	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	
effect	Taking  DRUG1  after drinking  DRUG2  may worsen side effects and may cause severe hypotension and cardiovascular collapse.	amyl nitrite	alcohol	[O-]N=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"The  DRUG1  ( DRUG2  and  DRUGOTHER ), a new class of oral  DRUGOTHER , are ""insulin sensitizers"""	thiazolidinediones	rosiglitazone	CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1	CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
other	"The  DRUG1  ( DRUGOTHER  and  DRUG2 ), a new class of oral  DRUGOTHER , are ""insulin sensitizers"""	thiazolidinediones	pioglitazone	CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1	CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
other	"The  DRUG1  ( DRUGOTHER  and  DRUGOTHER ), a new class of oral  DRUG2 , are ""insulin sensitizers"""	thiazolidinediones	antidiabetic agents	CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"The  DRUGOTHER  ( DRUG1  and  DRUG2 ), a new class of oral  DRUGOTHER , are ""insulin sensitizers"""	rosiglitazone	pioglitazone	CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1	CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
other	"The  DRUGOTHER  ( DRUG1  and  DRUGOTHER ), a new class of oral  DRUG2 , are ""insulin sensitizers"""	rosiglitazone	antidiabetic agents	CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"The  DRUGOTHER  ( DRUGOTHER  and  DRUG1 ), a new class of oral  DRUG2 , are ""insulin sensitizers"""	pioglitazone	antidiabetic agents	CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	When  DRUG1  or  DRUG2  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUGOTHER  and  DRUGOTHER  may enhance the action of  DRUGOTHER .	Bezalip	Bezalip retard	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	When  DRUG1  or  DRUGOTHER  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUG2  and  DRUGOTHER  may enhance the action of  DRUGOTHER .	Bezalip	Bezalip	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	When  DRUG1  or  DRUGOTHER  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUGOTHER  and  DRUG2  may enhance the action of  DRUGOTHER .	Bezalip	Bezalip retard	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	When  DRUG1  or  DRUGOTHER  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUGOTHER  and  DRUGOTHER  may enhance the action of  DRUG2 .	Bezalip	anticoagulants of the coumarin type	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	O=C1OC2=CC=CC=C2C=C1
other	When  DRUGOTHER  or  DRUG1  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUG2  and  DRUGOTHER  may enhance the action of  DRUGOTHER .	Bezalip retard	Bezalip	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	When  DRUGOTHER  or  DRUG1  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUGOTHER  and  DRUG2  may enhance the action of  DRUGOTHER .	Bezalip retard	Bezalip retard	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	When  DRUGOTHER  or  DRUG1  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUGOTHER  and  DRUGOTHER  may enhance the action of  DRUG2 .	Bezalip retard	anticoagulants of the coumarin type	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	O=C1OC2=CC=CC=C2C=C1
other	When  DRUGOTHER  or  DRUGOTHER  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUG1  and  DRUG2  may enhance the action of  DRUGOTHER .	Bezalip	Bezalip retard	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
effect	When  DRUGOTHER  or  DRUGOTHER  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUG1  and  DRUGOTHER  may enhance the action of  DRUG2 .	Bezalip	anticoagulants of the coumarin type	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	O=C1OC2=CC=CC=C2C=C1
effect	When  DRUGOTHER  or  DRUGOTHER  is used at the same time as other medicines or substances the following interactions must be taken into account: -  DRUGOTHER  and  DRUG1  may enhance the action of  DRUG2 .	Bezalip retard	anticoagulants of the coumarin type	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	O=C1OC2=CC=CC=C2C=C1
advise	"For this reason, the dose of the  DRUG1  should be reduced by 30 - 50% at the start of treatment with  DRUG2  or  DRUGOTHER  retard and then titrated according to the blood clotting parameters"	anticoagulant	Bezalip	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
advise	"For this reason, the dose of the  DRUG1  should be reduced by 30 - 50% at the start of treatment with  DRUGOTHER  or  DRUG2  retard and then titrated according to the blood clotting parameters"	anticoagulant	Bezalip	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"For this reason, the dose of the  DRUGOTHER  should be reduced by 30 - 50% at the start of treatment with  DRUG1  or  DRUG2  retard and then titrated according to the blood clotting parameters"	Bezalip	Bezalip	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	- The action of  DRUG1  and  DRUG2  may be enhanced by  DRUGOTHER  or  DRUGOTHER .	sulphonylureas	insulin	NC(N)=O	
effect	- The action of  DRUG1  and  DRUGOTHER  may be enhanced by  DRUG2  or  DRUGOTHER .	sulphonylureas	Bezalip	NC(N)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	- The action of  DRUG1  and  DRUGOTHER  may be enhanced by  DRUGOTHER  or  DRUG2 .	sulphonylureas	Bezalip retard	NC(N)=O	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
effect	- The action of  DRUGOTHER  and  DRUG1  may be enhanced by  DRUG2  or  DRUGOTHER .	insulin	Bezalip		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	- The action of  DRUGOTHER  and  DRUG1  may be enhanced by  DRUGOTHER  or  DRUG2 .	insulin	Bezalip retard		CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	- The action of  DRUGOTHER  and  DRUGOTHER  may be enhanced by  DRUG1  or  DRUG2 .	Bezalip	Bezalip retard	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
effect	"- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving  DRUG1  therapy and concomitant  DRUG2 ."	immuno-suppressant	bezafibrate	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	"- When  DRUG1  or  DRUG2  is used concurrently with  DRUGOTHER  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUGOTHER  is impaired"	Bezalip	Bezalip retard	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
advise	"- When  DRUG1  or  DRUGOTHER  is used concurrently with  DRUG2  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUGOTHER  is impaired"	Bezalip	anion-exchange resins	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
advise	"- When  DRUG1  or  DRUGOTHER  is used concurrently with  DRUGOTHER  (e.g.  DRUG2 ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUGOTHER  is impaired"	Bezalip	cholestryramine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CCCCCCCC(O)=O
other	"- When  DRUG1  or  DRUGOTHER  is used concurrently with  DRUGOTHER  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUG2  or  DRUGOTHER  is impaired"	Bezalip	Bezalip	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"- When  DRUG1  or  DRUGOTHER  is used concurrently with  DRUGOTHER  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUG2  is impaired"	Bezalip	Bezalip retard	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
advise	"- When  DRUGOTHER  or  DRUG1  is used concurrently with  DRUG2  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUGOTHER  is impaired"	Bezalip retard	anion-exchange resins	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	
advise	"- When  DRUGOTHER  or  DRUG1  is used concurrently with  DRUGOTHER  (e.g.  DRUG2 ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUGOTHER  is impaired"	Bezalip retard	cholestryramine	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"- When  DRUGOTHER  or  DRUG1  is used concurrently with  DRUGOTHER  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUG2  or  DRUGOTHER  is impaired"	Bezalip retard	Bezalip	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"- When  DRUGOTHER  or  DRUG1  is used concurrently with  DRUGOTHER  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUG2  is impaired"	Bezalip retard	Bezalip retard	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	"- When  DRUGOTHER  or  DRUGOTHER  is used concurrently with  DRUG1  (e.g.  DRUG2 ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUGOTHER  is impaired"	anion-exchange resins	cholestryramine		OC(=O)CCCCCCCC(O)=O
other	"- When  DRUGOTHER  or  DRUGOTHER  is used concurrently with  DRUG1  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUG2  or  DRUGOTHER  is impaired"	anion-exchange resins	Bezalip		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"- When  DRUGOTHER  or  DRUGOTHER  is used concurrently with  DRUG1  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUG2  is impaired"	anion-exchange resins	Bezalip retard		CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	"- When  DRUGOTHER  or  DRUGOTHER  is used concurrently with  DRUGOTHER  (e.g.  DRUG1 ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUG2  or  DRUGOTHER  is impaired"	cholestryramine	Bezalip	OC(=O)CCCCCCCC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"- When  DRUGOTHER  or  DRUGOTHER  is used concurrently with  DRUGOTHER  (e.g.  DRUG1 ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUGOTHER  or  DRUG2  is impaired"	cholestryramine	Bezalip retard	OC(=O)CCCCCCCC(O)=O	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	"- When  DRUGOTHER  or  DRUGOTHER  is used concurrently with  DRUGOTHER  (e.g.  DRUGOTHER ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  DRUG1  or  DRUG2  is impaired"	Bezalip	Bezalip retard	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	-  DRUG1  or  DRUG2  (with hepatotoxic potential) must not be administered together with  DRUGOTHER  or  DRUGOTHER .	Perhexiline hydrogen maleate	MAO-inhibitors	C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1	
advise	-  DRUG1  or  DRUGOTHER  (with hepatotoxic potential) must not be administered together with  DRUG2  or  DRUGOTHER .	Perhexiline hydrogen maleate	Bezalip	C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
advise	-  DRUG1  or  DRUGOTHER  (with hepatotoxic potential) must not be administered together with  DRUGOTHER  or  DRUG2 .	Perhexiline hydrogen maleate	Bezalip retard	C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
advise	-  DRUGOTHER  or  DRUG1  (with hepatotoxic potential) must not be administered together with  DRUG2  or  DRUGOTHER .	MAO-inhibitors	Bezalip		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
advise	-  DRUGOTHER  or  DRUG1  (with hepatotoxic potential) must not be administered together with  DRUGOTHER  or  DRUG2 .	MAO-inhibitors	Bezalip retard		CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	-  DRUGOTHER  or  DRUGOTHER  (with hepatotoxic potential) must not be administered together with  DRUG1  or  DRUG2 .	Bezalip	Bezalip retard	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
other	"In clinical studies performed with  DRUG1 , the concomitant use of oral  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	Fondaparinux	anticoagulants	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	
other	"In clinical studies performed with  DRUG1 , the concomitant use of oral  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	Fondaparinux	warfarin	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In clinical studies performed with  DRUG1 , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	Fondaparinux	platelet inhibitors	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	
other	"In clinical studies performed with  DRUG1 , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	Fondaparinux	acetylsalicylic acid	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	"In clinical studies performed with  DRUG1 , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	Fondaparinux	NSAIDs	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	
other	"In clinical studies performed with  DRUG1 , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	Fondaparinux	piroxicam	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In clinical studies performed with  DRUG1 , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	Fondaparinux	digoxin	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical studies performed with  DRUG1 , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUG2 ."	Fondaparinux	fondaparinux sodium	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	anticoagulants	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	anticoagulants	platelet inhibitors		
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	anticoagulants	acetylsalicylic acid		CC(=O)OC1=CC=CC=C1C(O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	anticoagulants	NSAIDs		
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	anticoagulants	piroxicam		CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	anticoagulants	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUG2 ."	anticoagulants	fondaparinux sodium		CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	warfarin	platelet inhibitors	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	warfarin	acetylsalicylic acid	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	warfarin	NSAIDs	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	warfarin	piroxicam	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	warfarin	digoxin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUG2 ."	warfarin	fondaparinux sodium	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	platelet inhibitors	acetylsalicylic acid		CC(=O)OC1=CC=CC=C1C(O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	platelet inhibitors	NSAIDs		
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	platelet inhibitors	piroxicam		CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	platelet inhibitors	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUG2 ."	platelet inhibitors	fondaparinux sodium		CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	acetylsalicylic acid	NSAIDs	CC(=O)OC1=CC=CC=C1C(O)=O	
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	acetylsalicylic acid	piroxicam	CC(=O)OC1=CC=CC=C1C(O)=O	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	acetylsalicylic acid	digoxin	CC(=O)OC1=CC=CC=C1C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUG2 ."	acetylsalicylic acid	fondaparinux sodium	CC(=O)OC1=CC=CC=C1C(O)=O	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	NSAIDs	piroxicam		CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ), and  DRUG2  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	NSAIDs	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUG2 ."	NSAIDs	fondaparinux sodium		CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ), and  DRUG2  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUGOTHER ."	piroxicam	digoxin	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ), and  DRUGOTHER  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUG2 ."	piroxicam	fondaparinux sodium	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"In clinical studies performed with  DRUGOTHER , the concomitant use of oral  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG1  did not significantly affect the pharmacokinetics/pharmacodynamics of  DRUG2 ."	digoxin	fondaparinux sodium	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"In addition,  DRUG1  neither influenced the pharmacodynamics of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , nor the pharmacokinetics of  DRUGOTHER  at steady state."	Fondaparinux	warfarin	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In addition,  DRUG1  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , nor the pharmacokinetics of  DRUGOTHER  at steady state."	Fondaparinux	acetylsalicylic acid	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	"In addition,  DRUG1  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , nor the pharmacokinetics of  DRUGOTHER  at steady state."	Fondaparinux	piroxicam	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In addition,  DRUG1  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , nor the pharmacokinetics of  DRUGOTHER  at steady state."	Fondaparinux	digoxin	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In addition,  DRUG1  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , nor the pharmacokinetics of  DRUG2  at steady state."	Fondaparinux	digoxin	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , nor the pharmacokinetics of  DRUGOTHER  at steady state."	warfarin	acetylsalicylic acid	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , nor the pharmacokinetics of  DRUGOTHER  at steady state."	warfarin	piroxicam	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , nor the pharmacokinetics of  DRUGOTHER  at steady state."	warfarin	digoxin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , nor the pharmacokinetics of  DRUG2  at steady state."	warfarin	digoxin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER , nor the pharmacokinetics of  DRUGOTHER  at steady state."	acetylsalicylic acid	piroxicam	CC(=O)OC1=CC=CC=C1C(O)=O	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 , nor the pharmacokinetics of  DRUGOTHER  at steady state."	acetylsalicylic acid	digoxin	CC(=O)OC1=CC=CC=C1C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , nor the pharmacokinetics of  DRUG2  at steady state."	acetylsalicylic acid	digoxin	CC(=O)OC1=CC=CC=C1C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 , nor the pharmacokinetics of  DRUGOTHER  at steady state."	piroxicam	digoxin	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , nor the pharmacokinetics of  DRUG2  at steady state."	piroxicam	digoxin	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In addition,  DRUGOTHER  neither influenced the pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , nor the pharmacokinetics of  DRUG2  at steady state."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	"In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of  DRUG1  by  DRUG2  (200 m m M i.e., 350 mg/L) was 17-28%."	coumarin	fondaparinux	O=C1OC2=CC=CC=C2C=C1	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	"Since  DRUG1  does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro,  DRUG2  is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes."	fondaparinux	fondaparinux sodium	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
other	 DRUG1  - Taking  DRUG2  and a  DRUGOTHER  together may increase the risk of convulsions (seizures).	Phenothiazines	piperazine	N1C2=CC=CC=C2SC2=CC=CC=C12	C1CNCCN1
other	 DRUG1  - Taking  DRUGOTHER  and a  DRUG2  together may increase the risk of convulsions (seizures).	Phenothiazines	phenothiazine	N1C2=CC=CC=C2SC2=CC=CC=C12	N1C2=CC=CC=C2SC2=CC=CC=C12
effect	 DRUGOTHER  - Taking  DRUG1  and a  DRUG2  together may increase the risk of convulsions (seizures).	piperazine	phenothiazine	C1CNCCN1	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUG1  (e.g.,  DRUG2 ) - Taking  DRUGOTHER  and  DRUGOTHER  together may decrease the effects of  DRUGOTHER ."	Pyrantel	Antiminth	[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1	CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1
other	" DRUG1  (e.g.,  DRUGOTHER ) - Taking  DRUG2  and  DRUGOTHER  together may decrease the effects of  DRUGOTHER ."	Pyrantel	piperazine	[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1	C1CNCCN1
other	" DRUG1  (e.g.,  DRUGOTHER ) - Taking  DRUGOTHER  and  DRUG2  together may decrease the effects of  DRUGOTHER ."	Pyrantel	pyrantel	[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1	[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1
other	" DRUG1  (e.g.,  DRUGOTHER ) - Taking  DRUGOTHER  and  DRUGOTHER  together may decrease the effects of  DRUG2 ."	Pyrantel	piperazine	[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1	C1CNCCN1
other	" DRUGOTHER  (e.g.,  DRUG1 ) - Taking  DRUG2  and  DRUGOTHER  together may decrease the effects of  DRUGOTHER ."	Antiminth	piperazine	CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1	C1CNCCN1
other	" DRUGOTHER  (e.g.,  DRUG1 ) - Taking  DRUGOTHER  and  DRUG2  together may decrease the effects of  DRUGOTHER ."	Antiminth	pyrantel	CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1	[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1
other	" DRUGOTHER  (e.g.,  DRUG1 ) - Taking  DRUGOTHER  and  DRUGOTHER  together may decrease the effects of  DRUG2 ."	Antiminth	piperazine	CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1	C1CNCCN1
effect	" DRUGOTHER  (e.g.,  DRUGOTHER ) - Taking  DRUG1  and  DRUG2  together may decrease the effects of  DRUGOTHER ."	piperazine	pyrantel	C1CNCCN1	[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1
other	" DRUGOTHER  (e.g.,  DRUGOTHER ) - Taking  DRUG1  and  DRUGOTHER  together may decrease the effects of  DRUG2 ."	piperazine	piperazine	C1CNCCN1	C1CNCCN1
other	" DRUGOTHER  (e.g.,  DRUGOTHER ) - Taking  DRUGOTHER  and  DRUG1  together may decrease the effects of  DRUG2 ."	pyrantel	piperazine	[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1	C1CNCCN1
other	 DRUG1  and  DRUG2  may decrease hypoprothrombinemic effect.	Dicumarol	warfarin	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Other depressasnts such as  DRUG1 ,  DRUG2 , and  DRUGOTHER  may enhance CNS depression when administered with  DRUGOTHER ."	alcohol	barbiturates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Other depressasnts such as  DRUG1 ,  DRUGOTHER , and  DRUG2  may enhance CNS depression when administered with  DRUGOTHER ."	alcohol	MAOIs	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
effect	"Other depressasnts such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  may enhance CNS depression when administered with  DRUG2 ."	alcohol	ethchlorvynol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H]C(Cl)=CC(O)(CC)C#C
other	"Other depressasnts such as  DRUGOTHER ,  DRUG1 , and  DRUG2  may enhance CNS depression when administered with  DRUGOTHER ."	barbiturates	MAOIs	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	
effect	"Other depressasnts such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  may enhance CNS depression when administered with  DRUG2 ."	barbiturates	ethchlorvynol	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	[H]C(Cl)=CC(O)(CC)C#C
effect	"Other depressasnts such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1  may enhance CNS depression when administered with  DRUG2 ."	MAOIs	ethchlorvynol		[H]C(Cl)=CC(O)(CC)C#C
effect	 DRUG1  enhance the renal toxicity of  DRUG2  in animals. 7  DRUGOTHER  interferes with the action of  DRUGOTHER  preparations by chelating the  DRUGOTHER . 7	Steroids	edetate calcium disodium	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
other	 DRUG1  enhance the renal toxicity of  DRUGOTHER  in animals. 7  DRUG2  interferes with the action of  DRUGOTHER  preparations by chelating the  DRUGOTHER . 7	Steroids	Edetate calcium disodium	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
other	 DRUG1  enhance the renal toxicity of  DRUGOTHER  in animals. 7  DRUGOTHER  interferes with the action of  DRUG2  preparations by chelating the  DRUGOTHER . 7	Steroids	zinc insulin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[Cl-].[Cl-].[Zn++]
other	 DRUG1  enhance the renal toxicity of  DRUGOTHER  in animals. 7  DRUGOTHER  interferes with the action of  DRUGOTHER  preparations by chelating the  DRUG2 . 7	Steroids	zinc	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	O=[Zn]
other	 DRUGOTHER  enhance the renal toxicity of  DRUG1  in animals. 7  DRUG2  interferes with the action of  DRUGOTHER  preparations by chelating the  DRUGOTHER . 7	edetate calcium disodium	Edetate calcium disodium	[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O	[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
other	 DRUGOTHER  enhance the renal toxicity of  DRUG1  in animals. 7  DRUGOTHER  interferes with the action of  DRUG2  preparations by chelating the  DRUGOTHER . 7	edetate calcium disodium	zinc insulin	[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O	[Cl-].[Cl-].[Zn++]
other	 DRUGOTHER  enhance the renal toxicity of  DRUG1  in animals. 7  DRUGOTHER  interferes with the action of  DRUGOTHER  preparations by chelating the  DRUG2 . 7	edetate calcium disodium	zinc	[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O	O=[Zn]
mechanism	 DRUGOTHER  enhance the renal toxicity of  DRUGOTHER  in animals. 7  DRUG1  interferes with the action of  DRUG2  preparations by chelating the  DRUGOTHER . 7	Edetate calcium disodium	zinc insulin	[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O	[Cl-].[Cl-].[Zn++]
other	 DRUGOTHER  enhance the renal toxicity of  DRUGOTHER  in animals. 7  DRUG1  interferes with the action of  DRUGOTHER  preparations by chelating the  DRUG2 . 7	Edetate calcium disodium	zinc	[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O	O=[Zn]
other	 DRUGOTHER  enhance the renal toxicity of  DRUGOTHER  in animals. 7  DRUGOTHER  interferes with the action of  DRUG1  preparations by chelating the  DRUG2 . 7	zinc insulin	zinc	[Cl-].[Cl-].[Zn++]	O=[Zn]
other	"Drugs that induce CYP3A4 activity would be expected to increase the clearance of  DRUG1 , resulting in lowered plasma concentrations of  DRUG2 ."	indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	Coadministration of  DRUG1  and other drugs that inhibit CYP3A4 may decrease the clearance of  DRUG2  and may result in increased plasma concentrations of  DRUGOTHER .	CRIXIVAN	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	Coadministration of  DRUG1  and other drugs that inhibit CYP3A4 may decrease the clearance of  DRUGOTHER  and may result in increased plasma concentrations of  DRUG2 .	CRIXIVAN	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	Coadministration of  DRUGOTHER  and other drugs that inhibit CYP3A4 may decrease the clearance of  DRUG1  and may result in increased plasma concentrations of  DRUG2 .	indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	 DRUG1 :  DRUG2 	Antiarrhythmics	amiodarone		CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Ergot derivatives:  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER "	dihydroergotamine	ergonovine	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	"Ergot derivatives:  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER "	dihydroergotamine	ergotamine	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	OC(=O)CCCCCCCC(O)=O
other	"Ergot derivatives:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 "	dihydroergotamine	methylergonovine	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	"Ergot derivatives:  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER "	ergonovine	ergotamine	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	OC(=O)CCCCCCCC(O)=O
other	"Ergot derivatives:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 "	ergonovine	methylergonovine	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	"Ergot derivatives:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 "	ergotamine	methylergonovine	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	" DRUG1 / DRUG2 :  DRUGOTHER ,  DRUGOTHER "	Sedative	hypnotics		
other	" DRUG1 / DRUGOTHER :  DRUG2 ,  DRUGOTHER "	Sedative	midazolam		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUG1 / DRUGOTHER :  DRUGOTHER ,  DRUG2 "	Sedative	triazolam		O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	" DRUGOTHER / DRUG1 :  DRUG2 ,  DRUGOTHER "	hypnotics	midazolam		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER / DRUG1 :  DRUGOTHER ,  DRUG2 "	hypnotics	triazolam		O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	" DRUGOTHER / DRUGOTHER :  DRUG1 ,  DRUG2 "	midazolam	triazolam	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	 DRUG1 :  DRUG2 	Neuroleptic	pimozide		FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	May lead to loss of virologic response and possible resistance to  DRUG1  or to the class of  DRUG2 .	CRIXIVAN	protease inhibitors	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	
other	 DRUG1 :  DRUG2 	Antimycobacterial	rifampin	NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	May lead to loss of virologic response and possible resistance to  DRUG1  or to the class of  DRUG2  or other coadministered  DRUGOTHER .	CRIXIVAN	protease inhibitors	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	
other	May lead to loss of virologic response and possible resistance to  DRUG1  or to the class of  DRUGOTHER  or other coadministered  DRUG2 .	CRIXIVAN	antiretroviral agents	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	May lead to loss of virologic response and possible resistance to  DRUGOTHER  or to the class of  DRUG1  or other coadministered  DRUG2 .	protease inhibitors	antiretroviral agents		CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUG1 :  DRUG2 ,  DRUGOTHER "	HMG-CoA Reductase inhibitors	lovastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	" DRUG1 :  DRUGOTHER ,  DRUG2 "	HMG-CoA Reductase inhibitors	simvastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
other	" DRUGOTHER :  DRUG1 ,  DRUG2 "	lovastatin	simvastatin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
other	 DRUG1 :  DRUG2 	Protease inhibitor	atazanavir		COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
other	Both  DRUG1  and  DRUG2  are associated with indirect (unconjugated) hyperbilirubinemia.	CRIXIVAN	atazanavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
advise	Combinations of these drugs have not been studied and coadministration of  DRUG1  and  DRUG2  is not recommended.	CRIXIVAN	atazanavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
advise	Dose reduction of  DRUG1  to 600 mg every 8 hours should be considered when taking  DRUG2  400 mg three times a day.	CRIXIVAN	delavirdine	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
advise	 DRUG1  and  DRUG2  formulations containing buffer should be administered at least one hour apart on an empty stomach.	Indinavir	didanosine	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O
other	"The optimal dose of  DRUG1 , when given in combination with  DRUG2 , is not known."	indinavir	efavirenz	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
other	Increasing the  DRUG1  dose to 1000 mg every 8 hours does not compensate for the increased  DRUG2  metabolism due to  DRUGOTHER .	indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	Increasing the  DRUG1  dose to 1000 mg every 8 hours does not compensate for the increased  DRUGOTHER  metabolism due to  DRUG2 .	indinavir	efavirenz	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
mechanism	Increasing the  DRUGOTHER  dose to 1000 mg every 8 hours does not compensate for the increased  DRUG1  metabolism due to  DRUG2 .	indinavir	efavirenz	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
mechanism	 DRUG1  concentrations may be decreased in the presence of  DRUG2 .	Indinavir	nevirapine	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
other	 DRUG1  concentration    DRUG2  concentration	indinavir	ritonavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
effect	Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving  DRUG1  in combination with  DRUG2  than those receiving  DRUGOTHER  800 mg q8h.	indinavir	ritonavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving  DRUG1  in combination with  DRUGOTHER  than those receiving  DRUG2  800 mg q8h.	indinavir	CRIXIVAN	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving  DRUGOTHER  in combination with  DRUG1  than those receiving  DRUG2  800 mg q8h.	ritonavir	CRIXIVAN	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	" DRUG1 :  DRUG2 ,  DRUGOTHER  (systemic) and  DRUGOTHER "	Antiarrhythmics	bepridil		CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
other	" DRUG1 :  DRUGOTHER ,  DRUG2  (systemic) and  DRUGOTHER "	Antiarrhythmics	lidocaine		
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER  (systemic) and  DRUG2 "	Antiarrhythmics	quinidine		CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUGOTHER :  DRUG1 ,  DRUG2  (systemic) and  DRUGOTHER "	bepridil	lidocaine	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1	
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER  (systemic) and  DRUG2 "	bepridil	quinidine	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1  (systemic) and  DRUG2 "	lidocaine	quinidine		CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
advise	Caution is warranted and therapeutic concentration monitoring is recommended for  DRUG1  when coadministered with  DRUG2 .	antiarrhythmics	CRIXIVAN		CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	" DRUG1 :  DRUG2 ,  DRUGOTHER ,  DRUGOTHER "	Anticonvulsants	carbamazepine	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUG1 :  DRUGOTHER ,  DRUG2 ,  DRUGOTHER "	Anticonvulsants	phenobarbital	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUG2 "	Anticonvulsants	phenytoin	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER :  DRUG1 ,  DRUG2 ,  DRUGOTHER "	carbamazepine	phenobarbital	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUG2 "	carbamazepine	phenytoin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUG2 "	phenobarbital	phenytoin	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
effect	 DRUG1  may not be effective due to decreased  DRUG2  concentrations in patients taking these agents concomitantly.	CRIXIVAN	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	" DRUG1 ,  DRUG2 : e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	Calcium Channel Blockers	Dihydropyridine	[Ca]	OCC(O)CO
other	" DRUG1 ,  DRUGOTHER : e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER "	Calcium Channel Blockers	felodipine	[Ca]	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUG1 ,  DRUGOTHER : e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER "	Calcium Channel Blockers	nifedipine	[Ca]	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUG1 ,  DRUGOTHER : e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 "	Calcium Channel Blockers	nicardipine	[Ca]	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER ,  DRUG1 : e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER "	Dihydropyridine	felodipine	OCC(O)CO	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUGOTHER ,  DRUG1 : e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER "	Dihydropyridine	nifedipine	OCC(O)CO	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER ,  DRUG1 : e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 "	Dihydropyridine	nicardipine	OCC(O)CO	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER ,  DRUGOTHER : e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER "	felodipine	nifedipine	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER ,  DRUGOTHER : e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 "	felodipine	nicardipine	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER ,  DRUGOTHER : e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 "	nifedipine	nicardipine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	 DRUG1  concentration    DRUG2  concentration	clarithromycin	indinavir	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	 DRUG1 :  DRUG2 	HMG-CoA Reductase Inhibitor	atorvastatin		CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Use lowest possible dose of  DRUG1  with careful monitoring, or consider  DRUG2  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  in combination with  DRUGOTHER ."	atorvastatin	HMG-CoA reductase inhibitors	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	
other	"Use lowest possible dose of  DRUG1  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  in combination with  DRUGOTHER ."	atorvastatin	pravastatin	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
other	"Use lowest possible dose of  DRUG1  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  in combination with  DRUGOTHER ."	atorvastatin	fluvastatin	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
other	"Use lowest possible dose of  DRUG1  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUGOTHER , or  DRUG2  in combination with  DRUGOTHER ."	atorvastatin	rosuvastatin	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
advise	"Use lowest possible dose of  DRUG1  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  in combination with  DRUG2 ."	atorvastatin	CRIXIVAN	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUG1  that are not primarily metabolized by CYP3A4, such as  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  in combination with  DRUGOTHER ."	HMG-CoA reductase inhibitors	pravastatin		[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUG1  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  in combination with  DRUGOTHER ."	HMG-CoA reductase inhibitors	fluvastatin		CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUG1  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUGOTHER , or  DRUG2  in combination with  DRUGOTHER ."	HMG-CoA reductase inhibitors	rosuvastatin		CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
advise	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUG1  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  in combination with  DRUG2 ."	HMG-CoA reductase inhibitors	CRIXIVAN		CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUG1 ,  DRUG2 , or  DRUGOTHER  in combination with  DRUGOTHER ."	pravastatin	fluvastatin	[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUG1 ,  DRUGOTHER , or  DRUG2  in combination with  DRUGOTHER ."	pravastatin	rosuvastatin	[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUG1 ,  DRUGOTHER , or  DRUGOTHER  in combination with  DRUG2 ."	pravastatin	CRIXIVAN	[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUG1 , or  DRUG2  in combination with  DRUGOTHER ."	fluvastatin	rosuvastatin	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUG1 , or  DRUGOTHER  in combination with  DRUG2 ."	fluvastatin	CRIXIVAN	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Use lowest possible dose of  DRUGOTHER  with careful monitoring, or consider  DRUGOTHER  that are not primarily metabolized by CYP3A4, such as  DRUGOTHER ,  DRUGOTHER , or  DRUG1  in combination with  DRUG2 ."	rosuvastatin	CRIXIVAN	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	" DRUG1 :  DRUG2 ,  DRUGOTHER ,  DRUGOTHER "	Immunosuppressants	cyclosporine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	" DRUG1 :  DRUGOTHER ,  DRUG2 ,  DRUGOTHER "	Immunosuppressants	tacrolimus	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUG2 "	Immunosuppressants	sirolimus	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
other	" DRUGOTHER :  DRUG1 ,  DRUG2 ,  DRUGOTHER "	cyclosporine	tacrolimus	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUG2 "	cyclosporine	sirolimus	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUG2 "	tacrolimus	sirolimus	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
advise	Dose reduction of  DRUG1  to 600 mg every 8 hours is recommended when administering  DRUG2  concurrently.	CRIXIVAN	itraconazole	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	 DRUG1  concentration    DRUG2  concentration	indinavir	rifabutin	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	Dose reduction of  DRUG1  to half the standard dose and a dose increase of  DRUG2  to 1000 mg (three 333-mg capsules) every 8 hours are recommended when  DRUGOTHER  and  DRUGOTHER  are coadministered.	rifabutin	CRIXIVAN	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	Dose reduction of  DRUG1  to half the standard dose and a dose increase of  DRUGOTHER  to 1000 mg (three 333-mg capsules) every 8 hours are recommended when  DRUG2  and  DRUGOTHER  are coadministered.	rifabutin	rifabutin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	Dose reduction of  DRUG1  to half the standard dose and a dose increase of  DRUGOTHER  to 1000 mg (three 333-mg capsules) every 8 hours are recommended when  DRUGOTHER  and  DRUG2  are coadministered.	rifabutin	CRIXIVAN	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	Dose reduction of  DRUGOTHER  to half the standard dose and a dose increase of  DRUG1  to 1000 mg (three 333-mg capsules) every 8 hours are recommended when  DRUG2  and  DRUGOTHER  are coadministered.	CRIXIVAN	rifabutin	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	Dose reduction of  DRUGOTHER  to half the standard dose and a dose increase of  DRUG1  to 1000 mg (three 333-mg capsules) every 8 hours are recommended when  DRUGOTHER  and  DRUG2  are coadministered.	CRIXIVAN	CRIXIVAN	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
advise	Dose reduction of  DRUGOTHER  to half the standard dose and a dose increase of  DRUGOTHER  to 1000 mg (three 333-mg capsules) every 8 hours are recommended when  DRUG1  and  DRUG2  are coadministered.	rifabutin	CRIXIVAN	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
advise	 DRUG1  dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant  DRUG2  therapy.	Sildenafil	indinavir	CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
advise	 DRUG1  dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant  DRUG2  therapy.	Tadalafil	indinavir	[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
advise	 DRUG1  dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant  DRUG2  therapy.	Vardenafil	indinavir	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	Prolonged recovery time may occur if  DRUG1  and/or  DRUG2  are used concurrently with  DRUGOTHER .	barbiturates	narcotics	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
effect	Prolonged recovery time may occur if  DRUG1  and/or  DRUGOTHER  are used concurrently with  DRUG2 .	barbiturates	ketamine	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl
effect	Prolonged recovery time may occur if  DRUGOTHER  and/or  DRUG1  are used concurrently with  DRUG2 .	narcotics	ketamine	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl
other	 DRUG1  is clinically compatible with the commonly used general and local  DRUG2  when an adequate respiratory exchange is maintained.	Ketamine	anesthetic agents	CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl	CCOC(=O)C1=CC=C(N)C=C1
effect	Preliminary data which suggest that  DRUG1  may inhibit the anti-inflammatory activity of  DRUG2  have not been confirmed.	dapsone	Lamprene	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1
advise	"If leprosy-associated inflammatory reactions develop in patients being treated with  DRUG1  and  DRUG2 , it is still advisable to continue treatment with both drugs."	dapsone	clofazimine	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1
int	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUG2  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	Monoamine oxidase inhibitors	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG2  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	MAOI	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG2  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	flupenthixol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG2  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	Arecoline	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	COC(=O)C1=CCCN(C)C1
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG2 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	Ethanol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG2  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	Flupenthixol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG2  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	Ethanol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	Tricyclic antidepressants	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	Flupenthixol	Flupenthixol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUG1  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	Flupenthixol	Tricyclic antidepressants	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUG2 ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	MAOI	OC(=O)CCCCCCCC(O)=O	
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUG2  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	MAOI	OC(=O)CCCCCCCC(O)=O	
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG2  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	flupenthixol	OC(=O)CCCCCCCC(O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG2  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	Arecoline	OC(=O)CCCCCCCC(O)=O	COC(=O)C1=CCCN(C)C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG2 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	Ethanol	OC(=O)CCCCCCCC(O)=O	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG2  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	Flupenthixol	OC(=O)CCCCCCCC(O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG2  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	Ethanol	OC(=O)CCCCCCCC(O)=O	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	Tricyclic antidepressants	OC(=O)CCCCCCCC(O)=O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	Monoamine oxidase inhibitors	Flupenthixol	OC(=O)CCCCCCCC(O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUG1  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	Monoamine oxidase inhibitors	Tricyclic antidepressants	OC(=O)CCCCCCCC(O)=O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUG2  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	MAOI		
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  could theoretically affect  DRUG2  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	flupenthixol		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG2  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Arecoline		COC(=O)C1=CCCN(C)C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG2 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Ethanol		OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG2  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Flupenthixol		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG2  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Ethanol		OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Tricyclic antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	MAOI	Flupenthixol		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	MAOI	Tricyclic antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
effect	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG1  could theoretically affect  DRUG2  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	flupenthixol		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG1  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG2  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Arecoline		COC(=O)C1=CCCN(C)C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG1  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG2 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Ethanol		OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG1  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG2  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Flupenthixol		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG1  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG2  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Ethanol		OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG1  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	MAOI	Tricyclic antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG1  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	MAOI	Flupenthixol		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUG1  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	MAOI	Tricyclic antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG1  pharmacodynamics -  DRUG2  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	flupenthixol	Arecoline	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	COC(=O)C1=CCCN(C)C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG1  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG2 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	flupenthixol	Ethanol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG1  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG2  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	flupenthixol	Flupenthixol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG1  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG2  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	flupenthixol	Ethanol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG1  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	flupenthixol	Tricyclic antidepressants	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG1  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	flupenthixol	Flupenthixol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUG1  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	flupenthixol	Tricyclic antidepressants	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG1  - Eproxindine -  DRUG2 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Arecoline	Ethanol	COC(=O)C1=CCCN(C)C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG1  - Eproxindine -  DRUGOTHER :  DRUG2  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Arecoline	Flupenthixol	COC(=O)C1=CCCN(C)C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG1  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG2  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Arecoline	Ethanol	COC(=O)C1=CCCN(C)C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG1  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	Arecoline	Tricyclic antidepressants	COC(=O)C1=CCCN(C)C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG1  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	Arecoline	Flupenthixol	COC(=O)C1=CCCN(C)C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUG1  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	Arecoline	Tricyclic antidepressants	COC(=O)C1=CCCN(C)C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG1 :  DRUG2  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Ethanol	Flupenthixol	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG1 :  DRUGOTHER  and  DRUG2  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Ethanol	Ethanol	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG1 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	Ethanol	Tricyclic antidepressants	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG1 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	Ethanol	Flupenthixol	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUG1 :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	Ethanol	Tricyclic antidepressants	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
effect	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG1  and  DRUG2  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	Ethanol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG1  and  DRUGOTHER  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	Flupenthixol	Tricyclic antidepressants	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG1  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	Flupenthixol	Flupenthixol	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUG1  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	Flupenthixol	Tricyclic antidepressants	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG1  cause additive CNS depression -  DRUG2 :  DRUGOTHER  increases the effect of  DRUGOTHER "	Ethanol	Tricyclic antidepressants	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG1  cause additive CNS depression -  DRUGOTHER :  DRUG2  increases the effect of  DRUGOTHER "	Ethanol	Flupenthixol	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUG1  cause additive CNS depression -  DRUGOTHER :  DRUGOTHER  increases the effect of  DRUG2 "	Ethanol	Tricyclic antidepressants	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG1 :  DRUG2  increases the effect of  DRUGOTHER "	Tricyclic antidepressants	Flupenthixol	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUG1 :  DRUGOTHER  increases the effect of  DRUG2 "	Tricyclic antidepressants	Tricyclic antidepressants	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
effect	"Drug Interactions:  DRUGOTHER  may interact with some drugs, like  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  could theoretically affect  DRUGOTHER  pharmacodynamics -  DRUGOTHER  - Eproxindine -  DRUGOTHER :  DRUGOTHER  and  DRUGOTHER  cause additive CNS depression -  DRUGOTHER :  DRUG1  increases the effect of  DRUG2 "	Flupenthixol	Tricyclic antidepressants	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
effect	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUG1  (1 mg/kg) removes the antiedematous action of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  and reduces the action of  DRUGOTHER ."	picrotoxin	diazepam	[H][C@@]12OC(=O)[C@@]34OC3C[C@@](O)(C3[C@@H](C1OC3=O)C(C)=C)[C@@]24C.[H][C@@]12C[C@@]3(O)C4[C@@H](C(OC4=O)[C@@]4([H])OC(=O)[C@]1(O2)[C@@]34C)C(C)(C)O	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
effect	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUG1  (1 mg/kg) removes the antiedematous action of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  and reduces the action of  DRUGOTHER ."	picrotoxin	phenazepam	[H][C@@]12OC(=O)[C@@]34OC3C[C@@](O)(C3[C@@H](C1OC3=O)C(C)=C)[C@@]24C.[H][C@@]12C[C@@]3(O)C4[C@@H](C(OC4=O)[C@@]4([H])OC(=O)[C@]1(O2)[C@@]34C)C(C)(C)O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  and reduces the action of  DRUGOTHER ."	diazepam	phenazepam	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  and reduces the action of  DRUGOTHER ."	diazepam	phenibut	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  and reduces the action of  DRUGOTHER ."	diazepam	amizyl	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC(=O)CCCCCCCC(O)=O
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  and reduces the action of  DRUG2 ."	diazepam	phentolamine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC(=O)CCCCCCCC(O)=O
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER  and reduces the action of  DRUGOTHER ."	phenazepam	phenibut	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2  and reduces the action of  DRUGOTHER ."	phenazepam	amizyl	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC(=O)CCCCCCCC(O)=O
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  and reduces the action of  DRUG2 ."	phenazepam	phentolamine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC(=O)CCCCCCCC(O)=O
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2  and reduces the action of  DRUGOTHER ."	phenibut	amizyl	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER  and reduces the action of  DRUG2 ."	phenibut	phentolamine	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that  DRUGOTHER  (1 mg/kg) removes the antiedematous action of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1  and reduces the action of  DRUG2 ."	amizyl	phentolamine	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	 DRUG1  -  DRUG2  may counteract the antinaturetic effect of  DRUGOTHER .	Cyclosporine	L-arginine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O
other	 DRUG1  -  DRUGOTHER  may counteract the antinaturetic effect of  DRUG2 .	Cyclosporine	cyclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
effect	 DRUGOTHER  -  DRUG1  may counteract the antinaturetic effect of  DRUG2 .	L-arginine	cyclosporin	N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUG1  -  DRUG2  may increase the absorption of  DRUGOTHER  if taken concomitantly.	Ibuprofen	L-arginine	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O
other	 DRUG1  -  DRUGOTHER  may increase the absorption of  DRUG2  if taken concomitantly.	Ibuprofen	ibuprofen	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
mechanism	 DRUGOTHER  -  DRUG1  may increase the absorption of  DRUG2  if taken concomitantly.	L-arginine	ibuprofen	N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	Organic  DRUG1  -  DRUG2  supplements theoretically may potentiate the effects of organic  DRUGOTHER  if taken concomitantly.	nitrates	L-arginine	[O-]N(=O)=O	N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O
other	Organic  DRUG1  -  DRUGOTHER  supplements theoretically may potentiate the effects of organic  DRUG2  if taken concomitantly.	nitrates	nitrates	[O-]N(=O)=O	[O-]N(=O)=O
effect	Organic  DRUGOTHER  -  DRUG1  supplements theoretically may potentiate the effects of organic  DRUG2  if taken concomitantly.	L-arginine	nitrates	N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O	[O-]N(=O)=O
other	" DRUG1  - Theoretically,  DRUG2  supplements taken concomitantly with  DRUGOTHER , may potentiate the effects of the drug."	Sildenafil citrate	L-arginine	CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1	N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O
other	" DRUG1  - Theoretically,  DRUGOTHER  supplements taken concomitantly with  DRUG2 , may potentiate the effects of the drug."	Sildenafil citrate	sildenafil citrate	CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1	CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
effect	" DRUGOTHER  - Theoretically,  DRUG1  supplements taken concomitantly with  DRUG2 , may potentiate the effects of the drug."	L-arginine	sildenafil citrate	N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O	CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
other	"Particular caution should be exercised in using preparations containing  DRUG1 ,  DRUG2 , or  DRUGOTHER  in combination with  DRUGOTHER  Gel."	sulfur	resorcinol	OS(O)(=O)=O	OC1=CC(O)=CC=C1
other	"Particular caution should be exercised in using preparations containing  DRUG1 ,  DRUGOTHER , or  DRUG2  in combination with  DRUGOTHER  Gel."	sulfur	salicylic acid	OS(O)(=O)=O	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
other	"Particular caution should be exercised in using preparations containing  DRUG1 ,  DRUGOTHER , or  DRUGOTHER  in combination with  DRUG2  Gel."	sulfur	DIFFERIN	OS(O)(=O)=O	COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2
other	"Particular caution should be exercised in using preparations containing  DRUGOTHER ,  DRUG1 , or  DRUG2  in combination with  DRUGOTHER  Gel."	resorcinol	salicylic acid	OC1=CC(O)=CC=C1	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
other	"Particular caution should be exercised in using preparations containing  DRUGOTHER ,  DRUG1 , or  DRUGOTHER  in combination with  DRUG2  Gel."	resorcinol	DIFFERIN	OC1=CC(O)=CC=C1	COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2
other	"Particular caution should be exercised in using preparations containing  DRUGOTHER ,  DRUGOTHER , or  DRUG1  in combination with  DRUG2  Gel."	salicylic acid	DIFFERIN	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1	COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2
other	"No interactions have been observed between  DRUG1  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	nizatidine	theophylline	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"No interactions have been observed between  DRUG1  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	nizatidine	chlordiazepoxide	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"No interactions have been observed between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	nizatidine	lorazepam	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"No interactions have been observed between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	nizatidine	lidocaine	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	
other	"No interactions have been observed between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	nizatidine	phenytoin	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"No interactions have been observed between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	nizatidine	warfarin	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No interactions have been observed between  DRUGOTHER  and  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	theophylline	chlordiazepoxide	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"No interactions have been observed between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	theophylline	lorazepam	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"No interactions have been observed between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	theophylline	lidocaine	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	
other	"No interactions have been observed between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	theophylline	phenytoin	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"No interactions have been observed between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	theophylline	warfarin	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	chlordiazepoxide	lorazepam	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	chlordiazepoxide	lidocaine	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1	
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	chlordiazepoxide	phenytoin	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	chlordiazepoxide	warfarin	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	lorazepam	lidocaine	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2	
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	lorazepam	phenytoin	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	lorazepam	warfarin	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	lidocaine	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	lidocaine	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No interactions have been observed between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	phenytoin	warfarin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In patients given very high doses (3900 mg) of  DRUG1  daily, increases in serum  DRUG2  levels were seen when  DRUGOTHER , 150 mg b.i.d., was administered concurrently."	aspirin	salicylate	CC(=O)OC1=CC=CC=C1C(O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
mechanism	"In patients given very high doses (3900 mg) of  DRUG1  daily, increases in serum  DRUGOTHER  levels were seen when  DRUG2 , 150 mg b.i.d., was administered concurrently."	aspirin	nizatidine	CC(=O)OC1=CC=CC=C1C(O)=O	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O
other	"In patients given very high doses (3900 mg) of  DRUGOTHER  daily, increases in serum  DRUG1  levels were seen when  DRUG2 , 150 mg b.i.d., was administered concurrently."	salicylate	nizatidine	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O
advise	 DRUG1  should be used with caution in patients who are receiving a  DRUG2  orally because of the potential for additive effects on systemic beta-blockade.	Ocupress	beta-adrenergic blocking agent	CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
advise	"Close observation of the patient is recommended when a  DRUG1  is administered to patients receiving catecholamine-depleting drugs such as  DRUG2 , because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension."	beta-blocker	reserpine		CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"These drugs include the  DRUG1  and other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	diuretics	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	corticosteroids	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	phenothiazines	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	thyroid products	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	estrogens	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	contraceptives	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	phenytoin	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	nicotinic acid	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	thiazides	sympathomimetics	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	thiazides	calcium channel-blocking drugs	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[Ca]
other	"These drugs include the  DRUG1  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	thiazides	isoniazid	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	corticosteroids	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	phenothiazines	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	thyroid products	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	estrogens	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	contraceptives	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	phenytoin	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	nicotinic acid	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	diuretics	sympathomimetics	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	diuretics	calcium channel-blocking drugs	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	diuretics	isoniazid	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	phenothiazines	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	thyroid products	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	estrogens	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	contraceptives	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	phenytoin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	nicotinic acid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	corticosteroids	sympathomimetics	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	corticosteroids	calcium channel-blocking drugs	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	corticosteroids	isoniazid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	thyroid products	N1C2=CC=CC=C2SC2=CC=CC=C12	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	estrogens	N1C2=CC=CC=C2SC2=CC=CC=C12	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	contraceptives	N1C2=CC=CC=C2SC2=CC=CC=C12	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	phenytoin	N1C2=CC=CC=C2SC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	nicotinic acid	N1C2=CC=CC=C2SC2=CC=CC=C12	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	phenothiazines	sympathomimetics	N1C2=CC=CC=C2SC2=CC=CC=C12	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	phenothiazines	calcium channel-blocking drugs	N1C2=CC=CC=C2SC2=CC=CC=C12	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	phenothiazines	isoniazid	N1C2=CC=CC=C2SC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	estrogens		C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	contraceptives		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	nicotinic acid		OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	thyroid products	sympathomimetics		
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	thyroid products	calcium channel-blocking drugs		[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	thyroid products	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	estrogens	contraceptives	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	estrogens	phenytoin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	estrogens	nicotinic acid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	estrogens	sympathomimetics	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	estrogens	calcium channel-blocking drugs	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	estrogens	isoniazid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	phenytoin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	nicotinic acid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	contraceptives	sympathomimetics	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	contraceptives	calcium channel-blocking drugs	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	contraceptives	isoniazid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenytoin	nicotinic acid	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	phenytoin	sympathomimetics	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	phenytoin	calcium channel-blocking drugs	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	phenytoin	isoniazid	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	nicotinic acid	sympathomimetics	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1	
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	nicotinic acid	calcium channel-blocking drugs	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1	[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	nicotinic acid	isoniazid	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	sympathomimetics	calcium channel-blocking drugs		[Ca]
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	sympathomimetics	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"These drugs include the  DRUGOTHER  and other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	calcium channel-blocking drugs	isoniazid	[Ca]	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"When such drugs are withdrawn from patients receiving  DRUG1  in combination with  DRUG2  or  DRUGOTHER , patients should be observed closely for any evidence of hypoglycemia."	Acarbose	sulfonylureas	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	NC(N)=O
other	"When such drugs are withdrawn from patients receiving  DRUG1  in combination with  DRUGOTHER  or  DRUG2 , patients should be observed closely for any evidence of hypoglycemia."	Acarbose	insulin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	
other	"When such drugs are withdrawn from patients receiving  DRUGOTHER  in combination with  DRUG1  or  DRUG2 , patients should be observed closely for any evidence of hypoglycemia."	sulfonylureas	insulin	NC(N)=O	
other	" DRUG1  (e. g.,  DRUG2 ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUGOTHER ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	Intestinal adsorbents	charcoal	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUG1  (e. g.,  DRUGOTHER ) and  DRUG2  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUGOTHER ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	Intestinal adsorbents	digestive enzyme preparations	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[Na+].[Na+].[O-]P([O-])(F)=O
other	" DRUG1  (e. g.,  DRUGOTHER ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUG2 ,  DRUGOTHER ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	Intestinal adsorbents	amylase	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUG1  (e. g.,  DRUGOTHER ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUG2 ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	Intestinal adsorbents	pancreatin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
mechanism	" DRUG1  (e. g.,  DRUGOTHER ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUGOTHER ) may reduce the effect of  DRUG2  and should not be taken concomitantly."	Intestinal adsorbents	Acarbose	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O
other	" DRUGOTHER  (e. g.,  DRUG1 ) and  DRUG2  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUGOTHER ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	charcoal	digestive enzyme preparations	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	[Na+].[Na+].[O-]P([O-])(F)=O
other	" DRUGOTHER  (e. g.,  DRUG1 ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUG2 ,  DRUGOTHER ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	charcoal	amylase	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	
other	" DRUGOTHER  (e. g.,  DRUG1 ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUG2 ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	charcoal	pancreatin	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	
mechanism	" DRUGOTHER  (e. g.,  DRUG1 ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUGOTHER ) may reduce the effect of  DRUG2  and should not be taken concomitantly."	charcoal	Acarbose	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O
other	" DRUGOTHER  (e. g.,  DRUGOTHER ) and  DRUG1  containing carbohydrate-splitting enzymes (e. g.,  DRUG2 ,  DRUGOTHER ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	digestive enzyme preparations	amylase	[Na+].[Na+].[O-]P([O-])(F)=O	
other	" DRUGOTHER  (e. g.,  DRUGOTHER ) and  DRUG1  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUG2 ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	digestive enzyme preparations	pancreatin	[Na+].[Na+].[O-]P([O-])(F)=O	
other	" DRUGOTHER  (e. g.,  DRUGOTHER ) and  DRUG1  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUGOTHER ) may reduce the effect of  DRUG2  and should not be taken concomitantly."	digestive enzyme preparations	Acarbose	[Na+].[Na+].[O-]P([O-])(F)=O	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O
other	" DRUGOTHER  (e. g.,  DRUGOTHER ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUG1 ,  DRUG2 ) may reduce the effect of  DRUGOTHER  and should not be taken concomitantly."	amylase	pancreatin		
mechanism	" DRUGOTHER  (e. g.,  DRUGOTHER ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUG1 ,  DRUGOTHER ) may reduce the effect of  DRUG2  and should not be taken concomitantly."	amylase	Acarbose		[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O
mechanism	" DRUGOTHER  (e. g.,  DRUGOTHER ) and  DRUGOTHER  containing carbohydrate-splitting enzymes (e. g.,  DRUGOTHER ,  DRUG1 ) may reduce the effect of  DRUG2  and should not be taken concomitantly."	pancreatin	Acarbose		[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O
mechanism	" DRUG1  has been shown to change the bioavailabillty  DRUG2  when they are co-administered, which may require  DRUGOTHER  dose adjustment."	Acarbose	digoxin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  has been shown to change the bioavailabillty  DRUGOTHER  when they are co-administered, which may require  DRUG2  dose adjustment."	Acarbose	digoxin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  has been shown to change the bioavailabillty  DRUG1  when they are co-administered, which may require  DRUG2  dose adjustment."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Studies in healthy volunteers have shown that  DRUG1  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ."	Acarbose	digoxin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Studies in healthy volunteers have shown that  DRUG1  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ."	Acarbose	nifedipine	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Studies in healthy volunteers have shown that  DRUG1  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ."	Acarbose	propranolol	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"Studies in healthy volunteers have shown that  DRUG1  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ."	Acarbose	ranitidine	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Studies in healthy volunteers have shown that  DRUGOTHER  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ."	digoxin	nifedipine	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Studies in healthy volunteers have shown that  DRUGOTHER  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ."	digoxin	propranolol	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"Studies in healthy volunteers have shown that  DRUGOTHER  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ."	digoxin	ranitidine	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Studies in healthy volunteers have shown that  DRUGOTHER  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER ."	nifedipine	propranolol	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"Studies in healthy volunteers have shown that  DRUGOTHER  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 ."	nifedipine	ranitidine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Studies in healthy volunteers have shown that  DRUGOTHER  has no effect on either the pharmacokinetics or pharmacodynamics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 ."	propranolol	ranitidine	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	 DRUG1  did not interfere with the absorption or disposition of the  DRUG2   DRUGOTHER  in diabetic patients.	Acarbose	sulfonylurea	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	NC(N)=O
other	 DRUG1  did not interfere with the absorption or disposition of the  DRUGOTHER   DRUG2  in diabetic patients.	Acarbose	glyburide	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	 DRUGOTHER  did not interfere with the absorption or disposition of the  DRUG1   DRUG2  in diabetic patients.	sulfonylurea	glyburide	NC(N)=O	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	" DRUG1  may affect  DRUG2  bioavailabillty and may require dose adjustment of  DRUGOTHER  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUGOTHER  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUGOTHER  by 9% (90% confidence limit: 19% decrease to 2% increase)."	Acarbose	digoxin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  may affect  DRUGOTHER  bioavailabillty and may require dose adjustment of  DRUG2  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUGOTHER  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUGOTHER  by 9% (90% confidence limit: 19% decrease to 2% increase)."	Acarbose	digoxin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  may affect  DRUGOTHER  bioavailabillty and may require dose adjustment of  DRUGOTHER  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUG2  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUGOTHER  by 9% (90% confidence limit: 19% decrease to 2% increase)."	Acarbose	digoxin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  may affect  DRUGOTHER  bioavailabillty and may require dose adjustment of  DRUGOTHER  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUGOTHER  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUG2  by 9% (90% confidence limit: 19% decrease to 2% increase)."	Acarbose	digoxin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may affect  DRUG1  bioavailabillty and may require dose adjustment of  DRUG2  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUGOTHER  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUGOTHER  by 9% (90% confidence limit: 19% decrease to 2% increase)."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may affect  DRUG1  bioavailabillty and may require dose adjustment of  DRUGOTHER  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUG2  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUGOTHER  by 9% (90% confidence limit: 19% decrease to 2% increase)."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may affect  DRUG1  bioavailabillty and may require dose adjustment of  DRUGOTHER  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUGOTHER  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUG2  by 9% (90% confidence limit: 19% decrease to 2% increase)."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may affect  DRUGOTHER  bioavailabillty and may require dose adjustment of  DRUG1  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUG2  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUGOTHER  by 9% (90% confidence limit: 19% decrease to 2% increase)."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may affect  DRUGOTHER  bioavailabillty and may require dose adjustment of  DRUG1  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUGOTHER  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUG2  by 9% (90% confidence limit: 19% decrease to 2% increase)."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may affect  DRUGOTHER  bioavailabillty and may require dose adjustment of  DRUGOTHER  by 16% (90% confidence interval: 8-23%), decrease mean C max  DRUG1  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  DRUG2  by 9% (90% confidence limit: 19% decrease to 2% increase)."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"The amount of  DRUG1  absorbed while taking  DRUG2  was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values."	metformin	Acarbose	CN(C)C(=N)NC(N)=N	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O
mechanism	"However, the peak plasma level of  DRUG1  was reduced by approximately 20% when taking  DRUG2  due to a slight delay in the absorption of  DRUGOTHER ."	metformin	Acarbose	CN(C)C(=N)NC(N)=N	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O
other	"However, the peak plasma level of  DRUG1  was reduced by approximately 20% when taking  DRUGOTHER  due to a slight delay in the absorption of  DRUG2 ."	metformin	metformin	CN(C)C(=N)NC(N)=N	CN(C)C(=N)NC(N)=N
mechanism	"However, the peak plasma level of  DRUGOTHER  was reduced by approximately 20% when taking  DRUG1  due to a slight delay in the absorption of  DRUG2 ."	Acarbose	metformin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	CN(C)C(=N)NC(N)=N
other	There is little if any clinically significant interaction between  DRUG1  and  DRUG2 .	Acarbose	metformin	[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O	CN(C)C(=N)NC(N)=N
advise	" DRUG1  should be administered with caution to patients receiving  DRUG2  ( DRUGOTHER , Wyeth-Ayerst Laboratories)."	Isocarboxazid	Antabuse	CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1	CCN(CC)C(=S)SSC(=S)N(CC)CC
advise	" DRUG1  should be administered with caution to patients receiving  DRUGOTHER  ( DRUG2 , Wyeth-Ayerst Laboratories)."	Isocarboxazid	disulfiram	CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1	CCN(CC)C(=S)SSC(=S)N(CC)CC
other	" DRUGOTHER  should be administered with caution to patients receiving  DRUG1  ( DRUG2 , Wyeth-Ayerst Laboratories)."	Antabuse	disulfiram	CCN(CC)C(=S)SSC(=S)N(CC)CC	CCN(CC)C(=S)SSC(=S)N(CC)CC
effect	"In a single study, rats given high intraperitoneal doses of an  DRUG1  plus  DRUG2  experienced severe toxicity, including convulsions and death."	MAO inhibitor	disulfiram	CN(CC#C)CC1=CC=CC=C1	CCN(CC)C(=S)SSC(=S)N(CC)CC
advise	Concomitant use of  DRUG1  and other  DRUG2  is generally not recommended because of possible potentiating effects.	Isocarboxazid	psychotropic agents	CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"The monoamine oxidase inhibitory effects of  DRUG1  may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following  DRUG2 ."	Isocarboxazid	Isocarboxazid	CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1	CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1
other	 DRUG1  has been administered to patients receiving  DRUG2  or  DRUGOTHER  without adverse effects.	TAMBOCOR	digitalis preparations	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	O=[Fe]O[Fe]=O
other	 DRUG1  has been administered to patients receiving  DRUGOTHER  or  DRUG2  without adverse effects.	TAMBOCOR	beta-adrenergic blocking agents	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	 DRUGOTHER  has been administered to patients receiving  DRUG1  or  DRUG2  without adverse effects.	digitalis preparations	beta-adrenergic blocking agents	O=[Fe]O[Fe]=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
mechanism	"During administration of multiple oral doses of  DRUG1  to healthy subjects stabilized on a maintenance dose of  DRUG2 , a 13%-19% increase in plasma  DRUGOTHER  levels occurred at six hours postdose."	TAMBOCOR	digoxin	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"During administration of multiple oral doses of  DRUG1  to healthy subjects stabilized on a maintenance dose of  DRUGOTHER , a 13%-19% increase in plasma  DRUG2  levels occurred at six hours postdose."	TAMBOCOR	digoxin	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"During administration of multiple oral doses of  DRUGOTHER  to healthy subjects stabilized on a maintenance dose of  DRUG1 , a 13%-19% increase in plasma  DRUG2  levels occurred at six hours postdose."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	"In a study involving healthy subjects receiving  DRUG1  and  DRUG2  concurrently, plasma  DRUGOTHER  levels were increased about 20% and  DRUGOTHER  levels were increased about 30% compared to control values."	TAMBOCOR	propranolol	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In a study involving healthy subjects receiving  DRUG1  and  DRUGOTHER  concurrently, plasma  DRUG2  levels were increased about 20% and  DRUGOTHER  levels were increased about 30% compared to control values."	TAMBOCOR	flecainide	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"In a study involving healthy subjects receiving  DRUG1  and  DRUGOTHER  concurrently, plasma  DRUGOTHER  levels were increased about 20% and  DRUG2  levels were increased about 30% compared to control values."	TAMBOCOR	propranolol	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In a study involving healthy subjects receiving  DRUGOTHER  and  DRUG1  concurrently, plasma  DRUG2  levels were increased about 20% and  DRUGOTHER  levels were increased about 30% compared to control values."	propranolol	flecainide	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"In a study involving healthy subjects receiving  DRUGOTHER  and  DRUG1  concurrently, plasma  DRUGOTHER  levels were increased about 20% and  DRUG2  levels were increased about 30% compared to control values."	propranolol	propranolol	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In a study involving healthy subjects receiving  DRUGOTHER  and  DRUGOTHER  concurrently, plasma  DRUG1  levels were increased about 20% and  DRUG2  levels were increased about 30% compared to control values."	flecainide	propranolol	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In this formal interaction study,  DRUG1  and  DRUG2  were each found to have negative inotropic effects;"	TAMBOCOR	propranolol	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
effect	The effects of concomitant administration of  DRUG1  and  DRUG2  on the PR interval were less than additive.	TAMBOCOR	propranolol	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In  DRUG1  clinical trials, patients who were receiving  DRUG2  concurrently did not experience an increased incidence of side effects."	TAMBOCOR	beta blockers	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	
effect	"Nevertheless, the possibility of additive negative inotropic effects of  DRUG1  and  DRUG2  should be recognized."	beta blockers	flecainide		FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	 DRUG1  has been used in a large number of patients receiving  DRUG2  without apparent interaction.	TAMBOCOR	diuretics	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Limited data in patients receiving known enzyme inducers (  DRUG1 ,  DRUG2 ,  DRUGOTHER  ) indicate only a 30% increase in the rate of  DRUGOTHER  elimination."	phenytoin	phenobarbital	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Limited data in patients receiving known enzyme inducers (  DRUG1 ,  DRUGOTHER ,  DRUG2  ) indicate only a 30% increase in the rate of  DRUGOTHER  elimination."	phenytoin	carbamazepine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
mechanism	"Limited data in patients receiving known enzyme inducers (  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  ) indicate only a 30% increase in the rate of  DRUG2  elimination."	phenytoin	flecainide	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"Limited data in patients receiving known enzyme inducers (  DRUGOTHER ,  DRUG1 ,  DRUG2  ) indicate only a 30% increase in the rate of  DRUGOTHER  elimination."	phenobarbital	carbamazepine	CCC1(CC)C(=O)NC(=O)NC1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
mechanism	"Limited data in patients receiving known enzyme inducers (  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  ) indicate only a 30% increase in the rate of  DRUG2  elimination."	phenobarbital	flecainide	CCC1(CC)C(=O)NC(=O)NC1=O	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
mechanism	"Limited data in patients receiving known enzyme inducers (  DRUGOTHER ,  DRUGOTHER ,  DRUG1  ) indicate only a 30% increase in the rate of  DRUG2  elimination."	carbamazepine	flecainide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
mechanism	"In healthy subjects receiving  DRUG1  (1 gm daily) for one week, plasma  DRUG2  levels increased by about 30% and half-life increased by about 10%."	cimetidine	flecainide	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
mechanism	"When  DRUG1  is added to  DRUG2  therapy, plasma  DRUGOTHER  levels may increase two-fold or more in some patients, if  DRUGOTHER  dosage is not reduced."	amiodarone	flecainide	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"When  DRUG1  is added to  DRUGOTHER  therapy, plasma  DRUG2  levels may increase two-fold or more in some patients, if  DRUGOTHER  dosage is not reduced."	amiodarone	flecainide	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"When  DRUG1  is added to  DRUGOTHER  therapy, plasma  DRUGOTHER  levels may increase two-fold or more in some patients, if  DRUG2  dosage is not reduced."	amiodarone	flecainide	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"When  DRUGOTHER  is added to  DRUG1  therapy, plasma  DRUG2  levels may increase two-fold or more in some patients, if  DRUGOTHER  dosage is not reduced."	flecainide	flecainide	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"When  DRUGOTHER  is added to  DRUG1  therapy, plasma  DRUGOTHER  levels may increase two-fold or more in some patients, if  DRUG2  dosage is not reduced."	flecainide	flecainide	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"When  DRUGOTHER  is added to  DRUGOTHER  therapy, plasma  DRUG1  levels may increase two-fold or more in some patients, if  DRUG2  dosage is not reduced."	flecainide	flecainide	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
mechanism	"Drugs that inhibit cytochrome P450IID6, such as  DRUG1  , might increase the plasma concentrations of  DRUG2  in patients that are on chronic  DRUGOTHER  therapy;"	quinidine	flecainide	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"Drugs that inhibit cytochrome P450IID6, such as  DRUG1  , might increase the plasma concentrations of  DRUGOTHER  in patients that are on chronic  DRUG2  therapy;"	quinidine	flecainide	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"Drugs that inhibit cytochrome P450IID6, such as  DRUGOTHER  , might increase the plasma concentrations of  DRUG1  in patients that are on chronic  DRUG2  therapy;"	flecainide	flecainide	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	There has been little experience with the coadministration of  DRUG1  and either  DRUG2  or  DRUGOTHER .	TAMBOCOR	disopyramide	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	OC(=O)CCCCCCCC(O)=O
other	There has been little experience with the coadministration of  DRUG1  and either  DRUGOTHER  or  DRUG2 .	TAMBOCOR	verapamil	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	There has been little experience with the coadministration of  DRUGOTHER  and either  DRUG1  or  DRUG2 .	disopyramide	verapamil	OC(=O)CCCCCCCC(O)=O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Because both of these drugs have negative inotropic properties and the effects of coadministration with  DRUG1  are unknown, neither  DRUG2  nor  DRUGOTHER  should be administered concurrently with  DRUGOTHER  unless, in the judgment of the physician, the benefits of this combination outweigh the risks."	TAMBOCOR	disopyramide	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Because both of these drugs have negative inotropic properties and the effects of coadministration with  DRUG1  are unknown, neither  DRUGOTHER  nor  DRUG2  should be administered concurrently with  DRUGOTHER  unless, in the judgment of the physician, the benefits of this combination outweigh the risks."	TAMBOCOR	verapamil	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Because both of these drugs have negative inotropic properties and the effects of coadministration with  DRUG1  are unknown, neither  DRUGOTHER  nor  DRUGOTHER  should be administered concurrently with  DRUG2  unless, in the judgment of the physician, the benefits of this combination outweigh the risks."	TAMBOCOR	TAMBOCOR	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"Because both of these drugs have negative inotropic properties and the effects of coadministration with  DRUGOTHER  are unknown, neither  DRUG1  nor  DRUG2  should be administered concurrently with  DRUGOTHER  unless, in the judgment of the physician, the benefits of this combination outweigh the risks."	disopyramide	verapamil	OC(=O)CCCCCCCC(O)=O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
advise	"Because both of these drugs have negative inotropic properties and the effects of coadministration with  DRUGOTHER  are unknown, neither  DRUG1  nor  DRUGOTHER  should be administered concurrently with  DRUG2  unless, in the judgment of the physician, the benefits of this combination outweigh the risks."	disopyramide	TAMBOCOR	OC(=O)CCCCCCCC(O)=O	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
advise	"Because both of these drugs have negative inotropic properties and the effects of coadministration with  DRUGOTHER  are unknown, neither  DRUGOTHER  nor  DRUG1  should be administered concurrently with  DRUG2  unless, in the judgment of the physician, the benefits of this combination outweigh the risks."	verapamil	TAMBOCOR	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	There has been too little experience with the coadministration of  DRUG1  with  DRUG2  or  DRUGOTHER  to recommend concomitant use.	TAMBOCOR	nifedipine	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	There has been too little experience with the coadministration of  DRUG1  with  DRUGOTHER  or  DRUG2  to recommend concomitant use.	TAMBOCOR	diltiazem	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	
other	There has been too little experience with the coadministration of  DRUGOTHER  with  DRUG1  or  DRUG2  to recommend concomitant use.	nifedipine	diltiazem	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	 DRUG1   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Itraconazole	Ketoconazole	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	 DRUG1   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Itraconazole	Erythromycin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	 DRUG1   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Itraconazole	Clarithromycin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	 DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Itraconazole	Telithromycin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	 DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Itraconazole	HIV protease inhibitors	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	
other	 DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Itraconazole	Nefazodone	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	 DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2  Large quantities of grapefruit juice ( 1 quart daily)	Itraconazole	Cyclosporine	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUGOTHER   DRUG1   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Ketoconazole	Erythromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	 DRUGOTHER   DRUG1   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Ketoconazole	Clarithromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	 DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Ketoconazole	Telithromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	 DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Ketoconazole	HIV protease inhibitors	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	
other	 DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Ketoconazole	Nefazodone	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	 DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2  Large quantities of grapefruit juice ( 1 quart daily)	Ketoconazole	Cyclosporine	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUGOTHER   DRUGOTHER   DRUG1   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Erythromycin	Clarithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	 DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Erythromycin	Telithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	 DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Erythromycin	HIV protease inhibitors	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	
other	 DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Erythromycin	Nefazodone	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	 DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2  Large quantities of grapefruit juice ( 1 quart daily)	Erythromycin	Cyclosporine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUG2   DRUGOTHER   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Clarithromycin	Telithromycin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUG2   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Clarithromycin	HIV protease inhibitors	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUG2   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Clarithromycin	Nefazodone	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG2  Large quantities of grapefruit juice ( 1 quart daily)	Clarithromycin	Cyclosporine	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUG2   DRUGOTHER   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Telithromycin	HIV protease inhibitors	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1	
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUG2   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	Telithromycin	Nefazodone	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUGOTHER   DRUG2  Large quantities of grapefruit juice ( 1 quart daily)	Telithromycin	Cyclosporine	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUG2   DRUGOTHER  Large quantities of grapefruit juice ( 1 quart daily)	HIV protease inhibitors	Nefazodone		NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUGOTHER   DRUG2  Large quantities of grapefruit juice ( 1 quart daily)	HIV protease inhibitors	Cyclosporine		CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUGOTHER   DRUG1   DRUG2  Large quantities of grapefruit juice ( 1 quart daily)	Nefazodone	Cyclosporine	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUG1  Other  DRUG2   DRUGOTHER  ( DRUGOTHER ) (=1 g/day)	Gemfibrozil	fibrates	CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1	
other	 DRUG1  Other  DRUGOTHER   DRUG2  ( DRUGOTHER ) (=1 g/day)	Gemfibrozil	Niacin	CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O
other	 DRUG1  Other  DRUGOTHER   DRUGOTHER  ( DRUG2 ) (=1 g/day)	Gemfibrozil	nicotinic acid	CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	 DRUGOTHER  Other  DRUG1   DRUG2  ( DRUGOTHER ) (=1 g/day)	fibrates	Niacin		NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O
other	 DRUGOTHER  Other  DRUG1   DRUGOTHER  ( DRUG2 ) (=1 g/day)	fibrates	nicotinic acid		OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	 DRUGOTHER  Other  DRUGOTHER   DRUG1  ( DRUG2 ) (=1 g/day)	Niacin	nicotinic acid	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	" DRUG1 : The risk of myopathy/rhabdomyolysis is increased by concomitant administration of  DRUG2  particularly with higher doses of  DRUGOTHER  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Danazol	danazol	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3
other	" DRUG1 : The risk of myopathy/rhabdomyolysis is increased by concomitant administration of  DRUGOTHER  particularly with higher doses of  DRUG2  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Danazol	lovastatin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
effect	" DRUGOTHER : The risk of myopathy/rhabdomyolysis is increased by concomitant administration of  DRUG1  particularly with higher doses of  DRUG2  (see WARNINGS, Myopathy/Rhabdomyolysis)."	danazol	lovastatin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	" DRUG1  or  DRUG2 : The risk of myopathy/rhabdomyolysis is increased when either  DRUGOTHER  or  DRUGOTHER  is used concomitantly with a closely related member of the  DRUGOTHER  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Amiodarone	Verapamil	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	" DRUG1  or  DRUGOTHER : The risk of myopathy/rhabdomyolysis is increased when either  DRUG2  or  DRUGOTHER  is used concomitantly with a closely related member of the  DRUGOTHER  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Amiodarone	amiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	" DRUG1  or  DRUGOTHER : The risk of myopathy/rhabdomyolysis is increased when either  DRUGOTHER  or  DRUG2  is used concomitantly with a closely related member of the  DRUGOTHER  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Amiodarone	verapamil	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	" DRUG1  or  DRUGOTHER : The risk of myopathy/rhabdomyolysis is increased when either  DRUGOTHER  or  DRUGOTHER  is used concomitantly with a closely related member of the  DRUG2  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Amiodarone	HMG-CoA reductase inhibitor class	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	
other	" DRUGOTHER  or  DRUG1 : The risk of myopathy/rhabdomyolysis is increased when either  DRUG2  or  DRUGOTHER  is used concomitantly with a closely related member of the  DRUGOTHER  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Verapamil	amiodarone	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	" DRUGOTHER  or  DRUG1 : The risk of myopathy/rhabdomyolysis is increased when either  DRUGOTHER  or  DRUG2  is used concomitantly with a closely related member of the  DRUGOTHER  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Verapamil	verapamil	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	" DRUGOTHER  or  DRUG1 : The risk of myopathy/rhabdomyolysis is increased when either  DRUGOTHER  or  DRUGOTHER  is used concomitantly with a closely related member of the  DRUG2  (see WARNINGS, Myopathy/Rhabdomyolysis)."	Verapamil	HMG-CoA reductase inhibitor class	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	
other	" DRUGOTHER  or  DRUGOTHER : The risk of myopathy/rhabdomyolysis is increased when either  DRUG1  or  DRUG2  is used concomitantly with a closely related member of the  DRUGOTHER  (see WARNINGS, Myopathy/Rhabdomyolysis)."	amiodarone	verapamil	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
effect	" DRUGOTHER  or  DRUGOTHER : The risk of myopathy/rhabdomyolysis is increased when either  DRUG1  or  DRUGOTHER  is used concomitantly with a closely related member of the  DRUG2  (see WARNINGS, Myopathy/Rhabdomyolysis)."	amiodarone	HMG-CoA reductase inhibitor class	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	
effect	" DRUGOTHER  or  DRUGOTHER : The risk of myopathy/rhabdomyolysis is increased when either  DRUGOTHER  or  DRUG1  is used concomitantly with a closely related member of the  DRUG2  (see WARNINGS, Myopathy/Rhabdomyolysis)."	verapamil	HMG-CoA reductase inhibitor class	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	
other	" DRUG1 s: In a small clinical trial in which  DRUG2  was administered to  DRUGOTHER  treated patients, no effect on prothrombin time was detected."	Coumarin Anticoagulant	lovastatin	O=C1OC2=CC=CC=C2C=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	" DRUG1 s: In a small clinical trial in which  DRUGOTHER  was administered to  DRUG2  treated patients, no effect on prothrombin time was detected."	Coumarin Anticoagulant	warfarin	O=C1OC2=CC=CC=C2C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUGOTHER s: In a small clinical trial in which  DRUG1  was administered to  DRUG2  treated patients, no effect on prothrombin time was detected."	lovastatin	warfarin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
effect	"However, another  DRUG1  has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of  DRUG2 ."	HMG-CoA reductase inhibitor	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
effect	"Also, bleeding and/or increased prothrombin time have been reported in a few patients taking  DRUG1 s concomitantly with  DRUG2 ."	coumarin anticoagulant	lovastatin	O=C1OC2=CC=CC=C2C=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
advise	"It is recommended that in patients taking  DRUG1 , prothrombin time be determined before starting  DRUG2  and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs."	anticoagulants	lovastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	 DRUG1  therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking  DRUG2 .	Lovastatin	anticoagulants	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	
other	" DRUG1 : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of  DRUG2  and  DRUGOTHER ."	Propranolol	lovastatin	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	" DRUG1 : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of  DRUGOTHER  and  DRUG2 ."	Propranolol	propranolol	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	" DRUGOTHER : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of  DRUG1  and  DRUG2 ."	lovastatin	propranolol	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	" DRUG1 : In patients with hypercholesterolemia, concomitant administration of  DRUG2  and  DRUGOTHER  resulted in no effect on  DRUGOTHER  plasma concentrations."	Digoxin	lovastatin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	" DRUG1 : In patients with hypercholesterolemia, concomitant administration of  DRUGOTHER  and  DRUG2  resulted in no effect on  DRUGOTHER  plasma concentrations."	Digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1 : In patients with hypercholesterolemia, concomitant administration of  DRUGOTHER  and  DRUGOTHER  resulted in no effect on  DRUG2  plasma concentrations."	Digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER : In patients with hypercholesterolemia, concomitant administration of  DRUG1  and  DRUG2  resulted in no effect on  DRUGOTHER  plasma concentrations."	lovastatin	digoxin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER : In patients with hypercholesterolemia, concomitant administration of  DRUG1  and  DRUGOTHER  resulted in no effect on  DRUG2  plasma concentrations."	lovastatin	digoxin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER : In patients with hypercholesterolemia, concomitant administration of  DRUGOTHER  and  DRUG1  resulted in no effect on  DRUG2  plasma concentrations."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Oral  DRUG1 : In pharmacokinetic studies of  DRUG2  in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with  DRUGOTHER  or with  DRUGOTHER "	Hypoglycemic Agents	MEVACOR	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Oral  DRUG1 : In pharmacokinetic studies of  DRUGOTHER  in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with  DRUG2  or with  DRUGOTHER "	Hypoglycemic Agents	glipizide	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"Oral  DRUG1 : In pharmacokinetic studies of  DRUGOTHER  in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with  DRUGOTHER  or with  DRUG2 "	Hypoglycemic Agents	chlorpropamide	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
other	"Oral  DRUGOTHER : In pharmacokinetic studies of  DRUG1  in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with  DRUG2  or with  DRUGOTHER "	MEVACOR	glipizide	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"Oral  DRUGOTHER : In pharmacokinetic studies of  DRUG1  in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with  DRUGOTHER  or with  DRUG2 "	MEVACOR	chlorpropamide	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
other	"Oral  DRUGOTHER : In pharmacokinetic studies of  DRUGOTHER  in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with  DRUG1  or with  DRUG2 "	glipizide	chlorpropamide	CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
other	Effect of  DRUG1  on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6):  DRUG2   is a strong in vitro inhibitor of CYP2D6.	Sensipar	Sensipar	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
other	"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and most  DRUGOTHER ) may be required."	flecainide	vinblastine	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC
other	"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2  and most  DRUGOTHER ) may be required."	flecainide	thioridazine	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and most  DRUG2 ) may be required."	flecainide	tricyclic antidepressants	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2  and most  DRUGOTHER ) may be required."	vinblastine	thioridazine	CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and most  DRUG2 ) may be required."	vinblastine	tricyclic antidepressants	CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and most  DRUG2 ) may be required."	thioridazine	tricyclic antidepressants	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUG1 : Concurrent administration of 25 mg or 100 mg  DRUG2  with 50 mg  DRUGOTHER  increased  DRUGOTHER  exposure and  DRUGOTHER  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	Amitriptyline	cinacalcet	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
other	 DRUG1 : Concurrent administration of 25 mg or 100 mg  DRUGOTHER  with 50 mg  DRUG2  increased  DRUGOTHER  exposure and  DRUGOTHER  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	Amitriptyline	amitriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUG1 : Concurrent administration of 25 mg or 100 mg  DRUGOTHER  with 50 mg  DRUGOTHER  increased  DRUG2  exposure and  DRUGOTHER  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	Amitriptyline	amitriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUG1 : Concurrent administration of 25 mg or 100 mg  DRUGOTHER  with 50 mg  DRUGOTHER  increased  DRUGOTHER  exposure and  DRUG2  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	Amitriptyline	nortriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
mechanism	 DRUGOTHER : Concurrent administration of 25 mg or 100 mg  DRUG1  with 50 mg  DRUG2  increased  DRUGOTHER  exposure and  DRUGOTHER  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	cinacalcet	amitriptyline	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUGOTHER : Concurrent administration of 25 mg or 100 mg  DRUG1  with 50 mg  DRUGOTHER  increased  DRUG2  exposure and  DRUGOTHER  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	cinacalcet	amitriptyline	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUGOTHER : Concurrent administration of 25 mg or 100 mg  DRUG1  with 50 mg  DRUGOTHER  increased  DRUGOTHER  exposure and  DRUG2  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	cinacalcet	nortriptyline	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUGOTHER : Concurrent administration of 25 mg or 100 mg  DRUGOTHER  with 50 mg  DRUG1  increased  DRUG2  exposure and  DRUGOTHER  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	amitriptyline	amitriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUGOTHER : Concurrent administration of 25 mg or 100 mg  DRUGOTHER  with 50 mg  DRUG1  increased  DRUGOTHER  exposure and  DRUG2  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	amitriptyline	nortriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUGOTHER : Concurrent administration of 25 mg or 100 mg  DRUGOTHER  with 50 mg  DRUGOTHER  increased  DRUG1  exposure and  DRUG2  (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.	amitriptyline	nortriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Effect of other drugs on  DRUG1  :  DRUG2   is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2."	Sensipar	Sensipar	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
other	 DRUG1 :  DRUG2  is metabolized in part by CYP3A4.	Ketoconazole	Sensipar	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
mechanism	"Co-administration of  DRUG1 , a strong inhibitor of CYP3A4, increased  DRUG2  exposure following a single 90 mg dose of  DRUGOTHER  by 2.3 fold."	ketoconazole	cinacalcet	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
other	"Co-administration of  DRUG1 , a strong inhibitor of CYP3A4, increased  DRUGOTHER  exposure following a single 90 mg dose of  DRUG2  by 2.3 fold."	ketoconazole	Sensipar	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
other	"Co-administration of  DRUGOTHER , a strong inhibitor of CYP3A4, increased  DRUG1  exposure following a single 90 mg dose of  DRUG2  by 2.3 fold."	cinacalcet	Sensipar	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
advise	"Dose adjustment of  DRUG1  may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ;"	Sensipar	ketoconazole	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
advise	"Dose adjustment of  DRUG1  may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ;"	Sensipar	erythromycin	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
advise	"Dose adjustment of  DRUG1  may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ;"	Sensipar	itraconazole	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Dose adjustment of  DRUGOTHER  may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ;"	ketoconazole	erythromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Dose adjustment of  DRUGOTHER  may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ;"	ketoconazole	itraconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Dose adjustment of  DRUGOTHER  may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ;"	erythromycin	itraconazole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
effect	"The concurrent use of  DRUG1  Injection with other  DRUG2  or medications with anticholinergic activity, such as  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	Robinul	anticholinergics	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	C[N+](C)(C)CCO
effect	"The concurrent use of  DRUG1  Injection with other  DRUGOTHER  or medications with anticholinergic activity, such as  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	Robinul	phenothiazines	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	N1C2=CC=CC=C2SC2=CC=CC=C12
effect	"The concurrent use of  DRUG1  Injection with other  DRUGOTHER  or medications with anticholinergic activity, such as  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	Robinul	antiparkinson drugs	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12
effect	"The concurrent use of  DRUG1  Injection with other  DRUGOTHER  or medications with anticholinergic activity, such as  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	Robinul	tricyclic antidepressants	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The concurrent use of  DRUGOTHER  Injection with other  DRUG1  or medications with anticholinergic activity, such as  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	anticholinergics	phenothiazines	C[N+](C)(C)CCO	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"The concurrent use of  DRUGOTHER  Injection with other  DRUG1  or medications with anticholinergic activity, such as  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	anticholinergics	antiparkinson drugs	C[N+](C)(C)CCO	CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12
other	"The concurrent use of  DRUGOTHER  Injection with other  DRUG1  or medications with anticholinergic activity, such as  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	anticholinergics	tricyclic antidepressants	C[N+](C)(C)CCO	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The concurrent use of  DRUGOTHER  Injection with other  DRUGOTHER  or medications with anticholinergic activity, such as  DRUG1 ,  DRUG2 , or  DRUGOTHER , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	phenothiazines	antiparkinson drugs	N1C2=CC=CC=C2SC2=CC=CC=C12	CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12
other	"The concurrent use of  DRUGOTHER  Injection with other  DRUGOTHER  or medications with anticholinergic activity, such as  DRUG1 ,  DRUGOTHER , or  DRUG2 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	phenothiazines	tricyclic antidepressants	N1C2=CC=CC=C2SC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The concurrent use of  DRUGOTHER  Injection with other  DRUGOTHER  or medications with anticholinergic activity, such as  DRUGOTHER ,  DRUG1 , or  DRUG2 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."	antiparkinson drugs	tricyclic antidepressants	CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
mechanism	Concomitant administration of  DRUG1  Injection and  DRUG2  in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.	Robinul	potassium chloride	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	[KH]
advise	"- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered  DRUG1  in patients to whom  DRUG2  are also being given should be avoided, except in life-threatening conditions."	bumetanide	aminoglycoside antibiotics	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	-  DRUG1 :  DRUG2  should generally not be given with  DRUGOTHER  (such as  DRUGOTHER ) because they reduce its renal clearance and add a high risk of  DRUGOTHER  toxicity.	Lithium	Lithium	[Li+]	[Li+]
other	-  DRUG1 :  DRUGOTHER  should generally not be given with  DRUG2  (such as  DRUGOTHER ) because they reduce its renal clearance and add a high risk of  DRUGOTHER  toxicity.	Lithium	diuretics	[Li+]	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	-  DRUG1 :  DRUGOTHER  should generally not be given with  DRUGOTHER  (such as  DRUG2 ) because they reduce its renal clearance and add a high risk of  DRUGOTHER  toxicity.	Lithium	bumetanide	[Li+]	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	-  DRUG1 :  DRUGOTHER  should generally not be given with  DRUGOTHER  (such as  DRUGOTHER ) because they reduce its renal clearance and add a high risk of  DRUG2  toxicity.	Lithium	lithium	[Li+]	[Li+]
advise	-  DRUGOTHER :  DRUG1  should generally not be given with  DRUG2  (such as  DRUGOTHER ) because they reduce its renal clearance and add a high risk of  DRUGOTHER  toxicity.	Lithium	diuretics	[Li+]	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
advise	-  DRUGOTHER :  DRUG1  should generally not be given with  DRUGOTHER  (such as  DRUG2 ) because they reduce its renal clearance and add a high risk of  DRUGOTHER  toxicity.	Lithium	bumetanide	[Li+]	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	-  DRUGOTHER :  DRUG1  should generally not be given with  DRUGOTHER  (such as  DRUGOTHER ) because they reduce its renal clearance and add a high risk of  DRUG2  toxicity.	Lithium	lithium	[Li+]	[Li+]
other	-  DRUGOTHER :  DRUGOTHER  should generally not be given with  DRUG1  (such as  DRUG2 ) because they reduce its renal clearance and add a high risk of  DRUGOTHER  toxicity.	diuretics	bumetanide	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	-  DRUGOTHER :  DRUGOTHER  should generally not be given with  DRUG1  (such as  DRUGOTHER ) because they reduce its renal clearance and add a high risk of  DRUG2  toxicity.	diuretics	lithium	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[Li+]
other	-  DRUGOTHER :  DRUGOTHER  should generally not be given with  DRUGOTHER  (such as  DRUG1 ) because they reduce its renal clearance and add a high risk of  DRUG2  toxicity.	bumetanide	lithium	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	[Li+]
other	-  DRUG1 : Pretreatment with  DRUG2  reduces both the natriuresis and hyperreninemia produced by  DRUGOTHER .	Probenecid	probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	-  DRUG1 : Pretreatment with  DRUGOTHER  reduces both the natriuresis and hyperreninemia produced by  DRUG2 .	Probenecid	bumetanide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
effect	-  DRUGOTHER : Pretreatment with  DRUG1  reduces both the natriuresis and hyperreninemia produced by  DRUG2 .	probenecid	bumetanide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
mechanism	This antagonistic effect of  DRUG1  on  DRUG2  natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of  DRUGOTHER .	probenecid	bumetanide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	This antagonistic effect of  DRUG1  on  DRUGOTHER  natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of  DRUG2 .	probenecid	bumetanide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	This antagonistic effect of  DRUGOTHER  on  DRUG1  natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of  DRUG2 .	bumetanide	bumetanide	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
advise	"Thus,  DRUG1  should not be administered concurrently with  DRUG2 ."	probenecid	bumetanide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	-  DRUG1 :  DRUG2  blunts the increases in urine volume and sodium excretion seen during  DRUGOTHER  treatment and inhibits the  DRUGOTHER -induced increase in plasma renin activity.	Indomethacin	Indomethacin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	-  DRUG1 :  DRUGOTHER  blunts the increases in urine volume and sodium excretion seen during  DRUG2  treatment and inhibits the  DRUGOTHER -induced increase in plasma renin activity.	Indomethacin	bumetanide	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	-  DRUG1 :  DRUGOTHER  blunts the increases in urine volume and sodium excretion seen during  DRUGOTHER  treatment and inhibits the  DRUG2 -induced increase in plasma renin activity.	Indomethacin	bumetanide	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
mechanism	-  DRUGOTHER :  DRUG1  blunts the increases in urine volume and sodium excretion seen during  DRUG2  treatment and inhibits the  DRUGOTHER -induced increase in plasma renin activity.	Indomethacin	bumetanide	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
effect	-  DRUGOTHER :  DRUG1  blunts the increases in urine volume and sodium excretion seen during  DRUGOTHER  treatment and inhibits the  DRUG2 -induced increase in plasma renin activity.	Indomethacin	bumetanide	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	-  DRUGOTHER :  DRUGOTHER  blunts the increases in urine volume and sodium excretion seen during  DRUG1  treatment and inhibits the  DRUG2 -induced increase in plasma renin activity.	bumetanide	bumetanide	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	"-  DRUG1 :  DRUG2  may potentiate the effect of various  DRUGOTHER , necessitating a reduction in the dosage of these drugs."	Antihypertensives	Bumetanide	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	"-  DRUG1 :  DRUGOTHER  may potentiate the effect of various  DRUG2 , necessitating a reduction in the dosage of these drugs."	Antihypertensives	antihypertensive drugs	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
effect	"-  DRUGOTHER :  DRUG1  may potentiate the effect of various  DRUG2 , necessitating a reduction in the dosage of these drugs."	Bumetanide	antihypertensive drugs	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	-  DRUG1 : Interaction studies in humans have shown no effect on  DRUG2  blood levels.	Digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	-  DRUG1 : Interaction studies in humans have shown  DRUG2  to have no effect on  DRUGOTHER  metabolism or on plasma prothrombin activity.	Anticoagulants	bumetanide		CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	-  DRUG1 : Interaction studies in humans have shown  DRUGOTHER  to have no effect on  DRUG2  metabolism or on plasma prothrombin activity.	Anticoagulants	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	-  DRUGOTHER : Interaction studies in humans have shown  DRUG1  to have no effect on  DRUG2  metabolism or on plasma prothrombin activity.	bumetanide	warfarin	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	Two different types of therapy with  DRUG1  are used: physiological oral  DRUG2  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUG1  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUG2  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUG1  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUG2  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUG1  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUG2  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUG1  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUG2  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUG1  supplementation which is totally atoxic since it palliates  DRUG2  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUG1  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUG2  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUG1  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUG2  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUG1  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUG2  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUG1  deficiencies by simply normalizing the  DRUG2  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUG1  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUG2  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUG1  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUG2  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUG1  intake and pharmacological  DRUG2  therapy which may induce toxicity since it creates iatrogenic  DRUGOTHER  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUG1  intake and pharmacological  DRUGOTHER  therapy which may induce toxicity since it creates iatrogenic  DRUG2  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Two different types of therapy with  DRUGOTHER  are used: physiological oral  DRUGOTHER  supplementation which is totally atoxic since it palliates  DRUGOTHER  deficiencies by simply normalizing the  DRUGOTHER  intake and pharmacological  DRUG1  therapy which may induce toxicity since it creates iatrogenic  DRUG2  overload.	magnesium	magnesium	[Mg++]	[Mg++]
other	Primary and secondary  DRUG1  deficiencies constitute the sole indication of physiological oral  DRUG2  therapy.	magnesium	magnesium	[Mg++]	[Mg++]
other	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  DRUG1  deficit and to discriminate between  DRUG2  deficiency due to an insufficient  DRUGOTHER  intake which only requires oral physiological supplementation and  DRUGOTHER  depletion related to a dysregulation of the control mechanisms of  DRUGOTHER  status which requires more or less specific regulation of its causal dysregulation.	magnesium	magnesium	[Mg++]	[Mg++]
other	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  DRUG1  deficit and to discriminate between  DRUGOTHER  deficiency due to an insufficient  DRUG2  intake which only requires oral physiological supplementation and  DRUGOTHER  depletion related to a dysregulation of the control mechanisms of  DRUGOTHER  status which requires more or less specific regulation of its causal dysregulation.	magnesium	magnesium	[Mg++]	[Mg++]
other	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  DRUG1  deficit and to discriminate between  DRUGOTHER  deficiency due to an insufficient  DRUGOTHER  intake which only requires oral physiological supplementation and  DRUG2  depletion related to a dysregulation of the control mechanisms of  DRUGOTHER  status which requires more or less specific regulation of its causal dysregulation.	magnesium	magnesium	[Mg++]	[Mg++]
other	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  DRUG1  deficit and to discriminate between  DRUGOTHER  deficiency due to an insufficient  DRUGOTHER  intake which only requires oral physiological supplementation and  DRUGOTHER  depletion related to a dysregulation of the control mechanisms of  DRUG2  status which requires more or less specific regulation of its causal dysregulation.	magnesium	magnesium	[Mg++]	[Mg++]
other	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  DRUGOTHER  deficit and to discriminate between  DRUG1  deficiency due to an insufficient  DRUG2  intake which only requires oral physiological supplementation and  DRUGOTHER  depletion related to a dysregulation of the control mechanisms of  DRUGOTHER  status which requires more or less specific regulation of its causal dysregulation.	magnesium	magnesium	[Mg++]	[Mg++]
other	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  DRUGOTHER  deficit and to discriminate between  DRUG1  deficiency due to an insufficient  DRUGOTHER  intake which only requires oral physiological supplementation and  DRUG2  depletion related to a dysregulation of the control mechanisms of  DRUGOTHER  status which requires more or less specific regulation of its causal dysregulation.	magnesium	magnesium	[Mg++]	[Mg++]
other	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  DRUGOTHER  deficit and to discriminate between  DRUG1  deficiency due to an insufficient  DRUGOTHER  intake which only requires oral physiological supplementation and  DRUGOTHER  depletion related to a dysregulation of the control mechanisms of  DRUG2  status which requires more or less specific regulation of its causal dysregulation.	magnesium	magnesium	[Mg++]	[Mg++]
other	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  DRUGOTHER  deficit and to discriminate between  DRUGOTHER  deficiency due to an insufficient  DRUG1  intake which only requires oral physiological supplementation and  DRUG2  depletion related to a dysregulation of the control mechanisms of  DRUGOTHER  status which requires more or less specific regulation of its causal dysregulation.	magnesium	magnesium	[Mg++]	[Mg++]
other	Physiological oral  DRUG1  load constitutes the best tool for diagnosis of  DRUG2  deficiency and the first step of its treatment.	magnesium	magnesium	[Mg++]	[Mg++]
other	"Physiological oral  DRUG1  supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with  DRUG2 s, with practically only one contra-indication: overt renal failure."	magnesium	magnesium salt	[Mg++]	[MgH2]
other	"Specific and aspecific treatments of  DRUG1  depletion are tricky using for example  DRUG2 , pharmacological doses of  DRUGOTHER , physiological doses of  DRUGOTHER  and of  DRUGOTHER ."	magnesium	magnesium sparing diuretics	[Mg++]	[MgH2]
other	"Specific and aspecific treatments of  DRUG1  depletion are tricky using for example  DRUGOTHER , pharmacological doses of  DRUG2 , physiological doses of  DRUGOTHER  and of  DRUGOTHER ."	magnesium	vitamin B6	[Mg++]	OC(=O)CCCCCCCC(O)=O
other	"Specific and aspecific treatments of  DRUG1  depletion are tricky using for example  DRUGOTHER , pharmacological doses of  DRUGOTHER , physiological doses of  DRUG2  and of  DRUGOTHER ."	magnesium	vitamin D	[Mg++]	OC(=O)CCCCCCCC(O)=O
other	"Specific and aspecific treatments of  DRUG1  depletion are tricky using for example  DRUGOTHER , pharmacological doses of  DRUGOTHER , physiological doses of  DRUGOTHER  and of  DRUG2 ."	magnesium	selenium	[Mg++]	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"Specific and aspecific treatments of  DRUGOTHER  depletion are tricky using for example  DRUG1 , pharmacological doses of  DRUG2 , physiological doses of  DRUGOTHER  and of  DRUGOTHER ."	magnesium sparing diuretics	vitamin B6	[MgH2]	OC(=O)CCCCCCCC(O)=O
other	"Specific and aspecific treatments of  DRUGOTHER  depletion are tricky using for example  DRUG1 , pharmacological doses of  DRUGOTHER , physiological doses of  DRUG2  and of  DRUGOTHER ."	magnesium sparing diuretics	vitamin D	[MgH2]	OC(=O)CCCCCCCC(O)=O
other	"Specific and aspecific treatments of  DRUGOTHER  depletion are tricky using for example  DRUG1 , pharmacological doses of  DRUGOTHER , physiological doses of  DRUGOTHER  and of  DRUG2 ."	magnesium sparing diuretics	selenium	[MgH2]	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"Specific and aspecific treatments of  DRUGOTHER  depletion are tricky using for example  DRUGOTHER , pharmacological doses of  DRUG1 , physiological doses of  DRUG2  and of  DRUGOTHER ."	vitamin B6	vitamin D	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Specific and aspecific treatments of  DRUGOTHER  depletion are tricky using for example  DRUGOTHER , pharmacological doses of  DRUG1 , physiological doses of  DRUGOTHER  and of  DRUG2 ."	vitamin B6	selenium	OC(=O)CCCCCCCC(O)=O	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"Specific and aspecific treatments of  DRUGOTHER  depletion are tricky using for example  DRUGOTHER , pharmacological doses of  DRUGOTHER , physiological doses of  DRUG1  and of  DRUG2 ."	vitamin D	selenium	OC(=O)CCCCCCCC(O)=O	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"Lastly local use of the mucocutaneous and cytoprotective properties of  DRUG1  is still valid, in  DRUG2  and for preservation of transplants particularly."	magnesium	cardioplegic solutions	[Mg++]	[Mg++].[Cl-].[Cl-]
effect	High-dose  DRUG1  with  DRUG2  protection.	cisplatin	sodium thiosulfate	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	OS(O)(=O)=S
effect	 DRUG1  is a neutralizing agent for  DRUG2  that protects against renal damage.	Sodium thiosulfate	cisplatin	OS(O)(=O)=S	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"To determine whether injection of  DRUG1  would permit larger doses of  DRUG2  to be administered, a fixed 9.9-g/m2 dose of  DRUGOTHER  was given intravenously over three hours concurrently with escalating doses of  DRUGOTHER ."	thiosulfate	cisplatin	OS(O)(=O)=S	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"To determine whether injection of  DRUG1  would permit larger doses of  DRUGOTHER  to be administered, a fixed 9.9-g/m2 dose of  DRUG2  was given intravenously over three hours concurrently with escalating doses of  DRUGOTHER ."	thiosulfate	thiosulfate	OS(O)(=O)=S	OS(O)(=O)=S
other	"To determine whether injection of  DRUG1  would permit larger doses of  DRUGOTHER  to be administered, a fixed 9.9-g/m2 dose of  DRUGOTHER  was given intravenously over three hours concurrently with escalating doses of  DRUG2 ."	thiosulfate	cisplatin	OS(O)(=O)=S	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"To determine whether injection of  DRUGOTHER  would permit larger doses of  DRUG1  to be administered, a fixed 9.9-g/m2 dose of  DRUG2  was given intravenously over three hours concurrently with escalating doses of  DRUGOTHER ."	cisplatin	thiosulfate	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	OS(O)(=O)=S
other	"To determine whether injection of  DRUGOTHER  would permit larger doses of  DRUG1  to be administered, a fixed 9.9-g/m2 dose of  DRUGOTHER  was given intravenously over three hours concurrently with escalating doses of  DRUG2 ."	cisplatin	cisplatin	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"To determine whether injection of  DRUGOTHER  would permit larger doses of  DRUGOTHER  to be administered, a fixed 9.9-g/m2 dose of  DRUG1  was given intravenously over three hours concurrently with escalating doses of  DRUG2 ."	thiosulfate	cisplatin	OS(O)(=O)=S	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	 DRUG1  was administered over the last two hours of the  DRUG2  infusion.	Cisplatin	thiosulfate	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	OS(O)(=O)=S
other	"Comparison of  DRUG1  pharmacokinetics in patients treated with 202.5 mg/m2 plus  DRUG2  to those in patients treated with 100 mg/m2 without  DRUGOTHER  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  DRUGOTHER ."	cisplatin	thiosulfate	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	OS(O)(=O)=S
other	"Comparison of  DRUG1  pharmacokinetics in patients treated with 202.5 mg/m2 plus  DRUGOTHER  to those in patients treated with 100 mg/m2 without  DRUG2  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  DRUGOTHER ."	cisplatin	thiosulfate	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	OS(O)(=O)=S
other	"Comparison of  DRUG1  pharmacokinetics in patients treated with 202.5 mg/m2 plus  DRUGOTHER  to those in patients treated with 100 mg/m2 without  DRUGOTHER  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  DRUG2 ."	cisplatin	cisplatin	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"Comparison of  DRUGOTHER  pharmacokinetics in patients treated with 202.5 mg/m2 plus  DRUG1  to those in patients treated with 100 mg/m2 without  DRUG2  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  DRUGOTHER ."	thiosulfate	thiosulfate	OS(O)(=O)=S	OS(O)(=O)=S
other	"Comparison of  DRUGOTHER  pharmacokinetics in patients treated with 202.5 mg/m2 plus  DRUG1  to those in patients treated with 100 mg/m2 without  DRUGOTHER  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  DRUG2 ."	thiosulfate	cisplatin	OS(O)(=O)=S	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"Comparison of  DRUGOTHER  pharmacokinetics in patients treated with 202.5 mg/m2 plus  DRUGOTHER  to those in patients treated with 100 mg/m2 without  DRUG1  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  DRUG2 ."	thiosulfate	cisplatin	OS(O)(=O)=S	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
mechanism	This study demonstrates that concurrent administration of  DRUG1  permits at least a twofold increase in dose and total exposure to  DRUG2 .	thiosulfate	cisplatin	OS(O)(=O)=S	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"Consequently, drugs with a low therapeutic margin, such as  DRUG1 ,  DRUG2 , and  DRUGOTHER , could have a delayed elimination and increases in their serum half-life leading to a toxic level."	vitamin K antagonists	phenytoin	OC(=O)CCCCCCCC(O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Consequently, drugs with a low therapeutic margin, such as  DRUG1 ,  DRUGOTHER , and  DRUG2 , could have a delayed elimination and increases in their serum half-life leading to a toxic level."	vitamin K antagonists	theophylline	OC(=O)CCCCCCCC(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Consequently, drugs with a low therapeutic margin, such as  DRUGOTHER ,  DRUG1 , and  DRUG2 , could have a delayed elimination and increases in their serum half-life leading to a toxic level."	phenytoin	theophylline	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
advise	"For example, when  DRUG1  are administered concomitantly with  DRUG2 , prothrombin time should be carefully monitored and if necessary, the dosage of  DRUGOTHER  should be reduced."	vitamin K antagonists	nilutamide	OC(=O)CCCCCCCC(O)=O	CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
other	"For example, when  DRUG1  are administered concomitantly with  DRUGOTHER , prothrombin time should be carefully monitored and if necessary, the dosage of  DRUG2  should be reduced."	vitamin K antagonists	vitamin K antagonists	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"For example, when  DRUGOTHER  are administered concomitantly with  DRUG1 , prothrombin time should be carefully monitored and if necessary, the dosage of  DRUG2  should be reduced."	nilutamide	vitamin K antagonists	CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F	OC(=O)CCCCCCCC(O)=O
other	"In normal volunteers receiving  DRUG1 , the administration of  DRUG2  decreased the renal clearance and significantly increased the plasma levels of  DRUGOTHER ."	indomethacin	diflunisal	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"In normal volunteers receiving  DRUG1 , the administration of  DRUGOTHER  decreased the renal clearance and significantly increased the plasma levels of  DRUG2 ."	indomethacin	indomethacin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
mechanism	"In normal volunteers receiving  DRUGOTHER , the administration of  DRUG1  decreased the renal clearance and significantly increased the plasma levels of  DRUG2 ."	diflunisal	indomethacin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
effect	"In some patients, combined use of  DRUG1  and  DRUG2  has been associated with fatal gastrointestinal hemorrhage."	INDOCIN	diflunisal	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
advise	"Therefore,  DRUG1  and  DRUG2  should not be used concomitantly."	diflunisal	INDOCIN	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
mechanism	"In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of  DRUG1  per day decreases  DRUG2  blood levels approximately 20%."	aspirin	indomethacin	CC(=O)OC1=CC=CC=C1C(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
advise	"The concomitant use of  DRUG1  with other  DRUG2  is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy."	INDOCIN	NSAIDs	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	
other	Clinical studies have shown that  DRUG1  does not influence the hypoprothrombinemia produced by  DRUG2 .	INDOCIN	anticoagulants	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	
advise	"However, when any additional drug, including  DRUG1 , is added to the treatment of patients on  DRUG2  therapy, the patients should be observed for alterations of the prothrombin time."	INDOCIN	anticoagulant	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
effect	"In post-marketing experience, bleeding has been reported in patients on concomitant treatment with  DRUG1  and  DRUG2 ."	anticoagulants	INDOCIN		COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
advise	Caution should be exercised when  DRUG1  and  DRUG2  are administered concomitantly.	INDOCIN	anticoagulants	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	
mechanism	"When  DRUG1  is given to patients receiving  DRUG2 , the plasma levels of  DRUGOTHER  are likely to be increased."	INDOCIN	probenecid	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"When  DRUG1  is given to patients receiving  DRUGOTHER , the plasma levels of  DRUG2  are likely to be increased."	INDOCIN	indomethacin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"When  DRUGOTHER  is given to patients receiving  DRUG1 , the plasma levels of  DRUG2  are likely to be increased."	probenecid	indomethacin	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
advise	Caution should be used if  DRUG1  is administered simultaneously with  DRUG2 .	INDOCIN	methotrexate	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mechanism	 DRUG1  has been reported to decrease the tubular secretion of  DRUG2  and to potentiate its toxicity.	INDOCIN	methotrexate	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
effect	"Administration of  DRUG1  concomitantly with  DRUG2  has been associated with an increase in  DRUGOTHER -induced toxicity, possibly due to decreased synthesis of renal prostacyclin."	non-steroidal anti-inflammatory drugs	cyclosporine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Administration of  DRUG1  concomitantly with  DRUGOTHER  has been associated with an increase in  DRUG2 -induced toxicity, possibly due to decreased synthesis of renal prostacyclin."	non-steroidal anti-inflammatory drugs	cyclosporine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Administration of  DRUGOTHER  concomitantly with  DRUG1  has been associated with an increase in  DRUG2 -induced toxicity, possibly due to decreased synthesis of renal prostacyclin."	cyclosporine	cyclosporine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
advise	" DRUG1  should be used with caution in patients taking  DRUG2 , and renal function should be carefully monitored."	NSAIDs	cyclosporine		CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
mechanism	Capsules  DRUG1  50 mg t.i.d. produced a clinically relevant elevation of plasma  DRUG2  and reduction in renal  DRUGOTHER  clearance in psychiatric patients and normal subjects with steady state plasma  DRUGOTHER  concentrations.	INDOCIN	lithium	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[Li+]
other	Capsules  DRUG1  50 mg t.i.d. produced a clinically relevant elevation of plasma  DRUGOTHER  and reduction in renal  DRUG2  clearance in psychiatric patients and normal subjects with steady state plasma  DRUGOTHER  concentrations.	INDOCIN	lithium	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[Li+]
other	Capsules  DRUG1  50 mg t.i.d. produced a clinically relevant elevation of plasma  DRUGOTHER  and reduction in renal  DRUGOTHER  clearance in psychiatric patients and normal subjects with steady state plasma  DRUG2  concentrations.	INDOCIN	lithium	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[Li+]
other	Capsules  DRUGOTHER  50 mg t.i.d. produced a clinically relevant elevation of plasma  DRUG1  and reduction in renal  DRUG2  clearance in psychiatric patients and normal subjects with steady state plasma  DRUGOTHER  concentrations.	lithium	lithium	[Li+]	[Li+]
other	Capsules  DRUGOTHER  50 mg t.i.d. produced a clinically relevant elevation of plasma  DRUG1  and reduction in renal  DRUGOTHER  clearance in psychiatric patients and normal subjects with steady state plasma  DRUG2  concentrations.	lithium	lithium	[Li+]	[Li+]
other	Capsules  DRUGOTHER  50 mg t.i.d. produced a clinically relevant elevation of plasma  DRUGOTHER  and reduction in renal  DRUG1  clearance in psychiatric patients and normal subjects with steady state plasma  DRUG2  concentrations.	lithium	lithium	[Li+]	[Li+]
advise	"As a consequence, when  DRUG1  and  DRUG2  are given concomitantly, the patient should be carefully observed for signs of  DRUGOTHER  toxicity."	INDOCIN	lithium	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[Li+]
other	"As a consequence, when  DRUG1  and  DRUGOTHER  are given concomitantly, the patient should be carefully observed for signs of  DRUG2  toxicity."	INDOCIN	lithium	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[Li+]
other	"As a consequence, when  DRUGOTHER  and  DRUG1  are given concomitantly, the patient should be carefully observed for signs of  DRUG2  toxicity."	lithium	lithium	[Li+]	[Li+]
mechanism	 DRUG1  given concomitantly with  DRUG2  has been reported to increase the serum concentration and prolong the half-life of  DRUGOTHER .	INDOCIN	digoxin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUG1  given concomitantly with  DRUGOTHER  has been reported to increase the serum concentration and prolong the half-life of  DRUG2 .	INDOCIN	digoxin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUGOTHER  given concomitantly with  DRUG1  has been reported to increase the serum concentration and prolong the half-life of  DRUG2 .	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
advise	"Therefore, when  DRUG1  and  DRUG2  are used concomitantly, serum  DRUGOTHER  levels should be closely monitored."	INDOCIN	digoxin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Therefore, when  DRUG1  and  DRUGOTHER  are used concomitantly, serum  DRUG2  levels should be closely monitored."	INDOCIN	digoxin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Therefore, when  DRUGOTHER  and  DRUG1  are used concomitantly, serum  DRUG2  levels should be closely monitored."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
effect	"In some patients, the administration of  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	INDOCIN	loop diuretics	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	
effect	"In some patients, the administration of  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	INDOCIN	potassium-sparing diuretics	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[KH]
effect	"In some patients, the administration of  DRUG1  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	INDOCIN	thiazide diuretics	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	
other	"In some patients, the administration of  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	loop diuretics	potassium-sparing diuretics		[KH]
other	"In some patients, the administration of  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	loop diuretics	thiazide diuretics		
other	"In some patients, the administration of  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	potassium-sparing diuretics	thiazide diuretics	[KH]	
other	"Therefore, when  DRUG1  and  DRUG2 ."	INDOCIN	INDOCIN	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"( DRUG1 )  DRUG2  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUGOTHER  is obtained."	Indomethacin	diuretics	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"( DRUG1 )  DRUGOTHER  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUG2  is obtained."	Indomethacin	diuretic	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"( DRUGOTHER )  DRUG1  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUG2  is obtained."	diuretics	diuretic	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	" DRUG1  reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by  DRUG2  administration, or salt or volume depletion."	INDOCIN	furosemide	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
effect	It has been reported that the addition of  DRUG1  to a maintenance schedule of  DRUG2  resulted in reversible acute renal failure in two of four healthy volunteers.	triamterene	INDOCIN	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
advise	 DRUG1  and  DRUG2  should not be administered together.	INDOCIN	triamterene	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
other	 DRUG1  and  DRUG2  each may be associated with increased serum potassium levels.	INDOCIN	potassium-sparing diuretics	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[KH]
effect	The potential effects of  DRUG1  and  DRUG2  on potassium kinetics and renal function should be considered when these agents are administered concurrently.	INDOCIN	potassium-sparing diuretics	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[KH]
effect	"Most of the above effects concerning  DRUG1  have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by  DRUG2 ."	diuretics	INDOCIN	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
effect	Blunting of the antihypertensive effect of  DRUG1  by  DRUG2  including  DRUGOTHER  has been reported.	beta-adrenoceptor blocking agents	non-steroidal antiinflammatory drugs	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	Blunting of the antihypertensive effect of  DRUG1  by  DRUGOTHER  including  DRUG2  has been reported.	beta-adrenoceptor blocking agents	INDOCIN	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	Blunting of the antihypertensive effect of  DRUGOTHER  by  DRUG1  including  DRUG2  has been reported.	non-steroidal antiinflammatory drugs	INDOCIN	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
effect	 DRUG1  can reduce the antihypertensive effects of  DRUG2  and  DRUGOTHER .	INDOCIN	captopril	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
effect	 DRUG1  can reduce the antihypertensive effects of  DRUGOTHER  and  DRUG2 .	INDOCIN	losartan	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
other	 DRUGOTHER  can reduce the antihypertensive effects of  DRUG1  and  DRUG2 .	captopril	losartan	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
effect	Interaction between  DRUG1  and  DRUG2  in the development of spontaneous motility in chick embryos.	glycine	glutamate	N[C@@H](C=C)C(O)=O	
advise	" DRUG1  should be administered with caution to patients who are taking other  DRUG2  or  DRUGOTHER , including  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	Nabilone	psychoactive drugs	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
advise	" DRUG1  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUG2 , including  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	Nabilone	CNS depressants	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
advise	" DRUG1  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUGOTHER , including  DRUG2 ,  DRUGOTHER  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	Nabilone	alcohol	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
advise	" DRUG1  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUGOTHER , including  DRUGOTHER ,  DRUG2  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	Nabilone	barbiturates	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
advise	" DRUG1  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUGOTHER , including  DRUGOTHER ,  DRUGOTHER  and  DRUG2 , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	Nabilone	narcotic analgesics	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUG1  or  DRUG2 , including  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	psychoactive drugs	CNS depressants	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUG1  or  DRUGOTHER , including  DRUG2 ,  DRUGOTHER  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	psychoactive drugs	alcohol	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUG1  or  DRUGOTHER , including  DRUGOTHER ,  DRUG2  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	psychoactive drugs	barbiturates	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUG1  or  DRUGOTHER , including  DRUGOTHER ,  DRUGOTHER  and  DRUG2 , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	psychoactive drugs	narcotic analgesics	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUG1 , including  DRUG2 ,  DRUGOTHER  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	CNS depressants	alcohol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUG1 , including  DRUGOTHER ,  DRUG2  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	CNS depressants	barbiturates	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUG1 , including  DRUGOTHER ,  DRUGOTHER  and  DRUG2 , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	CNS depressants	narcotic analgesics	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUGOTHER , including  DRUG1 ,  DRUG2  and  DRUGOTHER , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	alcohol	barbiturates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUGOTHER , including  DRUG1 ,  DRUGOTHER  and  DRUG2 , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	alcohol	narcotic analgesics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	" DRUGOTHER  should be administered with caution to patients who are taking other  DRUGOTHER  or  DRUGOTHER , including  DRUGOTHER ,  DRUG1  and  DRUG2 , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."	barbiturates	narcotic analgesics	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
effect	" DRUG1  has been shown to have an additive CNS depressant effect when given with either  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	Nabilone	diazepam	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
effect	" DRUG1  has been shown to have an additive CNS depressant effect when given with either  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	Nabilone	secobarbitone sodium	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	
effect	" DRUG1  has been shown to have an additive CNS depressant effect when given with either  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	Nabilone	alcohol	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	" DRUG1  has been shown to have an additive CNS depressant effect when given with either  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	Nabilone	codeine	[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	
other	" DRUGOTHER  has been shown to have an additive CNS depressant effect when given with either  DRUG1 ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	diazepam	secobarbitone sodium	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	
other	" DRUGOTHER  has been shown to have an additive CNS depressant effect when given with either  DRUG1 ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	diazepam	alcohol	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  has been shown to have an additive CNS depressant effect when given with either  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	diazepam	codeine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	
other	" DRUGOTHER  has been shown to have an additive CNS depressant effect when given with either  DRUGOTHER ,  DRUG1 ,  DRUG2  or  DRUGOTHER ."	secobarbitone sodium	alcohol		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  has been shown to have an additive CNS depressant effect when given with either  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUG2 ."	secobarbitone sodium	codeine		
other	" DRUGOTHER  has been shown to have an additive CNS depressant effect when given with either  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUG2 ."	alcohol	codeine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
effect	Administration of  DRUG1  to patients who are receiving  DRUG2  or  DRUGOTHER  may result in an additive pressor effect .	doxapram	sympathomimetic	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
effect	Administration of  DRUG1  to patients who are receiving  DRUGOTHER  or  DRUG2  may result in an additive pressor effect .	doxapram	monoamine oxidase inhibiting drugs	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
other	Administration of  DRUGOTHER  to patients who are receiving  DRUG1  or  DRUG2  may result in an additive pressor effect .	sympathomimetic	monoamine oxidase inhibiting drugs		OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
other	"In patients who have received  DRUG1 ,  DRUG2  may temporarily mask the residual effects of  DRUGOTHER ."	muscle relaxants	doxapram		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"In patients who have received  DRUG1 ,  DRUGOTHER  may temporarily mask the residual effects of  DRUG2 ."	muscle relaxants	muscle relaxant drugs		
effect	"In patients who have received  DRUGOTHER ,  DRUG1  may temporarily mask the residual effects of  DRUG2 ."	doxapram	muscle relaxant drugs	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	Poor metabolizers have higher than expected plasma concentrations of  DRUG1  ( DRUG2 ) when given usual doses.	tricyclic antidepressants	TCAs	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUG2 ,  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER  and  DRUGOTHER )."	cimetidine	antidepressants	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG2 , and the  DRUGOTHER   DRUGOTHER  and  DRUGOTHER )."	cimetidine	phenothiazines	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUG2   DRUGOTHER  and  DRUGOTHER )."	cimetidine	Type 1C antiarrhythmics	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUGOTHER   DRUG2  and  DRUGOTHER )."	cimetidine	propafenone	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUG1 ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER  and  DRUG2 )."	cimetidine	flecainide	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUG2 , and the  DRUGOTHER   DRUGOTHER  and  DRUGOTHER )."	antidepressants	phenothiazines	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUGOTHER , and the  DRUG2   DRUGOTHER  and  DRUGOTHER )."	antidepressants	Type 1C antiarrhythmics	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUGOTHER , and the  DRUGOTHER   DRUG2  and  DRUGOTHER )."	antidepressants	propafenone	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUG1 ,  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER  and  DRUG2 )."	antidepressants	flecainide	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG1 , and the  DRUG2   DRUGOTHER  and  DRUGOTHER )."	phenothiazines	Type 1C antiarrhythmics	N1C2=CC=CC=C2SC2=CC=CC=C12	
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG1 , and the  DRUGOTHER   DRUG2  and  DRUGOTHER )."	phenothiazines	propafenone	N1C2=CC=CC=C2SC2=CC=CC=C12	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUG1 , and the  DRUGOTHER   DRUGOTHER  and  DRUG2 )."	phenothiazines	flecainide	N1C2=CC=CC=C2SC2=CC=CC=C12	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUG1   DRUG2  and  DRUGOTHER )."	Type 1C antiarrhythmics	propafenone		CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUG1   DRUGOTHER  and  DRUG2 )."	Type 1C antiarrhythmics	flecainide		FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER ) and many that are substrates for P450 2D6 (many other  DRUGOTHER ,  DRUGOTHER , and the  DRUGOTHER   DRUG1  and  DRUG2 )."	propafenone	flecainide	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	"While all the  DRUG1  ( DRUG2 ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	SSRIs	NCCC1=CNC2=CC=C(O)C=C12	
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	citalopram	NCCC1=CNC2=CC=C(O)C=C12	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	escitalopram	NCCC1=CNC2=CC=C(O)C=C12	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	fluoxetine	NCCC1=CNC2=CC=C(O)C=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	sertraline	NCCC1=CNC2=CC=C(O)C=C12	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"While all the  DRUG1  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	selective serotonin reuptake inhibitors	paroxetine	NCCC1=CNC2=CC=C(O)C=C12	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	citalopram		[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	escitalopram		CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	fluoxetine		CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	sertraline		C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"While all the  DRUGOTHER  ( DRUG1 ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	SSRIs	paroxetine		FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	citalopram	escitalopram	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	citalopram	fluoxetine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	citalopram	sertraline	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	citalopram	paroxetine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	escitalopram	fluoxetine	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	escitalopram	sertraline	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	escitalopram	paroxetine	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER , inhibit P450 2D6, they may vary in the extent of inhibition."	fluoxetine	sertraline	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	fluoxetine	paroxetine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"While all the  DRUGOTHER  ( DRUGOTHER ), e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 , inhibit P450 2D6, they may vary in the extent of inhibition."	sertraline	paroxetine	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
int	The extent to which  DRUG1 - DRUG2  interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUGOTHER  involved.	SSRI	TCA		[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	The extent to which  DRUG1 - DRUGOTHER  interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUG2  involved.	SSRI	SSRI		
other	The extent to which  DRUGOTHER - DRUG1  interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  DRUG2  involved.	TCA	SSRI	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	
advise	"Nevertheless, caution is indicated in the co-administration of  DRUG1  with any of the  DRUG2  and also in switching from one class to the other."	TCAs	SSRIs		
other	Concomitant use of  DRUG1  with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the  DRUG2  or the other drug.	tricyclic antidepressants	tricyclic antidepressant	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	It is desirable to monitor  DRUG1  plasma levels whenever a  DRUG2  is going to be co-administered with another drug known to be an inhibitor of P450 2D6.	TCA	TCA	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	"Inhibitors or substrates of CYP2D6 (i.e.,  DRUG1 ,  DRUG2  [ DRUGOTHER ]) may increase the plasma concentration of  DRUGOTHER  when administered concomitantly."	quinidine	selective serotonin reuptake inhibitors	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	NCCC1=CNC2=CC=C(O)C=C12
other	"Inhibitors or substrates of CYP2D6 (i.e.,  DRUG1 ,  DRUGOTHER  [ DRUG2 ]) may increase the plasma concentration of  DRUGOTHER  when administered concomitantly."	quinidine	SSRIs	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	
mechanism	"Inhibitors or substrates of CYP2D6 (i.e.,  DRUG1 ,  DRUGOTHER  [ DRUGOTHER ]) may increase the plasma concentration of  DRUG2  when administered concomitantly."	quinidine	doxepin	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=CC=C2
other	"Inhibitors or substrates of CYP2D6 (i.e.,  DRUGOTHER ,  DRUG1  [ DRUG2 ]) may increase the plasma concentration of  DRUGOTHER  when administered concomitantly."	selective serotonin reuptake inhibitors	SSRIs	NCCC1=CNC2=CC=C(O)C=C12	
mechanism	"Inhibitors or substrates of CYP2D6 (i.e.,  DRUGOTHER ,  DRUG1  [ DRUGOTHER ]) may increase the plasma concentration of  DRUG2  when administered concomitantly."	selective serotonin reuptake inhibitors	doxepin	NCCC1=CNC2=CC=C(O)C=C12	CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=CC=C2
mechanism	"Inhibitors or substrates of CYP2D6 (i.e.,  DRUGOTHER ,  DRUGOTHER  [ DRUG1 ]) may increase the plasma concentration of  DRUG2  when administered concomitantly."	SSRIs	doxepin		CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=CC=C2
other	 DRUG1 : Serious side effects and even death have been reported following the concomitant use of certain drugs with  DRUG2 .	MAO Inhibitors	MAO inhibitors	CN(CC#C)CC1=CC=CC=C1	CN(CC#C)CC1=CC=CC=C1
advise	"Therefore,  DRUG1  should be discontinued at least two weeks prior to the cautious initiation of therapy with  DRUG2 ."	MAO inhibitors	SINEQUAN	CN(CC#C)CC1=CC=CC=C1	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
other	 DRUG1 :  DRUG2  has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various  DRUGOTHER .	Cimetidine	Cimetidine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	 DRUG1 :  DRUGOTHER  has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various  DRUG2 .	Cimetidine	tricyclic antidepressants	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
mechanism	 DRUGOTHER :  DRUG1  has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various  DRUG2 .	Cimetidine	tricyclic antidepressants	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
effect	"Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of  DRUG1  when  DRUG2  therapy is initiated."	tricyclic antidepressant	cimetidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
mechanism	"Additionally, higher than expected  DRUG1  levels have been observed when they are begun in patients already taking  DRUG2 ."	tricyclic antidepressant	cimetidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In patients who have been reported to be well controlled on  DRUG1  receiving concurrent  DRUG2  therapy, discontinuation of  DRUGOTHER  has been reported to decrease established steady-state serum  DRUGOTHER  levels and compromise their therapeutic effects."	tricyclic antidepressants	cimetidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In patients who have been reported to be well controlled on  DRUG1  receiving concurrent  DRUGOTHER  therapy, discontinuation of  DRUG2  has been reported to decrease established steady-state serum  DRUGOTHER  levels and compromise their therapeutic effects."	tricyclic antidepressants	cimetidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In patients who have been reported to be well controlled on  DRUG1  receiving concurrent  DRUGOTHER  therapy, discontinuation of  DRUGOTHER  has been reported to decrease established steady-state serum  DRUG2  levels and compromise their therapeutic effects."	tricyclic antidepressants	tricyclic antidepressant	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"In patients who have been reported to be well controlled on  DRUGOTHER  receiving concurrent  DRUG1  therapy, discontinuation of  DRUG2  has been reported to decrease established steady-state serum  DRUGOTHER  levels and compromise their therapeutic effects."	cimetidine	cimetidine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In patients who have been reported to be well controlled on  DRUGOTHER  receiving concurrent  DRUG1  therapy, discontinuation of  DRUGOTHER  has been reported to decrease established steady-state serum  DRUG2  levels and compromise their therapeutic effects."	cimetidine	tricyclic antidepressant	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
mechanism	"In patients who have been reported to be well controlled on  DRUGOTHER  receiving concurrent  DRUGOTHER  therapy, discontinuation of  DRUG1  has been reported to decrease established steady-state serum  DRUG2  levels and compromise their therapeutic effects."	cimetidine	tricyclic antidepressant	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUG1 : It should be borne in mind that  DRUG2  ingestion may increase the danger inherent in any intentional or unintentional  DRUGOTHER  overdosage.	Alcohol	alcohol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1 : It should be borne in mind that  DRUGOTHER  ingestion may increase the danger inherent in any intentional or unintentional  DRUG2  overdosage.	Alcohol	SINEQUAN	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
mechanism	 DRUGOTHER : It should be borne in mind that  DRUG1  ingestion may increase the danger inherent in any intentional or unintentional  DRUG2  overdosage.	alcohol	SINEQUAN	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
other	 DRUG1 : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on  DRUG2  (1 gm/day) 11 days after the addition of  DRUGOTHER  (75 mg/day).	Tolazamide	tolazamide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1
other	 DRUG1 : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on  DRUGOTHER  (1 gm/day) 11 days after the addition of  DRUG2  (75 mg/day).	Tolazamide	doxepin	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1	CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=CC=C2
effect	 DRUGOTHER : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on  DRUG1  (1 gm/day) 11 days after the addition of  DRUG2  (75 mg/day).	tolazamide	doxepin	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1	CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=CC=C2
other	The concomitant intake of  DRUG1  and  DRUG2  does not affect the pharmacokinetics of either  DRUGOTHER  or  DRUGOTHER .	alcohol	Acamprosate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	The concomitant intake of  DRUG1  and  DRUGOTHER  does not affect the pharmacokinetics of either  DRUG2  or  DRUGOTHER .	alcohol	alcohol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	The concomitant intake of  DRUG1  and  DRUGOTHER  does not affect the pharmacokinetics of either  DRUGOTHER  or  DRUG2 .	alcohol	acamprosate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	The concomitant intake of  DRUGOTHER  and  DRUG1  does not affect the pharmacokinetics of either  DRUG2  or  DRUGOTHER .	Acamprosate	alcohol	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	The concomitant intake of  DRUGOTHER  and  DRUG1  does not affect the pharmacokinetics of either  DRUGOTHER  or  DRUG2 .	Acamprosate	acamprosate	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	The concomitant intake of  DRUGOTHER  and  DRUGOTHER  does not affect the pharmacokinetics of either  DRUG1  or  DRUG2 .	alcohol	acamprosate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	Pharmacokinetic studies indicate that administration of  DRUG1  or  DRUG2  does not affect the pharmacokinetics of  DRUGOTHER .	disulfiram	diazepam	CCN(CC)C(=S)SSC(=S)N(CC)CC	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	Pharmacokinetic studies indicate that administration of  DRUG1  or  DRUGOTHER  does not affect the pharmacokinetics of  DRUG2 .	disulfiram	acamprosate	CCN(CC)C(=S)SSC(=S)N(CC)CC	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	Pharmacokinetic studies indicate that administration of  DRUGOTHER  or  DRUG1  does not affect the pharmacokinetics of  DRUG2 .	diazepam	acamprosate	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
mechanism	Co-administration of  DRUG1  with  DRUG2  produced a 25% increase in AUC and a 33% increase in the Cmax of  DRUGOTHER .	naltrexone	Acamprosate	C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	Co-administration of  DRUG1  with  DRUGOTHER  produced a 25% increase in AUC and a 33% increase in the Cmax of  DRUG2 .	naltrexone	acamprosate	C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	Co-administration of  DRUGOTHER  with  DRUG1  produced a 25% increase in AUC and a 33% increase in the Cmax of  DRUG2 .	Acamprosate	acamprosate	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	The pharmacokinetics of  DRUG1  and its major metabolite  DRUG2  were unaffected following co-administration with  DRUGOTHER .	naltrexone	6-beta-naltrexol	C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35	
other	The pharmacokinetics of  DRUG1  and its major metabolite  DRUGOTHER  were unaffected following co-administration with  DRUG2 .	naltrexone	Acamprosate	C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	The pharmacokinetics of  DRUGOTHER  and its major metabolite  DRUG1  were unaffected following co-administration with  DRUG2 .	6-beta-naltrexol	Acamprosate		OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUG1  concomitantly with  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  (including  DRUGOTHER ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	Acamprosate	anxiolytics	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	CCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C1=CC=CC=C1
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUG1  concomitantly with  DRUGOTHER ,  DRUG2  and  DRUGOTHER  (including  DRUGOTHER ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	Acamprosate	hypnotics	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUG1  concomitantly with  DRUGOTHER ,  DRUGOTHER  and  DRUG2  (including  DRUGOTHER ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	Acamprosate	sedatives	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUG1  concomitantly with  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  (including  DRUG2 ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	Acamprosate	benzodiazepines	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	N1N=CC=CC2=CC=CC=C12
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUG1  concomitantly with  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  (including  DRUGOTHER ), or  DRUG2  was similar to that of subjects taking placebo with these concomitant medications."	Acamprosate	non-opioid analgesics	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUG1 ,  DRUG2  and  DRUGOTHER  (including  DRUGOTHER ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	anxiolytics	hypnotics	CCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C1=CC=CC=C1	
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUG1 ,  DRUGOTHER  and  DRUG2  (including  DRUGOTHER ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	anxiolytics	sedatives	CCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C1=CC=CC=C1	
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  (including  DRUG2 ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	anxiolytics	benzodiazepines	CCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C1=CC=CC=C1	N1N=CC=CC2=CC=CC=C12
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  (including  DRUGOTHER ), or  DRUG2  was similar to that of subjects taking placebo with these concomitant medications."	anxiolytics	non-opioid analgesics	CCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C1=CC=CC=C1	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUGOTHER ,  DRUG1  and  DRUG2  (including  DRUGOTHER ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	hypnotics	sedatives		
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUGOTHER ,  DRUG1  and  DRUGOTHER  (including  DRUG2 ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	hypnotics	benzodiazepines		N1N=CC=CC2=CC=CC=C12
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUGOTHER ,  DRUG1  and  DRUGOTHER  (including  DRUGOTHER ), or  DRUG2  was similar to that of subjects taking placebo with these concomitant medications."	hypnotics	non-opioid analgesics		OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUGOTHER ,  DRUGOTHER  and  DRUG1  (including  DRUG2 ), or  DRUGOTHER  was similar to that of subjects taking placebo with these concomitant medications."	sedatives	benzodiazepines		N1N=CC=CC2=CC=CC=C12
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUGOTHER ,  DRUGOTHER  and  DRUG1  (including  DRUGOTHER ), or  DRUG2  was similar to that of subjects taking placebo with these concomitant medications."	sedatives	non-opioid analgesics		OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  DRUGOTHER  concomitantly with  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  (including  DRUG1 ), or  DRUG2  was similar to that of subjects taking placebo with these concomitant medications."	benzodiazepines	non-opioid analgesics	N1N=CC=CC2=CC=CC=C12	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
effect	"Patients taking  DRUG1  concomitantly with  DRUG2  more commonly reported both weight gain and weight loss, compared with patients taking either medication alone."	Acamprosate	antidepressants	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	 DRUG1 :  DRUG2  may diminish adrenal suppression by  DRUGOTHER .	Aminoglutethimide	Aminoglutethimide	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1
other	 DRUG1 :  DRUGOTHER  may diminish adrenal suppression by  DRUG2 .	Aminoglutethimide	corticosteroids	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
effect	 DRUGOTHER :  DRUG1  may diminish adrenal suppression by  DRUG2 .	Aminoglutethimide	corticosteroids	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1  injection and potassium-depleting agents: When  DRUG2  are administered concomitantly with potassium-depleting agents (e.g.,  DRUGOTHER ,  DRUGOTHER ), patients should be observed closely for development of hypokalemia."	Amphotericin B	corticosteroids	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1  injection and potassium-depleting agents: When  DRUGOTHER  are administered concomitantly with potassium-depleting agents (e.g.,  DRUG2 ,  DRUGOTHER ), patients should be observed closely for development of hypokalemia."	Amphotericin B	amphotericin B	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	" DRUG1  injection and potassium-depleting agents: When  DRUGOTHER  are administered concomitantly with potassium-depleting agents (e.g.,  DRUGOTHER ,  DRUG2 ), patients should be observed closely for development of hypokalemia."	Amphotericin B	diuretics	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
advise	" DRUGOTHER  injection and potassium-depleting agents: When  DRUG1  are administered concomitantly with potassium-depleting agents (e.g.,  DRUG2 ,  DRUGOTHER ), patients should be observed closely for development of hypokalemia."	corticosteroids	amphotericin B	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
advise	" DRUGOTHER  injection and potassium-depleting agents: When  DRUG1  are administered concomitantly with potassium-depleting agents (e.g.,  DRUGOTHER ,  DRUG2 ), patients should be observed closely for development of hypokalemia."	corticosteroids	diuretics	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	" DRUGOTHER  injection and potassium-depleting agents: When  DRUGOTHER  are administered concomitantly with potassium-depleting agents (e.g.,  DRUG1 ,  DRUG2 ), patients should be observed closely for development of hypokalemia."	amphotericin B	diuretics	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
effect	"In addition, there have been cases reported in which concomitant use of  DRUG1  and  DRUG2  was followed by cardiac enlargement and congestive heart failure."	amphotericin B	hydrocortisone	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
other	 DRUG1 :  DRUG2  have been reported to cause a significant decrease in  DRUGOTHER  clearance.	Antibiotics	Macrolide antibiotics	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	 DRUG1 :  DRUGOTHER  have been reported to cause a significant decrease in  DRUG2  clearance.	Antibiotics	corticosteroid	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	 DRUGOTHER :  DRUG1  have been reported to cause a significant decrease in  DRUG2  clearance.	Macrolide antibiotics	corticosteroid	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	 DRUG1 : Concomitant use of  DRUG2  and  DRUGOTHER  may produce severe weakness in patients with myasthenia gravis.	Anticholinesterases	anticholinesterase agents	C[N+](C)(C)CCO	C[N+](C)(C)CCO
other	 DRUG1 : Concomitant use of  DRUGOTHER  and  DRUG2  may produce severe weakness in patients with myasthenia gravis.	Anticholinesterases	corticosteroids	C[N+](C)(C)CCO	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
effect	 DRUGOTHER : Concomitant use of  DRUG1  and  DRUG2  may produce severe weakness in patients with myasthenia gravis.	anticholinesterase agents	corticosteroids	C[N+](C)(C)CCO	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
advise	"If possible,  DRUG1  should be withdrawn at least 24 hours before initiating  DRUG2  therapy."	anticholinesterase agents	corticosteroid	C[N+](C)(C)CCO	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1 , oral: Co-administration of  DRUG2  and  DRUGOTHER  usually results in inhibition of response to  DRUGOTHER , although there have been some conflicting reports."	Anticoagulants	corticosteroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1 , oral: Co-administration of  DRUGOTHER  and  DRUG2  usually results in inhibition of response to  DRUGOTHER , although there have been some conflicting reports."	Anticoagulants	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUG1 , oral: Co-administration of  DRUGOTHER  and  DRUGOTHER  usually results in inhibition of response to  DRUG2 , although there have been some conflicting reports."	Anticoagulants	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
effect	" DRUGOTHER , oral: Co-administration of  DRUG1  and  DRUG2  usually results in inhibition of response to  DRUGOTHER , although there have been some conflicting reports."	corticosteroids	warfarin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUGOTHER , oral: Co-administration of  DRUG1  and  DRUGOTHER  usually results in inhibition of response to  DRUG2 , although there have been some conflicting reports."	corticosteroids	warfarin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUGOTHER , oral: Co-administration of  DRUGOTHER  and  DRUG1  usually results in inhibition of response to  DRUG2 , although there have been some conflicting reports."	warfarin	warfarin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUG1 : Because  DRUG2  may increase blood glucose concentrations, dosage adjustments of  DRUGOTHER  may be required."	Antidiabetics	corticosteroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1 : Because  DRUGOTHER  may increase blood glucose concentrations, dosage adjustments of  DRUG2  may be required."	Antidiabetics	antidiabetic agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	" DRUGOTHER : Because  DRUG1  may increase blood glucose concentrations, dosage adjustments of  DRUG2  may be required."	corticosteroids	antidiabetic agents	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	 DRUG1 :  DRUG2  may increase the clearance of  DRUGOTHER .	Cholestyramine	Cholestyramine	NCCC1=CC=C(O)C=C1	NCCC1=CC=C(O)C=C1
other	 DRUG1 :  DRUGOTHER  may increase the clearance of  DRUG2 .	Cholestyramine	corticosteroids	NCCC1=CC=C(O)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	 DRUGOTHER :  DRUG1  may increase the clearance of  DRUG2 .	Cholestyramine	corticosteroids	NCCC1=CC=C(O)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	 DRUG1 : Increased activity of both  DRUG2  and  DRUGOTHER  may occur when the two are used concurrently.	Cyclosporine	cyclosporine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUG1 : Increased activity of both  DRUGOTHER  and  DRUG2  may occur when the two are used concurrently.	Cyclosporine	corticosteroids	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
effect	 DRUGOTHER : Increased activity of both  DRUG1  and  DRUG2  may occur when the two are used concurrently.	cyclosporine	corticosteroids	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	 DRUG1 : Patients on  DRUG2  may be at increased risk of arrhythmias due to hypokalemia.	Digitalis glycosides	digitalis glycosides	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1 :  DRUG2  may enhance the metabolic clearance of  DRUGOTHER , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in  DRUGOTHER  dosage."	Ephedrine	Ephedrine		
other	" DRUG1 :  DRUGOTHER  may enhance the metabolic clearance of  DRUG2 , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in  DRUGOTHER  dosage."	Ephedrine	corticosteroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1 :  DRUGOTHER  may enhance the metabolic clearance of  DRUGOTHER , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in  DRUG2  dosage."	Ephedrine	corticosteroid		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	" DRUGOTHER :  DRUG1  may enhance the metabolic clearance of  DRUG2 , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in  DRUGOTHER  dosage."	Ephedrine	corticosteroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER :  DRUG1  may enhance the metabolic clearance of  DRUGOTHER , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in  DRUG2  dosage."	Ephedrine	corticosteroid		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER :  DRUGOTHER  may enhance the metabolic clearance of  DRUG1 , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in  DRUG2  dosage."	corticosteroids	corticosteroid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1 , including oral  DRUG2 :  DRUGOTHER  may decrease the hepatic metabolism of certain  DRUGOTHER , thereby increasing their effect."	Estrogens	contraceptives	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	" DRUG1 , including oral  DRUGOTHER :  DRUG2  may decrease the hepatic metabolism of certain  DRUGOTHER , thereby increasing their effect."	Estrogens	Estrogens	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	" DRUG1 , including oral  DRUGOTHER :  DRUGOTHER  may decrease the hepatic metabolism of certain  DRUG2 , thereby increasing their effect."	Estrogens	corticosteroids	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER , including oral  DRUG1 :  DRUG2  may decrease the hepatic metabolism of certain  DRUGOTHER , thereby increasing their effect."	contraceptives	Estrogens	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	" DRUGOTHER , including oral  DRUG1 :  DRUGOTHER  may decrease the hepatic metabolism of certain  DRUG2 , thereby increasing their effect."	contraceptives	corticosteroids	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	" DRUGOTHER , including oral  DRUGOTHER :  DRUG1  may decrease the hepatic metabolism of certain  DRUG2 , thereby increasing their effect."	Estrogens	corticosteroids	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUGOTHER  be increased."	barbiturates	phenytoin	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUGOTHER  be increased."	barbiturates	carbamazepine	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUGOTHER  be increased."	barbiturates	rifampin	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
mechanism	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may enhance the metabolism of  DRUG2  and require that the dosage of the  DRUGOTHER  be increased."	barbiturates	corticosteroids	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUG2  be increased."	barbiturates	corticosteroid	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUGOTHER  be increased."	phenytoin	carbamazepine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUGOTHER  be increased."	phenytoin	rifampin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
mechanism	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) may enhance the metabolism of  DRUG2  and require that the dosage of the  DRUGOTHER  be increased."	phenytoin	corticosteroids	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUG2  be increased."	phenytoin	corticosteroid	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUGOTHER  be increased."	carbamazepine	rifampin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
mechanism	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) may enhance the metabolism of  DRUG2  and require that the dosage of the  DRUGOTHER  be increased."	carbamazepine	corticosteroids	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUG2  be increased."	carbamazepine	corticosteroid	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) may enhance the metabolism of  DRUG2  and require that the dosage of the  DRUGOTHER  be increased."	rifampin	corticosteroids	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) may enhance the metabolism of  DRUGOTHER  and require that the dosage of the  DRUG2  be increased."	rifampin	corticosteroid	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may enhance the metabolism of  DRUG1  and require that the dosage of the  DRUG2  be increased."	corticosteroids	corticosteroid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Drugs which inhibit CYP 3A4 (e.g.,  DRUG1 ,  DRUG2  such as  DRUGOTHER ) have the potential to result in increased plasma concentrations of  DRUGOTHER ."	ketoconazole	macrolide antibiotics	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs which inhibit CYP 3A4 (e.g.,  DRUG1 ,  DRUGOTHER  such as  DRUG2 ) have the potential to result in increased plasma concentrations of  DRUGOTHER ."	ketoconazole	erythromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
mechanism	"Drugs which inhibit CYP 3A4 (e.g.,  DRUG1 ,  DRUGOTHER  such as  DRUGOTHER ) have the potential to result in increased plasma concentrations of  DRUG2 ."	ketoconazole	corticosteroids	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Drugs which inhibit CYP 3A4 (e.g.,  DRUGOTHER ,  DRUG1  such as  DRUG2 ) have the potential to result in increased plasma concentrations of  DRUGOTHER ."	macrolide antibiotics	erythromycin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
mechanism	"Drugs which inhibit CYP 3A4 (e.g.,  DRUGOTHER ,  DRUG1  such as  DRUGOTHER ) have the potential to result in increased plasma concentrations of  DRUG2 ."	macrolide antibiotics	corticosteroids	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	"Drugs which inhibit CYP 3A4 (e.g.,  DRUGOTHER ,  DRUGOTHER  such as  DRUG1 ) have the potential to result in increased plasma concentrations of  DRUG2 ."	erythromycin	corticosteroids	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Co-administration with other drugs that are metabolized by CYP 3A4 (e.g.,  DRUG1 ,  DRUG2 ) may increase their clearance, resulting in decreased plasma concentration."	indinavir	erythromycin	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUG1 :  DRUG2  has been reported to decrease the metabolism of certain  DRUGOTHER  by up to 60%, leading to increased risk of  DRUGOTHER  side effects."	Ketoconazole	Ketoconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	" DRUG1 :  DRUGOTHER  has been reported to decrease the metabolism of certain  DRUG2  by up to 60%, leading to increased risk of  DRUGOTHER  side effects."	Ketoconazole	corticosteroids	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1 :  DRUGOTHER  has been reported to decrease the metabolism of certain  DRUGOTHER  by up to 60%, leading to increased risk of  DRUG2  side effects."	Ketoconazole	corticosteroid	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	" DRUGOTHER :  DRUG1  has been reported to decrease the metabolism of certain  DRUG2  by up to 60%, leading to increased risk of  DRUGOTHER  side effects."	Ketoconazole	corticosteroids	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER :  DRUG1  has been reported to decrease the metabolism of certain  DRUGOTHER  by up to 60%, leading to increased risk of  DRUG2  side effects."	Ketoconazole	corticosteroid	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUGOTHER :  DRUGOTHER  has been reported to decrease the metabolism of certain  DRUG1  by up to 60%, leading to increased risk of  DRUG2  side effects."	corticosteroids	corticosteroid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
effect	"In addition,  DRUG1  alone can inhibit adrenal  DRUG2  synthesis and may cause adrenal insufficiency during corticosteroid withdrawal."	ketoconazole	corticosteroid	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	 DRUG1  ( DRUG2 ): Concomitant use of  DRUGOTHER  (or other  DRUGOTHER ) and  DRUGOTHER  increases the risk of gastrointestinal side effects.	Nonsteroidal anti-inflammatory agents	NSAIDS	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	 DRUG1  ( DRUGOTHER ): Concomitant use of  DRUG2  (or other  DRUGOTHER ) and  DRUGOTHER  increases the risk of gastrointestinal side effects.	Nonsteroidal anti-inflammatory agents	aspirin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC(=O)OC1=CC=CC=C1C(O)=O
other	 DRUG1  ( DRUGOTHER ): Concomitant use of  DRUGOTHER  (or other  DRUG2 ) and  DRUGOTHER  increases the risk of gastrointestinal side effects.	Nonsteroidal anti-inflammatory agents	nonsteroidal antiinflammatory agents	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	 DRUG1  ( DRUGOTHER ): Concomitant use of  DRUGOTHER  (or other  DRUGOTHER ) and  DRUG2  increases the risk of gastrointestinal side effects.	Nonsteroidal anti-inflammatory agents	corticosteroids	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	 DRUGOTHER  ( DRUG1 ): Concomitant use of  DRUG2  (or other  DRUGOTHER ) and  DRUGOTHER  increases the risk of gastrointestinal side effects.	NSAIDS	aspirin		CC(=O)OC1=CC=CC=C1C(O)=O
other	 DRUGOTHER  ( DRUG1 ): Concomitant use of  DRUGOTHER  (or other  DRUG2 ) and  DRUGOTHER  increases the risk of gastrointestinal side effects.	NSAIDS	nonsteroidal antiinflammatory agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	 DRUGOTHER  ( DRUG1 ): Concomitant use of  DRUGOTHER  (or other  DRUGOTHER ) and  DRUG2  increases the risk of gastrointestinal side effects.	NSAIDS	corticosteroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	 DRUGOTHER  ( DRUGOTHER ): Concomitant use of  DRUG1  (or other  DRUG2 ) and  DRUGOTHER  increases the risk of gastrointestinal side effects.	aspirin	nonsteroidal antiinflammatory agents	CC(=O)OC1=CC=CC=C1C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	 DRUGOTHER  ( DRUGOTHER ): Concomitant use of  DRUG1  (or other  DRUGOTHER ) and  DRUG2  increases the risk of gastrointestinal side effects.	aspirin	corticosteroids	CC(=O)OC1=CC=CC=C1C(O)=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
effect	 DRUGOTHER  ( DRUGOTHER ): Concomitant use of  DRUGOTHER  (or other  DRUG1 ) and  DRUG2  increases the risk of gastrointestinal side effects.	nonsteroidal antiinflammatory agents	corticosteroids	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
advise	 DRUG1  should be used cautiously in conjunction with  DRUG2  in hypoprothrombinemia.	Aspirin	corticosteroids	CC(=O)OC1=CC=CC=C1C(O)=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	The clearance of  DRUG1  may be increased with concurrent use of  DRUG2 .	salicylates	corticosteroids	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1 : In post-marketing experience, there have been reports of both increases and decreases in  DRUG2  levels with  DRUGOTHER  co-administration, leading to alterations in seizure control."	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUG1 : In post-marketing experience, there have been reports of both increases and decreases in  DRUGOTHER  levels with  DRUG2  co-administration, leading to alterations in seizure control."	Phenytoin	dexamethasone	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
mechanism	" DRUGOTHER : In post-marketing experience, there have been reports of both increases and decreases in  DRUG1  levels with  DRUG2  co-administration, leading to alterations in seizure control."	phenytoin	dexamethasone	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	" DRUG1 : Co-administration with  DRUG2  should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use."	Thalidomide	thalidomide	O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12	O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12
other	 DRUG1 : Patients on  DRUG2  therapy may exhibit a diminished response to toxoids and  DRUGOTHER  or  DRUGOTHER  due to inhibition of antibody response.	Vaccines	corticosteroid		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	 DRUG1 : Patients on  DRUGOTHER  therapy may exhibit a diminished response to toxoids and  DRUG2  or  DRUGOTHER  due to inhibition of antibody response.	Vaccines	live vaccines		
other	 DRUG1 : Patients on  DRUGOTHER  therapy may exhibit a diminished response to toxoids and  DRUGOTHER  or  DRUG2  due to inhibition of antibody response.	Vaccines	inactivated vaccines		OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
effect	 DRUGOTHER : Patients on  DRUG1  therapy may exhibit a diminished response to toxoids and  DRUG2  or  DRUGOTHER  due to inhibition of antibody response.	corticosteroid	live vaccines	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
effect	 DRUGOTHER : Patients on  DRUG1  therapy may exhibit a diminished response to toxoids and  DRUGOTHER  or  DRUG2  due to inhibition of antibody response.	corticosteroid	inactivated vaccines	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	 DRUGOTHER : Patients on  DRUGOTHER  therapy may exhibit a diminished response to toxoids and  DRUG1  or  DRUG2  due to inhibition of antibody response.	live vaccines	inactivated vaccines		OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
effect	 DRUG1  may also potentiate the replication of some organisms contained in  DRUG2 .	Corticosteroids	live attenuated vaccines	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CCN(CC)C(C)C(=O)C1=CC=CC=C1
advise	Routine administration of  DRUG1  or toxoids should be deferred until  DRUG2  therapy is discontinued if possible.	vaccines	corticosteroid		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
mechanism	Plasma levels of  DRUG1  may become subtherapeutic during  DRUG2  therapy.	anticonvulsant agents	cisplatin	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
mechanism	Concurrent administration of  DRUG1  and  DRUG2  may result in elevated serum levels of  DRUGOTHER .	oxyphenbutazone	androgens		C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	Concurrent administration of  DRUG1  and  DRUGOTHER  may result in elevated serum levels of  DRUG2 .	oxyphenbutazone	oxyphenbutazone		
other	Concurrent administration of  DRUGOTHER  and  DRUG1  may result in elevated serum levels of  DRUG2 .	androgens	oxyphenbutazone	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
effect	"In diabetic patients, the metabolic effects of  DRUG1  may decrease blood glucose and therefore,  DRUG2  requirements."	androgens	insulin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
other	" DRUG1  containing  DRUG2 , when administered concomitantly with  DRUGOTHER , reduce both the rate and extent of absorption."	Antacids	magnesium trisilicate		[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	" DRUG1  containing  DRUGOTHER , when administered concomitantly with  DRUG2 , reduce both the rate and extent of absorption."	Antacids	nitrofurantoin		[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
mechanism	" DRUGOTHER  containing  DRUG1 , when administered concomitantly with  DRUG2 , reduce both the rate and extent of absorption."	magnesium trisilicate	nitrofurantoin	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O	[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
mechanism	The mechanism for this interaction probably is adsorption of  DRUG1  onto the surface of  DRUG2 .	nitrofurantoin	magnesium trisilicate	[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	" DRUG1 , such as  DRUG2  and  DRUGOTHER , can inhibit renal tubular secretion of  DRUGOTHER ."	Uricosuric drugs	probenecid		CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	" DRUG1 , such as  DRUGOTHER  and  DRUG2 , can inhibit renal tubular secretion of  DRUGOTHER ."	Uricosuric drugs	sulfinpyrazone		NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
mechanism	" DRUG1 , such as  DRUGOTHER  and  DRUGOTHER , can inhibit renal tubular secretion of  DRUG2 ."	Uricosuric drugs	nitrofurantoin		[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
other	" DRUGOTHER , such as  DRUG1  and  DRUG2 , can inhibit renal tubular secretion of  DRUGOTHER ."	probenecid	sulfinpyrazone	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
mechanism	" DRUGOTHER , such as  DRUG1  and  DRUGOTHER , can inhibit renal tubular secretion of  DRUG2 ."	probenecid	nitrofurantoin	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
mechanism	" DRUGOTHER , such as  DRUGOTHER  and  DRUG1 , can inhibit renal tubular secretion of  DRUG2 ."	sulfinpyrazone	nitrofurantoin	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
other	"The resulting increase in  DRUG1  serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract  DRUG2 ."	nitrofurantoin	antibacterial	[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O	CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1
effect	"Although acid-base and electrolyte disturbances were not reported in the clinical trials with  DRUG1 , these disturbances have been reported with oral  DRUG2  and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose  DRUGOTHER  therapy)."	dorzolamide	carbonic anhydrase inhibitors	CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O	OCC(O)CO
other	"Although acid-base and electrolyte disturbances were not reported in the clinical trials with  DRUG1 , these disturbances have been reported with oral  DRUGOTHER  and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose  DRUG2  therapy)."	dorzolamide	salicylate	CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Although acid-base and electrolyte disturbances were not reported in the clinical trials with  DRUGOTHER , these disturbances have been reported with oral  DRUG1  and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose  DRUG2  therapy)."	carbonic anhydrase inhibitors	salicylate	OCC(O)CO	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	Use in Conjunction with Other  DRUG1 : The addition of  DRUG2   to  DRUGOTHER  ( DRUGOTHER ) affects the steady-state plasma concentrations of  DRUGOTHER .	Antiepileptic Drugs	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Use in Conjunction with Other  DRUG1 : The addition of  DRUGOTHER   to  DRUG2  ( DRUGOTHER ) affects the steady-state plasma concentrations of  DRUGOTHER .	Antiepileptic Drugs	antiepileptic drugs		
other	Use in Conjunction with Other  DRUG1 : The addition of  DRUGOTHER   to  DRUGOTHER  ( DRUG2 ) affects the steady-state plasma concentrations of  DRUGOTHER .	Antiepileptic Drugs	AEDs		
other	Use in Conjunction with Other  DRUG1 : The addition of  DRUGOTHER   to  DRUGOTHER  ( DRUGOTHER ) affects the steady-state plasma concentrations of  DRUG2 .	Antiepileptic Drugs	AEDs		
mechanism	Use in Conjunction with Other  DRUGOTHER : The addition of  DRUG1   to  DRUG2  ( DRUGOTHER ) affects the steady-state plasma concentrations of  DRUGOTHER .	Felbatol	antiepileptic drugs	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
mechanism	Use in Conjunction with Other  DRUGOTHER : The addition of  DRUG1   to  DRUGOTHER  ( DRUG2 ) affects the steady-state plasma concentrations of  DRUGOTHER .	Felbatol	AEDs	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
other	Use in Conjunction with Other  DRUGOTHER : The addition of  DRUG1   to  DRUGOTHER  ( DRUGOTHER ) affects the steady-state plasma concentrations of  DRUG2 .	Felbatol	AEDs	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
other	Use in Conjunction with Other  DRUGOTHER : The addition of  DRUGOTHER   to  DRUG1  ( DRUG2 ) affects the steady-state plasma concentrations of  DRUGOTHER .	antiepileptic drugs	AEDs		
other	Use in Conjunction with Other  DRUGOTHER : The addition of  DRUGOTHER   to  DRUG1  ( DRUGOTHER ) affects the steady-state plasma concentrations of  DRUG2 .	antiepileptic drugs	AEDs		
other	Use in Conjunction with Other  DRUGOTHER : The addition of  DRUGOTHER   to  DRUGOTHER  ( DRUG1 ) affects the steady-state plasma concentrations of  DRUG2 .	AEDs	AEDs		
other	The net effect of these interactions is summarized in the following table:  DRUG1   DRUG2   DRUGOTHER 	AED	AED	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
other	The net effect of these interactions is summarized in the following table:  DRUG1   DRUGOTHER   DRUG2 	AED	Felbatol	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	The net effect of these interactions is summarized in the following table:  DRUGOTHER   DRUG1   DRUG2 	AED	Felbatol	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	 DRUG1  ( DRUG2 )	Carbamazepine	CBZ	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@](CC(C)C)(N=C(O)OCC1=CC=CC=C1)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(=O)CF
other	Specific Effects of  DRUG1   on Other  DRUG2   DRUGOTHER :  DRUGOTHER   causes an increase in steady-state  DRUGOTHER  plasma concentrations.	Felbatol	Antiepileptic Drugs	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
other	Specific Effects of  DRUG1   on Other  DRUGOTHER   DRUG2 :  DRUGOTHER   causes an increase in steady-state  DRUGOTHER  plasma concentrations.	Felbatol	Phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	Specific Effects of  DRUG1   on Other  DRUGOTHER   DRUGOTHER :  DRUG2   causes an increase in steady-state  DRUGOTHER  plasma concentrations.	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Specific Effects of  DRUG1   on Other  DRUGOTHER   DRUGOTHER :  DRUGOTHER   causes an increase in steady-state  DRUG2  plasma concentrations.	Felbatol	phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	Specific Effects of  DRUGOTHER   on Other  DRUG1   DRUG2 :  DRUGOTHER   causes an increase in steady-state  DRUGOTHER  plasma concentrations.	Antiepileptic Drugs	Phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	Specific Effects of  DRUGOTHER   on Other  DRUG1   DRUGOTHER :  DRUG2   causes an increase in steady-state  DRUGOTHER  plasma concentrations.	Antiepileptic Drugs	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Specific Effects of  DRUGOTHER   on Other  DRUG1   DRUGOTHER :  DRUGOTHER   causes an increase in steady-state  DRUG2  plasma concentrations.	Antiepileptic Drugs	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	Specific Effects of  DRUGOTHER   on Other  DRUGOTHER   DRUG1 :  DRUG2   causes an increase in steady-state  DRUGOTHER  plasma concentrations.	Phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Specific Effects of  DRUGOTHER   on Other  DRUGOTHER   DRUG1 :  DRUGOTHER   causes an increase in steady-state  DRUG2  plasma concentrations.	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	Specific Effects of  DRUGOTHER   on Other  DRUGOTHER   DRUGOTHER :  DRUG1   causes an increase in steady-state  DRUG2  plasma concentrations.	Felbatol	phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"In 10 otherwise healthy subjects with epilepsy ingesting  DRUG1 , the steadystate trough (Cmin)  DRUG2  plasma concentration was 17 5 micrograms/mL."	phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	Increasing the  DRUG1  dose to 1800 mg/day in six of these subjects increased the steady-state  DRUG2  Cmin to 25 7 micrograms/mL.	felbamate	phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"In order to maintain  DRUG1  levels, limit adverse experiences, and achieve the  DRUG2  dose of 3600 mg/day, a  DRUGOTHER  dose reduction of approximately 40% was necessary for eight of these 10 subjects."	phenytoin	felbamate	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"In order to maintain  DRUG1  levels, limit adverse experiences, and achieve the  DRUGOTHER  dose of 3600 mg/day, a  DRUG2  dose reduction of approximately 40% was necessary for eight of these 10 subjects."	phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
advise	"In order to maintain  DRUGOTHER  levels, limit adverse experiences, and achieve the  DRUG1  dose of 3600 mg/day, a  DRUG2  dose reduction of approximately 40% was necessary for eight of these 10 subjects."	felbamate	phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"In a controlled clinical trial, a 20% reduction of the  DRUG1  dose at the initiation of  DRUG2   therapy resulted in  DRUGOTHER  levels comparable to those prior to  DRUGOTHER   administration."	phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"In a controlled clinical trial, a 20% reduction of the  DRUG1  dose at the initiation of  DRUGOTHER   therapy resulted in  DRUG2  levels comparable to those prior to  DRUGOTHER   administration."	phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"In a controlled clinical trial, a 20% reduction of the  DRUG1  dose at the initiation of  DRUGOTHER   therapy resulted in  DRUGOTHER  levels comparable to those prior to  DRUG2   administration."	phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"In a controlled clinical trial, a 20% reduction of the  DRUGOTHER  dose at the initiation of  DRUG1   therapy resulted in  DRUG2  levels comparable to those prior to  DRUGOTHER   administration."	Felbatol	phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"In a controlled clinical trial, a 20% reduction of the  DRUGOTHER  dose at the initiation of  DRUG1   therapy resulted in  DRUGOTHER  levels comparable to those prior to  DRUG2   administration."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"In a controlled clinical trial, a 20% reduction of the  DRUGOTHER  dose at the initiation of  DRUGOTHER   therapy resulted in  DRUG1  levels comparable to those prior to  DRUG2   administration."	phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	 DRUG1 :  DRUG2   causes a decrease in the steady-state  DRUGOTHER  plasma concentrations and an increase in the steady-state  DRUGOTHER  plasma concentration.	Carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	 DRUG1 :  DRUGOTHER   causes a decrease in the steady-state  DRUG2  plasma concentrations and an increase in the steady-state  DRUGOTHER  plasma concentration.	Carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUG1 :  DRUGOTHER   causes a decrease in the steady-state  DRUGOTHER  plasma concentrations and an increase in the steady-state  DRUG2  plasma concentration.	Carbamazepine	carbamazepine epoxide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
mechanism	 DRUGOTHER :  DRUG1   causes a decrease in the steady-state  DRUG2  plasma concentrations and an increase in the steady-state  DRUGOTHER  plasma concentration.	Felbatol	carbamazepine	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUGOTHER :  DRUG1   causes a decrease in the steady-state  DRUGOTHER  plasma concentrations and an increase in the steady-state  DRUG2  plasma concentration.	Felbatol	carbamazepine epoxide	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUGOTHER :  DRUGOTHER   causes a decrease in the steady-state  DRUG1  plasma concentrations and an increase in the steady-state  DRUG2  plasma concentration.	carbamazepine	carbamazepine epoxide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"In nine otherwise healthy subjects with epilepsy ingesting  DRUG1 , the steady-state trough (Cmin)  DRUG2  concentration was 8 2 micrograms/mL."	carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
mechanism	"The  DRUG1  steady-state Cmin decreased 31% to 5 1 micrograms/mL when  DRUG2  (3000 mg/day, divided into three doses) was coadministered."	carbamazepine	felbamate	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	 DRUG1  steady-state Cmin concentrations increased 57% from 1.0 0.3 to 1.6 0.4 micrograms/mL with the addition of  DRUG2 .	Carbamazepine epoxide	felbamate	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"In clinical trials, similar changes in  DRUG1  and  DRUG2  were seen."	carbamazepine	carbamazepine epoxide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUG1 :  DRUG2   causes an increase in steady-state  DRUGOTHER  concentrations.	Valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	 DRUG1 :  DRUGOTHER   causes an increase in steady-state  DRUG2  concentrations.	Valproate	valproate		
mechanism	 DRUGOTHER :  DRUG1   causes an increase in steady-state  DRUG2  concentrations.	Felbatol	valproate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
other	"In four subjects with epilepsy ingesting  DRUG1 , the steady-state trough (Cmin)  DRUG2  plasma concentration was 63 16 micrograms/mL."	valproate	valproate		
mechanism	Increasing the  DRUG1  dose to 2400 mg/day increased the steadystate  DRUG2  Cmin to 96 25 micrograms/mL.	felbamate	valproate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
other	"Corresponding values for free  DRUG1  Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day  DRUG2  , respectively."	valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"The ratios of the AUCs of unbound  DRUG1  to the AUCs of the total  DRUG2  were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of  DRUGOTHER  , respectively."	valproate	valproate		
other	"The ratios of the AUCs of unbound  DRUG1  to the AUCs of the total  DRUGOTHER  were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of  DRUG2  , respectively."	valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"The ratios of the AUCs of unbound  DRUGOTHER  to the AUCs of the total  DRUG1  were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of  DRUG2  , respectively."	valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUG1 : Coadministration of  DRUG2  with  DRUGOTHER  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	Phenobarbital	felbamate	CCC1(CC)C(=O)NC(=O)NC1=O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUG1 : Coadministration of  DRUGOTHER  with  DRUG2  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	Phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  causes an increase in  DRUG2  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	Phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUG2 , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	Phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUG2  concentration was 14.2 micrograms/mL."	Phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
mechanism	" DRUGOTHER : Coadministration of  DRUG1  with  DRUG2  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	felbamate	phenobarbital	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  causes an increase in  DRUG2  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	felbamate	phenobarbital	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUG2 , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	felbamate	phenobarbital	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUG2  concentration was 14.2 micrograms/mL."	felbamate	phenobarbital	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  causes an increase in  DRUG2  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUG2 , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUG2  concentration was 14.2 micrograms/mL."	phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUGOTHER  causes an increase in  DRUG1  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUG2 , the steady-state trough (Cmin)  DRUGOTHER  concentration was 14.2 micrograms/mL."	phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUGOTHER  causes an increase in  DRUG1  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUGOTHER , the steady-state trough (Cmin)  DRUG2  concentration was 14.2 micrograms/mL."	phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	" DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUGOTHER  causes an increase in  DRUGOTHER  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  DRUG1 , the steady-state trough (Cmin)  DRUG2  concentration was 14.2 micrograms/mL."	phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Effects of Other  DRUG1  on  DRUG2    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Antiepileptic Drugs	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUG1  on  DRUGOTHER    DRUG2 :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Antiepileptic Drugs	Phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUG1  on  DRUGOTHER    DRUGOTHER :  DRUG2  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Antiepileptic Drugs	Phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUG1  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUG2   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Antiepileptic Drugs	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUG1  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUG2 ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Antiepileptic Drugs	felbamate		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUG1  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUG2  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Antiepileptic Drugs	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUG1  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Antiepileptic Drugs	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUG1  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	Antiepileptic Drugs	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUG1    DRUG2 :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	Phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUG1    DRUGOTHER :  DRUG2  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	Phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUG1    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUG2   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUG1    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUG2 ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	felbamate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUG1    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUG2  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUG1    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUG1    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUG1 :  DRUG2  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	Phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUG1 :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUG2   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUG1 :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUG2 ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	felbamate	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUG1 :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUG2  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUG1 :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUG1 :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	Phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
mechanism	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUG1  causes an approximate doubling of the clearance of  DRUG2   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
mechanism	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUG1  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUG2 ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	felbamate	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUG1  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUG2  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUG1  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUG1  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	Phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUG1   ( DRUG2 ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	felbamate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUG1   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUG2  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUG1   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUG1   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUG1 ) at steady state and, therefore, the addition of  DRUG2  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	felbamate	phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUG1 ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	felbamate	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUG1 ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	felbamate	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
mechanism	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUG1  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUG1  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	phenytoin	Felbatol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of Other  DRUGOTHER  on  DRUGOTHER    DRUGOTHER :  DRUGOTHER  causes an approximate doubling of the clearance of  DRUGOTHER   ( DRUGOTHER ) at steady state and, therefore, the addition of  DRUGOTHER  causes an approximate 45% decrease in the steady-state trough concentrations of  DRUG1   as compared to the same dose of  DRUG2   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUG1 :  DRUG2  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Carbamazepine	Carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUG1 :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUG2   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUG1 :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUG2  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUG1 :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUG1 :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	Carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
mechanism	" DRUGOTHER :  DRUG1  causes an approximate 50% increase in the clearance of  DRUG2   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER :  DRUG1  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUG2  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUG1  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER :  DRUG1  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	Carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUG1   at steady state and, therefore, the addition of  DRUG2  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	carbamazepine	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUG1   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUG1   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
mechanism	" DRUGOTHER :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUG1  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUG2   as compared to the same dose of  DRUGOTHER   given as monotherapy."	carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUG1  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUGOTHER   as compared to the same dose of  DRUG2   given as monotherapy."	carbamazepine	Felbatol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER :  DRUGOTHER  causes an approximate 50% increase in the clearance of  DRUGOTHER   at steady state and, therefore, the addition of  DRUGOTHER  results in an approximate 40% decrease in the steady-state trough concentrations of  DRUG1   as compared to the same dose of  DRUG2   given as monotherapy."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUG1 : Available data suggest that there is no significant effect of  DRUG2  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUGOTHER ) plasma concentrations."	Valproate	valproate		
other	" DRUG1 : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUG2   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUGOTHER ) plasma concentrations."	Valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUG1 : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUG2  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUGOTHER ) plasma concentrations."	Valproate	valproate		
other	" DRUG1 : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUG2   ( DRUGOTHER ) plasma concentrations."	Valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUG1 : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUG2 ) plasma concentrations."	Valproate	felbamate		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUG1  on the clearance of  DRUG2   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUGOTHER ) plasma concentrations."	valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUG1  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUG2  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUGOTHER ) plasma concentrations."	valproate	valproate		
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUG1  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUG2   ( DRUGOTHER ) plasma concentrations."	valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUG1  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUG2 ) plasma concentrations."	valproate	felbamate		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUG1   at steady state, Therefore, the addition of  DRUG2  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUGOTHER ) plasma concentrations."	Felbatol	valproate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUG1   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUG2   ( DRUGOTHER ) plasma concentrations."	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUG1   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUG2 ) plasma concentrations."	Felbatol	felbamate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUG1  is not expected to cause a clinically important effect on  DRUG2   ( DRUGOTHER ) plasma concentrations."	valproate	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUG1  is not expected to cause a clinically important effect on  DRUGOTHER   ( DRUG2 ) plasma concentrations."	valproate	felbamate		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	" DRUGOTHER : Available data suggest that there is no significant effect of  DRUGOTHER  on the clearance of  DRUGOTHER   at steady state, Therefore, the addition of  DRUGOTHER  is not expected to cause a clinically important effect on  DRUG1   ( DRUG2 ) plasma concentrations."	Felbatol	felbamate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	 DRUG1 : It appears that  DRUG2  may reduce plasma  DRUGOTHER  concentrations.	Phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	 DRUG1 : It appears that  DRUGOTHER  may reduce plasma  DRUG2  concentrations.	Phenobarbital	felbamate	CCC1(CC)C(=O)NC(=O)NC1=O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
mechanism	 DRUGOTHER : It appears that  DRUG1  may reduce plasma  DRUG2  concentrations.	phenobarbital	felbamate	CCC1(CC)C(=O)NC(=O)NC1=O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Steady-state plasma  DRUG1  concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of  DRUG2  a day.	felbamate	felbamate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Effects of  DRUG1  on  DRUG2   The rate and extent of absorption of a 2400 mg dose of  DRUGOTHER   as monotherapy given as tablets was not affected when coadministered with  DRUGOTHER .	Antacids	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Effects of  DRUG1  on  DRUGOTHER   The rate and extent of absorption of a 2400 mg dose of  DRUG2   as monotherapy given as tablets was not affected when coadministered with  DRUGOTHER .	Antacids	Felbatol		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Effects of  DRUG1  on  DRUGOTHER   The rate and extent of absorption of a 2400 mg dose of  DRUGOTHER   as monotherapy given as tablets was not affected when coadministered with  DRUG2 .	Antacids	antacids		
other	Effects of  DRUGOTHER  on  DRUG1   The rate and extent of absorption of a 2400 mg dose of  DRUG2   as monotherapy given as tablets was not affected when coadministered with  DRUGOTHER .	Felbatol	Felbatol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	Effects of  DRUGOTHER  on  DRUG1   The rate and extent of absorption of a 2400 mg dose of  DRUGOTHER   as monotherapy given as tablets was not affected when coadministered with  DRUG2 .	Felbatol	antacids	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
other	Effects of  DRUGOTHER  on  DRUGOTHER   The rate and extent of absorption of a 2400 mg dose of  DRUG1   as monotherapy given as tablets was not affected when coadministered with  DRUG2 .	Felbatol	antacids	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	
other	"Effects of  DRUG1  on  DRUG2   The coadministration of  DRUGOTHER  (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at  DRUGOTHER  daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy."	Erythromycin	Felbatol	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUG1  on  DRUGOTHER   The coadministration of  DRUG2  (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at  DRUGOTHER  daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy."	Erythromycin	erythromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Effects of  DRUG1  on  DRUGOTHER   The coadministration of  DRUGOTHER  (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at  DRUG2  daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy."	Erythromycin	felbamate	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUGOTHER  on  DRUG1   The coadministration of  DRUG2  (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at  DRUGOTHER  daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy."	Felbatol	erythromycin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Effects of  DRUGOTHER  on  DRUG1   The coadministration of  DRUGOTHER  (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at  DRUG2  daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy."	Felbatol	felbamate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUGOTHER  on  DRUGOTHER   The coadministration of  DRUG1  (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at  DRUG2  daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy."	erythromycin	felbamate	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUG1   on Low-Dose  DRUG2  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Felbatol	Combination Oral Contraceptives	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Effects of  DRUG1   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUG2  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Felbatol	contraceptive	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
other	"Effects of  DRUG1   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUG2  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Felbatol	ethinyl estradiol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Effects of  DRUG1   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUG2  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Felbatol	gestodene	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
other	"Effects of  DRUG1   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUG2  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Felbatol	felbamate	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUG1   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUG2  cycles."	Felbatol	contraceptive	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUG1  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUG2  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Combination Oral Contraceptives	contraceptive	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUG1  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUG2  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Combination Oral Contraceptives	ethinyl estradiol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Effects of  DRUGOTHER   on Low-Dose  DRUG1  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUG2  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Combination Oral Contraceptives	gestodene	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
other	"Effects of  DRUGOTHER   on Low-Dose  DRUG1  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUG2  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	Combination Oral Contraceptives	felbamate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUG1  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUG2  cycles."	Combination Oral Contraceptives	contraceptive	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUG1  regimen containing 30 mg  DRUG2  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	contraceptive	ethinyl estradiol	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUG1  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUG2  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	contraceptive	gestodene	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUG1  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUG2  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	contraceptive	felbamate	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUG1  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUG2  cycles."	contraceptive	contraceptive	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUG1  and 75 mg  DRUG2  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	ethinyl estradiol	gestodene	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUG1  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUG2  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	ethinyl estradiol	felbamate	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUG1  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUG2  cycles."	ethinyl estradiol	contraceptive	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUG1  for at least 3 months received 2400 mg/day of  DRUG2  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUGOTHER  cycles."	gestodene	felbamate	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUG1  for at least 3 months received 2400 mg/day of  DRUGOTHER  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUG2  cycles."	gestodene	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
other	"Effects of  DRUGOTHER   on Low-Dose  DRUGOTHER  A group of 24 nonsmoking, healthy white female volunteers established on an oral  DRUGOTHER  regimen containing 30 mg  DRUGOTHER  and 75 mg  DRUGOTHER  for at least 3 months received 2400 mg/day of  DRUG1  from midcycle (day 15) to midcycle (day 14) of two consecutive oral  DRUG2  cycles."	felbamate	contraceptive	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
mechanism	" DRUG1  treatment resulted in a 42% decrease in the  DRUG2  AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of  DRUGOTHER ."	Felbamate	gestodene	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
other	" DRUG1  treatment resulted in a 42% decrease in the  DRUGOTHER  AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of  DRUG2 ."	Felbamate	ethinyl estradiol	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	" DRUGOTHER  treatment resulted in a 42% decrease in the  DRUG1  AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of  DRUG2 ."	gestodene	ethinyl estradiol	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
effect	 DRUG1  toxicity may be aggravated by the initial release of norepinephrine caused by  DRUG2  Injection.	Digitalis	Bretylium Tosylate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC[N+](C)(C)CC1=CC=CC=C1Br
other	The pressor effects of  DRUG1  such as  DRUG2  or  DRUGOTHER  are enhanced by  DRUGOTHER .	catecholamines	dopamine	OC(=O)CCCCCCCC(O)=O	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	The pressor effects of  DRUG1  such as  DRUGOTHER  or  DRUG2  are enhanced by  DRUGOTHER .	catecholamines	norepinephrine	OC(=O)CCCCCCCC(O)=O	CNC[C@H](O)C1=CC(O)=C(O)C=C1
effect	The pressor effects of  DRUG1  such as  DRUGOTHER  or  DRUGOTHER  are enhanced by  DRUG2 .	catecholamines	Bretylium Tosylate	OC(=O)CCCCCCCC(O)=O	CC[N+](C)(C)CC1=CC=CC=C1Br
other	The pressor effects of  DRUGOTHER  such as  DRUG1  or  DRUG2  are enhanced by  DRUGOTHER .	dopamine	norepinephrine	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	CNC[C@H](O)C1=CC(O)=C(O)C=C1
effect	The pressor effects of  DRUGOTHER  such as  DRUG1  or  DRUGOTHER  are enhanced by  DRUG2 .	dopamine	Bretylium Tosylate	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	CC[N+](C)(C)CC1=CC=CC=C1Br
effect	The pressor effects of  DRUGOTHER  such as  DRUGOTHER  or  DRUG1  are enhanced by  DRUG2 .	norepinephrine	Bretylium Tosylate	CNC[C@H](O)C1=CC(O)=C(O)C=C1	CC[N+](C)(C)CC1=CC=CC=C1Br
other	"Although there is little published information on concomitant administration of  DRUG1  and  DRUG2 , these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy."	lidocaine	Bretylium Tosylate		CC[N+](C)(C)CC1=CC=CC=C1Br
other	 DRUG1  such as  DRUG2  or  DRUGOTHER ;	Antipsychotic drugs	phenothiazines		N1C2=CC=CC=C2SC2=CC=CC=C12
other	 DRUG1  such as  DRUGOTHER  or  DRUG2 ;	Antipsychotic drugs	haloperidol		OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	 DRUGOTHER  such as  DRUG1  or  DRUG2 ;	phenothiazines	haloperidol	N1C2=CC=CC=C2SC2=CC=CC=C12	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"In this study we investigated the effect of  DRUG1  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUG2   DRUGOTHER  (L-type),  DRUGOTHER  (N-type), or  DRUGOTHER  (P-type) in bovine chromaffin cells."	ginsenosides	selective Ca(2+) channel blockers	[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C	
other	"In this study we investigated the effect of  DRUG1  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUGOTHER   DRUG2  (L-type),  DRUGOTHER  (N-type), or  DRUGOTHER  (P-type) in bovine chromaffin cells."	ginsenosides	nimodipine	[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
other	"In this study we investigated the effect of  DRUG1  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUGOTHER   DRUGOTHER  (L-type),  DRUG2  (N-type), or  DRUGOTHER  (P-type) in bovine chromaffin cells."	ginsenosides	omega-conotoxin GVIA	[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C	
other	"In this study we investigated the effect of  DRUG1  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUGOTHER   DRUGOTHER  (L-type),  DRUGOTHER  (N-type), or  DRUG2  (P-type) in bovine chromaffin cells."	ginsenosides	omega-agatoxin IVA	[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C	
other	"In this study we investigated the effect of  DRUGOTHER  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUG1   DRUG2  (L-type),  DRUGOTHER  (N-type), or  DRUGOTHER  (P-type) in bovine chromaffin cells."	selective Ca(2+) channel blockers	nimodipine		COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
other	"In this study we investigated the effect of  DRUGOTHER  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUG1   DRUGOTHER  (L-type),  DRUG2  (N-type), or  DRUGOTHER  (P-type) in bovine chromaffin cells."	selective Ca(2+) channel blockers	omega-conotoxin GVIA		
other	"In this study we investigated the effect of  DRUGOTHER  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUG1   DRUGOTHER  (L-type),  DRUGOTHER  (N-type), or  DRUG2  (P-type) in bovine chromaffin cells."	selective Ca(2+) channel blockers	omega-agatoxin IVA		
other	"In this study we investigated the effect of  DRUGOTHER  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUGOTHER   DRUG1  (L-type),  DRUG2  (N-type), or  DRUGOTHER  (P-type) in bovine chromaffin cells."	nimodipine	omega-conotoxin GVIA	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C	
other	"In this study we investigated the effect of  DRUGOTHER  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUGOTHER   DRUG1  (L-type),  DRUGOTHER  (N-type), or  DRUG2  (P-type) in bovine chromaffin cells."	nimodipine	omega-agatoxin IVA	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C	
other	"In this study we investigated the effect of  DRUGOTHER  on high threshold voltage-dependent Ca(2+) channel subtypes using their  DRUGOTHER   DRUGOTHER  (L-type),  DRUG1  (N-type), or  DRUG2  (P-type) in bovine chromaffin cells."	omega-conotoxin GVIA	omega-agatoxin IVA		
other	 DRUG1  had no effect on  DRUG2  response.	Nimodipine	ginsenosides	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C	[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C
other	"Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by  DRUG1  in bovine chromaffin cell could be the cellular basis of antistress effects induced by  DRUG2 ."	ginsenosides	ginseng	[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C	CC1(C)C2CCC1(C)C(=O)C2
other	"The effectiveness of  DRUG1 -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUG2   DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER ."	progestin	anticonvulsants	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
effect	"The effectiveness of  DRUG1 -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUG2 ,  DRUGOTHER , and  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER ."	progestin	phenytoin	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
effect	"The effectiveness of  DRUG1 -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUG2 , and  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER ."	progestin	carbamazepine	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
effect	"The effectiveness of  DRUG1 -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUGOTHER , and  DRUG2 , and the  DRUGOTHER   DRUGOTHER ."	progestin	barbiturates	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"The effectiveness of  DRUG1 -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , and the  DRUG2   DRUGOTHER ."	progestin	antituberculosis drug	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	
effect	"The effectiveness of  DRUG1 -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , and the  DRUGOTHER   DRUG2 ."	progestin	rifampin	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUG1   DRUG2 ,  DRUGOTHER , and  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER ."	anticonvulsants	phenytoin	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUG1   DRUGOTHER ,  DRUG2 , and  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER ."	anticonvulsants	carbamazepine	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUG1   DRUGOTHER ,  DRUGOTHER , and  DRUG2 , and the  DRUGOTHER   DRUGOTHER ."	anticonvulsants	barbiturates	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUG1   DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , and the  DRUG2   DRUGOTHER ."	anticonvulsants	antituberculosis drug	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUG1   DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , and the  DRUGOTHER   DRUG2 ."	anticonvulsants	rifampin	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUG1 ,  DRUG2 , and  DRUGOTHER , and the  DRUGOTHER   DRUGOTHER ."	phenytoin	carbamazepine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUG1 ,  DRUGOTHER , and  DRUG2 , and the  DRUGOTHER   DRUGOTHER ."	phenytoin	barbiturates	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUG1 ,  DRUGOTHER , and  DRUGOTHER , and the  DRUG2   DRUGOTHER ."	phenytoin	antituberculosis drug	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUG1 ,  DRUGOTHER , and  DRUGOTHER , and the  DRUGOTHER   DRUG2 ."	phenytoin	rifampin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUG1 , and  DRUG2 , and the  DRUGOTHER   DRUGOTHER ."	carbamazepine	barbiturates	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUG1 , and  DRUGOTHER , and the  DRUG2   DRUGOTHER ."	carbamazepine	antituberculosis drug	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUG1 , and  DRUGOTHER , and the  DRUGOTHER   DRUG2 ."	carbamazepine	rifampin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUGOTHER , and  DRUG1 , and the  DRUG2   DRUGOTHER ."	barbiturates	antituberculosis drug	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUGOTHER , and  DRUG1 , and the  DRUGOTHER   DRUG2 ."	barbiturates	rifampin	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"The effectiveness of  DRUGOTHER -only pills is reduced by hepatic enzyme-inducing drugs such as the  DRUGOTHER   DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , and the  DRUG1   DRUG2 ."	antituberculosis drug	rifampin		CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Although the pressor activity of  DRUG1  is very low compared to its antidiuretic activity, large doses of  DRUG2  Tablets should be used with other pressor agents only with careful patient monitoring."	Desmopressin	Desmopressin	NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
effect	"Among the risk factors studied, two appear to increase the risk of ARE: the prescription of  DRUG1  to treat strongyloidiasis during the  DRUG2  cure and the bad general clinical conditions of patients."	thiabendazole	melarsoprol	N1C2=CC=CC=C2N=C1C1=CSC=N1	NC1=NC(NC2=CC=C(C=C2)[As]2SCC(CO)S2)=NC(N)=N1
other	"Recommendations were to avoid administration of diffusible  DRUG1  treatment during the cure, and to improve the general conditions of patients before the cure of  DRUG2 ."	anti-helminthic	melarsoprol	CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1	NC1=NC(NC2=CC=C(C=C2)[As]2SCC(CO)S2)=NC(N)=N1
other	"In patients receiving nonselective  DRUG1  ( DRUG2 ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	monoamine oxidase inhibitors	MAOIs	OC(=O)CCCCCCCC(O)=O	
other	"In patients receiving nonselective  DRUG1  ( DRUGOTHER ) (e.g.,  DRUG2 ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	monoamine oxidase inhibitors	selegiline hydrochloride	OC(=O)CCCCCCCC(O)=O	C[C@H](CC1=CC=CC=C1)N(C)CC#C
effect	"In patients receiving nonselective  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	monoamine oxidase inhibitors	serotoninergic agents	OC(=O)CCCCCCCC(O)=O	NCCC1=CNC2=CC=C(O)C=C12
effect	"In patients receiving nonselective  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	monoamine oxidase inhibitors	fluoxetine	OC(=O)CCCCCCCC(O)=O	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
effect	"In patients receiving nonselective  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	monoamine oxidase inhibitors	fluvoxamine	OC(=O)CCCCCCCC(O)=O	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
effect	"In patients receiving nonselective  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	monoamine oxidase inhibitors	paroxetine	OC(=O)CCCCCCCC(O)=O	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
effect	"In patients receiving nonselective  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	monoamine oxidase inhibitors	sertraline	OC(=O)CCCCCCCC(O)=O	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	"In patients receiving nonselective  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), there have been reports of serious, sometimes fatal, reactions."	monoamine oxidase inhibitors	venlafaxine	OC(=O)CCCCCCCC(O)=O	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUG2 ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	MAOIs	selegiline hydrochloride		C[C@H](CC1=CC=CC=C1)N(C)CC#C
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ) in combination with  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	MAOIs	serotoninergic agents		NCCC1=CNC2=CC=C(O)C=C12
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	MAOIs	fluoxetine		CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	MAOIs	fluvoxamine		ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	MAOIs	paroxetine		FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	MAOIs	sertraline		C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), there have been reports of serious, sometimes fatal, reactions."	MAOIs	venlafaxine		COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ) in combination with  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	selegiline hydrochloride	serotoninergic agents	C[C@H](CC1=CC=CC=C1)N(C)CC#C	NCCC1=CNC2=CC=C(O)C=C12
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ) in combination with  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	selegiline hydrochloride	fluoxetine	C[C@H](CC1=CC=CC=C1)N(C)CC#C	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	selegiline hydrochloride	fluvoxamine	C[C@H](CC1=CC=CC=C1)N(C)CC#C	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	selegiline hydrochloride	paroxetine	C[C@H](CC1=CC=CC=C1)N(C)CC#C	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	selegiline hydrochloride	sertraline	C[C@H](CC1=CC=CC=C1)N(C)CC#C	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), there have been reports of serious, sometimes fatal, reactions."	selegiline hydrochloride	venlafaxine	C[C@H](CC1=CC=CC=C1)N(C)CC#C	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	serotoninergic agents	fluoxetine	NCCC1=CNC2=CC=C(O)C=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	serotoninergic agents	fluvoxamine	NCCC1=CNC2=CC=C(O)C=C12	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	serotoninergic agents	paroxetine	NCCC1=CNC2=CC=C(O)C=C12	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	serotoninergic agents	sertraline	NCCC1=CNC2=CC=C(O)C=C12	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), there have been reports of serious, sometimes fatal, reactions."	serotoninergic agents	venlafaxine	NCCC1=CNC2=CC=C(O)C=C12	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	fluoxetine	fluvoxamine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	fluoxetine	paroxetine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	fluoxetine	sertraline	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), there have been reports of serious, sometimes fatal, reactions."	fluoxetine	venlafaxine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	fluvoxamine	paroxetine	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	fluvoxamine	sertraline	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), there have been reports of serious, sometimes fatal, reactions."	fluvoxamine	venlafaxine	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ), there have been reports of serious, sometimes fatal, reactions."	paroxetine	sertraline	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ), there have been reports of serious, sometimes fatal, reactions."	paroxetine	venlafaxine	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
other	"In patients receiving nonselective  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ) in combination with  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ), there have been reports of serious, sometimes fatal, reactions."	sertraline	venlafaxine	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
other	"Because  DRUG1  is a serotonin releaser and reuptake inhibitor,  DRUG2  should not be used concomitantly with a  DRUGOTHER ."	dexfenfluramine	dexfenfluramine	CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F	CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F
other	"Because  DRUG1  is a serotonin releaser and reuptake inhibitor,  DRUGOTHER  should not be used concomitantly with a  DRUG2 ."	dexfenfluramine	MAO inhibitor	CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F	CN(CC#C)CC1=CC=CC=C1
advise	"Because  DRUGOTHER  is a serotonin releaser and reuptake inhibitor,  DRUG1  should not be used concomitantly with a  DRUG2 ."	dexfenfluramine	MAO inhibitor	CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F	CN(CC#C)CC1=CC=CC=C1
advise	At least 14 days should elapse between discontinuation of a  DRUG1  and initiation of treatment with  DRUG2 .	MAO inhibitor	dexfenfluramine	CN(CC#C)CC1=CC=CC=C1	CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F
advise	At least 3 weeks should elapse between discontinuation of  DRUG1  and initiation of treatment with a  DRUG2 .	dexfenfluramine	MAO inhibitor	CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F	CN(CC#C)CC1=CC=CC=C1
other	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUG1  ( DRUG2 ) and agents for migraine therapy, such as  DRUGOTHER  ( DRUGOTHER ) and  DRUGOTHER ."	selective serotonin reuptake inhibitors	SSRIs	NCCC1=CNC2=CC=C(O)C=C12	
effect	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUG1  ( DRUGOTHER ) and agents for migraine therapy, such as  DRUG2  ( DRUGOTHER ) and  DRUGOTHER ."	selective serotonin reuptake inhibitors	Imitrex	NCCC1=CNC2=CC=C(O)C=C12	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
effect	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUG1  ( DRUGOTHER ) and agents for migraine therapy, such as  DRUGOTHER  ( DRUG2 ) and  DRUGOTHER ."	selective serotonin reuptake inhibitors	sumatriptan succinate	NCCC1=CNC2=CC=C(O)C=C12	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
effect	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUG1  ( DRUGOTHER ) and agents for migraine therapy, such as  DRUGOTHER  ( DRUGOTHER ) and  DRUG2 ."	selective serotonin reuptake inhibitors	dihydroergotamine	NCCC1=CNC2=CC=C(O)C=C12	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
effect	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUGOTHER  ( DRUG1 ) and agents for migraine therapy, such as  DRUG2  ( DRUGOTHER ) and  DRUGOTHER ."	SSRIs	Imitrex		CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
effect	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUGOTHER  ( DRUG1 ) and agents for migraine therapy, such as  DRUGOTHER  ( DRUG2 ) and  DRUGOTHER ."	SSRIs	sumatriptan succinate		CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
effect	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUGOTHER  ( DRUG1 ) and agents for migraine therapy, such as  DRUGOTHER  ( DRUGOTHER ) and  DRUG2 ."	SSRIs	dihydroergotamine		[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
other	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUGOTHER  ( DRUGOTHER ) and agents for migraine therapy, such as  DRUG1  ( DRUG2 ) and  DRUGOTHER ."	Imitrex	sumatriptan succinate	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
other	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUGOTHER  ( DRUGOTHER ) and agents for migraine therapy, such as  DRUG1  ( DRUGOTHER ) and  DRUG2 ."	Imitrex	dihydroergotamine	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
other	"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  DRUGOTHER  ( DRUGOTHER ) and agents for migraine therapy, such as  DRUGOTHER  ( DRUG1 ) and  DRUG2 ."	sumatriptan succinate	dihydroergotamine	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
advise	 DRUG1  should not be administered with other  DRUG2 .	Dexfenfluramine	serotoninergic agents	CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F	NCCC1=CNC2=CC=C(O)C=C12
other	Changes in urinary homocysteine following  DRUG1  and  DRUG2  administration to rats.	synthetic steroidal estrogen	synthetic steroidal progestogen	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"The present work involved the administration of both  DRUG1  and  DRUG2  to groups of rats, followed by determination of the homocysteine excretion rate in urine."	ethynyl estradiol	levonorgestrel	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C
other	The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and  DRUG1 -treated rats and the levels shown by rats treated with  DRUG2 .	levonorgestrel	ethynyl estradiol	CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Since  DRUG1  ( DRUG2 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	Zarontin	ethosuximide	CCC1(C)CC(=O)NC1=O	CCC1(C)CC(=O)NC1=O
int	"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUG2 , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	Zarontin	antiepileptic drugs	CCC1(C)CC(=O)NC1=O	
other	"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUG2  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	Zarontin	ethosuximide	CCC1(C)CC(=O)NC1=O	CCC1(C)CC(=O)NC1=O
other	"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUG2  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	Zarontin	phenytoin	CCC1(C)CC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUG2  has been reported to both increase and decrease  DRUGOTHER  levels)."	Zarontin	valproic acid	CCC1(C)CC(=O)NC1=O	CCCC(CCC)C(O)=O
other	"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUG2  levels)."	Zarontin	ethosuximide	CCC1(C)CC(=O)NC1=O	CCC1(C)CC(=O)NC1=O
int	"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUG2 , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	ethosuximide	antiepileptic drugs	CCC1(C)CC(=O)NC1=O	
other	"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUG2  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	ethosuximide	ethosuximide	CCC1(C)CC(=O)NC1=O	CCC1(C)CC(=O)NC1=O
other	"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUG2  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	ethosuximide	phenytoin	CCC1(C)CC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUG2  has been reported to both increase and decrease  DRUGOTHER  levels)."	ethosuximide	valproic acid	CCC1(C)CC(=O)NC1=O	CCCC(CCC)C(O)=O
other	"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUG2  levels)."	ethosuximide	ethosuximide	CCC1(C)CC(=O)NC1=O	CCC1(C)CC(=O)NC1=O
other	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUG1 , periodic serum level determinations of these drugs may be necessary (eg,  DRUG2  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	antiepileptic drugs	ethosuximide		CCC1(C)CC(=O)NC1=O
other	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUG1 , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUG2  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	antiepileptic drugs	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUG1 , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUG2  has been reported to both increase and decrease  DRUGOTHER  levels)."	antiepileptic drugs	valproic acid		CCCC(CCC)C(O)=O
other	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUG1 , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUG2  levels)."	antiepileptic drugs	ethosuximide		CCC1(C)CC(=O)NC1=O
mechanism	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUG1  may elevate  DRUG2  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUGOTHER  levels)."	ethosuximide	phenytoin	CCC1(C)CC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUG1  may elevate  DRUGOTHER  serum levels and  DRUG2  has been reported to both increase and decrease  DRUGOTHER  levels)."	ethosuximide	valproic acid	CCC1(C)CC(=O)NC1=O	CCCC(CCC)C(O)=O
other	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUG1  may elevate  DRUGOTHER  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUG2  levels)."	ethosuximide	ethosuximide	CCC1(C)CC(=O)NC1=O	CCC1(C)CC(=O)NC1=O
other	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUG1  serum levels and  DRUG2  has been reported to both increase and decrease  DRUGOTHER  levels)."	phenytoin	valproic acid	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCCC(CCC)C(O)=O
other	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUG1  serum levels and  DRUGOTHER  has been reported to both increase and decrease  DRUG2  levels)."	phenytoin	ethosuximide	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(C)CC(=O)NC1=O
mechanism	"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg,  DRUGOTHER  may elevate  DRUGOTHER  serum levels and  DRUG1  has been reported to both increase and decrease  DRUG2  levels)."	valproic acid	ethosuximide	CCCC(CCC)C(O)=O	CCC1(C)CC(=O)NC1=O
other	"The potential for clinically significant drug-drug interactions posed by  DRUG1  and  DRUG2  appears to be low for drugs commonly used in chemotherapy or surgery, because  DRUGOTHER  is eliminated by multiple routes."	dolasetron	hydrodolasetron	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"The potential for clinically significant drug-drug interactions posed by  DRUG1  and  DRUGOTHER  appears to be low for drugs commonly used in chemotherapy or surgery, because  DRUG2  is eliminated by multiple routes."	dolasetron	hydrodolasetron	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"The potential for clinically significant drug-drug interactions posed by  DRUGOTHER  and  DRUG1  appears to be low for drugs commonly used in chemotherapy or surgery, because  DRUG2  is eliminated by multiple routes."	hydrodolasetron	hydrodolasetron	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"Blood levels of  DRUG1  increased 24% when  DRUG2  was coadministered with  DRUGOTHER  (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of  DRUGOTHER  (potent inducer of cytochrome P-450) for 7 days."	hydrodolasetron	dolasetron	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"Blood levels of  DRUG1  increased 24% when  DRUGOTHER  was coadministered with  DRUG2  (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of  DRUGOTHER  (potent inducer of cytochrome P-450) for 7 days."	hydrodolasetron	cimetidine	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Blood levels of  DRUG1  increased 24% when  DRUGOTHER  was coadministered with  DRUGOTHER  (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of  DRUG2  (potent inducer of cytochrome P-450) for 7 days."	hydrodolasetron	rifampin	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
mechanism	"Blood levels of  DRUGOTHER  increased 24% when  DRUG1  was coadministered with  DRUG2  (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of  DRUGOTHER  (potent inducer of cytochrome P-450) for 7 days."	dolasetron	cimetidine	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
mechanism	"Blood levels of  DRUGOTHER  increased 24% when  DRUG1  was coadministered with  DRUGOTHER  (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of  DRUG2  (potent inducer of cytochrome P-450) for 7 days."	dolasetron	rifampin	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Blood levels of  DRUGOTHER  increased 24% when  DRUGOTHER  was coadministered with  DRUG1  (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of  DRUG2  (potent inducer of cytochrome P-450) for 7 days."	cimetidine	rifampin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"In patients taking  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	furosemide	nifedipine	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"In patients taking  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	furosemide	diltiazem	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	
other	"In patients taking  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	furosemide	ACE inhibitors	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	
other	"In patients taking  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	furosemide	verapamil	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"In patients taking  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	furosemide	glyburide	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"In patients taking  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	furosemide	propranolol	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In patients taking  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUG2 ."	furosemide	hydrodolasetron	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	nifedipine	diltiazem	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	"In patients taking  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	nifedipine	ACE inhibitors	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	"In patients taking  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	nifedipine	verapamil	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"In patients taking  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	nifedipine	glyburide	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"In patients taking  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	nifedipine	propranolol	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUG2 ."	nifedipine	hydrodolasetron	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	diltiazem	ACE inhibitors		
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	diltiazem	verapamil		COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	diltiazem	glyburide		COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	diltiazem	propranolol		CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUG2 ."	diltiazem	hydrodolasetron		[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	ACE inhibitors	verapamil		COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	ACE inhibitors	glyburide		COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	ACE inhibitors	propranolol		CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUG2 ."	ACE inhibitors	hydrodolasetron		[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	verapamil	glyburide	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	verapamil	propranolol	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUG2 ."	verapamil	hydrodolasetron	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and various chemotherapy agents, no effect was shown on the clearance of  DRUGOTHER ."	glyburide	propranolol	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and various chemotherapy agents, no effect was shown on the clearance of  DRUG2 ."	glyburide	hydrodolasetron	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	"In patients taking  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and various chemotherapy agents, no effect was shown on the clearance of  DRUG2 ."	propranolol	hydrodolasetron	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	Clearance of  DRUG1  decreased by about 27% when  DRUG2  was administered intravenously concomitantly with  DRUGOTHER .	hydrodolasetron	dolasetron mesylate	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
other	Clearance of  DRUG1  decreased by about 27% when  DRUGOTHER  was administered intravenously concomitantly with  DRUG2 .	hydrodolasetron	atenolol	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
mechanism	Clearance of  DRUGOTHER  decreased by about 27% when  DRUG1  was administered intravenously concomitantly with  DRUG2 .	dolasetron mesylate	atenolol	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	" DRUG1  did not inhibit the antitumor activity of four  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) in four murine models."	Dolasetron mesylate	chemotherapeutic agents	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	
other	" DRUG1  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) in four murine models."	Dolasetron mesylate	cisplatin	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	" DRUG1  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) in four murine models."	Dolasetron mesylate	5-fluorouracil	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	FC1=CNC(=O)NC1=O
other	" DRUG1  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) in four murine models."	Dolasetron mesylate	doxorubicin	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
other	" DRUG1  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) in four murine models."	Dolasetron mesylate	cyclophosphamide	[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2	ClCCN(CCCl)P1(=O)NCCCO1
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) in four murine models."	chemotherapeutic agents	cisplatin		[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) in four murine models."	chemotherapeutic agents	5-fluorouracil		FC1=CNC(=O)NC1=O
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) in four murine models."	chemotherapeutic agents	doxorubicin		COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) in four murine models."	chemotherapeutic agents	cyclophosphamide		ClCCN(CCCl)P1(=O)NCCCO1
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) in four murine models."	cisplatin	5-fluorouracil	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	FC1=CNC(=O)NC1=O
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) in four murine models."	cisplatin	doxorubicin	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) in four murine models."	cisplatin	cyclophosphamide	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	ClCCN(CCCl)P1(=O)NCCCO1
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ) in four murine models."	5-fluorouracil	doxorubicin	FC1=CNC(=O)NC1=O	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ) in four murine models."	5-fluorouracil	cyclophosphamide	FC1=CNC(=O)NC1=O	ClCCN(CCCl)P1(=O)NCCCO1
other	" DRUGOTHER  did not inhibit the antitumor activity of four  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ) in four murine models."	doxorubicin	cyclophosphamide	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1	ClCCN(CCCl)P1(=O)NCCCO1
other	"Since  DRUG1  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUG2  is coadministered with inhibitors of C.P.A. such as  DRUGOTHER  and  DRUGOTHER  or inhibitors of CYP2C19 such as  DRUGOTHER ."	PLETAL	PLETAL	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
other	"Since  DRUG1  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUGOTHER  is coadministered with inhibitors of C.P.A. such as  DRUG2  and  DRUGOTHER  or inhibitors of CYP2C19 such as  DRUGOTHER ."	PLETAL	ketoconazole	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Since  DRUG1  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUGOTHER  is coadministered with inhibitors of C.P.A. such as  DRUGOTHER  and  DRUG2  or inhibitors of CYP2C19 such as  DRUGOTHER ."	PLETAL	erythromycin	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Since  DRUG1  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUGOTHER  is coadministered with inhibitors of C.P.A. such as  DRUGOTHER  and  DRUGOTHER  or inhibitors of CYP2C19 such as  DRUG2 ."	PLETAL	omeprazole	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
advise	"Since  DRUGOTHER  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUG1  is coadministered with inhibitors of C.P.A. such as  DRUG2  and  DRUGOTHER  or inhibitors of CYP2C19 such as  DRUGOTHER ."	PLETAL	ketoconazole	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
advise	"Since  DRUGOTHER  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUG1  is coadministered with inhibitors of C.P.A. such as  DRUGOTHER  and  DRUG2  or inhibitors of CYP2C19 such as  DRUGOTHER ."	PLETAL	erythromycin	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
advise	"Since  DRUGOTHER  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUG1  is coadministered with inhibitors of C.P.A. such as  DRUGOTHER  and  DRUGOTHER  or inhibitors of CYP2C19 such as  DRUG2 ."	PLETAL	omeprazole	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
other	"Since  DRUGOTHER  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUGOTHER  is coadministered with inhibitors of C.P.A. such as  DRUG1  and  DRUG2  or inhibitors of CYP2C19 such as  DRUGOTHER ."	ketoconazole	erythromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Since  DRUGOTHER  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUGOTHER  is coadministered with inhibitors of C.P.A. such as  DRUG1  and  DRUGOTHER  or inhibitors of CYP2C19 such as  DRUG2 ."	ketoconazole	omeprazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
other	"Since  DRUGOTHER  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  DRUGOTHER  is coadministered with inhibitors of C.P.A. such as  DRUGOTHER  and  DRUG1  or inhibitors of CYP2C19 such as  DRUG2 ."	erythromycin	omeprazole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
other	Pharmacokinetic studies have demonstrated that  DRUG1  and  DRUG2  significantly increased the systemic exposure of  DRUGOTHER  and/or its major metabolites.	omeprazole	erythromycin	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
mechanism	Pharmacokinetic studies have demonstrated that  DRUG1  and  DRUGOTHER  significantly increased the systemic exposure of  DRUG2  and/or its major metabolites.	omeprazole	cilostazol	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
mechanism	Pharmacokinetic studies have demonstrated that  DRUGOTHER  and  DRUG1  significantly increased the systemic exposure of  DRUG2  and/or its major metabolites.	erythromycin	cilostazol	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
mechanism	"Population pharmacokinetic studies showed higher concentrations of  DRUG1  among patients concurrently treated with  DRUG2 , an inhibitor of C.P.A.."	cilostazol	diltiazem	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	
other	" DRUG1  does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on  DRUG2 , a drug with metabolism very sensitive to C.P.A. inhibition."	Pletal	lovastatin	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
int	" DRUG1  may interact with  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	acetaminophen	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	OC(=O)CCCCCCCC(O)=O
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	Tylenol	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	chloramphenicol	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	Chloromycetin	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG2  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	anesthetics	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	CCOC(=O)C1=CC=C(N)C=C1
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG2  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	benzocaine	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	lidocaine	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG2  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	para-aminobenzoic acid	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	NC1=CC=C(C=C1)C(O)=O
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	PABA	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	NC1=CC=C(C=C1)C(O)=O
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	multivitamins	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	NC(=O)C1=CC=CN=C1
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	procainamide	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	OC(=O)CCCCCCCC(O)=O
int	" DRUG1  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Bentiromide	Pronestyl	OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	Tylenol	OC(=O)CCCCCCCC(O)=O	
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	chloramphenicol	OC(=O)CCCCCCCC(O)=O	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	Chloromycetin	OC(=O)CCCCCCCC(O)=O	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG2  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	anesthetics	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=CC=C(N)C=C1
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG2  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	benzocaine	OC(=O)CCCCCCCC(O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	lidocaine	OC(=O)CCCCCCCC(O)=O	
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG2  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	para-aminobenzoic acid	OC(=O)CCCCCCCC(O)=O	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	PABA	OC(=O)CCCCCCCC(O)=O	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	multivitamins	OC(=O)CCCCCCCC(O)=O	NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	procainamide	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	Pronestyl	OC(=O)CCCCCCCC(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	sulfonamides	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	acetaminophen	thiazide diuretics	OC(=O)CCCCCCCC(O)=O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUG2  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	chloramphenicol		CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUG2 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	Chloromycetin		O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG2  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG2  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	benzocaine		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	lidocaine		
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG2  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	para-aminobenzoic acid		NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	PABA		NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	multivitamins		NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	procainamide		OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	Pronestyl		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	sulfonamides		OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Tylenol	thiazide diuretics		
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUG2 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	Chloromycetin	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUG2  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	anesthetics	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	CCOC(=O)C1=CC=C(N)C=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG2  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	benzocaine	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	lidocaine	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG2  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	para-aminobenzoic acid	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	PABA	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	multivitamins	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	procainamide	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	Pronestyl	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	sulfonamides	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	chloramphenicol	thiazide diuretics	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUG2  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	anesthetics	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	CCOC(=O)C1=CC=C(N)C=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUG2  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	benzocaine	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	lidocaine	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG2  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	para-aminobenzoic acid	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	PABA	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	multivitamins	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	procainamide	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	Pronestyl	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	sulfonamides	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Chloromycetin	thiazide diuretics	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUG2  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	benzocaine	CCOC(=O)C1=CC=C(N)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	lidocaine	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG2  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	para-aminobenzoic acid	CCOC(=O)C1=CC=C(N)C=C1	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	PABA	CCOC(=O)C1=CC=C(N)C=C1	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	multivitamins	CCOC(=O)C1=CC=C(N)C=C1	NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	procainamide	CCOC(=O)C1=CC=C(N)C=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	Pronestyl	CCOC(=O)C1=CC=C(N)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	sulfonamides	CCOC(=O)C1=CC=C(N)C=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	anesthetics	thiazide diuretics	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG1  and  DRUG2 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	benzocaine	lidocaine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ),  DRUG2  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	benzocaine	para-aminobenzoic acid	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ),  DRUGOTHER  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	benzocaine	PABA	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	benzocaine	multivitamins	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	benzocaine	procainamide	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	benzocaine	Pronestyl	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	benzocaine	sulfonamides	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	benzocaine	thiazide diuretics	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ),  DRUG2  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	lidocaine	para-aminobenzoic acid		NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	lidocaine	PABA		NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	lidocaine	multivitamins		NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	lidocaine	procainamide		OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	lidocaine	Pronestyl		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	lidocaine	sulfonamides		OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	lidocaine	thiazide diuretics		
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG1  ( DRUG2 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	para-aminobenzoic acid	PABA	NC1=CC=C(C=C1)C(O)=O	NC1=CC=C(C=C1)C(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG1  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	para-aminobenzoic acid	multivitamins	NC1=CC=C(C=C1)C(O)=O	NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG1  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	para-aminobenzoic acid	procainamide	NC1=CC=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG1  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	para-aminobenzoic acid	Pronestyl	NC1=CC=C(C=C1)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG1  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	para-aminobenzoic acid	sulfonamides	NC1=CC=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUG1  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	para-aminobenzoic acid	thiazide diuretics	NC1=CC=C(C=C1)C(O)=O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG1 )-containing preparations (e.g., sunscreens and some  DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	PABA	multivitamins	NC1=CC=C(C=C1)C(O)=O	NC(=O)C1=CC=CN=C1
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG1 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	PABA	procainamide	NC1=CC=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG1 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	PABA	Pronestyl	NC1=CC=C(C=C1)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG1 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	PABA	sulfonamides	NC1=CC=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUG1 )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	PABA	thiazide diuretics	NC1=CC=C(C=C1)C(O)=O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG1 ),  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	multivitamins	procainamide	NC(=O)C1=CC=CN=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG1 ),  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	multivitamins	Pronestyl	NC(=O)C1=CC=CN=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	multivitamins	sulfonamides	NC(=O)C1=CC=CN=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	multivitamins	thiazide diuretics	NC(=O)C1=CC=CN=C1	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG1  (e.g.,  DRUG2 ),  DRUGOTHER  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	procainamide	Pronestyl	OC(=O)CCCCCCCC(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	procainamide	sulfonamides	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	procainamide	thiazide diuretics	OC(=O)CCCCCCCC(O)=O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ),  DRUG2  (sulfa medicines),  DRUGOTHER  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Pronestyl	sulfonamides	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	Pronestyl	thiazide diuretics	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	" DRUGOTHER  may interact with  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), local  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER )-containing preparations (e.g., sunscreens and some  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  (sulfa medicines),  DRUG2  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."	sulfonamides	thiazide diuretics	OC(=O)CCCCCCCC(O)=O	
other	 DRUG1 :Clinical evidence has shown that  DRUG2  can be formed with concurrent ingestion of  DRUGOTHER  and  DRUGOTHER .	Ethanol	etretinate	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C
other	 DRUG1 :Clinical evidence has shown that  DRUGOTHER  can be formed with concurrent ingestion of  DRUG2  and  DRUGOTHER .	Ethanol	acitretin	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	 DRUG1 :Clinical evidence has shown that  DRUGOTHER  can be formed with concurrent ingestion of  DRUGOTHER  and  DRUG2 .	Ethanol	ethanol	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	 DRUGOTHER :Clinical evidence has shown that  DRUG1  can be formed with concurrent ingestion of  DRUG2  and  DRUGOTHER .	etretinate	acitretin	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	 DRUGOTHER :Clinical evidence has shown that  DRUG1  can be formed with concurrent ingestion of  DRUGOTHER  and  DRUG2 .	etretinate	ethanol	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
mechanism	 DRUGOTHER :Clinical evidence has shown that  DRUGOTHER  can be formed with concurrent ingestion of  DRUG1  and  DRUG2 .	acitretin	ethanol	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	" DRUG1 : In a study of 7 healthy male volunteers,  DRUG2  treatment potentiated the blood glucose lowering effect of  DRUGOTHER  (a  DRUGOTHER  similar to  DRUGOTHER ) in 3 of the 7 subjects."	Glibenclamide	acitretin		COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	" DRUG1 : In a study of 7 healthy male volunteers,  DRUGOTHER  treatment potentiated the blood glucose lowering effect of  DRUG2  (a  DRUGOTHER  similar to  DRUGOTHER ) in 3 of the 7 subjects."	Glibenclamide	glibenclamide		
other	" DRUG1 : In a study of 7 healthy male volunteers,  DRUGOTHER  treatment potentiated the blood glucose lowering effect of  DRUGOTHER  (a  DRUG2  similar to  DRUGOTHER ) in 3 of the 7 subjects."	Glibenclamide	sulfonylurea		NC(N)=O
other	" DRUG1 : In a study of 7 healthy male volunteers,  DRUGOTHER  treatment potentiated the blood glucose lowering effect of  DRUGOTHER  (a  DRUGOTHER  similar to  DRUG2 ) in 3 of the 7 subjects."	Glibenclamide	chlorpropamide		CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
effect	" DRUGOTHER : In a study of 7 healthy male volunteers,  DRUG1  treatment potentiated the blood glucose lowering effect of  DRUG2  (a  DRUGOTHER  similar to  DRUGOTHER ) in 3 of the 7 subjects."	acitretin	glibenclamide	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	
other	" DRUGOTHER : In a study of 7 healthy male volunteers,  DRUG1  treatment potentiated the blood glucose lowering effect of  DRUGOTHER  (a  DRUG2  similar to  DRUGOTHER ) in 3 of the 7 subjects."	acitretin	sulfonylurea	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	NC(N)=O
other	" DRUGOTHER : In a study of 7 healthy male volunteers,  DRUG1  treatment potentiated the blood glucose lowering effect of  DRUGOTHER  (a  DRUGOTHER  similar to  DRUG2 ) in 3 of the 7 subjects."	acitretin	chlorpropamide	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
other	" DRUGOTHER : In a study of 7 healthy male volunteers,  DRUGOTHER  treatment potentiated the blood glucose lowering effect of  DRUG1  (a  DRUG2  similar to  DRUGOTHER ) in 3 of the 7 subjects."	glibenclamide	sulfonylurea		NC(N)=O
other	" DRUGOTHER : In a study of 7 healthy male volunteers,  DRUGOTHER  treatment potentiated the blood glucose lowering effect of  DRUG1  (a  DRUGOTHER  similar to  DRUG2 ) in 3 of the 7 subjects."	glibenclamide	chlorpropamide		CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
other	" DRUGOTHER : In a study of 7 healthy male volunteers,  DRUGOTHER  treatment potentiated the blood glucose lowering effect of  DRUGOTHER  (a  DRUG1  similar to  DRUG2 ) in 3 of the 7 subjects."	sulfonylurea	chlorpropamide	NC(N)=O	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
other	Repeating the study with 6 healthy male volunteers in the absence of  DRUG1  did not detect an effect of  DRUG2  on glucose tolerance.	glibenclamide	acitretin		COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	 DRUG1 : It has not been established if there is a pharmacokinetic interaction between  DRUG2  and  DRUGOTHER .	Hormonal Contraceptives	acitretin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	 DRUG1 : It has not been established if there is a pharmacokinetic interaction between  DRUGOTHER  and  DRUG2 .	Hormonal Contraceptives	combined oral contraceptives	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUGOTHER : It has not been established if there is a pharmacokinetic interaction between  DRUG1  and  DRUG2 .	acitretin	combined oral contraceptives	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	"However, it has been established that  DRUG1  interferes with the contraceptive effect of microdosed  DRUG2  minipill preparations."	acitretin	progestin	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]
advise	Microdosed minipill  DRUG1  preparations are not recommended for use with  DRUG2 .	progestin	Soriatane	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	"It is not known whether other  DRUG1 , such as implants and injectables, are adequate methods of contraception during  DRUG2  therapy."	progestational contraceptives	acitretin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	 DRUG1 : An increased risk of hepatitis has been reported to result from combined use of  DRUG2  and  DRUGOTHER .	Methotrexate	methotrexate	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	 DRUG1 : An increased risk of hepatitis has been reported to result from combined use of  DRUGOTHER  and  DRUG2 .	Methotrexate	etretinate	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C
effect	 DRUGOTHER : An increased risk of hepatitis has been reported to result from combined use of  DRUG1  and  DRUG2 .	methotrexate	etretinate	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C
advise	"Consequently, the combination of  DRUG1  with  DRUG2  is also contraindicated."	methotrexate	acitretin	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	" DRUG1 : If  DRUG2  is given concurrently with  DRUGOTHER , the protein binding of  DRUGOTHER  may be reduced."	Phenytoin	acitretin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	" DRUG1 : If  DRUGOTHER  is given concurrently with  DRUG2 , the protein binding of  DRUGOTHER  may be reduced."	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUG1 : If  DRUGOTHER  is given concurrently with  DRUGOTHER , the protein binding of  DRUG2  may be reduced."	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	" DRUGOTHER : If  DRUG1  is given concurrently with  DRUG2 , the protein binding of  DRUGOTHER  may be reduced."	acitretin	phenytoin	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : If  DRUG1  is given concurrently with  DRUGOTHER , the protein binding of  DRUG2  may be reduced."	acitretin	phenytoin	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : If  DRUGOTHER  is given concurrently with  DRUG1 , the protein binding of  DRUG2  may be reduced."	phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUG1 : Since both  DRUG2  and  DRUGOTHER  can cause increased intracranial pressure, their combined use is contraindicated."	Tetracyclines	acitretin	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	" DRUG1 : Since both  DRUGOTHER  and  DRUG2  can cause increased intracranial pressure, their combined use is contraindicated."	Tetracyclines	tetracyclines	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
effect	" DRUGOTHER : Since both  DRUG1  and  DRUG2  can cause increased intracranial pressure, their combined use is contraindicated."	acitretin	tetracyclines	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
other	 DRUG1  and oral  DRUG2 : Concomitant administration of  DRUGOTHER  and/or other oral  DRUGOTHER  with  DRUGOTHER  must be avoided because of the risk of hypervitaminosis A.	Vitamin A	retinoids		C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
other	 DRUG1  and oral  DRUGOTHER : Concomitant administration of  DRUG2  and/or other oral  DRUGOTHER  with  DRUGOTHER  must be avoided because of the risk of hypervitaminosis A.	Vitamin A	vitamin A		
other	 DRUG1  and oral  DRUGOTHER : Concomitant administration of  DRUGOTHER  and/or other oral  DRUG2  with  DRUGOTHER  must be avoided because of the risk of hypervitaminosis A.	Vitamin A	retinoids		C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
other	 DRUG1  and oral  DRUGOTHER : Concomitant administration of  DRUGOTHER  and/or other oral  DRUGOTHER  with  DRUG2  must be avoided because of the risk of hypervitaminosis A.	Vitamin A	acitretin		COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	 DRUGOTHER  and oral  DRUG1 : Concomitant administration of  DRUG2  and/or other oral  DRUGOTHER  with  DRUGOTHER  must be avoided because of the risk of hypervitaminosis A.	retinoids	vitamin A	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	
other	 DRUGOTHER  and oral  DRUG1 : Concomitant administration of  DRUGOTHER  and/or other oral  DRUG2  with  DRUGOTHER  must be avoided because of the risk of hypervitaminosis A.	retinoids	retinoids	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
other	 DRUGOTHER  and oral  DRUG1 : Concomitant administration of  DRUGOTHER  and/or other oral  DRUGOTHER  with  DRUG2  must be avoided because of the risk of hypervitaminosis A.	retinoids	acitretin	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	 DRUGOTHER  and oral  DRUGOTHER : Concomitant administration of  DRUG1  and/or other oral  DRUG2  with  DRUGOTHER  must be avoided because of the risk of hypervitaminosis A.	vitamin A	retinoids		C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
advise	 DRUGOTHER  and oral  DRUGOTHER : Concomitant administration of  DRUG1  and/or other oral  DRUGOTHER  with  DRUG2  must be avoided because of the risk of hypervitaminosis A.	vitamin A	acitretin		COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
advise	 DRUGOTHER  and oral  DRUGOTHER : Concomitant administration of  DRUGOTHER  and/or other oral  DRUG1  with  DRUG2  must be avoided because of the risk of hypervitaminosis A.	retinoids	acitretin	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
other	"Other: There appears to be no pharmacokinetic interaction between  DRUG1  and  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ."	acitretin	cimetidine	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Other: There appears to be no pharmacokinetic interaction between  DRUG1  and  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ."	acitretin	digoxin	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other: There appears to be no pharmacokinetic interaction between  DRUG1  and  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ."	acitretin	glyburide	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"Other: There appears to be no pharmacokinetic interaction between  DRUGOTHER  and  DRUG1 ,  DRUG2 , or  DRUGOTHER ."	cimetidine	digoxin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Other: There appears to be no pharmacokinetic interaction between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER , or  DRUG2 ."	cimetidine	glyburide	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"Other: There appears to be no pharmacokinetic interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 , or  DRUG2 ."	digoxin	glyburide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	Investigations into the effect of  DRUG1  on the protein binding of  DRUG2  ( DRUGOTHER ) revealed no interaction.	acitretin	anticoagulants of the coumarin type	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	O=C1OC2=CC=CC=C2C=C1
other	Investigations into the effect of  DRUG1  on the protein binding of  DRUGOTHER  ( DRUG2 ) revealed no interaction.	acitretin	warfarin	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	Investigations into the effect of  DRUGOTHER  on the protein binding of  DRUG1  ( DRUG2 ) revealed no interaction.	anticoagulants of the coumarin type	warfarin	O=C1OC2=CC=CC=C2C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
int	Interaction of  DRUG1  and  DRUG2  in vitro.	clindamycin	gentamicin	CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
other	"The minimal inhibitory concentrations of  DRUG1  and  DRUG2  alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates."	clindamycin	gentamicin	CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
other	 DRUG1  did not interfere with the activity of  DRUG2  within the range of concentrations tested (0.1 to 100 mug/ml);	Gentamicin	clindamycin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
effect	Combinations of  DRUG1  and  DRUG2  were indifferent for 29 strains and synergistic for 33 strains.	clindamycin	gentamicin	CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
effect	Combinations of  DRUG1  and  DRUG2  were indifferent for 16 and synergistic for 11 of the resistant strains.	clindamycin	gentamicin	CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
other	"Coadministration of  DRUG1  and drugs primarily metabolized by CYP3A (e.g.,  DRUG2 ) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects."	VIRACEPT	dihydropyridine calcium channel blockers	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[Ca]
other	Coadministration of  DRUG1  and drugs that induce CYP3A may decrease  DRUG2  plasma concentrations and reduce its therapeutic effect.	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	Coadministration of  DRUG1  and drugs that inhibit CYP3A may increase  DRUG2  plasma concentrations.	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUG1  and  DRUG2 ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	VIRACEPT	dapsone	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUG1  and  DRUGOTHER ,  DRUG2 / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	VIRACEPT	trimethoprim	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUG1  and  DRUGOTHER ,  DRUGOTHER / DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	VIRACEPT	sulfamethoxazole	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUG1  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	VIRACEPT	clarithromycin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUG1  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	VIRACEPT	erythromycin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUG1  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	VIRACEPT	itraconazole	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUG1  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	VIRACEPT	fluconazole	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUG1 ,  DRUG2 / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	dapsone	trimethoprim	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER / DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	dapsone	sulfamethoxazole	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER / DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	dapsone	clarithromycin	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	dapsone	erythromycin	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	dapsone	itraconazole	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	dapsone	fluconazole	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 / DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	trimethoprim	sulfamethoxazole	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 / DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	trimethoprim	clarithromycin	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 / DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	trimethoprim	erythromycin	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	trimethoprim	itraconazole	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	trimethoprim	fluconazole	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	sulfamethoxazole	clarithromycin	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	sulfamethoxazole	erythromycin	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	sulfamethoxazole	itraconazole	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	sulfamethoxazole	fluconazole	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	clarithromycin	erythromycin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	clarithromycin	itraconazole	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	clarithromycin	fluconazole	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  or  DRUGOTHER ."	erythromycin	itraconazole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUG2 ."	erythromycin	fluconazole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Based on known metabolic profiles, clinically significant drug interactions are not expected between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER / DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUG2 ."	itraconazole	fluconazole	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
advise	"Drugs That Should Not Be Coadministered With  DRUG1   DRUG2 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	VIRACEPT	Antiarrhythmics	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	
advise	"Drugs That Should Not Be Coadministered With  DRUG1   DRUGOTHER :  DRUG2 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	VIRACEPT	amiodarone	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
advise	"Drugs That Should Not Be Coadministered With  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUG2   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	VIRACEPT	quinidine	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUG2 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	amiodarone		CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUG2   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	quinidine		CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUG2 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	Antihistamines		NCCC1=CNC=N1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG2 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	astemizole		FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG2  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	terfenadine		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG2   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	ergot derivatives		
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG2 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	Antimycobacterial agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG2   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	rifampin		CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	Benzodiazepines		N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antiarrhythmics	midazolam		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	Antiarrhythmics	triazolam		O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	Antiarrhythmics	cisapride		CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUG2   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	quinidine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUG2 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	Antihistamines	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	NCCC1=CNC=N1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUG2 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	astemizole	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG2  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	terfenadine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG2   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	ergot derivatives	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG2 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	Antimycobacterial agents	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG2   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	rifampin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	Benzodiazepines	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	amiodarone	midazolam	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	amiodarone	triazolam	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	amiodarone	cisapride	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUG2 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	quinidine	Antihistamines	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	NCCC1=CNC=N1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUG2 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	quinidine	astemizole	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUG2  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	quinidine	terfenadine	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG2   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	quinidine	ergot derivatives	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG2 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	quinidine	Antimycobacterial agents	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG2   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	quinidine	rifampin	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	quinidine	Benzodiazepines	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	quinidine	midazolam	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	quinidine	triazolam	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	quinidine	cisapride	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUG2 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antihistamines	astemizole	NCCC1=CNC=N1	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUG2  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antihistamines	terfenadine	NCCC1=CNC=N1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG2   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antihistamines	ergot derivatives	NCCC1=CNC=N1	
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG2 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antihistamines	Antimycobacterial agents	NCCC1=CNC=N1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG2   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antihistamines	rifampin	NCCC1=CNC=N1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antihistamines	Benzodiazepines	NCCC1=CNC=N1	N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antihistamines	midazolam	NCCC1=CNC=N1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	Antihistamines	triazolam	NCCC1=CNC=N1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUG1 :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	Antihistamines	cisapride	NCCC1=CNC=N1	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUG2  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	astemizole	terfenadine	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER  Antimigraine:  DRUG2   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	astemizole	ergot derivatives	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG2 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	astemizole	Antimycobacterial agents	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG2   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	astemizole	rifampin	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	astemizole	Benzodiazepines	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	astemizole	midazolam	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	astemizole	triazolam	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUG1 ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	astemizole	cisapride	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1  Antimigraine:  DRUG2   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	terfenadine	ergot derivatives	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1  Antimigraine:  DRUGOTHER   DRUG2 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	terfenadine	Antimycobacterial agents	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG2   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	terfenadine	rifampin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	terfenadine	Benzodiazepines	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	terfenadine	midazolam	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	terfenadine	triazolam	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUG1  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	terfenadine	cisapride	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG1   DRUG2 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	ergot derivatives	Antimycobacterial agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG1   DRUGOTHER :  DRUG2   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	ergot derivatives	rifampin		CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG1   DRUGOTHER :  DRUGOTHER   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	ergot derivatives	Benzodiazepines		N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG1   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	ergot derivatives	midazolam		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG1   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	ergot derivatives	triazolam		O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUG1   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	ergot derivatives	cisapride		CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG1 :  DRUG2   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antimycobacterial agents	rifampin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG1 :  DRUGOTHER   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antimycobacterial agents	Benzodiazepines	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG1 :  DRUGOTHER   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Antimycobacterial agents	midazolam	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG1 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	Antimycobacterial agents	triazolam	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUG1 :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	Antimycobacterial agents	cisapride	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG1   DRUG2   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	rifampin	Benzodiazepines	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	N1N=CC=CC2=CC=CC=C12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG1   DRUGOTHER   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	rifampin	midazolam	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG1   DRUGOTHER   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	rifampin	triazolam	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUG1   DRUGOTHER   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	rifampin	cisapride	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG1   DRUG2 ,  DRUGOTHER  GI motility agents:  DRUGOTHER "	Benzodiazepines	midazolam	N1N=CC=CC2=CC=CC=C12	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG1   DRUGOTHER ,  DRUG2  GI motility agents:  DRUGOTHER "	Benzodiazepines	triazolam	N1N=CC=CC2=CC=CC=C12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUG1   DRUGOTHER ,  DRUGOTHER  GI motility agents:  DRUG2 "	Benzodiazepines	cisapride	N1N=CC=CC2=CC=CC=C12	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG1 ,  DRUG2  GI motility agents:  DRUGOTHER "	midazolam	triazolam	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUG1 ,  DRUGOTHER  GI motility agents:  DRUG2 "	midazolam	cisapride	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Drugs That Should Not Be Coadministered With  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER   DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  Antimigraine:  DRUGOTHER   DRUGOTHER :  DRUGOTHER   DRUGOTHER   DRUGOTHER ,  DRUG1  GI motility agents:  DRUG2 "	triazolam	cisapride	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
advise	Drugs Which Require a Dose Reduction When Coadminstered With  DRUG1   DRUG2 :  DRUGOTHER 	VIRACEPT	Antimycobacterial agents	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
advise	Drugs Which Require a Dose Reduction When Coadminstered With  DRUG1   DRUGOTHER :  DRUG2 	VIRACEPT	rifabutin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	Drugs Which Require a Dose Reduction When Coadminstered With  DRUGOTHER   DRUG1 :  DRUG2 	Antimycobacterial agents	rifabutin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	* This table is not all inclusive **  DRUG1  may not be effective due to decreased  DRUG2  plasma concentrations in patients taking these agents concomitantly	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Administration of  DRUG2  with  DRUGOTHER  resulted in the appearance of unchanged  DRUGOTHER  in plasma;	Terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	 DRUG1 : Administration of  DRUGOTHER  with  DRUG2  resulted in the appearance of unchanged  DRUGOTHER  in plasma;	Terfenadine	VIRACEPT	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Administration of  DRUGOTHER  with  DRUGOTHER  resulted in the appearance of unchanged  DRUG2  in plasma;	Terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	 DRUGOTHER : Administration of  DRUG1  with  DRUG2  resulted in the appearance of unchanged  DRUGOTHER  in plasma;	terfenadine	VIRACEPT	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Administration of  DRUG1  with  DRUGOTHER  resulted in the appearance of unchanged  DRUG2  in plasma;	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	 DRUGOTHER : Administration of  DRUGOTHER  with  DRUG1  resulted in the appearance of unchanged  DRUG2  in plasma;	VIRACEPT	terfenadine	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
advise	"therefore,  DRUG1  should not be administered concurrently with  DRUG2  because of the potential for serious and/or life-threatening cardiac arrhythmias."	VIRACEPT	terfenadine	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
advise	"Because a similar interaction is likely,  DRUG1  should also not be administered concurrently with  DRUG2 ."	VIRACEPT	astemizole	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	 DRUG1 : Coadministration of  DRUG2  with  DRUGOTHER  resulted in an 83% increase in  DRUGOTHER  plasma AUC and a 51% increase in  DRUGOTHER  plasma A.C.	Indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	 DRUG1 : Coadministration of  DRUGOTHER  with  DRUG2  resulted in an 83% increase in  DRUGOTHER  plasma AUC and a 51% increase in  DRUGOTHER  plasma A.C.	Indinavir	VIRACEPT	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in an 83% increase in  DRUG2  plasma AUC and a 51% increase in  DRUGOTHER  plasma A.C.	Indinavir	nelfinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in an 83% increase in  DRUGOTHER  plasma AUC and a 51% increase in  DRUG2  plasma A.C.	Indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
mechanism	 DRUGOTHER : Coadministration of  DRUG1  with  DRUG2  resulted in an 83% increase in  DRUGOTHER  plasma AUC and a 51% increase in  DRUGOTHER  plasma A.C.	indinavir	VIRACEPT	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  resulted in an 83% increase in  DRUG2  plasma AUC and a 51% increase in  DRUGOTHER  plasma A.C.	indinavir	nelfinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  resulted in an 83% increase in  DRUGOTHER  plasma AUC and a 51% increase in  DRUG2  plasma A.C.	indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	 DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  resulted in an 83% increase in  DRUG2  plasma AUC and a 51% increase in  DRUGOTHER  plasma A.C.	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  resulted in an 83% increase in  DRUGOTHER  plasma AUC and a 51% increase in  DRUG2  plasma A.C.	VIRACEPT	indinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	 DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in an 83% increase in  DRUG1  plasma AUC and a 51% increase in  DRUG2  plasma A.C.	nelfinavir	indinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	 DRUG1 : Coadministration of  DRUG2  with  DRUGOTHER  resulted in a 152% increase in  DRUGOTHER  plasma AUC and very little change in  DRUGOTHER  plasma A.C.	Ritonavir	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	 DRUG1 : Coadministration of  DRUGOTHER  with  DRUG2  resulted in a 152% increase in  DRUGOTHER  plasma AUC and very little change in  DRUGOTHER  plasma A.C.	Ritonavir	VIRACEPT	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 152% increase in  DRUG2  plasma AUC and very little change in  DRUGOTHER  plasma A.C.	Ritonavir	nelfinavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 152% increase in  DRUGOTHER  plasma AUC and very little change in  DRUG2  plasma A.C.	Ritonavir	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
mechanism	 DRUGOTHER : Coadministration of  DRUG1  with  DRUG2  resulted in a 152% increase in  DRUGOTHER  plasma AUC and very little change in  DRUGOTHER  plasma A.C.	ritonavir	VIRACEPT	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  resulted in a 152% increase in  DRUG2  plasma AUC and very little change in  DRUGOTHER  plasma A.C.	ritonavir	nelfinavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  resulted in a 152% increase in  DRUGOTHER  plasma AUC and very little change in  DRUG2  plasma A.C.	ritonavir	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	 DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  resulted in a 152% increase in  DRUG2  plasma AUC and very little change in  DRUGOTHER  plasma A.C.	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  resulted in a 152% increase in  DRUGOTHER  plasma AUC and very little change in  DRUG2  plasma A.C.	VIRACEPT	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	 DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 152% increase in  DRUG1  plasma AUC and very little change in  DRUG2  plasma A.C.	nelfinavir	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	 DRUG1 : Coadministration of  DRUG2  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	Saquinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUG2  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	Saquinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUG2  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	Saquinavir	VIRACEPT	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUG2  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	Saquinavir	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUG2  plasma A.C.	Saquinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  (using an experimental soft-gelatin capsule formulation of  DRUG2  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	saquinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
mechanism	 DRUGOTHER : Coadministration of  DRUG1  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUG2  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	saquinavir	VIRACEPT	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUG2  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	saquinavir	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUG2  plasma A.C.	saquinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUG1  1200mg) with  DRUG2  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	saquinavir	VIRACEPT	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUG1  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUG2  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	saquinavir	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUG1  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUG2  plasma A.C.	saquinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUG1  resulted in an 18% increase in  DRUG2  plasma AUC and a 4-fold increase in  DRUGOTHER  plasma A.C.	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUG1  resulted in an 18% increase in  DRUGOTHER  plasma AUC and a 4-fold increase in  DRUG2  plasma A.C.	VIRACEPT	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  (using an experimental soft-gelatin capsule formulation of  DRUGOTHER  1200mg) with  DRUGOTHER  resulted in an 18% increase in  DRUG1  plasma AUC and a 4-fold increase in  DRUG2  plasma A.C.	nelfinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUG2  with  DRUGOTHER  resulted in a 35% increase in  DRUGOTHER  plasma A.C.	Ketoconazole	ketoconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	 DRUG1 : Coadministration of  DRUGOTHER  with  DRUG2  resulted in a 35% increase in  DRUGOTHER  plasma A.C.	Ketoconazole	VIRACEPT	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 35% increase in  DRUG2  plasma A.C.	Ketoconazole	nelfinavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
mechanism	 DRUGOTHER : Coadministration of  DRUG1  with  DRUG2  resulted in a 35% increase in  DRUGOTHER  plasma A.C.	ketoconazole	VIRACEPT	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  resulted in a 35% increase in  DRUG2  plasma A.C.	ketoconazole	nelfinavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  resulted in a 35% increase in  DRUG2  plasma A.C.	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	This change was not considered clinically significant and no dose adjustment is needed when  DRUG1  and  DRUG2  are coadministered.	ketoconazole	VIRACEPT	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : It is recommended that  DRUG2  be administered on an empty stomach;	Didanosine	didanosine	OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O	OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O
advise	"therefore,  DRUG1  should be administered (with food) one hour after or more than two hours before  DRUG2 ."	nelfinavir	didanosine	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O
advise	A dose adjustment is not needed when  DRUG1  is administered with  DRUG2 .	zidovudine	VIRACEPT	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	Little or no change in the pharmacokinetics of either drug was observed when  DRUG1  was coadministered with  DRUG2  or  DRUGOTHER .	VIRACEPT	lamivudine	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	OC(=O)CCCCCCCC(O)=O
other	Little or no change in the pharmacokinetics of either drug was observed when  DRUG1  was coadministered with  DRUGOTHER  or  DRUG2 .	VIRACEPT	stavudine	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
other	Little or no change in the pharmacokinetics of either drug was observed when  DRUGOTHER  was coadministered with  DRUG1  or  DRUG2 .	lamivudine	stavudine	OC(=O)CCCCCCCC(O)=O	CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
other	 DRUG1 : Coadministration of  DRUG2  and  DRUGOTHER  resulted in a 32% decrease in  DRUGOTHER  plasma AUC and a 207% increase in  DRUGOTHER  plasma A.C.	Rifabutin	rifabutin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	 DRUG1 : Coadministration of  DRUGOTHER  and  DRUG2  resulted in a 32% decrease in  DRUGOTHER  plasma AUC and a 207% increase in  DRUGOTHER  plasma A.C.	Rifabutin	VIRACEPT	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  and  DRUGOTHER  resulted in a 32% decrease in  DRUG2  plasma AUC and a 207% increase in  DRUGOTHER  plasma A.C.	Rifabutin	nelfinavir	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  and  DRUGOTHER  resulted in a 32% decrease in  DRUGOTHER  plasma AUC and a 207% increase in  DRUG2  plasma A.C.	Rifabutin	rifabutin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
mechanism	 DRUGOTHER : Coadministration of  DRUG1  and  DRUG2  resulted in a 32% decrease in  DRUGOTHER  plasma AUC and a 207% increase in  DRUGOTHER  plasma A.C.	rifabutin	VIRACEPT	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  and  DRUGOTHER  resulted in a 32% decrease in  DRUG2  plasma AUC and a 207% increase in  DRUGOTHER  plasma A.C.	rifabutin	nelfinavir	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  and  DRUGOTHER  resulted in a 32% decrease in  DRUGOTHER  plasma AUC and a 207% increase in  DRUG2  plasma A.C.	rifabutin	rifabutin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	 DRUGOTHER : Coadministration of  DRUGOTHER  and  DRUG1  resulted in a 32% decrease in  DRUG2  plasma AUC and a 207% increase in  DRUGOTHER  plasma A.C.	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  and  DRUG1  resulted in a 32% decrease in  DRUGOTHER  plasma AUC and a 207% increase in  DRUG2  plasma A.C.	VIRACEPT	rifabutin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	 DRUGOTHER : Coadministration of  DRUGOTHER  and  DRUGOTHER  resulted in a 32% decrease in  DRUG1  plasma AUC and a 207% increase in  DRUG2  plasma A.C.	nelfinavir	rifabutin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
advise	It is recommended that the dose of  DRUG1  be reduced to one-half the usual dose when administered with  DRUG2 .	rifabutin	VIRACEPT	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUG2  and  DRUGOTHER  resulted in an 82% decrease in  DRUGOTHER  plasma A.C.	Rifampin	rifampin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	 DRUG1 : Coadministration of  DRUGOTHER  and  DRUG2  resulted in an 82% decrease in  DRUGOTHER  plasma A.C.	Rifampin	VIRACEPT	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 : Coadministration of  DRUGOTHER  and  DRUGOTHER  resulted in an 82% decrease in  DRUG2  plasma A.C.	Rifampin	nelfinavir	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
mechanism	 DRUGOTHER : Coadministration of  DRUG1  and  DRUG2  resulted in an 82% decrease in  DRUGOTHER  plasma A.C.	rifampin	VIRACEPT	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUG1  and  DRUGOTHER  resulted in an 82% decrease in  DRUG2  plasma A.C.	rifampin	nelfinavir	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER : Coadministration of  DRUGOTHER  and  DRUG1  resulted in an 82% decrease in  DRUG2  plasma A.C.	VIRACEPT	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
advise	 DRUG1  and  DRUG2  should not be coadministered.	VIRACEPT	rifampin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	 DRUG1  and  DRUG2 : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUGOTHER  plasma concentrations.	Ethinyl Estradiol	Norethindrone	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	 DRUG1  and  DRUGOTHER : Coadministration of  DRUG2  with  DRUGOTHER  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUGOTHER  plasma concentrations.	Ethinyl Estradiol	VIRACEPT	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1  and  DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG2  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUGOTHER  plasma concentrations.	Ethinyl Estradiol	OVCON-35	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	
other	 DRUG1  and  DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 47% decrease in  DRUG2  and an 18% decrease in  DRUGOTHER  plasma concentrations.	Ethinyl Estradiol	ethinyl estradiol	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	 DRUG1  and  DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUG2  plasma concentrations.	Ethinyl Estradiol	norethindrone	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	 DRUGOTHER  and  DRUG1 : Coadministration of  DRUG2  with  DRUGOTHER  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUGOTHER  plasma concentrations.	Norethindrone	VIRACEPT	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER  and  DRUG1 : Coadministration of  DRUGOTHER  with  DRUG2  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUGOTHER  plasma concentrations.	Norethindrone	OVCON-35	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	
other	 DRUGOTHER  and  DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 47% decrease in  DRUG2  and an 18% decrease in  DRUGOTHER  plasma concentrations.	Norethindrone	ethinyl estradiol	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	 DRUGOTHER  and  DRUG1 : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUG2  plasma concentrations.	Norethindrone	norethindrone	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
mechanism	 DRUGOTHER  and  DRUGOTHER : Coadministration of  DRUG1  with  DRUG2  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUGOTHER  plasma concentrations.	VIRACEPT	OVCON-35	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	
other	 DRUGOTHER  and  DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  resulted in a 47% decrease in  DRUG2  and an 18% decrease in  DRUGOTHER  plasma concentrations.	VIRACEPT	ethinyl estradiol	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	 DRUGOTHER  and  DRUGOTHER : Coadministration of  DRUG1  with  DRUGOTHER  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUG2  plasma concentrations.	VIRACEPT	norethindrone	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	 DRUGOTHER  and  DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  resulted in a 47% decrease in  DRUG2  and an 18% decrease in  DRUGOTHER  plasma concentrations.	OVCON-35	ethinyl estradiol		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	 DRUGOTHER  and  DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUG1  resulted in a 47% decrease in  DRUGOTHER  and an 18% decrease in  DRUG2  plasma concentrations.	OVCON-35	norethindrone		[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	 DRUGOTHER  and  DRUGOTHER : Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in a 47% decrease in  DRUG1  and an 18% decrease in  DRUG2  plasma concentrations.	ethinyl estradiol	norethindrone	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
effect	"-  DRUG1  may enhance the CNS depressive effects of  DRUG2 ,  DRUGOTHER  and other  DRUGOTHER "	Lofexidine	alcohol	CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	"-  DRUG1  may enhance the CNS depressive effects of  DRUGOTHER ,  DRUG2  and other  DRUGOTHER "	Lofexidine	barbiturates	CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
effect	"-  DRUG1  may enhance the CNS depressive effects of  DRUGOTHER ,  DRUGOTHER  and other  DRUG2 "	Lofexidine	sedatives	CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1	
other	"-  DRUGOTHER  may enhance the CNS depressive effects of  DRUG1 ,  DRUG2  and other  DRUGOTHER "	alcohol	barbiturates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"-  DRUGOTHER  may enhance the CNS depressive effects of  DRUG1 ,  DRUGOTHER  and other  DRUG2 "	alcohol	sedatives	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"-  DRUGOTHER  may enhance the CNS depressive effects of  DRUGOTHER ,  DRUG1  and other  DRUG2 "	barbiturates	sedatives	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	
effect	-  DRUG1  may enhance the effects of  DRUG2  therapy	Lofexidine	anti-hypertensive drug	CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
effect	- Concomitant use of  DRUG1  may reduce the efficacy of  DRUG2 .	tricyclic antidepressants	lofexidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
effect	"Animal experience indicates that  DRUG1  prolongs the sleeping time after  DRUG2  or after  DRUGOTHER , increases the inhibitory effects of  DRUGOTHER , but does not exhibit monoamine oxidase inhibition."	clorazepate dipotassium	hexobarbital	OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1
effect	"Animal experience indicates that  DRUG1  prolongs the sleeping time after  DRUGOTHER  or after  DRUG2 , increases the inhibitory effects of  DRUGOTHER , but does not exhibit monoamine oxidase inhibition."	clorazepate dipotassium	ethyl alcohol	OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2	CC(C)O
effect	"Animal experience indicates that  DRUG1  prolongs the sleeping time after  DRUGOTHER  or after  DRUGOTHER , increases the inhibitory effects of  DRUG2 , but does not exhibit monoamine oxidase inhibition."	clorazepate dipotassium	chlorpromazine	OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2	CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12
other	"Animal experience indicates that  DRUGOTHER  prolongs the sleeping time after  DRUG1  or after  DRUG2 , increases the inhibitory effects of  DRUGOTHER , but does not exhibit monoamine oxidase inhibition."	hexobarbital	ethyl alcohol	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	CC(C)O
other	"Animal experience indicates that  DRUGOTHER  prolongs the sleeping time after  DRUG1  or after  DRUGOTHER , increases the inhibitory effects of  DRUG2 , but does not exhibit monoamine oxidase inhibition."	hexobarbital	chlorpromazine	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12
other	"Animal experience indicates that  DRUGOTHER  prolongs the sleeping time after  DRUGOTHER  or after  DRUG1 , increases the inhibitory effects of  DRUG2 , but does not exhibit monoamine oxidase inhibition."	ethyl alcohol	chlorpromazine	CC(C)O	CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12
effect	"The actions of the  DRUG1  may be potentiated by  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER ."	benzodiazepines	barbiturates	N1N=CC=CC2=CC=CC=C12	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
effect	"The actions of the  DRUG1  may be potentiated by  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER ."	benzodiazepines	narcotics	N1N=CC=CC2=CC=CC=C12	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
effect	"The actions of the  DRUG1  may be potentiated by  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or other  DRUGOTHER ."	benzodiazepines	phenothiazines	N1N=CC=CC2=CC=CC=C12	N1C2=CC=CC=C2SC2=CC=CC=C12
effect	"The actions of the  DRUG1  may be potentiated by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or other  DRUGOTHER ."	benzodiazepines	monoamine oxidase inhibitors	N1N=CC=CC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
effect	"The actions of the  DRUG1  may be potentiated by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or other  DRUG2 ."	benzodiazepines	antidepressants	N1N=CC=CC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER ."	barbiturates	narcotics	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or other  DRUGOTHER ."	barbiturates	phenothiazines	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or other  DRUGOTHER ."	barbiturates	monoamine oxidase inhibitors	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	OC(=O)CCCCCCCC(O)=O
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or other  DRUG2 ."	barbiturates	antidepressants	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  or other  DRUGOTHER ."	narcotics	phenothiazines	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  or other  DRUGOTHER ."	narcotics	monoamine oxidase inhibitors	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	OC(=O)CCCCCCCC(O)=O
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or other  DRUG2 ."	narcotics	antidepressants	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  or other  DRUGOTHER ."	phenothiazines	monoamine oxidase inhibitors	N1C2=CC=CC=C2SC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or other  DRUG2 ."	phenothiazines	antidepressants	N1C2=CC=CC=C2SC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The actions of the  DRUGOTHER  may be potentiated by  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or other  DRUG2 ."	monoamine oxidase inhibitors	antidepressants	OC(=O)CCCCCCCC(O)=O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"In bioavailability studies with normal subjects, the concurrent administration of  DRUG1  at therapeutic levels did not significantly influence the bioavailability of  DRUG2  tablets."	antacids	TRANXENE		OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2
other	" DRUG1  :  DRUG2  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	Probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	acetaminophen	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	acyclovir	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	angiotensin-converting enzyme inhibitors	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	aminosalicylic acid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	NC1=CC(O)=C(C=C1)C(O)=O
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	barbiturates	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	benzodiazepines	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	N1N=CC=CC2=CC=CC=C12
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	bumetanide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	clofibrate	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	methotrexate	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	famotidine	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	furosemide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	nonsteroidal anti-inflammatory	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	Probenecid	theophylline	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUG1  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	Probenecid	zidovudine	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	acetaminophen	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	acyclovir	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	angiotensin-converting enzyme inhibitors	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	aminosalicylic acid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	NC1=CC(O)=C(C=C1)C(O)=O
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	barbiturates	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	benzodiazepines	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	N1N=CC=CC2=CC=CC=C12
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	bumetanide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	clofibrate	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	methotrexate	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	famotidine	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	furosemide	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
mechanism	" DRUGOTHER  :  DRUG1  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	Probenecid	nonsteroidal anti-inflammatory	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	acyclovir	OC(=O)CCCCCCCC(O)=O	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	angiotensin-converting enzyme inhibitors	OC(=O)CCCCCCCC(O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	aminosalicylic acid	OC(=O)CCCCCCCC(O)=O	NC1=CC(O)=C(C=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	barbiturates	OC(=O)CCCCCCCC(O)=O	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	benzodiazepines	OC(=O)CCCCCCCC(O)=O	N1N=CC=CC2=CC=CC=C12
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	bumetanide	OC(=O)CCCCCCCC(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	clofibrate	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	methotrexate	OC(=O)CCCCCCCC(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	famotidine	OC(=O)CCCCCCCC(O)=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	furosemide	OC(=O)CCCCCCCC(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	acetaminophen	nonsteroidal anti-inflammatory	OC(=O)CCCCCCCC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	acetaminophen	theophylline	OC(=O)CCCCCCCC(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	acetaminophen	zidovudine	OC(=O)CCCCCCCC(O)=O	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	angiotensin-converting enzyme inhibitors	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	aminosalicylic acid	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	NC1=CC(O)=C(C=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	barbiturates	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	benzodiazepines	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	N1N=CC=CC2=CC=CC=C12
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	bumetanide	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	clofibrate	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	methotrexate	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	famotidine	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	furosemide	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	acyclovir	nonsteroidal anti-inflammatory	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	acyclovir	theophylline	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	acyclovir	zidovudine	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	aminosalicylic acid	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	NC1=CC(O)=C(C=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	barbiturates	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	benzodiazepines	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	N1N=CC=CC2=CC=CC=C12
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	bumetanide	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	clofibrate	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	methotrexate	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	famotidine	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	furosemide	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	nonsteroidal anti-inflammatory	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	angiotensin-converting enzyme inhibitors	theophylline	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	angiotensin-converting enzyme inhibitors	zidovudine	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	aminosalicylic acid	barbiturates	NC1=CC(O)=C(C=C1)C(O)=O	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	aminosalicylic acid	benzodiazepines	NC1=CC(O)=C(C=C1)C(O)=O	N1N=CC=CC2=CC=CC=C12
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	aminosalicylic acid	bumetanide	NC1=CC(O)=C(C=C1)C(O)=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	aminosalicylic acid	clofibrate	NC1=CC(O)=C(C=C1)C(O)=O	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	aminosalicylic acid	methotrexate	NC1=CC(O)=C(C=C1)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	aminosalicylic acid	famotidine	NC1=CC(O)=C(C=C1)C(O)=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	aminosalicylic acid	furosemide	NC1=CC(O)=C(C=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	aminosalicylic acid	nonsteroidal anti-inflammatory	NC1=CC(O)=C(C=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	aminosalicylic acid	theophylline	NC1=CC(O)=C(C=C1)C(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	aminosalicylic acid	zidovudine	NC1=CC(O)=C(C=C1)C(O)=O	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	barbiturates	benzodiazepines	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	N1N=CC=CC2=CC=CC=C12
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	barbiturates	bumetanide	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	barbiturates	clofibrate	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	barbiturates	methotrexate	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	barbiturates	famotidine	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	barbiturates	furosemide	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	barbiturates	nonsteroidal anti-inflammatory	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	barbiturates	theophylline	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	barbiturates	zidovudine	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	benzodiazepines	bumetanide	N1N=CC=CC2=CC=CC=C12	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	benzodiazepines	clofibrate	N1N=CC=CC2=CC=CC=C12	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	benzodiazepines	methotrexate	N1N=CC=CC2=CC=CC=C12	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	benzodiazepines	famotidine	N1N=CC=CC2=CC=CC=C12	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	benzodiazepines	furosemide	N1N=CC=CC2=CC=CC=C12	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	benzodiazepines	nonsteroidal anti-inflammatory	N1N=CC=CC2=CC=CC=C12	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	benzodiazepines	theophylline	N1N=CC=CC2=CC=CC=C12	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	benzodiazepines	zidovudine	N1N=CC=CC2=CC=CC=C12	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	bumetanide	clofibrate	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	bumetanide	methotrexate	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	bumetanide	famotidine	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	bumetanide	furosemide	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	bumetanide	nonsteroidal anti-inflammatory	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	bumetanide	theophylline	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	bumetanide	zidovudine	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	clofibrate	methotrexate	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	clofibrate	famotidine	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	clofibrate	furosemide	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	clofibrate	nonsteroidal anti-inflammatory	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	clofibrate	theophylline	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	clofibrate	zidovudine	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	methotrexate	famotidine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	methotrexate	furosemide	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	methotrexate	nonsteroidal anti-inflammatory	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	methotrexate	theophylline	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	methotrexate	zidovudine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUGOTHER )."	famotidine	furosemide	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	famotidine	nonsteroidal anti-inflammatory	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	famotidine	theophylline	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	famotidine	zidovudine	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  agents,  DRUGOTHER , and  DRUGOTHER )."	furosemide	nonsteroidal anti-inflammatory	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  agents,  DRUG2 , and  DRUGOTHER )."	furosemide	theophylline	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  agents,  DRUGOTHER , and  DRUG2 )."	furosemide	zidovudine	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  agents,  DRUG2 , and  DRUGOTHER )."	nonsteroidal anti-inflammatory	theophylline	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  agents,  DRUGOTHER , and  DRUG2 )."	nonsteroidal anti-inflammatory	zidovudine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	" DRUGOTHER  :  DRUGOTHER  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  agents,  DRUG1 , and  DRUG2 )."	theophylline	zidovudine	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
advise	 DRUG1  should either be temporarily discontinued or decreased by 50% when coadministered with  DRUG2  on the day of  DRUGOTHER  infusion.	Zidovudine	probenecid	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	 DRUG1  should either be temporarily discontinued or decreased by 50% when coadministered with  DRUGOTHER  on the day of  DRUG2  infusion.	Zidovudine	VISTIDE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1
other	 DRUGOTHER  should either be temporarily discontinued or decreased by 50% when coadministered with  DRUG1  on the day of  DRUG2  infusion.	probenecid	VISTIDE	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	VISTIDE	aminoglycosides	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	OC(=O)CCCCCCCC(O)=O
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	VISTIDE	tobramycin	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	VISTIDE	gentamicin	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	VISTIDE	amikacin	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	OC(=O)CCCCCCCC(O)=O
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2 ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	VISTIDE	amphotericin B	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUG2 , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	VISTIDE	foscarnet	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	NC(=O)NC1NC(=O)NC1=O
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	VISTIDE	pentamidine	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	OC(=O)CCCCCCCC(O)=O
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ] is contraindicated."	VISTIDE	vancomycin	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
advise	"Nephrotoxic agents : Concomitant administration of  DRUG1  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ] is contraindicated."	VISTIDE	non-steroidal anti-inflammatory agents	NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	aminoglycosides	tobramycin	OC(=O)CCCCCCCC(O)=O	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	aminoglycosides	gentamicin	OC(=O)CCCCCCCC(O)=O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	aminoglycosides	amikacin	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2 ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	aminoglycosides	amphotericin B	OC(=O)CCCCCCCC(O)=O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUG2 , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	aminoglycosides	foscarnet	OC(=O)CCCCCCCC(O)=O	NC(=O)NC1NC(=O)NC1=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	aminoglycosides	pentamidine	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ] is contraindicated."	aminoglycosides	vancomycin	OC(=O)CCCCCCCC(O)=O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ] is contraindicated."	aminoglycosides	non-steroidal anti-inflammatory agents	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	tobramycin	gentamicin	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	tobramycin	amikacin	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2 ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	tobramycin	amphotericin B	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUG2 , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	tobramycin	foscarnet	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	NC(=O)NC1NC(=O)NC1=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	tobramycin	pentamidine	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ] is contraindicated."	tobramycin	vancomycin	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ] is contraindicated."	tobramycin	non-steroidal anti-inflammatory agents	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUG2 ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	gentamicin	amikacin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUG2 ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	gentamicin	amphotericin B	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUGOTHER ,  DRUG2 , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	gentamicin	foscarnet	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	NC(=O)NC1NC(=O)NC1=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	gentamicin	pentamidine	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ] is contraindicated."	gentamicin	vancomycin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ] is contraindicated."	gentamicin	non-steroidal anti-inflammatory agents	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUG2 ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	amikacin	amphotericin B	OC(=O)CCCCCCCC(O)=O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUGOTHER ,  DRUG2 , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	amikacin	foscarnet	OC(=O)CCCCCCCC(O)=O	NC(=O)NC1NC(=O)NC1=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	amikacin	pentamidine	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ] is contraindicated."	amikacin	vancomycin	OC(=O)CCCCCCCC(O)=O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ] is contraindicated."	amikacin	non-steroidal anti-inflammatory agents	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG1 ,  DRUG2 , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	amphotericin B	foscarnet	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	NC(=O)NC1NC(=O)NC1=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG1 ,  DRUGOTHER , intravenous  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	amphotericin B	pentamidine	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG1 ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ] is contraindicated."	amphotericin B	vancomycin	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG1 ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ] is contraindicated."	amphotericin B	non-steroidal anti-inflammatory agents	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUG1 , intravenous  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ] is contraindicated."	foscarnet	pentamidine	NC(=O)NC1NC(=O)NC1=O	OC(=O)CCCCCCCC(O)=O
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUG1 , intravenous  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ] is contraindicated."	foscarnet	vancomycin	NC(=O)NC1NC(=O)NC1=O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUG1 , intravenous  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ] is contraindicated."	foscarnet	non-steroidal anti-inflammatory agents	NC(=O)NC1NC(=O)NC1=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUG1 ,  DRUG2 , and  DRUGOTHER ] is contraindicated."	pentamidine	vancomycin	OC(=O)CCCCCCCC(O)=O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUG1 ,  DRUGOTHER , and  DRUG2 ] is contraindicated."	pentamidine	non-steroidal anti-inflammatory agents	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Nephrotoxic agents : Concomitant administration of  DRUGOTHER  and agents with nephrotoxic potential [e.g., intravenous  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER , intravenous  DRUGOTHER ,  DRUG1 , and  DRUG2 ] is contraindicated."	vancomycin	non-steroidal anti-inflammatory agents	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUG1  (CNS) drugs including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	alcohol	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	antidepressants	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	antihistamines	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	NCCC1=CNC=N1
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	antipsychotics	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	reserpine	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	methyldopa	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	beta-blockers	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	muscle relaxants	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	Central nervous system depressant	narcotics	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	Central nervous system depressant	sedatives	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
other	" DRUG1  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	Central nervous system depressant	tranquilizers	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	alcohol	antidepressants	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	alcohol	antihistamines	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCCC1=CNC=N1
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	alcohol	antipsychotics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	alcohol	reserpine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	alcohol	methyldopa	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	alcohol	beta-blockers	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	alcohol	muscle relaxants	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	alcohol	narcotics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	alcohol	sedatives	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUGOTHER  (CNS) drugs including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	alcohol	tranquilizers	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antidepressants	antihistamines	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	NCCC1=CNC=N1
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antidepressants	antipsychotics	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antidepressants	reserpine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antidepressants	methyldopa	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antidepressants	beta-blockers	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antidepressants	muscle relaxants	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antidepressants	narcotics	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	antidepressants	sedatives	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	antidepressants	tranquilizers	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antihistamines	antipsychotics	NCCC1=CNC=N1	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , blood pressure medications ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antihistamines	reserpine	NCCC1=CNC=N1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antihistamines	methyldopa	NCCC1=CNC=N1	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antihistamines	beta-blockers	NCCC1=CNC=N1	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antihistamines	muscle relaxants	NCCC1=CNC=N1	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antihistamines	narcotics	NCCC1=CNC=N1	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	antihistamines	sedatives	NCCC1=CNC=N1	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	antihistamines	tranquilizers	NCCC1=CNC=N1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , blood pressure medications ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antipsychotics	reserpine		CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , blood pressure medications ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antipsychotics	methyldopa		C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antipsychotics	beta-blockers		
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antipsychotics	muscle relaxants		
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	antipsychotics	narcotics		CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	antipsychotics	sedatives		
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	antipsychotics	tranquilizers		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG1 ,  DRUG2 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	reserpine	methyldopa	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG1 ,  DRUGOTHER ,  DRUG2 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	reserpine	beta-blockers	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	reserpine	muscle relaxants	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	reserpine	narcotics	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	reserpine	sedatives	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	reserpine	tranquilizers	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG1 ,  DRUG2 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	methyldopa	beta-blockers	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ), motion sickness medications,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	methyldopa	muscle relaxants	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	methyldopa	narcotics	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	methyldopa	sedatives	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	methyldopa	tranquilizers	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ), motion sickness medications,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	beta-blockers	muscle relaxants		
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ), motion sickness medications,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	beta-blockers	narcotics		CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	beta-blockers	sedatives		
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	beta-blockers	tranquilizers		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG1 ,  DRUG2 ,  DRUGOTHER , sleeping pills and  DRUGOTHER "	muscle relaxants	narcotics		CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG1 ,  DRUGOTHER ,  DRUG2 , sleeping pills and  DRUGOTHER "	muscle relaxants	sedatives		
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , sleeping pills and  DRUG2 "	muscle relaxants	tranquilizers		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG1 ,  DRUG2 , sleeping pills and  DRUGOTHER "	narcotics	sedatives	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , sleeping pills and  DRUG2 "	narcotics	tranquilizers	CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  (CNS) drugs including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , blood pressure medications ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ), motion sickness medications,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , sleeping pills and  DRUG2 "	sedatives	tranquilizers		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	aminoglycosides	gentamicin	OC(=O)CCCCCCCC(O)=O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	aminoglycosides	amikacin	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	aminoglycosides	amphotericin B	OC(=O)CCCCCCCC(O)=O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	aminoglycosides	cyclosporine	OC(=O)CCCCCCCC(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	aminoglycosides	non-steroidal anti-inflammatory	OC(=O)CCCCCCCC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ."	aminoglycosides	ibuprofen	OC(=O)CCCCCCCC(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ."	aminoglycosides	tacrolimus	OC(=O)CCCCCCCC(O)=O	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ."	aminoglycosides	vancomycin	OC(=O)CCCCCCCC(O)=O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	gentamicin	amikacin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	OC(=O)CCCCCCCC(O)=O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	gentamicin	amphotericin B	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	gentamicin	cyclosporine	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	gentamicin	non-steroidal anti-inflammatory	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ."	gentamicin	ibuprofen	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ."	gentamicin	tacrolimus	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ."	gentamicin	vancomycin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	amikacin	amphotericin B	OC(=O)CCCCCCCC(O)=O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	amikacin	cyclosporine	OC(=O)CCCCCCCC(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	amikacin	non-steroidal anti-inflammatory	OC(=O)CCCCCCCC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ."	amikacin	ibuprofen	OC(=O)CCCCCCCC(O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ."	amikacin	tacrolimus	OC(=O)CCCCCCCC(O)=O	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ."	amikacin	vancomycin	OC(=O)CCCCCCCC(O)=O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUG2 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	amphotericin B	cyclosporine	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUG2  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	amphotericin B	non-steroidal anti-inflammatory	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ."	amphotericin B	ibuprofen	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ."	amphotericin B	tacrolimus	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ."	amphotericin B	vancomycin	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUG2  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ."	cyclosporine	non-steroidal anti-inflammatory	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  drugs (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ."	cyclosporine	ibuprofen	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ."	cyclosporine	tacrolimus	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ."	cyclosporine	vancomycin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  drugs (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ."	non-steroidal anti-inflammatory	ibuprofen	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  drugs (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ."	non-steroidal anti-inflammatory	tacrolimus	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  drugs (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ."	non-steroidal anti-inflammatory	vancomycin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG1 ),  DRUG2 ,  DRUGOTHER ."	ibuprofen	tacrolimus	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUG2 ."	ibuprofen	vancomycin	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUG2 ."	tacrolimus	vancomycin	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
other	"In vivo interaction studies in humans have demonstrated that  DRUG1  and  DRUG2  do not affect the PK properties of  DRUGOTHER , nor does  DRUGOTHER  affect the PK properties of  DRUGOTHER  or  DRUGOTHER ."	digoxin	warfarin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In vivo interaction studies in humans have demonstrated that  DRUG1  and  DRUGOTHER  do not affect the PK properties of  DRUG2 , nor does  DRUGOTHER  affect the PK properties of  DRUGOTHER  or  DRUGOTHER ."	digoxin	anagrelide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
other	"In vivo interaction studies in humans have demonstrated that  DRUG1  and  DRUGOTHER  do not affect the PK properties of  DRUGOTHER , nor does  DRUG2  affect the PK properties of  DRUGOTHER  or  DRUGOTHER ."	digoxin	anagrelide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
other	"In vivo interaction studies in humans have demonstrated that  DRUG1  and  DRUGOTHER  do not affect the PK properties of  DRUGOTHER , nor does  DRUGOTHER  affect the PK properties of  DRUG2  or  DRUGOTHER ."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In vivo interaction studies in humans have demonstrated that  DRUG1  and  DRUGOTHER  do not affect the PK properties of  DRUGOTHER , nor does  DRUGOTHER  affect the PK properties of  DRUGOTHER  or  DRUG2 ."	digoxin	warfarin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUG1  do not affect the PK properties of  DRUG2 , nor does  DRUGOTHER  affect the PK properties of  DRUGOTHER  or  DRUGOTHER ."	warfarin	anagrelide	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUG1  do not affect the PK properties of  DRUGOTHER , nor does  DRUG2  affect the PK properties of  DRUGOTHER  or  DRUGOTHER ."	warfarin	anagrelide	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUG1  do not affect the PK properties of  DRUGOTHER , nor does  DRUGOTHER  affect the PK properties of  DRUG2  or  DRUGOTHER ."	warfarin	digoxin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUG1  do not affect the PK properties of  DRUGOTHER , nor does  DRUGOTHER  affect the PK properties of  DRUGOTHER  or  DRUG2 ."	warfarin	warfarin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUGOTHER  do not affect the PK properties of  DRUG1 , nor does  DRUG2  affect the PK properties of  DRUGOTHER  or  DRUGOTHER ."	anagrelide	anagrelide	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUGOTHER  do not affect the PK properties of  DRUG1 , nor does  DRUGOTHER  affect the PK properties of  DRUG2  or  DRUGOTHER ."	anagrelide	digoxin	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUGOTHER  do not affect the PK properties of  DRUG1 , nor does  DRUGOTHER  affect the PK properties of  DRUGOTHER  or  DRUG2 ."	anagrelide	warfarin	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUGOTHER  do not affect the PK properties of  DRUGOTHER , nor does  DRUG1  affect the PK properties of  DRUG2  or  DRUGOTHER ."	anagrelide	digoxin	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUGOTHER  do not affect the PK properties of  DRUGOTHER , nor does  DRUG1  affect the PK properties of  DRUGOTHER  or  DRUG2 ."	anagrelide	warfarin	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In vivo interaction studies in humans have demonstrated that  DRUGOTHER  and  DRUGOTHER  do not affect the PK properties of  DRUGOTHER , nor does  DRUGOTHER  affect the PK properties of  DRUG1  or  DRUG2 ."	digoxin	warfarin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUG1  in clinical trials were  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	anagrelide	aspirin	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	CC(=O)OC1=CC=CC=C1C(O)=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUG1  in clinical trials were  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	anagrelide	acetaminophen	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	OC(=O)CCCCCCCC(O)=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUG1  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	anagrelide	furosemide	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUG1  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	anagrelide	iron	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUG1  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	anagrelide	ranitidine	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUG1  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	anagrelide	hydroxyurea	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	NC(=O)NO
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUG1  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	anagrelide	allopurinol	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	O=C1N=CN=C2NNC=C12
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aspirin	acetaminophen	CC(=O)OC1=CC=CC=C1C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aspirin	furosemide	CC(=O)OC1=CC=CC=C1C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aspirin	iron	CC(=O)OC1=CC=CC=C1C(O)=O	
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	aspirin	ranitidine	CC(=O)OC1=CC=CC=C1C(O)=O	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	aspirin	hydroxyurea	CC(=O)OC1=CC=CC=C1C(O)=O	NC(=O)NO
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	aspirin	allopurinol	CC(=O)OC1=CC=CC=C1C(O)=O	O=C1N=CN=C2NNC=C12
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	acetaminophen	furosemide	OC(=O)CCCCCCCC(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	acetaminophen	iron	OC(=O)CCCCCCCC(O)=O	
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	acetaminophen	ranitidine	OC(=O)CCCCCCCC(O)=O	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	acetaminophen	hydroxyurea	OC(=O)CCCCCCCC(O)=O	NC(=O)NO
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	acetaminophen	allopurinol	OC(=O)CCCCCCCC(O)=O	O=C1N=CN=C2NNC=C12
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	furosemide	iron	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	furosemide	ranitidine	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	furosemide	hydroxyurea	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NC(=O)NO
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	furosemide	allopurinol	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	O=C1N=CN=C2NNC=C12
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	iron	ranitidine		CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	iron	hydroxyurea		NC(=O)NO
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	iron	allopurinol		O=C1N=CN=C2NNC=C12
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	ranitidine	hydroxyurea	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	NC(=O)NO
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	ranitidine	allopurinol	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	O=C1N=CN=C2NNC=C12
other	"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  DRUGOTHER  in clinical trials were  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	hydroxyurea	allopurinol	NC(=O)NO	O=C1N=CN=C2NNC=C12
other	An in vivo interaction study in humans demonstrated that a single 1mg dose of  DRUG1  administered concomitantly with a single 900 mg dose of  DRUG2  was generally well tolerated.	anagrelide	aspirin	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	CC(=O)OC1=CC=CC=C1C(O)=O
other	No clinically relevant pharmacokinetic interactions between  DRUG1  and  DRUG2  were observed.	anagrelide	acetylsalicylic acid	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	CC(=O)OC1=CC=CC=C1C(O)=O
effect	" DRUG1  alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by  DRUG2 ."	Anagrelide	aspirin	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	CC(=O)OC1=CC=CC=C1C(O)=O
mechanism	"It is known that CYP1A2 is inhibited by several medicinal products, including  DRUG1 , and such medicinal products could theoretically adversely influence the clearance of  DRUG2 ."	fluvoxamine	anagrelide	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
mechanism	 DRUG1  demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g.  DRUG2 .	Anagrelide	theophylline	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"The effects of medicinal products with similar properties such as inotropes  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  may be exacerbated by  DRUGOTHER ."	milrinone	enoximone	[Mg++].[O-]C([O-])=O	CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1
other	"The effects of medicinal products with similar properties such as inotropes  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  may be exacerbated by  DRUGOTHER ."	milrinone	amrinone	[Mg++].[O-]C([O-])=O	NC1=CC(=CNC1=O)C1=CC=NC=C1
other	"The effects of medicinal products with similar properties such as inotropes  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  may be exacerbated by  DRUGOTHER ."	milrinone	olprinone	[Mg++].[O-]C([O-])=O	[Mg++].[O-]C([O-])=O
other	"The effects of medicinal products with similar properties such as inotropes  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  may be exacerbated by  DRUGOTHER ."	milrinone	cilostazol	[Mg++].[O-]C([O-])=O	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
effect	"The effects of medicinal products with similar properties such as inotropes  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  may be exacerbated by  DRUG2 ."	milrinone	anagrelide	[Mg++].[O-]C([O-])=O	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
other	"The effects of medicinal products with similar properties such as inotropes  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  may be exacerbated by  DRUGOTHER ."	enoximone	amrinone	CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1	NC1=CC(=CNC1=O)C1=CC=NC=C1
other	"The effects of medicinal products with similar properties such as inotropes  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  may be exacerbated by  DRUGOTHER ."	enoximone	olprinone	CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1	[Mg++].[O-]C([O-])=O
other	"The effects of medicinal products with similar properties such as inotropes  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  may be exacerbated by  DRUGOTHER ."	enoximone	cilostazol	CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
other	"The effects of medicinal products with similar properties such as inotropes  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER  may be exacerbated by  DRUGOTHER ."	amrinone	olprinone	NC1=CC(=CNC1=O)C1=CC=NC=C1	[Mg++].[O-]C([O-])=O
other	"The effects of medicinal products with similar properties such as inotropes  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2  may be exacerbated by  DRUGOTHER ."	amrinone	cilostazol	NC1=CC(=CNC1=O)C1=CC=NC=C1	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
other	"The effects of medicinal products with similar properties such as inotropes  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2  may be exacerbated by  DRUGOTHER ."	olprinone	cilostazol	[Mg++].[O-]C([O-])=O	O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
mechanism	"There is a single case report, which suggests that  DRUG1  may interfere with  DRUG2  absorption."	sucralfate	anagrelide	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
other	" DRUG1 , other, especially  DRUG2 , or pre DRUGOTHER  and anesthetic agents used in surgery or  DRUGOTHER , nondepolarizing, used in surgery"	Antihypertensive medications	diazoxide	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2
other	" DRUG1 , other, especially  DRUGOTHER , or pre DRUG2  and anesthetic agents used in surgery or  DRUGOTHER , nondepolarizing, used in surgery"	Antihypertensive medications	anesthetic	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
other	" DRUG1 , other, especially  DRUGOTHER , or pre DRUGOTHER  and anesthetic agents used in surgery or  DRUG2 , nondepolarizing, used in surgery"	Antihypertensive medications	skeletal-muscle relaxants	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
other	" DRUGOTHER , other, especially  DRUG1 , or pre DRUG2  and anesthetic agents used in surgery or  DRUGOTHER , nondepolarizing, used in surgery"	diazoxide	anesthetic	CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2	
other	" DRUGOTHER , other, especially  DRUG1 , or pre DRUGOTHER  and anesthetic agents used in surgery or  DRUG2 , nondepolarizing, used in surgery"	diazoxide	skeletal-muscle relaxants	CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2	
other	" DRUGOTHER , other, especially  DRUGOTHER , or pre DRUG1  and anesthetic agents used in surgery or  DRUG2 , nondepolarizing, used in surgery"	anesthetic	skeletal-muscle relaxants		
other	 DRUG1  or  DRUG2  or  DRUGOTHER  ( DRUGOTHER )	Amphotericin B	Corticosteroids	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	 DRUG1  or  DRUGOTHER  or  DRUG2  ( DRUGOTHER )	Amphotericin B	Corticotropin	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	
other	 DRUG1  or  DRUGOTHER  or  DRUGOTHER  ( DRUG2 )	Amphotericin B	ACTH	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1
other	 DRUGOTHER  or  DRUG1  or  DRUG2  ( DRUGOTHER )	Corticosteroids	Corticotropin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
other	 DRUGOTHER  or  DRUG1  or  DRUGOTHER  ( DRUG2 )	Corticosteroids	ACTH	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1
other	 DRUGOTHER  or  DRUGOTHER  or  DRUG1  ( DRUG2 )	Corticotropin	ACTH		NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1
advise	"for adult-onset diabetics, dosage adjustment of  DRUG1  may be necessary during and after  DRUG2  therapy;"	hypoglycemic medications	thiazide diuretic		
other	"(Concurrent use with  DRUG1  is not recommended, as they may provoke  DRUG2  toxicity because of reduced renal clearance.)"	thiazide diuretics	lithium		[Li+]
other	"(In some patients, the  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	loop diuretics	potassium sparing diuretics		[KH]
other	"(In some patients, the  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	loop diuretics	thiazide diuretics		
other	"(In some patients, the  DRUGOTHER  can reduce the diuretic, natriuretic, and antihypertensive effects of  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	potassium sparing diuretics	thiazide diuretics	[KH]	
advise	"Therefore, when  DRUG1  and  DRUG2  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUGOTHER  is obtained.)"	hydroflumethiazide	nonsteroidal anti-inflammatory agents	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Therefore, when  DRUG1  and  DRUGOTHER  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUG2  is obtained.)"	hydroflumethiazide	diuretic	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Therefore, when  DRUGOTHER  and  DRUG1  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  DRUG2  is obtained.)"	nonsteroidal anti-inflammatory agents	diuretic	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
effect	( DRUG1  may decrease arterial responsiveness to  DRUG2 .	Thiazides	norepinephrine	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CNC[C@H](O)C1=CC(O)=C(O)C=C1
effect	( DRUG1  may increase the responsiveness to  DRUG2 .)	Thiazide drugs	tubocurarine		[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3
advise	 DRUG1  should not be used with other  DRUG2 .	RAPTIVA	immunosuppressive drugs		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUG1 ,  DRUG2  and  DRUGOTHER  should not be administered during  DRUGOTHER  treatment."	Acellular vaccines	live vaccines		
other	" DRUG1 ,  DRUGOTHER  and  DRUG2  should not be administered during  DRUGOTHER  treatment."	Acellular vaccines	live-attenuated vaccines		CCN(CC)C(C)C(=O)C1=CC=CC=C1
advise	" DRUG1 ,  DRUGOTHER  and  DRUGOTHER  should not be administered during  DRUG2  treatment."	Acellular vaccines	RAPTIVA		
other	" DRUGOTHER ,  DRUG1  and  DRUG2  should not be administered during  DRUGOTHER  treatment."	live vaccines	live-attenuated vaccines		CCN(CC)C(C)C(=O)C1=CC=CC=C1
advise	" DRUGOTHER ,  DRUG1  and  DRUGOTHER  should not be administered during  DRUG2  treatment."	live vaccines	RAPTIVA		
advise	" DRUGOTHER ,  DRUGOTHER  and  DRUG1  should not be administered during  DRUG2  treatment."	live-attenuated vaccines	RAPTIVA	CCN(CC)C(C)C(=O)C1=CC=CC=C1	
other	"Note: dissolution of aerosol particles of  DRUG1  in  DRUG2 , a model  DRUGOTHER ."	budesonide	Survanta	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	
other	"Note: dissolution of aerosol particles of  DRUG1  in  DRUGOTHER , a model  DRUG2 ."	budesonide	lung surfactant	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
other	"Note: dissolution of aerosol particles of  DRUGOTHER  in  DRUG1 , a model  DRUG2 ."	Survanta	lung surfactant		CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
other	"The effect of a  DRUG1  extract from bovine lung,  DRUG2 , on the dissolution rate of aerosol particles of  DRUGOTHER  was determined."	pulmonary surfactant	Survanta	NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1	
other	"The effect of a  DRUG1  extract from bovine lung,  DRUGOTHER , on the dissolution rate of aerosol particles of  DRUG2  was determined."	pulmonary surfactant	budesonide	NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	"The effect of a  DRUGOTHER  extract from bovine lung,  DRUG1 , on the dissolution rate of aerosol particles of  DRUG2  was determined."	Survanta	budesonide		[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	"Aerosol particles of  DRUG1  were generated from an  DRUG2  solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments."	budesonide	ethanol	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	" DRUG1  increased the extent of dissolution of  DRUG2  in proportion to the added concentration, which was also verified by equilibrium solubilization studies."	Survanta	budesonide		[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	" DRUG1  also increased rate of dissolution, in a manner similar to  DRUG2 ."	Survanta	sodium dodecyl sulfate		CCCCCCCCCCCCOS(O)(=O)=O
other	Analysis of the concentration of  DRUG1  following ultracentrifugation indicated that there is rapid equilibration of  DRUG2  between the  DRUGOTHER  and aqueous phase.	budesonide	budesonide	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	Analysis of the concentration of  DRUG1  following ultracentrifugation indicated that there is rapid equilibration of  DRUGOTHER  between the  DRUG2  and aqueous phase.	budesonide	Survanta	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	
other	Analysis of the concentration of  DRUGOTHER  following ultracentrifugation indicated that there is rapid equilibration of  DRUG1  between the  DRUG2  and aqueous phase.	budesonide	Survanta	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	
advise	Renal function should be monitored carefully if high doses of  DRUG1  are to be administered with  DRUG2  because of the increased potential of nephrotoxicity and ototoxicity of  DRUGOTHER .	aminoglycosides	MAXIPIME	OC(=O)CCCCCCCC(O)=O	CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1
other	Renal function should be monitored carefully if high doses of  DRUG1  are to be administered with  DRUGOTHER  because of the increased potential of nephrotoxicity and ototoxicity of  DRUG2 .	aminoglycosides	aminoglycoside antibiotics	OC(=O)CCCCCCCC(O)=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	Renal function should be monitored carefully if high doses of  DRUGOTHER  are to be administered with  DRUG1  because of the increased potential of nephrotoxicity and ototoxicity of  DRUG2 .	MAXIPIME	aminoglycoside antibiotics	CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	Nephrotoxicity has been reported following concomitant administration of other  DRUGOTHER  with potent  DRUG1  such as  DRUG2 .	diuretics	furosemide	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	 DRUG1  is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered  DRUG2 .	Gabapentin	antiepileptic drugs	NCC1(CC(O)=O)CCCCC1	
other	" DRUG1 : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUG2  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	Phenytoin	Neurontin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	" DRUG1 : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUG2  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUG1 : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUG2  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	Phenytoin	gabapentin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	" DRUG1 : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUG2  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUG1 : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUG2  had no effect on  DRUGOTHER  pharmacokinetics."	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUG1 : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUG2  pharmacokinetics."	Phenytoin	gabapentin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUG1  in epileptic patients (N=8) maintained on  DRUG2  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	Neurontin	phenytoin	NCC1(CC(O)=O)CCCCC1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUG1  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUG2  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	Neurontin	gabapentin	NCC1(CC(O)=O)CCCCC1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUG1  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUG2  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	Neurontin	phenytoin	NCC1(CC(O)=O)CCCCC1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUG1  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUG2  had no effect on  DRUGOTHER  pharmacokinetics."	Neurontin	phenytoin	NCC1(CC(O)=O)CCCCC1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUG1  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUG2  pharmacokinetics."	Neurontin	gabapentin	NCC1(CC(O)=O)CCCCC1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUG1  monotherapy for at least 2 months,  DRUG2  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	phenytoin	gabapentin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUG1  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUG2  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUG1  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUG2  had no effect on  DRUGOTHER  pharmacokinetics."	phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUG1  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUG2  pharmacokinetics."	phenytoin	gabapentin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUG1  had no effect on the steady-state trough plasma concentrations of  DRUG2  and  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	gabapentin	phenytoin	NCC1(CC(O)=O)CCCCC1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUG1  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUG2  had no effect on  DRUGOTHER  pharmacokinetics."	gabapentin	phenytoin	NCC1(CC(O)=O)CCCCC1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUG1  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUGOTHER  had no effect on  DRUG2  pharmacokinetics."	gabapentin	gabapentin	NCC1(CC(O)=O)CCCCC1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUG1  and  DRUG2  had no effect on  DRUGOTHER  pharmacokinetics."	phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUG1  and  DRUGOTHER  had no effect on  DRUG2  pharmacokinetics."	phenytoin	gabapentin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : In a single (400 mg) and multiple dose (400 mg TID) study of  DRUGOTHER  in epileptic patients (N=8) maintained on  DRUGOTHER  monotherapy for at least 2 months,  DRUGOTHER  had no effect on the steady-state trough plasma concentrations of  DRUGOTHER  and  DRUG1  had no effect on  DRUG2  pharmacokinetics."	phenytoin	gabapentin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	 DRUG1 : Steady-state trough plasma  DRUG2  and  DRUGOTHER  concentrations were not affected by concomitant  DRUGOTHER  (400 mg TID;	Carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUG1 : Steady-state trough plasma  DRUGOTHER  and  DRUG2  concentrations were not affected by concomitant  DRUGOTHER  (400 mg TID;	Carbamazepine	"carbamazepine 10, 11 epoxide"	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUG1 : Steady-state trough plasma  DRUGOTHER  and  DRUGOTHER  concentrations were not affected by concomitant  DRUG2  (400 mg TID;	Carbamazepine	gabapentin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NCC1(CC(O)=O)CCCCC1
other	 DRUGOTHER : Steady-state trough plasma  DRUG1  and  DRUG2  concentrations were not affected by concomitant  DRUGOTHER  (400 mg TID;	carbamazepine	"carbamazepine 10, 11 epoxide"	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUGOTHER : Steady-state trough plasma  DRUG1  and  DRUGOTHER  concentrations were not affected by concomitant  DRUG2  (400 mg TID;	carbamazepine	gabapentin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NCC1(CC(O)=O)CCCCC1
other	 DRUGOTHER : Steady-state trough plasma  DRUGOTHER  and  DRUG1  concentrations were not affected by concomitant  DRUG2  (400 mg TID;	"carbamazepine 10, 11 epoxide"	gabapentin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NCC1(CC(O)=O)CCCCC1
other	"Likewise,  DRUG1  pharmacokinetics were unaltered by  DRUG2  administration."	gabapentin	carbamazepine	NCC1(CC(O)=O)CCCCC1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	 DRUG1 : The mean steady-state trough serum  DRUG2  concentrations prior to and during concomitant  DRUGOTHER  administration (400 mg TID;	Valproic Acid	valproic acid	CCCC(CCC)C(O)=O	CCCC(CCC)C(O)=O
other	 DRUG1 : The mean steady-state trough serum  DRUGOTHER  concentrations prior to and during concomitant  DRUG2  administration (400 mg TID;	Valproic Acid	gabapentin	CCCC(CCC)C(O)=O	NCC1(CC(O)=O)CCCCC1
other	 DRUGOTHER : The mean steady-state trough serum  DRUG1  concentrations prior to and during concomitant  DRUG2  administration (400 mg TID;	valproic acid	gabapentin	CCCC(CCC)C(O)=O	NCC1(CC(O)=O)CCCCC1
other	N=17) were not different and neither were  DRUG1  pharmacokinetic parameters affected by  DRUG2 .	gabapentin	valproic acid	NCC1(CC(O)=O)CCCCC1	CCCC(CCC)C(O)=O
other	 DRUG1 : Estimates of steady-state pharmacokinetic parameters for  DRUG2  or  DRUGOTHER  (300 mg TID;	Phenobarbital	phenobarbital	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	 DRUG1 : Estimates of steady-state pharmacokinetic parameters for  DRUGOTHER  or  DRUG2  (300 mg TID;	Phenobarbital	gabapentin	CCC1(CC)C(=O)NC(=O)NC1=O	NCC1(CC(O)=O)CCCCC1
other	 DRUGOTHER : Estimates of steady-state pharmacokinetic parameters for  DRUG1  or  DRUG2  (300 mg TID;	phenobarbital	gabapentin	CCC1(CC)C(=O)NC(=O)NC1=O	NCC1(CC(O)=O)CCCCC1
other	 DRUG1 : Coadministration (N=18) of  DRUG2  capsules (250 mg) with  DRUGOTHER  (125 mg) appears to increase the amount of  DRUGOTHER  absorbed by 12% to 15%.	Naproxen	naproxen sodium	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	 DRUG1 : Coadministration (N=18) of  DRUGOTHER  capsules (250 mg) with  DRUG2  (125 mg) appears to increase the amount of  DRUGOTHER  absorbed by 12% to 15%.	Naproxen	Neurontin	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1	NCC1(CC(O)=O)CCCCC1
other	 DRUG1 : Coadministration (N=18) of  DRUGOTHER  capsules (250 mg) with  DRUGOTHER  (125 mg) appears to increase the amount of  DRUG2  absorbed by 12% to 15%.	Naproxen	gabapentin	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1	NCC1(CC(O)=O)CCCCC1
mechanism	 DRUGOTHER : Coadministration (N=18) of  DRUG1  capsules (250 mg) with  DRUG2  (125 mg) appears to increase the amount of  DRUGOTHER  absorbed by 12% to 15%.	naproxen sodium	Neurontin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	 DRUGOTHER : Coadministration (N=18) of  DRUG1  capsules (250 mg) with  DRUGOTHER  (125 mg) appears to increase the amount of  DRUG2  absorbed by 12% to 15%.	naproxen sodium	gabapentin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	NCC1(CC(O)=O)CCCCC1
other	 DRUGOTHER : Coadministration (N=18) of  DRUGOTHER  capsules (250 mg) with  DRUG1  (125 mg) appears to increase the amount of  DRUG2  absorbed by 12% to 15%.	Neurontin	gabapentin	NCC1(CC(O)=O)CCCCC1	NCC1(CC(O)=O)CCCCC1
other	 DRUG1  had no effect on  DRUG2  pharmacokinetic parameters.	Gabapentin	naproxen	NCC1(CC(O)=O)CCCCC1	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	 DRUG1 : Coadministration of  DRUG2   (125 to 500 mg;	Hydrocodone	Neurontin	[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O	NCC1(CC(O)=O)CCCCC1
other	"Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg  DRUG1   and 21% to 22% lower, respectively, after administration of 500 mg  DRUG2  ."	Neurontin	Neurontin	NCC1(CC(O)=O)CCCCC1	NCC1(CC(O)=O)CCCCC1
mechanism	 DRUG1  increases  DRUG2  AUC values by 14%.	Hydrocodone	gabapentin	[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O	NCC1(CC(O)=O)CCCCC1
other	" DRUG1 : A literature article reported that when a 60-mg controlled-release  DRUG2  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUGOTHER ."	Morphine	morphine	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	" DRUG1 : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUG2   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUGOTHER ."	Morphine	Neurontin	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	NCC1(CC(O)=O)CCCCC1
other	" DRUG1 : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUG2  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUGOTHER ."	Morphine	gabapentin	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	NCC1(CC(O)=O)CCCCC1
other	" DRUG1 : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUG2  administered without  DRUGOTHER ."	Morphine	gabapentin	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	NCC1(CC(O)=O)CCCCC1
other	" DRUG1 : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUG2 ."	Morphine	morphine	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
mechanism	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUG1  capsule was administered 2 hours prior to a 600-mg  DRUG2   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUGOTHER ."	morphine	Neurontin	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUG1  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUG2  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUGOTHER ."	morphine	gabapentin	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUG1  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUG2  administered without  DRUGOTHER ."	morphine	gabapentin	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUG1  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUG2 ."	morphine	morphine	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUG1   capsule (N=12), mean  DRUG2  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUGOTHER ."	Neurontin	gabapentin	NCC1(CC(O)=O)CCCCC1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUG1   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUG2  administered without  DRUGOTHER ."	Neurontin	gabapentin	NCC1(CC(O)=O)CCCCC1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUG1   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUG2 ."	Neurontin	morphine	NCC1(CC(O)=O)CCCCC1	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUG1  AUC increased by 44% compared to  DRUG2  administered without  DRUGOTHER ."	gabapentin	gabapentin	NCC1(CC(O)=O)CCCCC1	NCC1(CC(O)=O)CCCCC1
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUG1  AUC increased by 44% compared to  DRUGOTHER  administered without  DRUG2 ."	gabapentin	morphine	NCC1(CC(O)=O)CCCCC1	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	" DRUGOTHER : A literature article reported that when a 60-mg controlled-release  DRUGOTHER  capsule was administered 2 hours prior to a 600-mg  DRUGOTHER   capsule (N=12), mean  DRUGOTHER  AUC increased by 44% compared to  DRUG1  administered without  DRUG2 ."	gabapentin	morphine	NCC1(CC(O)=O)CCCCC1	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	 DRUG1  pharmacokinetic parameter values were not affected by administration of  DRUG2   2 hours after  DRUGOTHER .	Morphine	Neurontin	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	NCC1(CC(O)=O)CCCCC1
other	 DRUG1  pharmacokinetic parameter values were not affected by administration of  DRUGOTHER   2 hours after  DRUG2 .	Morphine	morphine	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	 DRUGOTHER  pharmacokinetic parameter values were not affected by administration of  DRUG1   2 hours after  DRUG2 .	Neurontin	morphine	NCC1(CC(O)=O)CCCCC1	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	 DRUG1 : In the presence of  DRUG2  at 300 mg QID (N=12) the mean apparent oral clearance of  DRUGOTHER  fell by 14% and creatinine clearance fell by 10%.	Cimetidine	cimetidine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	 DRUG1 : In the presence of  DRUGOTHER  at 300 mg QID (N=12) the mean apparent oral clearance of  DRUG2  fell by 14% and creatinine clearance fell by 10%.	Cimetidine	gabapentin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	NCC1(CC(O)=O)CCCCC1
mechanism	 DRUGOTHER : In the presence of  DRUG1  at 300 mg QID (N=12) the mean apparent oral clearance of  DRUG2  fell by 14% and creatinine clearance fell by 10%.	cimetidine	gabapentin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	NCC1(CC(O)=O)CCCCC1
mechanism	"Thus  DRUG1  appeared to alter the renal excretion of both  DRUG2  and creatinine, an endogenous marker of renal function."	cimetidine	gabapentin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	NCC1(CC(O)=O)CCCCC1
mechanism	This small decrease in excretion of  DRUG1  by  DRUG2  is not expected to be of clinical importance.	gabapentin	cimetidine	NCC1(CC(O)=O)CCCCC1	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	The effect of  DRUG1  on  DRUG2  was not evaluated.	gabapentin	cimetidine	NCC1(CC(O)=O)CCCCC1	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Oral  DRUG1 : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUG2  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	Contraceptive	norethindrone	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	"Oral  DRUG1 : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUG2  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	Contraceptive	ethinyl estradiol	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUG1 : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUG2  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	Contraceptive	norethindrone acetate	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	"Oral  DRUG1 : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUG2  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	Contraceptive	ethinyl estradiol	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUG1 : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUG2  (400 mg TID;"	Contraceptive	gabapentin	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	NCC1(CC(O)=O)CCCCC1
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUG1  and  DRUG2  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	norethindrone	ethinyl estradiol	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUG1  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUG2  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	norethindrone	norethindrone acetate	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUG1  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUG2  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	norethindrone	ethinyl estradiol	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUG1  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUG2  (400 mg TID;"	norethindrone	gabapentin	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	NCC1(CC(O)=O)CCCCC1
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUG1  following administration of tablets containing 2.5 mg of  DRUG2  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	ethinyl estradiol	norethindrone acetate	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUG1  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUG2  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	ethinyl estradiol	ethinyl estradiol	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUG1  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUG2  (400 mg TID;"	ethinyl estradiol	gabapentin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	NCC1(CC(O)=O)CCCCC1
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUG1  and 50 mcg of  DRUG2  were similar with and without coadministration of  DRUGOTHER  (400 mg TID;"	norethindrone acetate	ethinyl estradiol	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUG1  and 50 mcg of  DRUGOTHER  were similar with and without coadministration of  DRUG2  (400 mg TID;"	norethindrone acetate	gabapentin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	NCC1(CC(O)=O)CCCCC1
other	"Oral  DRUGOTHER : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of tablets containing 2.5 mg of  DRUGOTHER  and 50 mcg of  DRUG1  were similar with and without coadministration of  DRUG2  (400 mg TID;"	ethinyl estradiol	gabapentin	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	NCC1(CC(O)=O)CCCCC1
mechanism	The Cmax of  DRUG1  was 13% higher when it was coadministered with  DRUG2 ;	norethindrone	gabapentin	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	NCC1(CC(O)=O)CCCCC1
other	 DRUG1  ( DRUG2  ):  DRUGOTHER  reduced the bioavailability of  DRUGOTHER  (N=16) by about 20%.	Antacid	Maalox	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1  ( DRUGOTHER  ):  DRUG2  reduced the bioavailability of  DRUGOTHER  (N=16) by about 20%.	Antacid	Maalox	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1  ( DRUGOTHER  ):  DRUGOTHER  reduced the bioavailability of  DRUG2  (N=16) by about 20%.	Antacid	gabapentin	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	NCC1(CC(O)=O)CCCCC1
other	 DRUGOTHER  ( DRUG1  ):  DRUG2  reduced the bioavailability of  DRUGOTHER  (N=16) by about 20%.	Maalox	Maalox	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUGOTHER  ( DRUG1  ):  DRUGOTHER  reduced the bioavailability of  DRUG2  (N=16) by about 20%.	Maalox	gabapentin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCC1(CC(O)=O)CCCCC1
mechanism	 DRUGOTHER  ( DRUGOTHER  ):  DRUG1  reduced the bioavailability of  DRUG2  (N=16) by about 20%.	Maalox	gabapentin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCC1(CC(O)=O)CCCCC1
mechanism	This decrease in bioavailability was about 5% when  DRUG1  was administered 2 hours after  DRUG2 .	gabapentin	Maalox	NCC1(CC(O)=O)CCCCC1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	Effect of  DRUG1 :  DRUG2  is a blocker of renal tubular secretion.	Probenecid	Probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	 DRUG1  pharmacokinetic parameters without and with  DRUG2  were comparable.	Gabapentin	probenecid	NCC1(CC(O)=O)CCCCC1	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	This indicates that  DRUG1  does not undergo renal tubular secretion by the pathway that is blocked by  DRUG2 .	gabapentin	probenecid	NCC1(CC(O)=O)CCCCC1	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when  DRUG1  was added to other  DRUG2 , the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein"	gabapentin	antiepileptic drugs	NCC1(CC(O)=O)CCCCC1	
other	"The results of a study of coadministration of  DRUG1  (50 mg/kg) with an  DRUGOTHER  containing  DRUG2  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUGOTHER ."	ethambutol	antacid	NC(CO)(CO)CO	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"The results of a study of coadministration of  DRUG1  (50 mg/kg) with an  DRUGOTHER  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUG2  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUGOTHER ."	ethambutol	ethambutol	NC(CO)(CO)CO	NC(CO)(CO)CO
other	"The results of a study of coadministration of  DRUG1  (50 mg/kg) with an  DRUGOTHER  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUG2  may be reduced by these  DRUGOTHER ."	ethambutol	ethambutol	NC(CO)(CO)CO	NC(CO)(CO)CO
other	"The results of a study of coadministration of  DRUG1  (50 mg/kg) with an  DRUGOTHER  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUG2 ."	ethambutol	antacid products	NC(CO)(CO)CO	
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUG1  containing  DRUG2  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUGOTHER ."	aluminum hydroxide	antacid	[OH-].[OH-].[OH-].[Al+3]	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUG1  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUG2  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUGOTHER ."	aluminum hydroxide	ethambutol	[OH-].[OH-].[OH-].[Al+3]	NC(CO)(CO)CO
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUG1  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUG2  may be reduced by these  DRUGOTHER ."	aluminum hydroxide	ethambutol	[OH-].[OH-].[OH-].[Al+3]	NC(CO)(CO)CO
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUG1  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUG2 ."	aluminum hydroxide	antacid products	[OH-].[OH-].[OH-].[Al+3]	
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUGOTHER  containing  DRUG1  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUG2  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUGOTHER ."	antacid	ethambutol	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	NC(CO)(CO)CO
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUGOTHER  containing  DRUG1  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUG2  may be reduced by these  DRUGOTHER ."	antacid	ethambutol	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	NC(CO)(CO)CO
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUGOTHER  containing  DRUG1  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUG2 ."	antacid	antacid products	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUGOTHER  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUG1  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUG2  may be reduced by these  DRUGOTHER ."	ethambutol	ethambutol	NC(CO)(CO)CO	NC(CO)(CO)CO
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUGOTHER  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUG1  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUGOTHER  may be reduced by these  DRUG2 ."	ethambutol	antacid products	NC(CO)(CO)CO	
other	"The results of a study of coadministration of  DRUGOTHER  (50 mg/kg) with an  DRUGOTHER  containing  DRUGOTHER  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  DRUGOTHER  of approximately 20% and 13%, respectively, suggesting that the oral absorption of  DRUG1  may be reduced by these  DRUG2 ."	ethambutol	antacid products	NC(CO)(CO)CO	
advise	It is recommended to avoid concurrent administration of  DRUG1  with  DRUG2  containing  DRUGOTHER  for at least 4 hours following  DRUGOTHER  administration.	ethambutol	aluminum hydroxide	NC(CO)(CO)CO	[OH-].[OH-].[OH-].[Al+3]
other	It is recommended to avoid concurrent administration of  DRUG1  with  DRUGOTHER  containing  DRUG2  for at least 4 hours following  DRUGOTHER  administration.	ethambutol	antacids	NC(CO)(CO)CO	
other	It is recommended to avoid concurrent administration of  DRUG1  with  DRUGOTHER  containing  DRUGOTHER  for at least 4 hours following  DRUG2  administration.	ethambutol	ethambutol	NC(CO)(CO)CO	NC(CO)(CO)CO
other	It is recommended to avoid concurrent administration of  DRUGOTHER  with  DRUG1  containing  DRUG2  for at least 4 hours following  DRUGOTHER  administration.	aluminum hydroxide	antacids	[OH-].[OH-].[OH-].[Al+3]	
other	It is recommended to avoid concurrent administration of  DRUGOTHER  with  DRUG1  containing  DRUGOTHER  for at least 4 hours following  DRUG2  administration.	aluminum hydroxide	ethambutol	[OH-].[OH-].[OH-].[Al+3]	NC(CO)(CO)CO
other	It is recommended to avoid concurrent administration of  DRUGOTHER  with  DRUGOTHER  containing  DRUG1  for at least 4 hours following  DRUG2  administration.	antacids	ethambutol		NC(CO)(CO)CO
other	"The EC50 values for  DRUG1 , which is not a substrate for  DRUG2  uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium."	isoproterenol	norepinephrine	CC(C)O	CNC[C@H](O)C1=CC(O)=C(O)C=C1
other	The uptake inhibitors  DRUG1  and  DRUG2  (3 mumol/liter) potentiated the positive inotropic effects of  DRUGOTHER  in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.	cocaine	desipramine	CCOC(=O)C1=CC=C(N)C=C1	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
effect	The uptake inhibitors  DRUG1  and  DRUGOTHER  (3 mumol/liter) potentiated the positive inotropic effects of  DRUG2  in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.	cocaine	norepinephrine	CCOC(=O)C1=CC=C(N)C=C1	CNC[C@H](O)C1=CC(O)=C(O)C=C1
effect	The uptake inhibitors  DRUGOTHER  and  DRUG1  (3 mumol/liter) potentiated the positive inotropic effects of  DRUG2  in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.	desipramine	norepinephrine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CNC[C@H](O)C1=CC(O)=C(O)C=C1
other	Radioligand binding experiments using the uptake inhibitor hydrogen-3  DRUG1  revealed a significant decrease by approximately 30% in  DRUG2  uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).	mazindol	norepinephrine	OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1	CNC[C@H](O)C1=CC(O)=C(O)C=C1
other	"This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as  DRUG1  and  DRUG2 , in the nonfailing heart only."	cocaine	desipramine	CCOC(=O)C1=CC=C(N)C=C1	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	Compromised  DRUG1  uptake-1 in functional class IV cannot be further increased by  DRUG2  and  DRUGOTHER .	norepinephrine	cocaine	CNC[C@H](O)C1=CC(O)=C(O)C=C1	CCOC(=O)C1=CC=C(N)C=C1
other	Compromised  DRUG1  uptake-1 in functional class IV cannot be further increased by  DRUGOTHER  and  DRUG2 .	norepinephrine	desipramine	CNC[C@H](O)C1=CC(O)=C(O)C=C1	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	Compromised  DRUGOTHER  uptake-1 in functional class IV cannot be further increased by  DRUG1  and  DRUG2 .	cocaine	desipramine	CCOC(=O)C1=CC=C(N)C=C1	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	 DRUG1  and  DRUG2  -  DRUGOTHER  may decrease hepatic toxicity in those with  DRUGOTHER  overdosage or in those taking  DRUGOTHER .	Acetaminophen	methotrexate	OC(=O)CCCCCCCC(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	 DRUG1  and  DRUGOTHER  -  DRUG2  may decrease hepatic toxicity in those with  DRUGOTHER  overdosage or in those taking  DRUGOTHER .	Acetaminophen	L-methionine	OC(=O)CCCCCCCC(O)=O	CSCC[C@H](N)C(O)=O
other	 DRUG1  and  DRUGOTHER  -  DRUGOTHER  may decrease hepatic toxicity in those with  DRUG2  overdosage or in those taking  DRUGOTHER .	Acetaminophen	acetaminophen	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	 DRUG1  and  DRUGOTHER  -  DRUGOTHER  may decrease hepatic toxicity in those with  DRUGOTHER  overdosage or in those taking  DRUG2 .	Acetaminophen	methotrexate	OC(=O)CCCCCCCC(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	 DRUGOTHER  and  DRUG1  -  DRUG2  may decrease hepatic toxicity in those with  DRUGOTHER  overdosage or in those taking  DRUGOTHER .	methotrexate	L-methionine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CSCC[C@H](N)C(O)=O
other	 DRUGOTHER  and  DRUG1  -  DRUGOTHER  may decrease hepatic toxicity in those with  DRUG2  overdosage or in those taking  DRUGOTHER .	methotrexate	acetaminophen	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	 DRUGOTHER  and  DRUG1  -  DRUGOTHER  may decrease hepatic toxicity in those with  DRUGOTHER  overdosage or in those taking  DRUG2 .	methotrexate	methotrexate	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	 DRUGOTHER  and  DRUGOTHER  -  DRUGOTHER  may decrease hepatic toxicity in those with  DRUG1  overdosage or in those taking  DRUG2 .	acetaminophen	methotrexate	OC(=O)CCCCCCCC(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	 DRUG1  -  DRUG2  may protect against the ototoxic effects of  DRUGOTHER .	Gentamicin	Methionine	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CSCC[C@H](N)C(O)=O
other	 DRUG1  -  DRUGOTHER  may protect against the ototoxic effects of  DRUG2 .	Gentamicin	gentamicin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
effect	 DRUGOTHER  -  DRUG1  may protect against the ototoxic effects of  DRUG2 .	Methionine	gentamicin	CSCC[C@H](N)C(O)=O	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
effect	 DRUG1  are a major contributing factor to  DRUG2  toxicity.	Potassium-depleting diuretics	digitalis	[KH]	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	Quinidine	verapamil	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	" DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	Quinidine	amiodarone	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	Quinidine	propafenone	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	Quinidine	indomethacin	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	Quinidine	itraconazole	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	Quinidine	alprazolam	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	Quinidine	spironolactone	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
mechanism	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUG2  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	Quinidine	digoxin	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	Quinidine	digitalis	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	verapamil	amiodarone	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	verapamil	propafenone	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	verapamil	indomethacin	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	verapamil	itraconazole	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	verapamil	alprazolam	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	verapamil	spironolactone	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
mechanism	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUG2  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	verapamil	digoxin	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	verapamil	digitalis	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	amiodarone	propafenone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	amiodarone	indomethacin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	amiodarone	itraconazole	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	amiodarone	alprazolam	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	amiodarone	spironolactone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
mechanism	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUG2  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	amiodarone	digoxin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	amiodarone	digitalis	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	propafenone	indomethacin	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	propafenone	itraconazole	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	propafenone	alprazolam	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	propafenone	spironolactone	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
mechanism	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUG2  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	propafenone	digoxin	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	propafenone	digitalis	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	indomethacin	itraconazole	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	indomethacin	alprazolam	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	indomethacin	spironolactone	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
mechanism	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUG2  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	indomethacin	digoxin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	indomethacin	digitalis	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	itraconazole	alprazolam	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	itraconazole	spironolactone	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
mechanism	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUG2  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	itraconazole	digoxin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	itraconazole	digitalis	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	alprazolam	spironolactone	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
mechanism	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  raise the serum  DRUG2  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	alprazolam	digoxin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	alprazolam	digitalis	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1  raise the serum  DRUG2  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUGOTHER  intoxication may result."	spironolactone	digoxin	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1  raise the serum  DRUGOTHER  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	spironolactone	digitalis	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  raise the serum  DRUG1  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  DRUG2  intoxication may result."	digoxin	digitalis	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1  and  DRUG2  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	Erythromycin	clarithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	" DRUG1  and  DRUGOTHER  (and possibly other  DRUG2 ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	Erythromycin	macrolide antibiotics	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	" DRUG1  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUG2  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	Erythromycin	tetracycline	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C
mechanism	" DRUG1  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUG2  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	Erythromycin	digoxin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUG2  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	Erythromycin	digoxin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUG2  intoxication may result."	Erythromycin	digitalis	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  and  DRUG1  (and possibly other  DRUG2 ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	clarithromycin	macrolide antibiotics	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	" DRUGOTHER  and  DRUG1  (and possibly other  DRUGOTHER ) and  DRUG2  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	clarithromycin	tetracycline	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C
mechanism	" DRUGOTHER  and  DRUG1  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUG2  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	clarithromycin	digoxin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  and  DRUG1  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUG2  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	clarithromycin	digoxin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  and  DRUG1  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUG2  intoxication may result."	clarithromycin	digitalis	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUG1 ) and  DRUG2  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	macrolide antibiotics	tetracycline	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C
mechanism	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUG1 ) and  DRUGOTHER  may increase  DRUG2  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	macrolide antibiotics	digoxin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUG1 ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUG2  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	macrolide antibiotics	digoxin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUG1 ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUG2  intoxication may result."	macrolide antibiotics	digitalis	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUG1  may increase  DRUG2  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	tetracycline	digoxin	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUG1  may increase  DRUGOTHER  absorption in patients who inactivate  DRUG2  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	tetracycline	digoxin	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUG1  may increase  DRUGOTHER  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUG2  intoxication may result."	tetracycline	digitalis	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUG1  absorption in patients who inactivate  DRUG2  by bacterial metabolism in the lower intestine, so that  DRUGOTHER  intoxication may result."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUG1  absorption in patients who inactivate  DRUGOTHER  by bacterial metabolism in the lower intestine, so that  DRUG2  intoxication may result."	digoxin	digitalis	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  and  DRUGOTHER  (and possibly other  DRUGOTHER ) and  DRUGOTHER  may increase  DRUGOTHER  absorption in patients who inactivate  DRUG1  by bacterial metabolism in the lower intestine, so that  DRUG2  intoxication may result."	digoxin	digitalis	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1  and  DRUG2 , by decreasing gut motility, may increase  DRUGOTHER  absorption."	Propantheline	diphenoxylate	CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl	CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1
mechanism	" DRUG1  and  DRUGOTHER , by decreasing gut motility, may increase  DRUG2  absorption."	Propantheline	digoxin	CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	" DRUGOTHER  and  DRUG1 , by decreasing gut motility, may increase  DRUG2  absorption."	diphenoxylate	digoxin	CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1 ,  DRUG2 -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	Antacids	kaolin		O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-]
other	" DRUG1 ,  DRUGOTHER -pectin,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	Antacids	sulfasalazine		OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1
other	" DRUG1 ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	Antacids	neomycin		
other	" DRUG1 ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	Antacids	cholestyramine		NCCC1=CC=C(O)C=C1
other	" DRUG1 ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUG2  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	Antacids	metoclopramide		OC(=O)CCCCCCCC(O)=O
mechanism	" DRUG1 ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUG2  absorption, resulting in unexpectedly low serum concentrations."	Antacids	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUG1 -pectin,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	kaolin	sulfasalazine	O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-]	OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1
other	" DRUGOTHER ,  DRUG1 -pectin,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	kaolin	neomycin	O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-]	
other	" DRUGOTHER ,  DRUG1 -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	kaolin	cholestyramine	O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-]	NCCC1=CC=C(O)C=C1
other	" DRUGOTHER ,  DRUG1 -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUG2  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	kaolin	metoclopramide	O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-]	OC(=O)CCCCCCCC(O)=O
mechanism	" DRUGOTHER ,  DRUG1 -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUG2  absorption, resulting in unexpectedly low serum concentrations."	kaolin	digoxin	O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-]	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUG1 ,  DRUG2 ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	sulfasalazine	neomycin	OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1	
other	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUG1 ,  DRUGOTHER ,  DRUG2 , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	sulfasalazine	cholestyramine	OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1	NCCC1=CC=C(O)C=C1
other	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUG2  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	sulfasalazine	metoclopramide	OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1	OC(=O)CCCCCCCC(O)=O
mechanism	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUG2  absorption, resulting in unexpectedly low serum concentrations."	sulfasalazine	digoxin	OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUG1 ,  DRUG2 , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	neomycin	cholestyramine		NCCC1=CC=C(O)C=C1
other	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , certain anticancer drugs, and  DRUG2  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	neomycin	metoclopramide		OC(=O)CCCCCCCC(O)=O
mechanism	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUG2  absorption, resulting in unexpectedly low serum concentrations."	neomycin	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , certain anticancer drugs, and  DRUG2  may interfere with intestinal  DRUGOTHER  absorption, resulting in unexpectedly low serum concentrations."	cholestyramine	metoclopramide	NCCC1=CC=C(O)C=C1	OC(=O)CCCCCCCC(O)=O
mechanism	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , certain anticancer drugs, and  DRUGOTHER  may interfere with intestinal  DRUG2  absorption, resulting in unexpectedly low serum concentrations."	cholestyramine	digoxin	NCCC1=CC=C(O)C=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	" DRUGOTHER ,  DRUGOTHER -pectin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , certain anticancer drugs, and  DRUG1  may interfere with intestinal  DRUG2  absorption, resulting in unexpectedly low serum concentrations."	metoclopramide	digoxin	OC(=O)CCCCCCCC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	" DRUG1  may decrease serum  DRUG2  concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of  DRUGOTHER ."	Rifampin	digoxin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  may decrease serum  DRUGOTHER  concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of  DRUG2 ."	Rifampin	digoxin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUGOTHER  may decrease serum  DRUG1  concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of  DRUG2 ."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"There have been inconsistent reports regarding the effects of other drugs (e.g.,  DRUG1 ,  DRUG2 ) on serum  DRUGOTHER  concentration."	quinine	penicillamine	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	[H][C@](N)(C(O)=O)C(C)(C)S
other	"There have been inconsistent reports regarding the effects of other drugs (e.g.,  DRUG1 ,  DRUGOTHER ) on serum  DRUG2  concentration."	quinine	digoxin	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"There have been inconsistent reports regarding the effects of other drugs (e.g.,  DRUGOTHER ,  DRUG1 ) on serum  DRUG2  concentration."	penicillamine	digoxin	[H][C@](N)(C(O)=O)C(C)(C)S	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
advise	" DRUG1  administration to a digitalized, hypothyroid patient may increase the dose requirement of  DRUG2 ."	Thyroid	digoxin	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
effect	Concomitant use of  DRUG1  and  DRUG2  increases the risk of cardiac arrhythmias.	digoxin	sympathomimetics	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	
other	"Although  DRUG1  or  DRUG2  and  DRUGOTHER  may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block."	beta-adrenergic blockers	calcium channel blockers		[Ca]
other	"Furthermore, caution should be exercised when combining  DRUG1  with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of  DRUG2 ."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
effect	Tissue culture and animal studies indicate that  DRUG1  can diminish or abolish the effect of  DRUG2  on malignant cells.14 This effect on  DRUGOTHER  activity persists as long as plasma asparagine levels are suppressed.	ELSPAR	methotrexate		CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	Tissue culture and animal studies indicate that  DRUG1  can diminish or abolish the effect of  DRUGOTHER  on malignant cells.14 This effect on  DRUG2  activity persists as long as plasma asparagine levels are suppressed.	ELSPAR	methotrexate		CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	Tissue culture and animal studies indicate that  DRUGOTHER  can diminish or abolish the effect of  DRUG1  on malignant cells.14 This effect on  DRUG2  activity persists as long as plasma asparagine levels are suppressed.	methotrexate	methotrexate	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
advise	"These results would seem to dictate against the clinical use of  DRUG1  with  DRUG2 , or during the period following  DRUGOTHER  therapy when plasma asparagine levels are below normal."	methotrexate	ELSPAR	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	
other	"These results would seem to dictate against the clinical use of  DRUG1  with  DRUGOTHER , or during the period following  DRUG2  therapy when plasma asparagine levels are below normal."	methotrexate	ELSPAR	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	
other	"These results would seem to dictate against the clinical use of  DRUGOTHER  with  DRUG1 , or during the period following  DRUG2  therapy when plasma asparagine levels are below normal."	ELSPAR	ELSPAR		
other	" DRUG1 / DRUG2 / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Anesthetics	Sedatives	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUG1 / DRUGOTHER / DRUG2 / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Anesthetics	Hypnotics	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUG1 / DRUGOTHER / DRUGOTHER / DRUG2 : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Anesthetics	Opioids	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUG1 / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUG2  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Anesthetics	PRECEDEX	CCOC(=O)C1=CC=C(N)C=C1	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
other	" DRUG1 / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Anesthetics	anesthetics	CCOC(=O)C1=CC=C(N)C=C1	CCOC(=O)C1=CC=C(N)C=C1
other	" DRUG1 / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Anesthetics	sedatives	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUG1 / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Anesthetics	hypnotics	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUG1 / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  is likely to lead to an enhancement of effects."	Anesthetics	opioids	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUGOTHER / DRUG1 / DRUG2 / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Sedatives	Hypnotics		
other	" DRUGOTHER / DRUG1 / DRUGOTHER / DRUG2 : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Sedatives	Opioids		
other	" DRUGOTHER / DRUG1 / DRUGOTHER / DRUGOTHER : Co-administration of  DRUG2  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Sedatives	PRECEDEX		C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
other	" DRUGOTHER / DRUG1 / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Sedatives	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	" DRUGOTHER / DRUG1 / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Sedatives	sedatives		
other	" DRUGOTHER / DRUG1 / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Sedatives	hypnotics		
other	" DRUGOTHER / DRUG1 / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  is likely to lead to an enhancement of effects."	Sedatives	opioids		
other	" DRUGOTHER / DRUGOTHER / DRUG1 / DRUG2 : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Hypnotics	Opioids		
other	" DRUGOTHER / DRUGOTHER / DRUG1 / DRUGOTHER : Co-administration of  DRUG2  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Hypnotics	PRECEDEX		C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
other	" DRUGOTHER / DRUGOTHER / DRUG1 / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Hypnotics	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	" DRUGOTHER / DRUGOTHER / DRUG1 / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Hypnotics	sedatives		
other	" DRUGOTHER / DRUGOTHER / DRUG1 / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Hypnotics	hypnotics		
other	" DRUGOTHER / DRUGOTHER / DRUG1 / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  is likely to lead to an enhancement of effects."	Hypnotics	opioids		
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUG1 : Co-administration of  DRUG2  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Opioids	PRECEDEX		C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUG1 : Co-administration of  DRUGOTHER  with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Opioids	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUG1 : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Opioids	sedatives		
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUG1 : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  is likely to lead to an enhancement of effects."	Opioids	hypnotics		
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUG1 : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  is likely to lead to an enhancement of effects."	Opioids	opioids		
effect	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUG1  with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	PRECEDEX	anesthetics	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	CCOC(=O)C1=CC=C(N)C=C1
effect	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUG1  with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	PRECEDEX	sedatives	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	
effect	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUG1  with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  is likely to lead to an enhancement of effects."	PRECEDEX	hypnotics	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	
effect	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUG1  with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  is likely to lead to an enhancement of effects."	PRECEDEX	opioids	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  is likely to lead to an enhancement of effects."	anesthetics	sedatives	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  is likely to lead to an enhancement of effects."	anesthetics	hypnotics	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  is likely to lead to an enhancement of effects."	anesthetics	opioids	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER  is likely to lead to an enhancement of effects."	sedatives	hypnotics		
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2  is likely to lead to an enhancement of effects."	sedatives	opioids		
other	" DRUGOTHER / DRUGOTHER / DRUGOTHER / DRUGOTHER : Co-administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2  is likely to lead to an enhancement of effects."	hypnotics	opioids		
other	"Specific studies have confirmed these effects with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	sevoflurane	isoflurane	FCOC(C(F)(F)F)C(F)(F)F	FC(F)OC(Cl)C(F)(F)F
other	"Specific studies have confirmed these effects with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	sevoflurane	propofol	FCOC(C(F)(F)F)C(F)(F)F	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O
other	"Specific studies have confirmed these effects with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	sevoflurane	alfentanil	FCOC(C(F)(F)F)C(F)(F)F	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Specific studies have confirmed these effects with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	sevoflurane	midazolam	FCOC(C(F)(F)F)C(F)(F)F	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Specific studies have confirmed these effects with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	isoflurane	propofol	FC(F)OC(Cl)C(F)(F)F	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O
other	"Specific studies have confirmed these effects with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	isoflurane	alfentanil	FC(F)OC(Cl)C(F)(F)F	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Specific studies have confirmed these effects with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	isoflurane	midazolam	FC(F)OC(Cl)C(F)(F)F	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Specific studies have confirmed these effects with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	propofol	alfentanil	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Specific studies have confirmed these effects with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	propofol	midazolam	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Specific studies have confirmed these effects with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	alfentanil	midazolam	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"No pharmacokinetic interactions between  DRUG1  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  have been demonstrated."	dexmedetomidine	isoflurane	CC(C1=CN=CN1)C1=CC=CC(C)=C1C	FC(F)OC(Cl)C(F)(F)F
other	"No pharmacokinetic interactions between  DRUG1  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  have been demonstrated."	dexmedetomidine	propofol	CC(C1=CN=CN1)C1=CC=CC(C)=C1C	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O
other	"No pharmacokinetic interactions between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  have been demonstrated."	dexmedetomidine	alfentanil	CC(C1=CN=CN1)C1=CC=CC(C)=C1C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"No pharmacokinetic interactions between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  have been demonstrated."	dexmedetomidine	midazolam	CC(C1=CN=CN1)C1=CC=CC(C)=C1C	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"No pharmacokinetic interactions between  DRUGOTHER  and  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  have been demonstrated."	isoflurane	propofol	FC(F)OC(Cl)C(F)(F)F	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O
other	"No pharmacokinetic interactions between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  have been demonstrated."	isoflurane	alfentanil	FC(F)OC(Cl)C(F)(F)F	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"No pharmacokinetic interactions between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  have been demonstrated."	isoflurane	midazolam	FC(F)OC(Cl)C(F)(F)F	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"No pharmacokinetic interactions between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER  have been demonstrated."	propofol	alfentanil	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"No pharmacokinetic interactions between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2  have been demonstrated."	propofol	midazolam	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"No pharmacokinetic interactions between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2  have been demonstrated."	alfentanil	midazolam	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUG1 , a reduction in dosage of  DRUG2  on the concomitant  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER  may be required."	PRECEDEX	PRECEDEX	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUG1 , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER  may be required."	PRECEDEX	anesthetic	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUG1 , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER  may be required."	PRECEDEX	sedative	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUG1 , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER  may be required."	PRECEDEX	hypnotic	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	O=[Ti]=O
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUG1 , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2  may be required."	PRECEDEX	opioid	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUGOTHER , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUG1 ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER  may be required."	anesthetic	sedative		
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUGOTHER , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUG1 ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER  may be required."	anesthetic	hypnotic		O=[Ti]=O
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUGOTHER , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2  may be required."	anesthetic	opioid		
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUGOTHER , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUGOTHER ,  DRUG1 ,  DRUG2  or  DRUGOTHER  may be required."	sedative	hypnotic		O=[Ti]=O
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUGOTHER , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUG2  may be required."	sedative	opioid		
other	"However, due to possible pharmacodynamic interactions, when co-administered with  DRUGOTHER , a reduction in dosage of  DRUGOTHER  on the concomitant  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUG2  may be required."	hypnotic	opioid	O=[Ti]=O	
other	" DRUG1 : In one study of 10 healthy volunteers, administration of  DRUG2  for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with  DRUGOTHER  administration."	Neuromuscular Blockers	PRECEDEX		C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
other	" DRUG1 : In one study of 10 healthy volunteers, administration of  DRUGOTHER  for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with  DRUG2  administration."	Neuromuscular Blockers	rocuronium		[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1
other	" DRUGOTHER : In one study of 10 healthy volunteers, administration of  DRUG1  for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with  DRUG2  administration."	PRECEDEX	rocuronium	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1
other	"Although the occurrence has not been reported with  DRUG1 , nephrotoxicity has been reported following concomitant administration of other  DRUG2  and  DRUGOTHER ."	Cefizox	cephalosporins	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Although the occurrence has not been reported with  DRUG1 , nephrotoxicity has been reported following concomitant administration of other  DRUGOTHER  and  DRUG2 ."	Cefizox	aminoglycosides	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Repeated oral administration of  DRUG1  in sheep: interactions of  DRUG2  with  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	coumaphos	coumaphos	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2
other	"Repeated oral administration of  DRUG1  in sheep: interactions of  DRUGOTHER  with  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	coumaphos	bishydroxycoumarin	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	O=C1OC2=CC=CC=C2C=C1
other	"Repeated oral administration of  DRUG1  in sheep: interactions of  DRUGOTHER  with  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	coumaphos	trichlorfon	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Repeated oral administration of  DRUG1  in sheep: interactions of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	coumaphos	phenobarbital sodium	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Repeated oral administration of  DRUGOTHER  in sheep: interactions of  DRUG1  with  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	coumaphos	bishydroxycoumarin	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	O=C1OC2=CC=CC=C2C=C1
other	"Repeated oral administration of  DRUGOTHER  in sheep: interactions of  DRUG1  with  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	coumaphos	trichlorfon	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Repeated oral administration of  DRUGOTHER  in sheep: interactions of  DRUG1  with  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	coumaphos	phenobarbital sodium	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Repeated oral administration of  DRUGOTHER  in sheep: interactions of  DRUGOTHER  with  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	bishydroxycoumarin	trichlorfon	O=C1OC2=CC=CC=C2C=C1	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Repeated oral administration of  DRUGOTHER  in sheep: interactions of  DRUGOTHER  with  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	bishydroxycoumarin	phenobarbital sodium	O=C1OC2=CC=CC=C2C=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Repeated oral administration of  DRUGOTHER  in sheep: interactions of  DRUGOTHER  with  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	trichlorfon	phenobarbital sodium	COP(=O)(OC)C(O)C(Cl)(Cl)Cl	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Interactions between treatments with  DRUG1 ,  DRUG2  (an  DRUGOTHER ),  DRUGOTHER  (an  DRUGOTHER ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	coumaphos	bishydroxycoumarin	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	O=C1OC2=CC=CC=C2C=C1
other	"Interactions between treatments with  DRUG1 ,  DRUGOTHER  (an  DRUG2 ),  DRUGOTHER  (an  DRUGOTHER ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	coumaphos	anticoagulant	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	"Interactions between treatments with  DRUG1 ,  DRUGOTHER  (an  DRUGOTHER ),  DRUG2  (an  DRUGOTHER ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	coumaphos	trichlorfon	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Interactions between treatments with  DRUG1 ,  DRUGOTHER  (an  DRUGOTHER ),  DRUGOTHER  (an  DRUG2 ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	coumaphos	organophosphorous compound	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Interactions between treatments with  DRUG1 ,  DRUGOTHER  (an  DRUGOTHER ),  DRUGOTHER  (an  DRUGOTHER ), and  DRUG2  (an inducer of microsomal enzymes) were investigated in sheep."	coumaphos	phenobarbital sodium	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Interactions between treatments with  DRUGOTHER ,  DRUG1  (an  DRUG2 ),  DRUGOTHER  (an  DRUGOTHER ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	bishydroxycoumarin	anticoagulant	O=C1OC2=CC=CC=C2C=C1	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	"Interactions between treatments with  DRUGOTHER ,  DRUG1  (an  DRUGOTHER ),  DRUG2  (an  DRUGOTHER ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	bishydroxycoumarin	trichlorfon	O=C1OC2=CC=CC=C2C=C1	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Interactions between treatments with  DRUGOTHER ,  DRUG1  (an  DRUGOTHER ),  DRUGOTHER  (an  DRUG2 ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	bishydroxycoumarin	organophosphorous compound	O=C1OC2=CC=CC=C2C=C1	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Interactions between treatments with  DRUGOTHER ,  DRUG1  (an  DRUGOTHER ),  DRUGOTHER  (an  DRUGOTHER ), and  DRUG2  (an inducer of microsomal enzymes) were investigated in sheep."	bishydroxycoumarin	phenobarbital sodium	O=C1OC2=CC=CC=C2C=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Interactions between treatments with  DRUGOTHER ,  DRUGOTHER  (an  DRUG1 ),  DRUG2  (an  DRUGOTHER ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	anticoagulant	trichlorfon	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Interactions between treatments with  DRUGOTHER ,  DRUGOTHER  (an  DRUG1 ),  DRUGOTHER  (an  DRUG2 ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	anticoagulant	organophosphorous compound	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Interactions between treatments with  DRUGOTHER ,  DRUGOTHER  (an  DRUG1 ),  DRUGOTHER  (an  DRUGOTHER ), and  DRUG2  (an inducer of microsomal enzymes) were investigated in sheep."	anticoagulant	phenobarbital sodium	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Interactions between treatments with  DRUGOTHER ,  DRUGOTHER  (an  DRUGOTHER ),  DRUG1  (an  DRUG2 ), and  DRUGOTHER  (an inducer of microsomal enzymes) were investigated in sheep."	trichlorfon	organophosphorous compound	COP(=O)(OC)C(O)C(Cl)(Cl)Cl	COP(=O)(OC)C(O)C(Cl)(Cl)Cl
other	"Interactions between treatments with  DRUGOTHER ,  DRUGOTHER  (an  DRUGOTHER ),  DRUG1  (an  DRUGOTHER ), and  DRUG2  (an inducer of microsomal enzymes) were investigated in sheep."	trichlorfon	phenobarbital sodium	COP(=O)(OC)C(O)C(Cl)(Cl)Cl	CCC1(CC)C(=O)NC(=O)NC1=O
effect	"The treatment of ewes with an intravenous (IV) injection of  DRUG1 , insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of  DRUG2 /kg/day."	trichlorfon	coumaphos	COP(=O)(OC)C(O)C(Cl)(Cl)Cl	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2
effect	"In ewes given 40 mg of  DRUG1 /kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of  DRUG2 /kg was significantly reduced and signs of toxicity were not present."	phenobarbital sodium	coumaphos	CCC1(CC)C(=O)NC(=O)NC1=O	CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2
other	"In a Phase I trial using escalating doses of  DRUG1  (110-200 mg/m2) and  DRUG2  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUGOTHER  before  DRUGOTHER )."	TAXOL	cisplatin	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"In a Phase I trial using escalating doses of  DRUG1  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUG2  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUGOTHER  before  DRUGOTHER )."	TAXOL	TAXOL	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
other	"In a Phase I trial using escalating doses of  DRUG1  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUG2  than with the alternate sequence (ie,  DRUGOTHER  before  DRUGOTHER )."	TAXOL	cisplatin	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"In a Phase I trial using escalating doses of  DRUG1  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUG2  before  DRUGOTHER )."	TAXOL	TAXOL	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
other	"In a Phase I trial using escalating doses of  DRUG1  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUGOTHER  before  DRUG2 )."	TAXOL	cisplatin	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUG1  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUG2  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUGOTHER  before  DRUGOTHER )."	cisplatin	TAXOL	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUG1  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUG2  than with the alternate sequence (ie,  DRUGOTHER  before  DRUGOTHER )."	cisplatin	cisplatin	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUG1  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUG2  before  DRUGOTHER )."	cisplatin	TAXOL	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUG1  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUGOTHER  before  DRUG2 )."	cisplatin	cisplatin	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
effect	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUG1  was given after  DRUG2  than with the alternate sequence (ie,  DRUGOTHER  before  DRUGOTHER )."	TAXOL	cisplatin	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUG1  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUG2  before  DRUGOTHER )."	TAXOL	TAXOL	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUG1  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUGOTHER  before  DRUG2 )."	TAXOL	cisplatin	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUG1  than with the alternate sequence (ie,  DRUG2  before  DRUGOTHER )."	cisplatin	TAXOL	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUG1  than with the alternate sequence (ie,  DRUGOTHER  before  DRUG2 )."	cisplatin	cisplatin	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"In a Phase I trial using escalating doses of  DRUGOTHER  (110-200 mg/m2) and  DRUGOTHER  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  DRUGOTHER  was given after  DRUGOTHER  than with the alternate sequence (ie,  DRUG1  before  DRUG2 )."	TAXOL	cisplatin	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	Pharmacokinetic data from these patients demonstrated a decrease in  DRUG1  clearance of approximately 33% when  DRUG2  was administered following  DRUGOTHER .	paclitaxel	TAXOL	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
other	Pharmacokinetic data from these patients demonstrated a decrease in  DRUG1  clearance of approximately 33% when  DRUGOTHER  was administered following  DRUG2 .	paclitaxel	cisplatin	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
mechanism	Pharmacokinetic data from these patients demonstrated a decrease in  DRUGOTHER  clearance of approximately 33% when  DRUG1  was administered following  DRUG2 .	TAXOL	cisplatin	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"Potential interactions between  DRUG1 , a substrate of CYP3A4, and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	TAXOL	protease inhibitors	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	
other	"Potential interactions between  DRUG1 , a substrate of CYP3A4, and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	TAXOL	ritonavir	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Potential interactions between  DRUG1 , a substrate of CYP3A4, and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	TAXOL	saquinavir	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Potential interactions between  DRUG1 , a substrate of CYP3A4, and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	TAXOL	indinavir	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Potential interactions between  DRUG1 , a substrate of CYP3A4, and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	TAXOL	nelfinavir	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	protease inhibitors	ritonavir		CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	protease inhibitors	saquinavir		[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	protease inhibitors	indinavir		CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	protease inhibitors	nelfinavir		[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	ritonavir	saquinavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	ritonavir	indinavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	ritonavir	nelfinavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	saquinavir	indinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	saquinavir	nelfinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Potential interactions between  DRUGOTHER , a substrate of CYP3A4, and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."	indinavir	nelfinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	Reports in the literature suggest that plasma levels of  DRUG1  (and its active metabolite  DRUG2 ) may be increased when  DRUGOTHER  and  DRUGOTHER  are used in combination.	doxorubicin	doxorubicinol	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
other	Reports in the literature suggest that plasma levels of  DRUG1  (and its active metabolite  DRUGOTHER ) may be increased when  DRUG2  and  DRUGOTHER  are used in combination.	doxorubicin	paclitaxel	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1
other	Reports in the literature suggest that plasma levels of  DRUG1  (and its active metabolite  DRUGOTHER ) may be increased when  DRUGOTHER  and  DRUG2  are used in combination.	doxorubicin	doxorubicin	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
other	Reports in the literature suggest that plasma levels of  DRUGOTHER  (and its active metabolite  DRUG1 ) may be increased when  DRUG2  and  DRUGOTHER  are used in combination.	doxorubicinol	paclitaxel	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1
other	Reports in the literature suggest that plasma levels of  DRUGOTHER  (and its active metabolite  DRUG1 ) may be increased when  DRUGOTHER  and  DRUG2  are used in combination.	doxorubicinol	doxorubicin	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
mechanism	Reports in the literature suggest that plasma levels of  DRUGOTHER  (and its active metabolite  DRUGOTHER ) may be increased when  DRUG1  and  DRUG2  are used in combination.	paclitaxel	doxorubicin	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
other	"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg,  DRUG1  for injection concentrate and  DRUG2  for injection concentrate) should not be treated with  DRUGOTHER ."	cyclosporin	teniposide	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@]12COC(=O)[C@]1([H])[C@]([H])(C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@]2([H])O[C@]1([H])O[C@]2([H])CO[C@]([H])(O[C@@]2([H])[C@]([H])(O)[C@@]1([H])O)C1=CC=CS1
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUG1  should be premedicated with  DRUG2  (such as  DRUGOTHER ), diphen-hydramine and  DRUGOTHER  (such as  DRUGOTHER  or  DRUGOTHER )."	TAXOL	corticosteroids	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUG1  should be premedicated with  DRUGOTHER  (such as  DRUG2 ), diphen-hydramine and  DRUGOTHER  (such as  DRUGOTHER  or  DRUGOTHER )."	TAXOL	dexamethasone	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUG1  should be premedicated with  DRUGOTHER  (such as  DRUGOTHER ), diphen-hydramine and  DRUG2  (such as  DRUGOTHER  or  DRUGOTHER )."	TAXOL	H2 antagonists	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUG1  should be premedicated with  DRUGOTHER  (such as  DRUGOTHER ), diphen-hydramine and  DRUGOTHER  (such as  DRUG2  or  DRUGOTHER )."	TAXOL	cimetidine	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUG1  should be premedicated with  DRUGOTHER  (such as  DRUGOTHER ), diphen-hydramine and  DRUGOTHER  (such as  DRUGOTHER  or  DRUG2 )."	TAXOL	ranitidine	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUG1  (such as  DRUG2 ), diphen-hydramine and  DRUGOTHER  (such as  DRUGOTHER  or  DRUGOTHER )."	corticosteroids	dexamethasone	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUG1  (such as  DRUGOTHER ), diphen-hydramine and  DRUG2  (such as  DRUGOTHER  or  DRUGOTHER )."	corticosteroids	H2 antagonists	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUG1  (such as  DRUGOTHER ), diphen-hydramine and  DRUGOTHER  (such as  DRUG2  or  DRUGOTHER )."	corticosteroids	cimetidine	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUG1  (such as  DRUGOTHER ), diphen-hydramine and  DRUGOTHER  (such as  DRUGOTHER  or  DRUG2 )."	corticosteroids	ranitidine	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUGOTHER  (such as  DRUG1 ), diphen-hydramine and  DRUG2  (such as  DRUGOTHER  or  DRUGOTHER )."	dexamethasone	H2 antagonists	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUGOTHER  (such as  DRUG1 ), diphen-hydramine and  DRUGOTHER  (such as  DRUG2  or  DRUGOTHER )."	dexamethasone	cimetidine	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUGOTHER  (such as  DRUG1 ), diphen-hydramine and  DRUGOTHER  (such as  DRUGOTHER  or  DRUG2 )."	dexamethasone	ranitidine	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUGOTHER  (such as  DRUGOTHER ), diphen-hydramine and  DRUG1  (such as  DRUG2  or  DRUGOTHER )."	H2 antagonists	cimetidine		CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUGOTHER  (such as  DRUGOTHER ), diphen-hydramine and  DRUG1  (such as  DRUGOTHER  or  DRUG2 )."	H2 antagonists	ranitidine		CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  DRUGOTHER  should be premedicated with  DRUGOTHER  (such as  DRUGOTHER ), diphen-hydramine and  DRUGOTHER  (such as  DRUG1  or  DRUG2 )."	cimetidine	ranitidine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"However, severe reactions, such as hypotension requiring treatment, dyspnea requiring  DRUG1 , angioedema, or generalized urticaria require immediate discontinuation of  DRUG2  and aggressive symptomatic therapy."	bronchodilators	TAXOL		[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
advise	 DRUG1  should not be used in patients who have previously received the recommended maximum cumulative doses of  DRUG2  or  DRUGOTHER .	Cerubidine	doxorubicin	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
other	 DRUG1  should not be used in patients who have previously received the recommended maximum cumulative doses of  DRUGOTHER  or  DRUG2 .	Cerubidine	Cerubidine	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
other	 DRUGOTHER  should not be used in patients who have previously received the recommended maximum cumulative doses of  DRUG1  or  DRUG2 .	doxorubicin	Cerubidine	COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
effect	 DRUG1  used concurrently with  DRUG2  may also result in increased cardiotoxicity.	Cyclophosphamide	Cerubidine	ClCCN(CCCl)P1(=O)NCCCO1	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
other	" DRUGOTHER  in large amounts may counteract the antiepileptic effect of  DRUG1 ,  DRUG2  and  DRUGOTHER , and increase the frequency of seizures in susceptible pediatric patients."	phenobarbital	phenytoin	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	" DRUGOTHER  in large amounts may counteract the antiepileptic effect of  DRUG1 ,  DRUGOTHER  and  DRUG2 , and increase the frequency of seizures in susceptible pediatric patients."	phenobarbital	primidone	CCC1(CC)C(=O)NC(=O)NC1=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  in large amounts may counteract the antiepileptic effect of  DRUGOTHER ,  DRUG1  and  DRUG2 , and increase the frequency of seizures in susceptible pediatric patients."	phenytoin	primidone	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Preliminary animal and human studies have shown that small quantities of systemically administered  DRUG1  enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual  DRUG2  concentrations following intrathecal administration."	leucovorin	methotrexate	NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
effect	 DRUG1  may enhance the toxicity of  DRUG2 .	Leucovorin	5-fluorouracil	NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1	FC1=CNC(=O)NC1=O
other	 DRUG1 : A report of severe  DRUG2  toxicity was reported in a patient receiving  DRUGOTHER .	Acetaminophen	acetaminophen	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	 DRUG1 : A report of severe  DRUGOTHER  toxicity was reported in a patient receiving  DRUG2 .	Acetaminophen	Isoniazid	OC(=O)CCCCCCCC(O)=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
effect	 DRUGOTHER : A report of severe  DRUG1  toxicity was reported in a patient receiving  DRUG2 .	acetaminophen	Isoniazid	OC(=O)CCCCCCCC(O)=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
mechanism	"Furthermore it has been proposed that  DRUG1  resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested  DRUG2  being converted to the toxic metabolites."	isoniazid	acetaminophen	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	OC(=O)CCCCCCCC(O)=O
other	" DRUG1 :  DRUG2  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Carbamazepine	Isoniazid	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	" DRUG1 :  DRUGOTHER  is known to slow the metabolism of  DRUG2  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUG1 :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUG2  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Carbamazepine	Carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUG1 :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUG2 , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Carbamazepine	isoniazid	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	" DRUG1 :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUG2  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUG1 :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUG2  should be made."	Carbamazepine	anticonvulsant	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
mechanism	" DRUGOTHER :  DRUG1  is known to slow the metabolism of  DRUG2  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Isoniazid	carbamazepine	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUG1  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUG2  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Isoniazid	Carbamazepine	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUG1  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUG2 , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Isoniazid	isoniazid	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	" DRUGOTHER :  DRUG1  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUG2  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Isoniazid	carbamazepine	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUG1  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUG2  should be made."	Isoniazid	anticonvulsant	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUG1  and increase its serum levels  DRUG2  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	carbamazepine	Carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUG1  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUG2 , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	carbamazepine	isoniazid	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUG1  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUG2  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUG1  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUG2  should be made."	carbamazepine	anticonvulsant	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUG1  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUG2  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	Carbamazepine	carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUG1  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUG2  should be made."	Carbamazepine	anticonvulsant	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUG1 , signs and symptoms of  DRUG2  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUGOTHER  should be made."	isoniazid	carbamazepine	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUG1 , signs and symptoms of  DRUGOTHER  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUG2  should be made."	isoniazid	anticonvulsant	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	" DRUGOTHER :  DRUGOTHER  is known to slow the metabolism of  DRUGOTHER  and increase its serum levels  DRUGOTHER  levels should be determined prior to concurrent administration with  DRUGOTHER , signs and symptoms of  DRUG1  toxicity should be monitored closely, and appropriate dosage adjustment of the  DRUG2  should be made."	carbamazepine	anticonvulsant	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	 DRUG1 : Potential interaction of  DRUG2  and  DRUGOTHER  may exist.	Ketoconazole	Ketoconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	 DRUG1 : Potential interaction of  DRUGOTHER  and  DRUG2  may exist.	Ketoconazole	Isoniazid	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	 DRUG1 :  DRUG2  may increase serum levels of  DRUGOTHER .	Phenytoin	Isoniazid	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	 DRUG1 :  DRUGOTHER  may increase serum levels of  DRUG2 .	Phenytoin	phenytoin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	 DRUGOTHER :  DRUG1  may increase serum levels of  DRUG2 .	Isoniazid	phenytoin	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"To avoid  DRUG1  intoxication, appropriate adjustment of the  DRUG2  should be made."	phenytoin	anticonvulsant	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
mechanism	"Therophylline: A recent study has shown that concomitan administration of  DRUG1  and  DRUG2  may cause elevated plasma levels of  DRUGOTHER , and in some instances a slight decrease in the elimination of  DRUGOTHER ."	isoniazid	theophylline	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Therophylline: A recent study has shown that concomitan administration of  DRUG1  and  DRUGOTHER  may cause elevated plasma levels of  DRUG2 , and in some instances a slight decrease in the elimination of  DRUGOTHER ."	isoniazid	theophylline	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Therophylline: A recent study has shown that concomitan administration of  DRUG1  and  DRUGOTHER  may cause elevated plasma levels of  DRUGOTHER , and in some instances a slight decrease in the elimination of  DRUG2 ."	isoniazid	isoniazid	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Therophylline: A recent study has shown that concomitan administration of  DRUGOTHER  and  DRUG1  may cause elevated plasma levels of  DRUG2 , and in some instances a slight decrease in the elimination of  DRUGOTHER ."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Therophylline: A recent study has shown that concomitan administration of  DRUGOTHER  and  DRUG1  may cause elevated plasma levels of  DRUGOTHER , and in some instances a slight decrease in the elimination of  DRUG2 ."	theophylline	isoniazid	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Therophylline: A recent study has shown that concomitan administration of  DRUGOTHER  and  DRUGOTHER  may cause elevated plasma levels of  DRUG1 , and in some instances a slight decrease in the elimination of  DRUG2 ."	theophylline	isoniazid	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Since the therapeutic range of  DRUG1  is narrow  DRUG2  serum levels should be monitored closely, and appropriate dosage adjustments of  DRUGOTHER  should be made."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Since the therapeutic range of  DRUG1  is narrow  DRUGOTHER  serum levels should be monitored closely, and appropriate dosage adjustments of  DRUG2  should be made."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Since the therapeutic range of  DRUGOTHER  is narrow  DRUG1  serum levels should be monitored closely, and appropriate dosage adjustments of  DRUG2  should be made."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	 DRUG1 : A recent case study has shown a possible increase in the plasma level of  DRUG2  when co administered with  DRUGOTHER .	Valproate	valproate		
other	 DRUG1 : A recent case study has shown a possible increase in the plasma level of  DRUGOTHER  when co administered with  DRUG2 .	Valproate	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
mechanism	 DRUGOTHER : A recent case study has shown a possible increase in the plasma level of  DRUG1  when co administered with  DRUG2 .	valproate	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Plasma  DRUG1  concentration should be monitored when  DRUG2  and  DRUGOTHER  are co administered, and appropriate dosage adjustments of  DRUGOTHER  should be made."	valproate	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Plasma  DRUG1  concentration should be monitored when  DRUGOTHER  and  DRUG2  are co administered, and appropriate dosage adjustments of  DRUGOTHER  should be made."	valproate	valproate		
other	"Plasma  DRUG1  concentration should be monitored when  DRUGOTHER  and  DRUGOTHER  are co administered, and appropriate dosage adjustments of  DRUG2  should be made."	valproate	valproate		
advise	"Plasma  DRUGOTHER  concentration should be monitored when  DRUG1  and  DRUG2  are co administered, and appropriate dosage adjustments of  DRUGOTHER  should be made."	isoniazid	valproate	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	
other	"Plasma  DRUGOTHER  concentration should be monitored when  DRUG1  and  DRUGOTHER  are co administered, and appropriate dosage adjustments of  DRUG2  should be made."	isoniazid	valproate	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	
other	"Plasma  DRUGOTHER  concentration should be monitored when  DRUGOTHER  and  DRUG1  are co administered, and appropriate dosage adjustments of  DRUG2  should be made."	valproate	valproate		
other	The in vitro interaction between  DRUG1  and the  DRUG2   DRUGOTHER  is complex.	nevirapine	antithrombotic agent	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	The in vitro interaction between  DRUGOTHER  and the  DRUG1   DRUG2  is complex.	antithrombotic agent	warfarin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
mechanism	 DRUG1  exposure was significantly decreased by  DRUG2 ;	Clarithromycin	nevirapine	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
other	"Alternatives to  DRUG1 ,such as  DRUG2 , should be considered."	clarithromycin	azithromycin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	 DRUG1  and  DRUG2 	Ethinyl estradiol	Norethindrone	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
other	 DRUG1   DRUG2 	Ethinyl estradiol	Norethindrone	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
advise	 DRUG1  and  DRUG2  should not beadministered concomitantly becausedecreases in  DRUGOTHER  plasmaconcentrations may reduce the efficacy of the drug.	Nevirapine	ketoconazole	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	 DRUG1  and  DRUGOTHER  should not beadministered concomitantly becausedecreases in  DRUG2  plasmaconcentrations may reduce the efficacy of the drug.	Nevirapine	ketoconazole	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	 DRUGOTHER  and  DRUG1  should not beadministered concomitantly becausedecreases in  DRUG2  plasmaconcentrations may reduce the efficacy of the drug.	ketoconazole	ketoconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	 DRUG1 / DRUG2 	Lopinavir	Ritonavir	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	A dose increase of  DRUG1 / DRUG2  to 533/133 mg twice daily with food isrecommended in combination with  DRUGOTHER .	lopinavir	ritonavir	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
advise	A dose increase of  DRUG1 / DRUGOTHER  to 533/133 mg twice daily with food isrecommended in combination with  DRUG2 .	lopinavir	nevirapine	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
advise	A dose increase of  DRUGOTHER / DRUG1  to 533/133 mg twice daily with food isrecommended in combination with  DRUG2 .	ritonavir	nevirapine	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
other	 DRUG1  levels may be decreased; increased dosages may be required to prevent symptoms of  DRUG2  withdrawal.  DRUGOTHER  maintained patients beginning  DRUGOTHER  therapy should be monitored forevidence of withdrawal and  DRUGOTHER  dose should be adjusted accordingly.	Methadone	opiate	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	 DRUG1  levels may be decreased; increased dosages may be required to prevent symptoms of  DRUGOTHER  withdrawal.  DRUG2  maintained patients beginning  DRUGOTHER  therapy should be monitored forevidence of withdrawal and  DRUGOTHER  dose should be adjusted accordingly.	Methadone	Methadone	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	 DRUG1  levels may be decreased; increased dosages may be required to prevent symptoms of  DRUGOTHER  withdrawal.  DRUGOTHER  maintained patients beginning  DRUG2  therapy should be monitored forevidence of withdrawal and  DRUGOTHER  dose should be adjusted accordingly.	Methadone	nevirapine	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
other	 DRUG1  levels may be decreased; increased dosages may be required to prevent symptoms of  DRUGOTHER  withdrawal.  DRUGOTHER  maintained patients beginning  DRUGOTHER  therapy should be monitored forevidence of withdrawal and  DRUG2  dose should be adjusted accordingly.	Methadone	methadone	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	 DRUGOTHER  levels may be decreased; increased dosages may be required to prevent symptoms of  DRUG1  withdrawal.  DRUG2  maintained patients beginning  DRUGOTHER  therapy should be monitored forevidence of withdrawal and  DRUGOTHER  dose should be adjusted accordingly.	opiate	Methadone	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"The appropriate dose for  DRUG1  incombination with  DRUG2 , with respectto safety and efficacy, has not been established."	nelfinavir	nevirapine	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
other	 DRUG1  and  DRUGOTHER  should not beadministered concomitantly becausedecreases in  DRUG2  plasmaconcentrations may reduce the efficacy ofthe drug.	Nevirapine	nevirapine	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
other	 DRUGOTHER  and  DRUG1  should not beadministered concomitantly becausedecreases in  DRUG2  plasmaconcentrations may reduce the efficacy ofthe drug.	rifampin	nevirapine	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
other	Physicians needing to treatpatients co-infected with tuberculosis andusing a  DRUG1  containing regimen mayuse  DRUG2  instead.	nevirapine	rifabutin	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	"aBased on reports of narcotic withdrawal syndrome in patients treated with  DRUG1  and  DRUGOTHER  concurrently, and evidence of decreased plasma concentrations of  DRUG2 ."	nevirapine	methadone	CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"aBased on reports of narcotic withdrawal syndrome in patients treated with  DRUGOTHER  and  DRUG1  concurrently, and evidence of decreased plasma concentrations of  DRUG2 ."	methadone	methadone	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	" DRUG1 ,  DRUG2 ,  DRUGOTHER "	Amiodarone	disopyramide	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	OC(=O)CCCCCCCC(O)=O
other	" DRUG1 ,  DRUGOTHER ,  DRUG2 "	Amiodarone	lidocaine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	
other	" DRUGOTHER ,  DRUG1 ,  DRUG2 "	disopyramide	lidocaine	OC(=O)CCCCCCCC(O)=O	
other	" DRUG1 ,  DRUG2 ,  DRUGOTHER "	Carbamazepine	clonazepam	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUG1 ,  DRUGOTHER ,  DRUG2 "	Carbamazepine	ethosuximide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(C)CC(=O)NC1=O
other	" DRUGOTHER ,  DRUG1 ,  DRUG2 "	clonazepam	ethosuximide	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCC1(C)CC(=O)NC1=O
other	" DRUG1 ,  DRUG2 ,  DRUGOTHER "	Diltiazem	nifedipine		CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUG1 ,  DRUGOTHER ,  DRUG2 "	Diltiazem	verapamil		COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	" DRUGOTHER ,  DRUG1 ,  DRUG2 "	nifedipine	verapamil	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	" DRUG1 ,  DRUG2 ,  DRUGOTHER "	Cyclosporin	tacrolimus	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	" DRUG1 ,  DRUGOTHER ,  DRUG2 "	Cyclosporin	sirolimus	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
other	" DRUGOTHER ,  DRUG1 ,  DRUG2 "	tacrolimus	sirolimus	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
other	Considerable caution should be exercised if  DRUGOTHER  is administered concurrently with  DRUG1  ( DRUG2 ) since paranoid symptoms have been reported during therapy with this combination.	Phenurone	phenacemide	NC(=O)NC(=O)CC1=CC=CC=C1	NC(=O)NC(=O)CC1=CC=CC=C1
int	"A two-way interaction between the  DRUG1 ,  DRUG2 , and the  DRUGOTHER s has been suggested."	hydantoin antiepileptic	phenytoin	CC(N)COC1=C(C)C=CC=C1C	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
int	"A two-way interaction between the  DRUG1 ,  DRUGOTHER , and the  DRUG2 s has been suggested."	hydantoin antiepileptic	coumarin anticoagulant	CC(N)COC1=C(C)C=CC=C1C	O=C1OC2=CC=CC=C2C=C1
other	"A two-way interaction between the  DRUGOTHER ,  DRUG1 , and the  DRUG2 s has been suggested."	phenytoin	coumarin anticoagulant	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	O=C1OC2=CC=CC=C2C=C1
mechanism	"Presumably,  DRUG1  acts as a stimulator of  DRUG2  metabolism and has been reported to cause decreased serum levels of the  DRUGOTHER  and increased prothrombin-proconvertin concentrations."	phenytoin	coumarin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	O=C1OC2=CC=CC=C2C=C1
mechanism	"Presumably,  DRUG1  acts as a stimulator of  DRUGOTHER  metabolism and has been reported to cause decreased serum levels of the  DRUG2  and increased prothrombin-proconvertin concentrations."	phenytoin	coumarin anticoagulants	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	O=C1OC2=CC=CC=C2C=C1
other	"Presumably,  DRUGOTHER  acts as a stimulator of  DRUG1  metabolism and has been reported to cause decreased serum levels of the  DRUG2  and increased prothrombin-proconvertin concentrations."	coumarin	coumarin anticoagulants	O=C1OC2=CC=CC=C2C=C1	O=C1OC2=CC=CC=C2C=C1
other	"Although there is no documentation of such, a similar interaction between  DRUG1  and the  DRUG2  may occur."	ethotoin	coumarin anticoagulants	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	O=C1OC2=CC=CC=C2C=C1
other	"By this procedure, it was observed that  DRUG1  is rapidly and essentially completely absorbed (80-95%) from the lumen at  DRUG2  concentrations up to 5 mM, declining to about 50% absorption at 50 mM."	arsenate	As(V)	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
mechanism	" DRUG1  administration to rachitic chicks was effective in significantly elevating duodenal  DRUG2  absorption, acting primarily to enhance serosal transport."	Vitamin D3	arsenate		ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"In vitro studies demonstrated that the plasma protein binding of  DRUG1  was not affected by  DRUG2  or  DRUGOTHER , indicating no potential for protein binding-based drug interactions."	des-ciclesonide	warfarin	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In vitro studies demonstrated that the plasma protein binding of  DRUG1  was not affected by  DRUGOTHER  or  DRUG2 , indicating no potential for protein binding-based drug interactions."	des-ciclesonide	salicylic acid	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
other	"In vitro studies demonstrated that the plasma protein binding of  DRUGOTHER  was not affected by  DRUG1  or  DRUG2 , indicating no potential for protein binding-based drug interactions."	warfarin	salicylic acid	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
mechanism	"In another drug interaction study, co-administration of orally inhaled  DRUG1  and oral  DRUG2 , a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of  DRUGOTHER  by approximately 3.6-fold at steady state, while levels of  DRUGOTHER  remained unchanged."	ciclesonide	ketoconazole	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	There is a significant increase in exposure to  DRUG1  when  DRUG2  is coadministered with  DRUGOTHER  (CYP3A4 inhibitor).	imatinib	Gleevec	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
other	There is a significant increase in exposure to  DRUG1  when  DRUGOTHER  is coadministered with  DRUG2  (CYP3A4 inhibitor).	imatinib	ketoconazole	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	Drugs that may decrease  DRUG1  plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease  DRUG2  plasma concentrations.	imatinib	imatinib	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
other	"Co-medications that induce CYP3A4 (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or St."	dexamethasone	phenytoin	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Co-medications that induce CYP3A4 (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or St."	dexamethasone	carbamazepine	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Co-medications that induce CYP3A4 (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or St."	dexamethasone	rifampin	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Co-medications that induce CYP3A4 (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or St."	dexamethasone	phenobarbital	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Co-medications that induce CYP3A4 (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or St."	phenytoin	carbamazepine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Co-medications that induce CYP3A4 (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or St."	phenytoin	rifampin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Co-medications that induce CYP3A4 (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or St."	phenytoin	phenobarbital	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Co-medications that induce CYP3A4 (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  or St."	carbamazepine	rifampin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Co-medications that induce CYP3A4 (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  or St."	carbamazepine	phenobarbital	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Co-medications that induce CYP3A4 (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  or St."	rifampin	phenobarbital	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CCC1(CC)C(=O)NC(=O)NC1=O
mechanism	"Pretreatment of healthy volunteers with multiple doses of  DRUG1  followed by a single dose of  DRUG2 , increased  DRUGOTHER  oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8)."	rifampin	Gleevec	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
mechanism	"Drugs that may have their plasma concentration altered by  DRUGOTHER   DRUG1  increases the mean cmax and AUC of  DRUG2  (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by  DRUGOTHER ."	Gleevec	simvastatin	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
other	"Particular caution is recommended when administering  DRUGOTHER  with CYP3A4 substrates that have a narrow therapeutic window (e.g.,  DRUG1  or  DRUG2 )."	cyclosporine	pimozide	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
mechanism	" DRUG1  will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo- DRUG2 ,  DRUGOTHER , certain  DRUGOTHER , etc.)."	Gleevec	benzodiazepines	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1	N1N=CC=CC2=CC=CC=C12
mechanism	" DRUG1  will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo- DRUGOTHER ,  DRUG2 , certain  DRUGOTHER , etc.)."	Gleevec	dihydropyridine calcium channel blockers	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1	[Ca]
mechanism	" DRUG1  will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo- DRUGOTHER ,  DRUGOTHER , certain  DRUG2 , etc.)."	Gleevec	HMG-CoA reductase inhibitors	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1	
other	"Because  DRUG1  is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard  DRUG2 ."	warfarin	heparin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
mechanism	Systemic exposure to  DRUG1  is expected to be increased when coadministered with  DRUG2 .	acetaminophen	Gleevec	OC(=O)CCCCCCCC(O)=O	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
other	 DRUG1  as potent  DRUG2  of glucocorticoid-induced mouse mammary tumor virus gene expression.	Green tea polyphenols	enhancers	OC1=CC=CC=C1	[Ba++].[O-]S([O-])(=O)=O
other	"As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by  DRUG1  ( DRUG2 ) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects."	methamphetamine	METH	CC(N)CC1=CC=CC=C1	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O
effect	"Using in situ hybridization, we observed that  DRUG1  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  DRUG2  but not by an  DRUGOTHER   DRUGOTHER ."	METH	SCH-23390	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O	
other	"Using in situ hybridization, we observed that  DRUG1  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  DRUGOTHER  but not by an  DRUG2   DRUGOTHER ."	METH	atypical neuroleptic	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Using in situ hybridization, we observed that  DRUG1  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  DRUGOTHER  but not by an  DRUGOTHER   DRUG2 ."	METH	clozapine	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Using in situ hybridization, we observed that  DRUGOTHER  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  DRUG1  but not by an  DRUG2   DRUGOTHER ."	SCH-23390	atypical neuroleptic		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Using in situ hybridization, we observed that  DRUGOTHER  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  DRUG1  but not by an  DRUGOTHER   DRUG2 ."	SCH-23390	clozapine		CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Using in situ hybridization, we observed that  DRUGOTHER  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  DRUGOTHER  but not by an  DRUG1   DRUG2 ."	atypical neuroleptic	clozapine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
effect	"Patients receiving catecholamine-depleting drugs, such as  DRUG1  or  DRUGOTHER , should be closely monitored, because the added beta-adrenergic blocking action of  DRUG2  may produce excessive reduction of sympathetic activity."	reserpine	ZEBETA	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
effect	"Patients receiving catecholamine-depleting drugs, such as  DRUGOTHER  or  DRUG1 , should be closely monitored, because the added beta-adrenergic blocking action of  DRUG2  may produce excessive reduction of sympathetic activity."	guanethidine	ZEBETA	NC(N)=NCCN1CCCCCCC1	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
other	"In patients receiving concurrent therapy with  DRUG1 , if therapy is to be discontinued, it is suggested that  DRUG2  be discontinued for several days before the withdrawal of  DRUGOTHER ."	clonidine	ZEBETA	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
other	"In patients receiving concurrent therapy with  DRUG1 , if therapy is to be discontinued, it is suggested that  DRUGOTHER  be discontinued for several days before the withdrawal of  DRUG2 ."	clonidine	clonidine	ClC1=CC=CC(Cl)=C1NC1=NCCN1	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	"Concurrent use of  DRUG1  increases the metabolic clearance of  DRUGOTHER , resulting in a shortened elimination half-life of  DRUG2 ."	rifampin	ZEBETA	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
other	"Concurrent use of  DRUGOTHER  increases the metabolic clearance of  DRUG1 , resulting in a shortened elimination half-life of  DRUG2 ."	ZEBETA	ZEBETA	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
other	"Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	thiazide diuretics	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	thiazide diuretics	cimetidine		CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	digoxin	cimetidine	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	There was no effect of  DRUG1  on prothrombin time in patients on stable doses of  DRUG2 .	ZEBETA	warfarin	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
effect	The vasodilating effects of  DRUG1  may be additive with those of other  DRUG2 .	nitroglycerin	vasodilators	OCC(O)CO	
other	Pharmacokinetic Interaction between  DRUG1  and  DRUG2  or  DRUGOTHER  in healthy males.	amprenavir	rifabutin	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	The objective of this study was to determine if there is a pharmacokinetic interaction when  DRUG1  is given with  DRUG2  or  DRUGOTHER  and to determine the effects of these drugs on the erythromycin breath test (ERMBT).	amprenavir	rifabutin	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	The objective of this study was to determine if there is a pharmacokinetic interaction when  DRUG1  is given with  DRUGOTHER  or  DRUG2  and to determine the effects of these drugs on the erythromycin breath test (ERMBT).	amprenavir	rifampin	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	The objective of this study was to determine if there is a pharmacokinetic interaction when  DRUGOTHER  is given with  DRUG1  or  DRUG2  and to determine the effects of these drugs on the erythromycin breath test (ERMBT).	rifabutin	rifampin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
mechanism	 DRUG1  significantly increased the area under the curve at steady state (AUC(ss)) of  DRUG2  by 2.93-fold and the AUC(ss) of  DRUGOTHER  by 13.3-fold.	Amprenavir	rifabutin	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
mechanism	 DRUG1  significantly increased the area under the curve at steady state (AUC(ss)) of  DRUGOTHER  by 2.93-fold and the AUC(ss) of  DRUG2  by 13.3-fold.	Amprenavir	25-O-desacetylrifabutin	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	 DRUGOTHER  significantly increased the area under the curve at steady state (AUC(ss)) of  DRUG1  by 2.93-fold and the AUC(ss) of  DRUG2  by 13.3-fold.	rifabutin	25-O-desacetylrifabutin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
mechanism	" DRUG1  significantly decreased the AUC(ss) of  DRUG2  by 82%, but  DRUGOTHER  had no effect on  DRUGOTHER  pharmacokinetics."	Rifampin	amprenavir	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
mechanism	" DRUG1  markedly increases the metabolic clearance of  DRUG2 , and coadministration is contraindicated."	Rifampin	amprenavir	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
mechanism	" DRUG1  significantly decreases clearance of  DRUG2  and  DRUGOTHER , and the combination is poorly tolerated."	Amprenavir	rifabutin	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
mechanism	" DRUG1  significantly decreases clearance of  DRUGOTHER  and  DRUG2 , and the combination is poorly tolerated."	Amprenavir	25-O-desacetylrifabutin	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
other	 DRUGOTHER  should not be administered concomitantly with other  DRUG1  (such as  DRUG2 ) because of possible additive effects and increased toxicity.	sympathomimetic drugs	isoproterenol		CC(C)O
other	"Administration of  DRUGOTHER  to patients receiving  DRUG1  or  DRUG2  such as  DRUGOTHER  which sensitize the myocardium, may induce cardiac arrhythmia.."	cyclopropane	halogenated hydrocarbon general anesthetics	C1CC1	CCOC(=O)C1=CC=C(N)C=C1
other	"Administration of  DRUGOTHER  to patients receiving  DRUG1  or  DRUGOTHER  such as  DRUG2  which sensitize the myocardium, may induce cardiac arrhythmia.."	cyclopropane	halothane	C1CC1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Administration of  DRUGOTHER  to patients receiving  DRUGOTHER  or  DRUG1  such as  DRUG2  which sensitize the myocardium, may induce cardiac arrhythmia.."	halogenated hydrocarbon general anesthetics	halothane	CCOC(=O)C1=CC=C(N)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1  also should be used cautiously with other drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ) that sensitize the myocardium to the actions of  DRUG2 ."	Epinephrine	sympathomimetic drugs		
other	" DRUGOTHER  also should be used cautiously with other drugs (e.g.,  DRUG1 ,  DRUG2 ) that sensitize the myocardium to the actions of  DRUGOTHER ."	digitalis	glycosides	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUGOTHER  also should be used cautiously with other drugs (e.g.,  DRUG1 ,  DRUGOTHER ) that sensitize the myocardium to the actions of  DRUG2 ."	digitalis	sympathomimetic drugs	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	" DRUGOTHER  also should be used cautiously with other drugs (e.g.,  DRUGOTHER ,  DRUG1 ) that sensitize the myocardium to the actions of  DRUG2 ."	glycosides	sympathomimetic drugs		
other	"Drug-Drug Interactions Given the primary CNS effects of  DRUG1 , caution should be used when  DRUG2  is taken in combination with other  DRUGOTHER  and  DRUGOTHER ."	aripiprazole	ABILIFY	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
other	"Drug-Drug Interactions Given the primary CNS effects of  DRUG1 , caution should be used when  DRUGOTHER  is taken in combination with other  DRUG2  and  DRUGOTHER ."	aripiprazole	centrally acting drugs	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Drug-Drug Interactions Given the primary CNS effects of  DRUG1 , caution should be used when  DRUGOTHER  is taken in combination with other  DRUGOTHER  and  DRUG2 ."	aripiprazole	alcohol	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Drug-Drug Interactions Given the primary CNS effects of  DRUGOTHER , caution should be used when  DRUGOTHER  is taken in combination with other  DRUG1  and  DRUG2 ."	centrally acting drugs	alcohol	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	"Inhibitors of CYP3A4 (eg,  DRUG1 ) or CYP2D6 (eg,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ) can inhibit  DRUG2  elimination and cause increased blood levels."	ketoconazole	aripiprazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
mechanism	"Inhibitors of CYP3A4 (eg,  DRUGOTHER ) or CYP2D6 (eg,  DRUG1 ,  DRUGOTHER , or  DRUGOTHER ) can inhibit  DRUG2  elimination and cause increased blood levels."	quinidine	aripiprazole	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
mechanism	"Inhibitors of CYP3A4 (eg,  DRUGOTHER ) or CYP2D6 (eg,  DRUGOTHER ,  DRUG1 , or  DRUGOTHER ) can inhibit  DRUG2  elimination and cause increased blood levels."	fluoxetine	aripiprazole	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
mechanism	"Inhibitors of CYP3A4 (eg,  DRUGOTHER ) or CYP2D6 (eg,  DRUGOTHER ,  DRUGOTHER , or  DRUG1 ) can inhibit  DRUG2  elimination and cause increased blood levels."	paroxetine	aripiprazole	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
mechanism	" DRUGOTHER : Coadministration of  DRUG1  (200 mg/day for 14 days) with a 15-mg single dose of  DRUG2  increased the AUC of  DRUGOTHER  and its active metabolite by 63% and 77%, respectively."	ketoconazole	aripiprazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"When concomitant administration of  DRUG1  with  DRUGOTHER  occurs,  DRUG2  dose should be reduced to one-half of its normal dose."	ketoconazole	aripiprazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"When concomitant administration of  DRUGOTHER  with  DRUG1  occurs,  DRUG2  dose should be reduced to one-half of its normal dose."	aripiprazole	aripiprazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	" DRUG1 : Coadministration of a 10-mg single dose of  DRUG2  with  DRUGOTHER  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUGOTHER  by 112% but decreased the AUC of its active metabolite,  DRUGOTHER , by 35%."	Quinidine	aripiprazole	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	" DRUG1 : Coadministration of a 10-mg single dose of  DRUGOTHER  with  DRUG2  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUGOTHER  by 112% but decreased the AUC of its active metabolite,  DRUGOTHER , by 35%."	Quinidine	quinidine	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUG1 : Coadministration of a 10-mg single dose of  DRUGOTHER  with  DRUGOTHER  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUG2  by 112% but decreased the AUC of its active metabolite,  DRUGOTHER , by 35%."	Quinidine	aripiprazole	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	" DRUG1 : Coadministration of a 10-mg single dose of  DRUGOTHER  with  DRUGOTHER  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUGOTHER  by 112% but decreased the AUC of its active metabolite,  DRUG2 , by 35%."	Quinidine	dehydroaripiprazole	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
other	" DRUGOTHER : Coadministration of a 10-mg single dose of  DRUG1  with  DRUGOTHER  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUG2  by 112% but decreased the AUC of its active metabolite,  DRUGOTHER , by 35%."	aripiprazole	aripiprazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	" DRUGOTHER : Coadministration of a 10-mg single dose of  DRUG1  with  DRUGOTHER  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUGOTHER  by 112% but decreased the AUC of its active metabolite,  DRUG2 , by 35%."	aripiprazole	dehydroaripiprazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
other	" DRUGOTHER : Coadministration of a 10-mg single dose of  DRUGOTHER  with  DRUG1  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUG2  by 112% but decreased the AUC of its active metabolite,  DRUGOTHER , by 35%."	quinidine	aripiprazole	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	" DRUGOTHER : Coadministration of a 10-mg single dose of  DRUGOTHER  with  DRUG1  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUGOTHER  by 112% but decreased the AUC of its active metabolite,  DRUG2 , by 35%."	quinidine	dehydroaripiprazole	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
other	" DRUGOTHER : Coadministration of a 10-mg single dose of  DRUGOTHER  with  DRUGOTHER  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of  DRUG1  by 112% but decreased the AUC of its active metabolite,  DRUG2 , by 35%."	aripiprazole	dehydroaripiprazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
other	 DRUG1  dose should be reduced to one-half of its normal dose when concomitant administration of  DRUG2  with  DRUGOTHER  occurs.	Aripiprazole	quinidine	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	 DRUG1  dose should be reduced to one-half of its normal dose when concomitant administration of  DRUGOTHER  with  DRUG2  occurs.	Aripiprazole	aripiprazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"Other significant inhibitors of CYP2D6, such as  DRUG1  or  DRUG2 , would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions."	fluoxetine	paroxetine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"When  DRUG1  is added to  DRUGOTHER  therapy,  DRUG2  dose should be doubled."	carbamazepine	aripiprazole	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"When  DRUGOTHER  is added to  DRUG1  therapy,  DRUG2  dose should be doubled."	aripiprazole	aripiprazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"No clinically significant effect of  DRUG1 ,  DRUG2 , or  DRUGOTHER  was seen on the pharmacokinetics of  DRUGOTHER  (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."	famotidine	valproate	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	
other	"No clinically significant effect of  DRUG1 ,  DRUGOTHER , or  DRUG2  was seen on the pharmacokinetics of  DRUGOTHER  (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."	famotidine	lithium	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	[Li+]
other	"No clinically significant effect of  DRUG1 ,  DRUGOTHER , or  DRUGOTHER  was seen on the pharmacokinetics of  DRUG2  (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."	famotidine	aripiprazole	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"No clinically significant effect of  DRUGOTHER ,  DRUG1 , or  DRUG2  was seen on the pharmacokinetics of  DRUGOTHER  (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."	valproate	lithium		[Li+]
other	"No clinically significant effect of  DRUGOTHER ,  DRUG1 , or  DRUGOTHER  was seen on the pharmacokinetics of  DRUG2  (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."	valproate	aripiprazole		CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"No clinically significant effect of  DRUGOTHER ,  DRUGOTHER , or  DRUG1  was seen on the pharmacokinetics of  DRUG2  (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."	lithium	aripiprazole	[Li+]	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	Potential for  DRUG1  to Affect Other Drugs  DRUG2  is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.	ABILIFY	Aripiprazole	ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUG1  had no significant effect on metabolism by CYP2D6 ( DRUG2 ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUGOTHER ,  DRUGOTHER ), and CYP3A4 ( DRUGOTHER ) substrates."	aripiprazole	dextromethorphan	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUG1  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUG2 ), CYP2C19 ( DRUGOTHER ,  DRUGOTHER ), and CYP3A4 ( DRUGOTHER ) substrates."	aripiprazole	warfarin	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUG1  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUG2 ,  DRUGOTHER ), and CYP3A4 ( DRUGOTHER ) substrates."	aripiprazole	omeprazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUG1  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUGOTHER ,  DRUG2 ), and CYP3A4 ( DRUGOTHER ) substrates."	aripiprazole	warfarin	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUG1  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUGOTHER ,  DRUGOTHER ), and CYP3A4 ( DRUG2 ) substrates."	aripiprazole	dextromethorphan	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUG1 ), CYP2C9 ( DRUG2 ), CYP2C19 ( DRUGOTHER ,  DRUGOTHER ), and CYP3A4 ( DRUGOTHER ) substrates."	dextromethorphan	warfarin	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUG1 ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUG2 ,  DRUGOTHER ), and CYP3A4 ( DRUGOTHER ) substrates."	dextromethorphan	omeprazole	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUG1 ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUGOTHER ,  DRUG2 ), and CYP3A4 ( DRUGOTHER ) substrates."	dextromethorphan	warfarin	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUG1 ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUGOTHER ,  DRUGOTHER ), and CYP3A4 ( DRUG2 ) substrates."	dextromethorphan	dextromethorphan	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUG1 ), CYP2C19 ( DRUG2 ,  DRUGOTHER ), and CYP3A4 ( DRUGOTHER ) substrates."	warfarin	omeprazole	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUG1 ), CYP2C19 ( DRUGOTHER ,  DRUG2 ), and CYP3A4 ( DRUGOTHER ) substrates."	warfarin	warfarin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUG1 ), CYP2C19 ( DRUGOTHER ,  DRUGOTHER ), and CYP3A4 ( DRUG2 ) substrates."	warfarin	dextromethorphan	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUG1 ,  DRUG2 ), and CYP3A4 ( DRUGOTHER ) substrates."	omeprazole	warfarin	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUG1 ,  DRUGOTHER ), and CYP3A4 ( DRUG2 ) substrates."	omeprazole	dextromethorphan	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C
other	"In in vivo studies, 10- to 30-mg/day doses of  DRUGOTHER  had no significant effect on metabolism by CYP2D6 ( DRUGOTHER ), CYP2C9 ( DRUGOTHER ), CYP2C19 ( DRUGOTHER ,  DRUG1 ), and CYP3A4 ( DRUG2 ) substrates."	warfarin	dextromethorphan	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C
other	"Additionally,  DRUG1  and  DRUG2  did not show potential for altering CYP1A2-mediated metabolism in vitro."	aripiprazole	dehydroaripiprazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
other	 DRUG1 : There was no significant difference between  DRUG2  coadministered with  DRUGOTHER  and placebo coadministered with  DRUGOTHER  on performance of gross motor skills or stimulus response in healthy subjects.	Alcohol	aripiprazole	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	 DRUG1 : There was no significant difference between  DRUGOTHER  coadministered with  DRUG2  and placebo coadministered with  DRUGOTHER  on performance of gross motor skills or stimulus response in healthy subjects.	Alcohol	ethanol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	 DRUG1 : There was no significant difference between  DRUGOTHER  coadministered with  DRUGOTHER  and placebo coadministered with  DRUG2  on performance of gross motor skills or stimulus response in healthy subjects.	Alcohol	ethanol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	 DRUGOTHER : There was no significant difference between  DRUG1  coadministered with  DRUG2  and placebo coadministered with  DRUGOTHER  on performance of gross motor skills or stimulus response in healthy subjects.	aripiprazole	ethanol	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	 DRUGOTHER : There was no significant difference between  DRUG1  coadministered with  DRUGOTHER  and placebo coadministered with  DRUG2  on performance of gross motor skills or stimulus response in healthy subjects.	aripiprazole	ethanol	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	 DRUGOTHER : There was no significant difference between  DRUGOTHER  coadministered with  DRUG1  and placebo coadministered with  DRUG2  on performance of gross motor skills or stimulus response in healthy subjects.	ethanol	ethanol	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	[The effect of  DRUG1  on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the  DRUG2 --the drug  DRUGOTHER --on hepatic microsomal monooxygenase activities were studied.	sandimmune	immunodepressant	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	[The effect of  DRUG1  on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the  DRUGOTHER --the drug  DRUG2 --on hepatic microsomal monooxygenase activities were studied.	sandimmune	sandimmune	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	[The effect of  DRUGOTHER  on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the  DRUG1 --the drug  DRUG2 --on hepatic microsomal monooxygenase activities were studied.	immunodepressant	sandimmune	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUG1  is metabolized to  DRUG2  by cytochrome CYP 3A4.	Buprenorphine	norbuprenorphine		CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
other	"Because CYP 3A4 inhibitors may increase plasma concentrations of  DRUG1 , patients already on CYP 3A4 inhibitors such as  DRUG2  (e.g."	buprenorphine	azole antifungals		OC(=O)CCCCCCCCC=C
other	"In many of these cases,  DRUG1  was misused by self-injection of crushed  DRUG2  tablets."	buprenorphine	SUBUTEX		CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
other	Patients should be warned of the potential danger of the intravenous self-administration of  DRUGOTHER  while under treatment with  DRUG1  or  DRUG2 .	SUBOXONE	SUBUTEX	OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
other	An immune response to  DRUG1  may interfere with subsequent diagnostic serum tests that utilize  DRUG2 	Campath	antibodies		
other	" DRUGOTHER  in combination with other  DRUG1 , general  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	narcotic analgesics	anesthetics	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	CCOC(=O)C1=CC=C(N)C=C1
other	" DRUGOTHER  in combination with other  DRUG1 , general  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	narcotic analgesics	phenothiazines	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUGOTHER  in combination with other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	narcotic analgesics	tranquilizers	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  in combination with other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	narcotic analgesics	sedative-hypnotics	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	
other	" DRUGOTHER  in combination with other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or other  DRUG2  (including  DRUGOTHER ) has additive depressant effects."	narcotic analgesics	CNS depressants	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  in combination with other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUG2 ) has additive depressant effects."	narcotic analgesics	alcohol	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	anesthetics	phenothiazines	CCOC(=O)C1=CC=C(N)C=C1	N1C2=CC=CC=C2SC2=CC=CC=C12
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	anesthetics	tranquilizers	CCOC(=O)C1=CC=C(N)C=C1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	anesthetics	sedative-hypnotics	CCOC(=O)C1=CC=C(N)C=C1	
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or other  DRUG2  (including  DRUGOTHER ) has additive depressant effects."	anesthetics	CNS depressants	CCOC(=O)C1=CC=C(N)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUG2 ) has additive depressant effects."	anesthetics	alcohol	CCOC(=O)C1=CC=C(N)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	phenothiazines	tranquilizers	N1C2=CC=CC=C2SC2=CC=CC=C12	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	phenothiazines	sedative-hypnotics	N1C2=CC=CC=C2SC2=CC=CC=C12	
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or other  DRUG2  (including  DRUGOTHER ) has additive depressant effects."	phenothiazines	CNS depressants	N1C2=CC=CC=C2SC2=CC=CC=C12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUG2 ) has additive depressant effects."	phenothiazines	alcohol	N1C2=CC=CC=C2SC2=CC=CC=C12	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or other  DRUGOTHER  (including  DRUGOTHER ) has additive depressant effects."	tranquilizers	sedative-hypnotics	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or other  DRUG2  (including  DRUGOTHER ) has additive depressant effects."	tranquilizers	CNS depressants	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or other  DRUGOTHER  (including  DRUG2 ) has additive depressant effects."	tranquilizers	alcohol	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or other  DRUG2  (including  DRUGOTHER ) has additive depressant effects."	sedative-hypnotics	CNS depressants		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or other  DRUGOTHER  (including  DRUG2 ) has additive depressant effects."	sedative-hypnotics	alcohol		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  in combination with other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or other  DRUG1  (including  DRUG2 ) has additive depressant effects."	CNS depressants	alcohol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"These medications have included  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	heparin	warfarin	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"These medications have included  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	heparin	beta-adrenergic receptor blockers	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	
other	"These medications have included  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	heparin	calcium channel antagonists	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	[Ca]
other	"These medications have included  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	heparin	angiotensin converting enzyme inhibitors	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"These medications have included  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	heparin	nitrates	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	[O-]N(=O)=O
other	"These medications have included  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	heparin	ticlopidine	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
other	"These medications have included  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	heparin	aspirin	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	"These medications have included  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	warfarin	beta-adrenergic receptor blockers	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
other	"These medications have included  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	warfarin	calcium channel antagonists	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[Ca]
other	"These medications have included  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	warfarin	angiotensin converting enzyme inhibitors	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"These medications have included  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	warfarin	nitrates	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[O-]N(=O)=O
other	"These medications have included  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	warfarin	ticlopidine	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
other	"These medications have included  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	warfarin	aspirin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	beta-adrenergic receptor blockers	calcium channel antagonists		[Ca]
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	beta-adrenergic receptor blockers	angiotensin converting enzyme inhibitors		ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	beta-adrenergic receptor blockers	nitrates		[O-]N(=O)=O
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	beta-adrenergic receptor blockers	ticlopidine		ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	beta-adrenergic receptor blockers	aspirin		CC(=O)OC1=CC=CC=C1C(O)=O
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	calcium channel antagonists	angiotensin converting enzyme inhibitors	[Ca]	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , intravenous and oral  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	calcium channel antagonists	nitrates	[Ca]	[O-]N(=O)=O
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	calcium channel antagonists	ticlopidine	[Ca]	ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	calcium channel antagonists	aspirin	[Ca]	CC(=O)OC1=CC=CC=C1C(O)=O
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , intravenous and oral  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	angiotensin converting enzyme inhibitors	nitrates	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[O-]N(=O)=O
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , intravenous and oral  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	angiotensin converting enzyme inhibitors	ticlopidine	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , intravenous and oral  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	angiotensin converting enzyme inhibitors	aspirin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(=O)OC1=CC=CC=C1C(O)=O
other	"These medications have included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , intravenous and oral  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	nitrates	ticlopidine	[O-]N(=O)=O	ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
effect	"Twelve strains of Staphylococcus aureus (a frequent cause of infection in  DRUGOTHER , but not in  DRUG1  and  DRUG2 , addicts) were completely inhibited by the drug combination."	pentazocine	tripelennamine	C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C	OC(=O)CCCCCCCC(O)=O
effect	"Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that  DRUG1  was responsible for the inhibitory activity, which was partially antagonized by  DRUG2 ."	tripelennamine	pentazocine	OC(=O)CCCCCCCC(O)=O	C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C
effect	CNS-Active Drugs  DRUGOTHER  An additive effect on psychomotor performance was seen with coadministration of  DRUG1  and  DRUG2  0.70 g/kg for up to 4 hours after  DRUGOTHER  administration.	eszopiclone	ethanol	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
mechanism	Absorption of  DRUG1  is impaired by  DRUG2 .	tetracycline	bismuth subsalicylate	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	" DRUG1 ,  DRUG2 , and  DRUGOTHER  decrease the half-life of  DRUGOTHER ."	Barbiturates	carbamazepine	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	" DRUG1 ,  DRUGOTHER , and  DRUG2  decrease the half-life of  DRUGOTHER ."	Barbiturates	phenytoin	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	" DRUG1 ,  DRUGOTHER , and  DRUGOTHER  decrease the half-life of  DRUG2 ."	Barbiturates	doxycycline	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	" DRUGOTHER ,  DRUG1 , and  DRUG2  decrease the half-life of  DRUGOTHER ."	carbamazepine	phenytoin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	" DRUGOTHER ,  DRUG1 , and  DRUGOTHER  decrease the half-life of  DRUG2 ."	carbamazepine	doxycycline	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
mechanism	" DRUGOTHER ,  DRUGOTHER , and  DRUG1  decrease the half-life of  DRUG2 ."	phenytoin	doxycycline	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	 DRUG1  did not affect  DRUG2  pharmacokinetics.	Digoxin	BREVIBLOC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	
other	The concomitant use of  DRUG1  or other  DRUG2  may have an additive effect.	alcohol	central nervous system depressants	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	"Therefore,  DRUG1  for Oral Suspension can be administered with  DRUG2 -fortified infant formula."	OMNICEF	iron	[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O	
effect	"For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with  DRUG1  and a  DRUG2  do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure."	lovastatin	fibrate	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCOC(=O)C1=CN=CC=C1
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	Acetazolamide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	azole antifungals	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	OC(=O)CCCCCCCCC=C
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	cimetidine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	clarithromycin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	dalfopristin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	danazol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	delavirdine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	diltiazem	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	erythromycin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	fluoxetine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	fluvoxamine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	isoniazid	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	itraconazole	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	ketoconazole	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
mechanism	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	EQUETROTM	loratadine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	azole antifungals	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCCC=C
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	cimetidine	OC(=O)CCCCCCCC(O)=O	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	clarithromycin	OC(=O)CCCCCCCC(O)=O	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	dalfopristin	OC(=O)CCCCCCCC(O)=O	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	danazol	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	delavirdine	OC(=O)CCCCCCCC(O)=O	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	diltiazem	OC(=O)CCCCCCCC(O)=O	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	erythromycin	OC(=O)CCCCCCCC(O)=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	fluoxetine	OC(=O)CCCCCCCC(O)=O	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	fluvoxamine	OC(=O)CCCCCCCC(O)=O	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	isoniazid	OC(=O)CCCCCCCC(O)=O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	itraconazole	OC(=O)CCCCCCCC(O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	ketoconazole	OC(=O)CCCCCCCC(O)=O	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	loratadine	OC(=O)CCCCCCCC(O)=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	nefazodone	OC(=O)CCCCCCCC(O)=O	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	niacinamide	OC(=O)CCCCCCCC(O)=O	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	nicotinamide	OC(=O)CCCCCCCC(O)=O	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	protease inhibitors	OC(=O)CCCCCCCC(O)=O	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	propoxyphene	OC(=O)CCCCCCCC(O)=O	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	quinine	OC(=O)CCCCCCCC(O)=O	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	quinupristin	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	troleandomycin	OC(=O)CCCCCCCC(O)=O	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	Acetazolamide	valproate	OC(=O)CCCCCCCC(O)=O	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	Acetazolamide	verapamil	OC(=O)CCCCCCCC(O)=O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	Acetazolamide	zileuton	OC(=O)CCCCCCCC(O)=O	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	cimetidine	OC(=O)CCCCCCCCC=C	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	clarithromycin	OC(=O)CCCCCCCCC=C	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	dalfopristin	OC(=O)CCCCCCCCC=C	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	danazol	OC(=O)CCCCCCCCC=C	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	delavirdine	OC(=O)CCCCCCCCC=C	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	diltiazem	OC(=O)CCCCCCCCC=C	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	erythromycin	OC(=O)CCCCCCCCC=C	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	fluoxetine	OC(=O)CCCCCCCCC=C	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	fluvoxamine	OC(=O)CCCCCCCCC=C	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	isoniazid	OC(=O)CCCCCCCCC=C	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	itraconazole	OC(=O)CCCCCCCCC=C	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	ketoconazole	OC(=O)CCCCCCCCC=C	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	loratadine	OC(=O)CCCCCCCCC=C	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	nefazodone	OC(=O)CCCCCCCCC=C	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	niacinamide	OC(=O)CCCCCCCCC=C	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	nicotinamide	OC(=O)CCCCCCCCC=C	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	protease inhibitors	OC(=O)CCCCCCCCC=C	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	propoxyphene	OC(=O)CCCCCCCCC=C	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	quinine	OC(=O)CCCCCCCCC=C	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	quinupristin	OC(=O)CCCCCCCCC=C	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	troleandomycin	OC(=O)CCCCCCCCC=C	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	azole antifungals	valproate	OC(=O)CCCCCCCCC=C	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	azole antifungals	verapamil	OC(=O)CCCCCCCCC=C	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	azole antifungals	zileuton	OC(=O)CCCCCCCCC=C	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	clarithromycin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	dalfopristin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	danazol	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	delavirdine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	diltiazem	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	erythromycin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	fluoxetine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	fluvoxamine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	isoniazid	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	itraconazole	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	ketoconazole	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	loratadine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	nefazodone	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	niacinamide	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	nicotinamide	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	protease inhibitors	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	propoxyphene	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	quinine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	quinupristin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	troleandomycin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	cimetidine	valproate	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	cimetidine	verapamil	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	cimetidine	zileuton	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	dalfopristin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	danazol	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	delavirdine	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	diltiazem	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	erythromycin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	fluoxetine	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	fluvoxamine	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	isoniazid	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	itraconazole	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	ketoconazole	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	loratadine	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	nefazodone	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	niacinamide	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	nicotinamide	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	protease inhibitors	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	propoxyphene	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	quinine	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	quinupristin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	troleandomycin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	clarithromycin	valproate	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	clarithromycin	verapamil	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	clarithromycin	zileuton	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	danazol	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	delavirdine	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	diltiazem	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	erythromycin	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	fluoxetine	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	fluvoxamine	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	isoniazid	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	itraconazole	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	ketoconazole	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	loratadine	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	nefazodone	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	niacinamide	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	nicotinamide	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	protease inhibitors	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	propoxyphene	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	quinine	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	quinupristin	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	troleandomycin	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	dalfopristin	valproate	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	dalfopristin	verapamil	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	dalfopristin	zileuton	[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	delavirdine	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	diltiazem	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	erythromycin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	fluoxetine	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	fluvoxamine	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	isoniazid	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	itraconazole	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	ketoconazole	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	loratadine	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	nefazodone	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	niacinamide	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	nicotinamide	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	protease inhibitors	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	propoxyphene	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	quinine	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	quinupristin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	troleandomycin	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	danazol	valproate	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	danazol	verapamil	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	danazol	zileuton	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	diltiazem	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	erythromycin	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	fluoxetine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	fluvoxamine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	isoniazid	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	itraconazole	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	ketoconazole	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	loratadine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	nefazodone	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	niacinamide	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	nicotinamide	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	protease inhibitors	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	propoxyphene	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	quinine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	quinupristin	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	troleandomycin	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	delavirdine	valproate	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	delavirdine	verapamil	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	delavirdine	zileuton	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	erythromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	fluoxetine		CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	fluvoxamine		ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	itraconazole		ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	ketoconazole		CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	loratadine		CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	nefazodone		NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	niacinamide		OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	nicotinamide		NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	protease inhibitors		
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	propoxyphene		[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	quinine		[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	quinupristin		[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	troleandomycin		CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	diltiazem	valproate		
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	diltiazem	verapamil		COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	diltiazem	zileuton		CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	fluoxetine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	fluvoxamine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	isoniazid	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	itraconazole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	ketoconazole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	loratadine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	nefazodone	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	niacinamide	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	nicotinamide	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	protease inhibitors	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	propoxyphene	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	quinine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	quinupristin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	troleandomycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	erythromycin	valproate	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	erythromycin	verapamil	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	erythromycin	zileuton	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	fluvoxamine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	isoniazid	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	itraconazole	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	ketoconazole	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	loratadine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	nefazodone	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	niacinamide	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	nicotinamide	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	protease inhibitors	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	propoxyphene	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	quinine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	quinupristin	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	troleandomycin	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	fluoxetine	valproate	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	fluoxetine	verapamil	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	fluoxetine	zileuton	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	isoniazid	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	itraconazole	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	ketoconazole	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	loratadine	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	nefazodone	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	niacinamide	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	nicotinamide	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	protease inhibitors	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	propoxyphene	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	quinine	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	quinupristin	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	troleandomycin	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	fluvoxamine	valproate	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	fluvoxamine	verapamil	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	fluvoxamine	zileuton	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	itraconazole	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	ketoconazole	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	loratadine	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	nefazodone	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	niacinamide	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	nicotinamide	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	protease inhibitors	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	propoxyphene	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	quinine	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	quinupristin	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	troleandomycin	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	isoniazid	valproate	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	isoniazid	verapamil	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	isoniazid	zileuton	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	ketoconazole	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	loratadine	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	nefazodone	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	niacinamide	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	nicotinamide	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	protease inhibitors	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	propoxyphene	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	quinine	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	quinupristin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	troleandomycin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	itraconazole	valproate	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	itraconazole	verapamil	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	itraconazole	zileuton	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	loratadine	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	nefazodone	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	niacinamide	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	nicotinamide	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	protease inhibitors	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	propoxyphene	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	quinine	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	quinupristin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	troleandomycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	ketoconazole	valproate	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	ketoconazole	verapamil	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	ketoconazole	zileuton	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	nefazodone	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	niacinamide	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	nicotinamide	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	protease inhibitors	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	propoxyphene	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	quinine	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	quinupristin	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	troleandomycin	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	loratadine	valproate	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	loratadine	verapamil	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	loratadine	zileuton	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nefazodone	niacinamide	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	OC(=O)C1=CN=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nefazodone	nicotinamide	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nefazodone	protease inhibitors	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nefazodone	propoxyphene	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nefazodone	quinine	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nefazodone	quinupristin	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nefazodone	troleandomycin	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	nefazodone	valproate	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	nefazodone	verapamil	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	nefazodone	zileuton	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	niacinamide	nicotinamide	OC(=O)C1=CN=CC=C1	NC(=O)C1=CC=CN=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	niacinamide	protease inhibitors	OC(=O)C1=CN=CC=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	niacinamide	propoxyphene	OC(=O)C1=CN=CC=C1	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	niacinamide	quinine	OC(=O)C1=CN=CC=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	niacinamide	quinupristin	OC(=O)C1=CN=CC=C1	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	niacinamide	troleandomycin	OC(=O)C1=CN=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	niacinamide	valproate	OC(=O)C1=CN=CC=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	niacinamide	verapamil	OC(=O)C1=CN=CC=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	niacinamide	zileuton	OC(=O)C1=CN=CC=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nicotinamide	protease inhibitors	NC(=O)C1=CC=CN=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nicotinamide	propoxyphene	NC(=O)C1=CC=CN=C1	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nicotinamide	quinine	NC(=O)C1=CC=CN=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nicotinamide	quinupristin	NC(=O)C1=CC=CN=C1	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	nicotinamide	troleandomycin	NC(=O)C1=CC=CN=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	nicotinamide	valproate	NC(=O)C1=CC=CN=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	nicotinamide	verapamil	NC(=O)C1=CC=CN=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	nicotinamide	zileuton	NC(=O)C1=CC=CN=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	protease inhibitors	propoxyphene		[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	protease inhibitors	quinine		[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	protease inhibitors	quinupristin		[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	protease inhibitors	troleandomycin		CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	protease inhibitors	valproate		
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	protease inhibitors	verapamil		COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	protease inhibitors	zileuton		CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	propoxyphene	quinine	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	propoxyphene	quinupristin	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	propoxyphene	troleandomycin	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	propoxyphene	valproate	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	propoxyphene	verapamil	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	propoxyphene	zileuton	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	quinine	quinupristin	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	quinine	troleandomycin	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	quinine	valproate	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	quinine	verapamil	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	quinine	zileuton	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ."	quinupristin	troleandomycin	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	quinupristin	valproate	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	quinupristin	verapamil	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	quinupristin	zileuton	[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 (1),  DRUGOTHER ,  DRUGOTHER ."	troleandomycin	valproate	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUG2 ,  DRUGOTHER ."	troleandomycin	verapamil	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (1),  DRUGOTHER ,  DRUG2 ."	troleandomycin	zileuton	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUG2 ,  DRUGOTHER ."	valproate	verapamil		COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (1),  DRUGOTHER ,  DRUG2 ."	valproate	zileuton		CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
other	"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (1),  DRUG1 ,  DRUG2 ."	verapamil	zileuton	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
mechanism	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUG1  are the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	EQUETROTM	Cisplatin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
mechanism	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	EQUETROTM	doxorubicin HCL	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
mechanism	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	EQUETROTM	felbamate	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	EQUETROTM	EQUETROTM	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUG1  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	EQUETROTM	EQUETROTM	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	doxorubicin HCL	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	felbamate	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	rifampin	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	phenobarbital	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	Phenytoin	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	primidone	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	methsuximide	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUG2  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	theophylline	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Cisplatin	EQUETROTM	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	Cisplatin	EQUETROTM	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	doxorubicin HCL	felbamate	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	doxorubicin HCL	rifampin	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	doxorubicin HCL	phenobarbital	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	doxorubicin HCL	Phenytoin	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	doxorubicin HCL	primidone	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	doxorubicin HCL	methsuximide	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUG2  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	doxorubicin HCL	theophylline	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	doxorubicin HCL	EQUETROTM	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	doxorubicin HCL	EQUETROTM	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	felbamate	rifampin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	felbamate	phenobarbital	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	felbamate	Phenytoin	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	felbamate	primidone	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	felbamate	methsuximide	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUG2  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	felbamate	theophylline	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	felbamate	EQUETROTM	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	felbamate	EQUETROTM	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	rifampin	phenobarbital	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	rifampin	Phenytoin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (2),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	rifampin	primidone	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	rifampin	methsuximide	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUG2  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	rifampin	theophylline	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	rifampin	EQUETROTM	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	rifampin	EQUETROTM	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	phenobarbital	Phenytoin	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (2),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	phenobarbital	primidone	CCC1(CC)C(=O)NC(=O)NC1=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (2),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	phenobarbital	methsuximide	CCC1(CC)C(=O)NC(=O)NC1=O	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUG2  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	phenobarbital	theophylline	CCC1(CC)C(=O)NC(=O)NC1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	phenobarbital	EQUETROTM	CCC1(CC)C(=O)NC(=O)NC1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	phenobarbital	EQUETROTM	CCC1(CC)C(=O)NC(=O)NC1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (2),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Phenytoin	primidone	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (2),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Phenytoin	methsuximide	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (2),  DRUGOTHER ,  DRUGOTHER , and  DRUG2  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Phenytoin	theophylline	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	Phenytoin	EQUETROTM	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	Phenytoin	EQUETROTM	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUG1 ,  DRUG2 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	primidone	methsuximide	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUG1 ,  DRUGOTHER , and  DRUG2  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	primidone	theophylline	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	primidone	EQUETROTM	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	primidone	EQUETROTM	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUG1 , and  DRUG2  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	methsuximide	theophylline	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	methsuximide	EQUETROTM	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	methsuximide	EQUETROTM	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUG1  Thus, if a patient has been titrated to a stable dosage on  DRUG2 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUGOTHER  may be necessary."	theophylline	EQUETROTM	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUG1  Thus, if a patient has been titrated to a stable dosage on  DRUGOTHER , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	theophylline	EQUETROTM	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  DRUGOTHER  are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (2),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on  DRUG1 , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  DRUG2  may be necessary."	EQUETROTM	EQUETROTM	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	alprazolam	OC(=O)CCCCCCCC(O)=O	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	amitriptyline	OC(=O)CCCCCCCC(O)=O	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	bupropion	OC(=O)CCCCCCCC(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	buspirone	OC(=O)CCCCCCCC(O)=O	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	citalopram	OC(=O)CCCCCCCC(O)=O	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	clobazam	OC(=O)CCCCCCCC(O)=O	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	clonazepam	OC(=O)CCCCCCCC(O)=O	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	clozapine	OC(=O)CCCCCCCC(O)=O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	cyclosporin	OC(=O)CCCCCCCC(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	delavirdine	OC(=O)CCCCCCCC(O)=O	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	desipramine	OC(=O)CCCCCCCC(O)=O	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	diazepam	OC(=O)CCCCCCCC(O)=O	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	dicumarol	OC(=O)CCCCCCCC(O)=O	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	doxycycline	OC(=O)CCCCCCCC(O)=O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	ethosuximide	OC(=O)CCCCCCCC(O)=O	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	felbamate	OC(=O)CCCCCCCC(O)=O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	felodipine	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	glucocorticoids	OC(=O)CCCCCCCC(O)=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	haloperidol	OC(=O)CCCCCCCC(O)=O	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	itraconazole	OC(=O)CCCCCCCC(O)=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	lamotrigine	OC(=O)CCCCCCCC(O)=O	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	levothyroxine	OC(=O)CCCCCCCC(O)=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	lorazepam	OC(=O)CCCCCCCC(O)=O	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	methadone	OC(=O)CCCCCCCC(O)=O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	midazolam	OC(=O)CCCCCCCC(O)=O	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	mirtazapine	OC(=O)CCCCCCCC(O)=O	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	nortriptyline	OC(=O)CCCCCCCC(O)=O	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	olanzapine	OC(=O)CCCCCCCC(O)=O	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	contraceptives	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	oxcarbazepine	OC(=O)CCCCCCCC(O)=O	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	Phenytoin	OC(=O)CCCCCCCC(O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	praziquantel	OC(=O)CCCCCCCC(O)=O	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	protease inhibitors	OC(=O)CCCCCCCC(O)=O	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	quetiapine	OC(=O)CCCCCCCC(O)=O	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	risperidone	OC(=O)CCCCCCCC(O)=O	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	theophylline	OC(=O)CCCCCCCC(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	topiramate	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	tiagabine	OC(=O)CCCCCCCC(O)=O	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	tramadol	OC(=O)CCCCCCCC(O)=O	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	triazolam	OC(=O)CCCCCCCC(O)=O	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	valproate	OC(=O)CCCCCCCC(O)=O	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	Acetaminophen	warfarin	OC(=O)CCCCCCCC(O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	Acetaminophen	ziprasidone	OC(=O)CCCCCCCC(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	Acetaminophen	zonisamide	OC(=O)CCCCCCCC(O)=O	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	amitriptyline	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	bupropion	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	buspirone	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	citalopram	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	clobazam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	clonazepam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	clozapine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	cyclosporin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	delavirdine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	desipramine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	diazepam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	dicumarol	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	doxycycline	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	ethosuximide	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	felbamate	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	felodipine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	glucocorticoids	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	haloperidol	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	itraconazole	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	lamotrigine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	levothyroxine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	lorazepam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	methadone	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	midazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	mirtazapine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	nortriptyline	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	olanzapine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	contraceptives	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	oxcarbazepine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	Phenytoin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	praziquantel	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	protease inhibitors	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	quetiapine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	risperidone	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	theophylline	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	topiramate	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	tiagabine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	tramadol	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	triazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	valproate	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	warfarin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	alprazolam	ziprasidone	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	alprazolam	zonisamide	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	bupropion	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	buspirone	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	citalopram	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	clobazam	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	clonazepam	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	clozapine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	cyclosporin	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	delavirdine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	desipramine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	diazepam	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	dicumarol	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	doxycycline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	ethosuximide	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	felbamate	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	felodipine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	glucocorticoids	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	haloperidol	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	itraconazole	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	lamotrigine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	levothyroxine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	lorazepam	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	methadone	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	midazolam	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	mirtazapine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	nortriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	olanzapine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	contraceptives	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	oxcarbazepine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	Phenytoin	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	praziquantel	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	protease inhibitors	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	quetiapine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	risperidone	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	theophylline	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	topiramate	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	tiagabine	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	tramadol	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	triazolam	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	valproate	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	amitriptyline	warfarin	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	amitriptyline	ziprasidone	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	amitriptyline	zonisamide	CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	buspirone	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	citalopram	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	clobazam	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	clonazepam	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	clozapine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	cyclosporin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	delavirdine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	desipramine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	diazepam	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	dicumarol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	doxycycline	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	ethosuximide	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	felbamate	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	felodipine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	glucocorticoids	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	haloperidol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	itraconazole	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	lamotrigine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	levothyroxine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	lorazepam	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	methadone	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	midazolam	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	mirtazapine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	nortriptyline	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	olanzapine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	contraceptives	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	oxcarbazepine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	Phenytoin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	praziquantel	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	protease inhibitors	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	quetiapine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	risperidone	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	theophylline	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	topiramate	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	tiagabine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	tramadol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	triazolam	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	valproate	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	bupropion	warfarin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	bupropion	ziprasidone	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	bupropion	zonisamide	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	citalopram		[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	clobazam		CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	clonazepam		[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	clozapine		CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	cyclosporin		CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	delavirdine		CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	desipramine		CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	diazepam		CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	dicumarol		OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	doxycycline		[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	ethosuximide		CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	felbamate		NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	felodipine		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	glucocorticoids		COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	haloperidol		OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	itraconazole		ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	lamotrigine		NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	levothyroxine		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	lorazepam		OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	methadone		CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	midazolam		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	mirtazapine		[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	nortriptyline		CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	olanzapine		CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	contraceptives		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	oxcarbazepine		NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	Phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	praziquantel		O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	protease inhibitors		
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	quetiapine		OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	risperidone		CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	theophylline		CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	topiramate		[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	tiagabine		NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	tramadol		CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	triazolam		O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	valproate		
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	buspirone	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	buspirone	ziprasidone		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	buspirone	zonisamide		NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	clobazam	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	clonazepam	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	clozapine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	cyclosporin	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	delavirdine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	desipramine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	diazepam	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	dicumarol	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	doxycycline	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	ethosuximide	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	felbamate	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	felodipine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	glucocorticoids	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	haloperidol	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	itraconazole	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	lamotrigine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	levothyroxine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	lorazepam	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	methadone	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	midazolam	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	mirtazapine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	nortriptyline	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	olanzapine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	contraceptives	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	oxcarbazepine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	Phenytoin	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	praziquantel	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	protease inhibitors	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	quetiapine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	risperidone	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	theophylline	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	topiramate	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	tiagabine	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	tramadol	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	triazolam	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	valproate	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	citalopram	warfarin	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	citalopram	ziprasidone	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	citalopram	zonisamide	[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	clonazepam	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	clozapine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	cyclosporin	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	delavirdine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	desipramine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	diazepam	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	dicumarol	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	doxycycline	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	ethosuximide	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	felbamate	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	felodipine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	glucocorticoids	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	haloperidol	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	itraconazole	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	lamotrigine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	levothyroxine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	lorazepam	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	methadone	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	midazolam	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	mirtazapine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	nortriptyline	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	olanzapine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	contraceptives	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	oxcarbazepine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	Phenytoin	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	praziquantel	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	protease inhibitors	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	quetiapine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	risperidone	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	theophylline	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	topiramate	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	tiagabine	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	tramadol	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	triazolam	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	valproate	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	clobazam	warfarin	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	clobazam	ziprasidone	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	clobazam	zonisamide	CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	clozapine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	cyclosporin	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	delavirdine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	desipramine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	diazepam	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	dicumarol	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	doxycycline	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	ethosuximide	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	felbamate	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	felodipine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	glucocorticoids	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	haloperidol	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	itraconazole	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	lamotrigine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	levothyroxine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	lorazepam	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	methadone	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	midazolam	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	mirtazapine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	nortriptyline	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	olanzapine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	contraceptives	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	oxcarbazepine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	Phenytoin	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	praziquantel	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	protease inhibitors	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	quetiapine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	risperidone	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	theophylline	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	topiramate	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	tiagabine	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	tramadol	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	triazolam	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	valproate	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	clonazepam	warfarin	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	clonazepam	ziprasidone	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	clonazepam	zonisamide	[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	cyclosporin	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	delavirdine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	desipramine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	diazepam	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	dicumarol	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	doxycycline	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	ethosuximide	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	felbamate	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	felodipine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	glucocorticoids	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	haloperidol	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	itraconazole	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	lamotrigine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	levothyroxine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	lorazepam	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	methadone	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	midazolam	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	mirtazapine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	nortriptyline	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	olanzapine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	contraceptives	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	oxcarbazepine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	Phenytoin	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	praziquantel	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	protease inhibitors	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	quetiapine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	risperidone	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	theophylline	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	topiramate	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	tiagabine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	tramadol	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	triazolam	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	valproate	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	clozapine	warfarin	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	clozapine	ziprasidone	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	clozapine	zonisamide	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	delavirdine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	desipramine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	diazepam	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	dicumarol	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	doxycycline	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	ethosuximide	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	felbamate	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	felodipine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	glucocorticoids	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	haloperidol	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	itraconazole	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	lamotrigine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	levothyroxine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	lorazepam	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	methadone	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	midazolam	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	mirtazapine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	nortriptyline	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	olanzapine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	contraceptives	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	oxcarbazepine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	Phenytoin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	praziquantel	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	protease inhibitors	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	quetiapine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	risperidone	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	theophylline	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	topiramate	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	tiagabine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	tramadol	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	triazolam	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	valproate	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporin	warfarin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	cyclosporin	ziprasidone	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	cyclosporin	zonisamide	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	desipramine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	diazepam	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	dicumarol	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	doxycycline	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	ethosuximide	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	felbamate	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	felodipine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	glucocorticoids	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	haloperidol	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	itraconazole	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	lamotrigine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	levothyroxine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	lorazepam	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	methadone	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	midazolam	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	mirtazapine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	nortriptyline	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	olanzapine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	contraceptives	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	oxcarbazepine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	Phenytoin	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	praziquantel	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	protease inhibitors	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	quetiapine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	risperidone	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	theophylline	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	topiramate	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	tiagabine	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	tramadol	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	triazolam	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	valproate	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	delavirdine	warfarin	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	delavirdine	ziprasidone	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	delavirdine	zonisamide	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	diazepam	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	dicumarol	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	doxycycline	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	ethosuximide	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	felbamate	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	felodipine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	glucocorticoids	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	haloperidol	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	itraconazole	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	lamotrigine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	levothyroxine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	lorazepam	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	methadone	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	midazolam	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	mirtazapine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	nortriptyline	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	olanzapine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	contraceptives	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	oxcarbazepine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	Phenytoin	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	praziquantel	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	protease inhibitors	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	quetiapine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	risperidone	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	theophylline	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	topiramate	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	tiagabine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	tramadol	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	triazolam	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	valproate	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	desipramine	warfarin	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	desipramine	ziprasidone	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	desipramine	zonisamide	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	dicumarol	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	doxycycline	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	ethosuximide	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	felbamate	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	felodipine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	glucocorticoids	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	haloperidol	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	itraconazole	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	lamotrigine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	levothyroxine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	lorazepam	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	methadone	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	midazolam	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	mirtazapine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	nortriptyline	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	olanzapine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	contraceptives	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	oxcarbazepine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	Phenytoin	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	praziquantel	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	protease inhibitors	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	quetiapine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	risperidone	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	theophylline	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	topiramate	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	tiagabine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	tramadol	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	triazolam	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	valproate	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	diazepam	warfarin	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	diazepam	ziprasidone	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	diazepam	zonisamide	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	doxycycline	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	ethosuximide	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	felbamate	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	felodipine	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	glucocorticoids	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	haloperidol	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	itraconazole	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	lamotrigine	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	levothyroxine	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	lorazepam	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	methadone	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	midazolam	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	mirtazapine	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	nortriptyline	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	olanzapine	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	contraceptives	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUG2 ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	oxcarbazepine	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUG2 (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	Phenytoin	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	praziquantel	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	protease inhibitors	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	quetiapine	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	risperidone	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	theophylline	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	topiramate	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	tiagabine	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	tramadol	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CC(=O)NC1=CC=C(O)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	triazolam	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	valproate	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 (5) ,  DRUGOTHER , and  DRUGOTHER ."	dicumarol	warfarin	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUG2 , and  DRUGOTHER ."	dicumarol	ziprasidone	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUG2 ."	dicumarol	zonisamide	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2	NS(=O)(=O)CC1=NOC2=CC=CC=C12
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	doxycycline	ethosuximide	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	CCC1(C)CC(=O)NC1=O
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	doxycycline	felbamate	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	doxycycline	felodipine	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	doxycycline	glucocorticoids	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	doxycycline	haloperidol	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Agents that have been found, or are expected to have decreased plasma levels in the presence of  DRUGOTHER  due to induction of CYP enzymes are the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER (3),  DRUGOTHER ,  DRUGOTHER (4),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER (5) ,  DRUGOTHER , and  DRUGOTHER ."	doxycycline	itraconazole	[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Agents with Increased Levels in the Presence of  DRUG1 :  DRUG2  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUGOTHER (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Carbamazepine	EQUETROTM	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents with Increased Levels in the Presence of  DRUG1 :  DRUGOTHER  increases the plasma levels of the following agents:  DRUG2 ,  DRUGOTHER (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Carbamazepine	Clomipramine HCl	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
other	"Agents with Increased Levels in the Presence of  DRUG1 :  DRUGOTHER  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUG2 (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Carbamazepine	Phenytoin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents with Increased Levels in the Presence of  DRUG1 :  DRUGOTHER  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUGOTHER (6), and  DRUG2  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Carbamazepine	primidone	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents with Increased Levels in the Presence of  DRUG1 :  DRUGOTHER  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUGOTHER (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUG2 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Carbamazepine	EQUETROTM	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
mechanism	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUG1  increases the plasma levels of the following agents:  DRUG2 ,  DRUGOTHER (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	EQUETROTM	Clomipramine HCl	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
mechanism	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUG1  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUG2 (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	EQUETROTM	Phenytoin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUG1  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUGOTHER (6), and  DRUG2  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	EQUETROTM	primidone	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUG1  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUGOTHER (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUG2 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	EQUETROTM	EQUETROTM	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUGOTHER  increases the plasma levels of the following agents:  DRUG1 ,  DRUG2 (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Clomipramine HCl	Phenytoin	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUGOTHER  increases the plasma levels of the following agents:  DRUG1 ,  DRUGOTHER (6), and  DRUG2  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Clomipramine HCl	primidone	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUGOTHER  increases the plasma levels of the following agents:  DRUG1 ,  DRUGOTHER (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUG2 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Clomipramine HCl	EQUETROTM	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUGOTHER  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUG1 (6), and  DRUG2  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUGOTHER , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Phenytoin	primidone	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUGOTHER  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUG1 (6), and  DRUGOTHER  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUG2 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	Phenytoin	EQUETROTM	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Agents with Increased Levels in the Presence of  DRUGOTHER :  DRUGOTHER  increases the plasma levels of the following agents:  DRUGOTHER ,  DRUGOTHER (6), and  DRUG1  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with  DRUG2 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."	primidone	EQUETROTM	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
effect	"Patients who are treated with  DRUG1  and concomitant  DRUG2  should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination)."	ZYVOX	serotonergic agents	CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	 DRUG1  have been reported to blunt the hypotensive effect of systemic  DRUG2 .It is not known whether the concurrent use of these agents with  DRUGOTHER  in humans can lead to resulting interference with the IOP lowering effect.	Tricyclic antidepressants	clonidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	ClC1=CC=CC(Cl)=C1NC1=NCCN1
other	 DRUG1  (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with  DRUG2  (8 micromol/l) or  DRUGOTHER  (125 mmol/l) from both lean and dietary-obese rats.	Resveratrol	noradrenaline	OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1	CNC[C@H](O)C1=CC(O)=C(O)C=C1
other	 DRUG1  (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with  DRUGOTHER  (8 micromol/l) or  DRUG2  (125 mmol/l) from both lean and dietary-obese rats.	Resveratrol	KCl	OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1	[Cl-].[K+]
other	 DRUGOTHER  (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with  DRUG1  (8 micromol/l) or  DRUG2  (125 mmol/l) from both lean and dietary-obese rats.	noradrenaline	KCl	CNC[C@H](O)C1=CC(O)=C(O)C=C1	[Cl-].[K+]
other	"In the present study, the  DRUG1   DRUG2  was tested in combination with an active dose of  DRUGOTHER  in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures."	atypical antipsychotic	clozapine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"In the present study, the  DRUG1   DRUGOTHER  was tested in combination with an active dose of  DRUG2  in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures."	atypical antipsychotic	PCP	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	"In the present study, the  DRUGOTHER   DRUG1  was tested in combination with an active dose of  DRUG2  in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures."	clozapine	PCP	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	 DRUG1  produced distinctive effects in each task: it substituted for the training dose in  DRUG2  discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.	PCP	PCP	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O
other	"For  DRUG1  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( DRUG2  +  DRUGOTHER /placebo +  DRUGOTHER ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively."	digoxin	rofecoxib	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
other	"For  DRUG1  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( DRUGOTHER  +  DRUG2 /placebo +  DRUGOTHER ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"For  DRUG1  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( DRUGOTHER  +  DRUGOTHER /placebo +  DRUG2 ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"For  DRUGOTHER  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( DRUG1  +  DRUG2 /placebo +  DRUGOTHER ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively."	rofecoxib	digoxin	CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"For  DRUGOTHER  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( DRUG1  +  DRUGOTHER /placebo +  DRUG2 ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively."	rofecoxib	digoxin	CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"The mean (SD) cumulative urinary excretion of immunoreactive  DRUG1  after concurrent treatment with  DRUG2  or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively."	digoxin	rofecoxib	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
other	 DRUG1 :  DRUG2  concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with  DRUGOTHER  (10 mg/kg/day) (n=7) compared with  DRUGOTHER  (20 mg/kg/day) alone (n=12).	Cimetidine	Albendazole sulfoxide	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CC(=O)NC1=NN=C(S1)S(N)(=O)=O
other	 DRUG1 :  DRUGOTHER  concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with  DRUG2  (10 mg/kg/day) (n=7) compared with  DRUGOTHER  (20 mg/kg/day) alone (n=12).	Cimetidine	cimetidine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	 DRUG1 :  DRUGOTHER  concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with  DRUGOTHER  (10 mg/kg/day) (n=7) compared with  DRUG2  (20 mg/kg/day) alone (n=12).	Cimetidine	albendazole	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CCCS(=O)C1=CC2=C(C=C1)N=C(N2)N=C(O)OC
other	 DRUGOTHER :  DRUG1  concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with  DRUGOTHER  (10 mg/kg/day) (n=7) compared with  DRUG2  (20 mg/kg/day) alone (n=12).	Albendazole sulfoxide	albendazole	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CCCS(=O)C1=CC2=C(C=C1)N=C(N2)N=C(O)OC
other	 DRUGOTHER :  DRUGOTHER  concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with  DRUG1  (10 mg/kg/day) (n=7) compared with  DRUG2  (20 mg/kg/day) alone (n=12).	cimetidine	albendazole	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CCCS(=O)C1=CC2=C(C=C1)N=C(N2)N=C(O)OC
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUG2  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	aspirin	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	CC(=O)OC1=CC=CC=C1C(O)=O
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG2  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	salicylate	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	magnesium/choline salicylate	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	Trilisate	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	salsalate	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	Disalcid	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	choline salicylate	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	Arthropan	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	magnesium salicylate	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	glimepiride	Magan	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	glimepiride	bismuth subsalicylate	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
advise	"Before taking  DRUG1 , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	glimepiride	Pepto-Bismol	[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUG2  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	salicylate	CC(=O)OC1=CC=CC=C1C(O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	magnesium/choline salicylate	CC(=O)OC1=CC=CC=C1C(O)=O	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	Trilisate	CC(=O)OC1=CC=CC=C1C(O)=O	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	salsalate	CC(=O)OC1=CC=CC=C1C(O)=O	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	Disalcid	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	choline salicylate	CC(=O)OC1=CC=CC=C1C(O)=O	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	Arthropan	CC(=O)OC1=CC=CC=C1C(O)=O	
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	magnesium salicylate	CC(=O)OC1=CC=CC=C1C(O)=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	aspirin	Magan	CC(=O)OC1=CC=CC=C1C(O)=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	aspirin	bismuth subsalicylate	CC(=O)OC1=CC=CC=C1C(O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUG1  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	aspirin	Pepto-Bismol	CC(=O)OC1=CC=CC=C1C(O)=O	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salicylate	magnesium/choline salicylate	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salicylate	Trilisate	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salicylate	salsalate	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salicylate	Disalcid	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salicylate	choline salicylate	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salicylate	Arthropan	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salicylate	magnesium salicylate	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	salicylate	Magan	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	salicylate	bismuth subsalicylate	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	salicylate	Pepto-Bismol	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	magnesium/choline salicylate	Trilisate	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	magnesium/choline salicylate	salsalate	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	magnesium/choline salicylate	Disalcid	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	magnesium/choline salicylate	choline salicylate	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	magnesium/choline salicylate	Arthropan	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	magnesium/choline salicylate	magnesium salicylate	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	magnesium/choline salicylate	Magan	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	magnesium/choline salicylate	bismuth subsalicylate	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	magnesium/choline salicylate	Pepto-Bismol	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Trilisate	salsalate	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Trilisate	Disalcid	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Trilisate	choline salicylate	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Trilisate	Arthropan	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Trilisate	magnesium salicylate	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	Trilisate	Magan	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	Trilisate	bismuth subsalicylate	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	Trilisate	Pepto-Bismol	[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salsalate	Disalcid	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER , others),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salsalate	choline salicylate	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salsalate	Arthropan	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O	
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	salsalate	magnesium salicylate	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	salsalate	Magan	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	salsalate	bismuth subsalicylate	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	salsalate	Pepto-Bismol	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 , others),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Disalcid	choline salicylate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 , others),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Disalcid	Arthropan	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Disalcid	magnesium salicylate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	Disalcid	Magan	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	Disalcid	bismuth subsalicylate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	Disalcid	Pepto-Bismol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	choline salicylate	Arthropan	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	choline salicylate	magnesium salicylate	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	choline salicylate	Magan	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	choline salicylate	bismuth subsalicylate	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	choline salicylate	Pepto-Bismol	C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER );"	Arthropan	magnesium salicylate		[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	Arthropan	Magan		[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	Arthropan	bismuth subsalicylate		CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	Arthropan	Pepto-Bismol		[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER );"	magnesium salicylate	Magan	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER );"	magnesium salicylate	bismuth subsalicylate	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 );"	magnesium salicylate	Pepto-Bismol	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ), or  DRUG2  ( DRUGOTHER );"	Magan	bismuth subsalicylate	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ), or  DRUGOTHER  ( DRUG2 );"	Magan	Pepto-Bismol	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"Before taking  DRUGOTHER , tell your doctor if you are taking any of the following medicines: -  DRUGOTHER  or another  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG1  ( DRUG2 );"	bismuth subsalicylate	Pepto-Bismol	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
other	"- a  DRUG1  ( DRUG2 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	NSAID	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	ibuprofen	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Motrin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Advil	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Nuprin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	ketoprofen	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Orudis	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Orudis KT	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Oruvail	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	diclofenac	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Voltaren	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Cataflam	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	etodolac	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Lodine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	indomethacin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Indocin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	nabumetone	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Relafen	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	oxaprozin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Daypro	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	naproxen	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Anaprox	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	nonsteroidal anti-inflammatory drug	Naprosyn	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	nonsteroidal anti-inflammatory drug	Aleve	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	ibuprofen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Motrin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Advil	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Nuprin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	ketoprofen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Orudis	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Orudis KT	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Oruvail	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	diclofenac	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Voltaren	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Cataflam	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	etodolac	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Lodine	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	indomethacin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Indocin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	nabumetone	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Relafen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	oxaprozin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Daypro	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	naproxen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	NSAID	Anaprox	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	NSAID	Naprosyn	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	NSAID	Aleve	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Motrin	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Advil	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Nuprin	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	ketoprofen	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Orudis	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Orudis KT	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Oruvail	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	diclofenac	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Voltaren	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Cataflam	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	etodolac	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Lodine	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	indomethacin	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Indocin	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	nabumetone	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Relafen	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	oxaprozin	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Daypro	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	naproxen	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	ibuprofen	Anaprox	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	ibuprofen	Naprosyn	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	ibuprofen	Aleve	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Advil	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Nuprin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	ketoprofen	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Orudis	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Orudis KT	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Oruvail	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	diclofenac	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Voltaren	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Cataflam	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	etodolac	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Lodine	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	indomethacin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Indocin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	nabumetone	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Relafen	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	oxaprozin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Daypro	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	naproxen	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	Motrin	Anaprox	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	Motrin	Naprosyn	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	Motrin	Aleve	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Nuprin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	ketoprofen	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Orudis	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Orudis KT	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Oruvail	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	diclofenac	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Voltaren	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Cataflam	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	etodolac	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Lodine	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	indomethacin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Indocin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	nabumetone	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Relafen	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	oxaprozin	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Daypro	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Advil	naproxen	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	Advil	Anaprox	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	Advil	Naprosyn	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	Advil	Aleve	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	ketoprofen	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Orudis	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Orudis KT	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Oruvail	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	diclofenac	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Voltaren	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Cataflam	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	etodolac	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Lodine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	indomethacin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Indocin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	nabumetone	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Relafen	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	oxaprozin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Daypro	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	naproxen	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	Nuprin	Anaprox	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	Nuprin	Naprosyn	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	Nuprin	Aleve	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Orudis	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Orudis KT	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Oruvail	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	diclofenac	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Voltaren	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Cataflam	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	etodolac	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Lodine	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	indomethacin	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Indocin	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	nabumetone	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Relafen	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	oxaprozin	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Daypro	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	naproxen	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	ketoprofen	Anaprox	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	ketoprofen	Naprosyn	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	ketoprofen	Aleve	[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Orudis KT	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Oruvail	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	diclofenac	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Voltaren	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Cataflam	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	etodolac	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Lodine	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	indomethacin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Indocin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	nabumetone	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Relafen	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	oxaprozin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Daypro	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	naproxen	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	Orudis	Anaprox	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	Orudis	Naprosyn	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	Orudis	Aleve	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	Oruvail	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	diclofenac	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	Voltaren	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	Cataflam	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	etodolac	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	Lodine	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	indomethacin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	Indocin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	nabumetone	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	Relafen	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	oxaprozin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	Daypro	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	naproxen	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	Orudis KT	Anaprox	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	Orudis KT	Naprosyn	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	Orudis KT	Aleve	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUG2  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	diclofenac	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	Voltaren	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	Cataflam	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	etodolac	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	Lodine	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	indomethacin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	Indocin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	nabumetone	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	Relafen	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	oxaprozin	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	Daypro	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	naproxen	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	Oruvail	Anaprox	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	Oruvail	Naprosyn	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	Oruvail	Aleve	CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUG2 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	Voltaren	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	Cataflam	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	etodolac	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	Lodine	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	indomethacin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	Indocin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	nabumetone	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	Relafen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	oxaprozin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	Daypro	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	naproxen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	diclofenac	Anaprox	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	diclofenac	Naprosyn	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	diclofenac	Aleve	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	Cataflam	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	etodolac	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	Lodine	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	indomethacin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	Indocin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	nabumetone	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	Relafen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	oxaprozin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	Daypro	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	naproxen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	Voltaren	Anaprox	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	Voltaren	Naprosyn	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	Voltaren	Aleve	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	etodolac	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	Lodine	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	indomethacin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	Indocin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	nabumetone	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	Relafen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	oxaprozin	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	Daypro	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	naproxen	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER );"	Cataflam	Anaprox	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER );"	Cataflam	Naprosyn	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 );"	Cataflam	Aleve	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	etodolac	Lodine	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
other	"- a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , others),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER );"	etodolac	indomethacin	CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
effect	" DRUGOTHER : Concurrent administration of  DRUG1  (an  DRUGOTHER ) and another  DRUG2  has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone."	anakinra	TNF-blocking agent		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	" DRUGOTHER : Concurrent administration of  DRUGOTHER  (an  DRUG1 ) and another  DRUG2  has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone."	interleukin-1 antagonist	TNF-blocking agent		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"In this study, the effects of  DRUG1  upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day  DRUG2  or placebo for 1-month."	etofibrate	etofibrate	CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCOC(=O)C1=CN=CC=C1	CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCOC(=O)C1=CN=CC=C1
effect	 DRUG1  elicited 62% enhancement of post- DRUG2  lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.	Etofibrate	heparin	CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCOC(=O)C1=CN=CC=C1	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
effect	"Patients receiving other  DRUG1 s, general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER  (including  DRUGOTHER ) concomitantly with  DRUG2  may exhibit an additive CNS depression."	narcotic analgesic	DILAUDID	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
effect	"Patients receiving other  DRUGOTHER s, general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER  (including  DRUGOTHER ) concomitantly with  DRUG2  may exhibit an additive CNS depression."	anesthetics	DILAUDID	CCOC(=O)C1=CC=C(N)C=C1	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
effect	"Patients receiving other  DRUGOTHER s, general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER  (including  DRUGOTHER ) concomitantly with  DRUG2  may exhibit an additive CNS depression."	phenothiazines	DILAUDID	N1C2=CC=CC=C2SC2=CC=CC=C12	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
effect	"Patients receiving other  DRUGOTHER s, general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or other  DRUGOTHER  (including  DRUGOTHER ) concomitantly with  DRUG2  may exhibit an additive CNS depression."	tranquilizers	DILAUDID	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
other	"(1968, 1970), the higher serum concentrations of  DRUG1  and  DRUG2  reached after administration of  DRUGOTHER  are due not only to slower renal elimination but also to an altered distribution in the body."	penicillins	cephaloridine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(C)CS1
other	"To determine whether  DRUG1  has a direct effect on the distribution of  DRUG2 , the elimination and distribution of  DRUGOTHER  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  DRUGOTHER ."	probenecid	cloxacillin	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O
other	"To determine whether  DRUG1  has a direct effect on the distribution of  DRUGOTHER , the elimination and distribution of  DRUG2  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  DRUGOTHER ."	probenecid	cloxacillin	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O
other	"To determine whether  DRUG1  has a direct effect on the distribution of  DRUGOTHER , the elimination and distribution of  DRUGOTHER  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  DRUG2 ."	probenecid	probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"To determine whether  DRUGOTHER  has a direct effect on the distribution of  DRUG1 , the elimination and distribution of  DRUG2  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  DRUGOTHER ."	cloxacillin	cloxacillin	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O
other	"To determine whether  DRUGOTHER  has a direct effect on the distribution of  DRUG1 , the elimination and distribution of  DRUGOTHER  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  DRUG2 ."	cloxacillin	probenecid	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	"To determine whether  DRUGOTHER  has a direct effect on the distribution of  DRUGOTHER , the elimination and distribution of  DRUG1  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  DRUG2 ."	cloxacillin	probenecid	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
mechanism	This might be explained by a blockade by  DRUG1  of the elimination of  DRUG2  by the liver.	probenecid	cloxacillin	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O
effect	It was observed that  DRUG1  induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by  DRUG2  pretreatment.	MPTP	pargyline		CN(CC#C)CC1=CC=CC=C1
effect	The  DRUG1 -induced neuronal damage produced a tolerance to the disruptive effects of  DRUG2  and a supersensitivity to the disruptive effects of  DRUGOTHER  in rats responding in a schedule controlled paradigm.	MPTP	amphetamine		CC(N)CC1=CC=C(O)C=C1
other	The  DRUGOTHER -induced neuronal damage produced a tolerance to the disruptive effects of  DRUG1  and a supersensitivity to the disruptive effects of  DRUG2  in rats responding in a schedule controlled paradigm.	amphetamine	apomorphine	CC(N)CC1=CC=C(O)C=C1	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
effect	" DRUG1 , like  DRUGOTHER , produced depletions of striatal dopamine but these actions were potentiated by  DRUG2  pretreatment."	Methamphetamine	pargyline	CC(N)CC1=CC=CC=C1	CN(CC#C)CC1=CC=CC=C1
other	"Like  DRUG1  (40 mg/kg),  DRUG2  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUGOTHER  and the oral self-administration of  DRUGOTHER  and  DRUGOTHER  in rats;"	ibogaine	18-MC		
other	"Like  DRUG1  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUG2  and  DRUGOTHER  and the oral self-administration of  DRUGOTHER  and  DRUGOTHER  in rats;"	ibogaine	morphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"Like  DRUG1  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUG2  and the oral self-administration of  DRUGOTHER  and  DRUGOTHER  in rats;"	ibogaine	cocaine		CCOC(=O)C1=CC=C(N)C=C1
other	"Like  DRUG1  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUGOTHER  and the oral self-administration of  DRUG2  and  DRUGOTHER  in rats;"	ibogaine	ethanol		OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Like  DRUG1  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUGOTHER  and the oral self-administration of  DRUGOTHER  and  DRUG2  in rats;"	ibogaine	nicotine		CN1CCC[C@H]1C1=CN=CC=C1
other	"Like  DRUGOTHER  (40 mg/kg),  DRUG1  (40 mg/kg) decreases the intravenous self-administration of  DRUG2  and  DRUGOTHER  and the oral self-administration of  DRUGOTHER  and  DRUGOTHER  in rats;"	18-MC	morphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
other	"Like  DRUGOTHER  (40 mg/kg),  DRUG1  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUG2  and the oral self-administration of  DRUGOTHER  and  DRUGOTHER  in rats;"	18-MC	cocaine		CCOC(=O)C1=CC=C(N)C=C1
other	"Like  DRUGOTHER  (40 mg/kg),  DRUG1  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUGOTHER  and the oral self-administration of  DRUG2  and  DRUGOTHER  in rats;"	18-MC	ethanol		OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Like  DRUGOTHER  (40 mg/kg),  DRUG1  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUGOTHER  and the oral self-administration of  DRUGOTHER  and  DRUG2  in rats;"	18-MC	nicotine		CN1CCC[C@H]1C1=CN=CC=C1
other	"Like  DRUGOTHER  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUG1  and  DRUG2  and the oral self-administration of  DRUGOTHER  and  DRUGOTHER  in rats;"	morphine	cocaine	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	CCOC(=O)C1=CC=C(N)C=C1
other	"Like  DRUGOTHER  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUG1  and  DRUGOTHER  and the oral self-administration of  DRUG2  and  DRUGOTHER  in rats;"	morphine	ethanol	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Like  DRUGOTHER  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUG1  and  DRUGOTHER  and the oral self-administration of  DRUGOTHER  and  DRUG2  in rats;"	morphine	nicotine	[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23	CN1CCC[C@H]1C1=CN=CC=C1
other	"Like  DRUGOTHER  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUG1  and the oral self-administration of  DRUG2  and  DRUGOTHER  in rats;"	cocaine	ethanol	CCOC(=O)C1=CC=C(N)C=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"Like  DRUGOTHER  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUG1  and the oral self-administration of  DRUGOTHER  and  DRUG2  in rats;"	cocaine	nicotine	CCOC(=O)C1=CC=C(N)C=C1	CN1CCC[C@H]1C1=CN=CC=C1
other	"Like  DRUGOTHER  (40 mg/kg),  DRUGOTHER  (40 mg/kg) decreases the intravenous self-administration of  DRUGOTHER  and  DRUGOTHER  and the oral self-administration of  DRUG1  and  DRUG2  in rats;"	ethanol	nicotine	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	CN1CCC[C@H]1C1=CN=CC=C1
effect	Both  DRUG1  and  DRUGOTHER  block  DRUG2 -induced and  DRUGOTHER -induced dopamine release in the nucleus accumbens;	ibogaine	morphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
effect	Both  DRUG1  and  DRUGOTHER  block  DRUGOTHER -induced and  DRUG2 -induced dopamine release in the nucleus accumbens;	ibogaine	nicotine		CN1CCC[C@H]1C1=CN=CC=C1
effect	Both  DRUGOTHER  and  DRUG1  block  DRUG2 -induced and  DRUGOTHER -induced dopamine release in the nucleus accumbens;	18-MC	morphine		[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
effect	Both  DRUGOTHER  and  DRUG1  block  DRUGOTHER -induced and  DRUG2 -induced dopamine release in the nucleus accumbens;	18-MC	nicotine		CN1CCC[C@H]1C1=CN=CC=C1
other	"While  DRUG1  and  DRUG2  have similar affinities for kappa opioid and possibly nicotinic receptors,  DRUGOTHER  has much lower affinities than  DRUGOTHER  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter."	18-MC	ibogaine		
effect	It was shown that  DRUG1  antagonized evidently the antinociceptive effect of  DRUG2  and their analogue.	neurotensin	enkephalins	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	It is concluded that  DRUG1  modulates in an opposite way the function of the enkephalinergic neurons and the central action of  DRUG2 .	neurotensin	tuftsin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	FC1=CN(C2CCCO2)C(=O)NC1=O
mechanism	" DRUG1  reduced the blood AUC0-12 of  DRUG2  by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when  DRUGOTHER  (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of  DRUGOTHER  70 mg daily, as compared to results from a control period in which  DRUGOTHER  was administered alone."	CANCIDAS	tacrolimus	CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
effect	"Interactions with Other CNS Agents: Concurrent use of  DRUG1  with all  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	Levo-Dromoran	central nervous system depressants	[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	"Interactions with Other CNS Agents: Concurrent use of  DRUG1  with all  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	Levo-Dromoran	alcohol	[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	"Interactions with Other CNS Agents: Concurrent use of  DRUG1  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	Levo-Dromoran	sedatives	[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	alcohol	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	sedatives	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	hypnotics	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUG2 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	opioids	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	anesthetics	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CCOC(=O)C1=CC=C(N)C=C1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	barbiturates	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	tricyclic antidepressants	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	phenothiazines	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	tranquilizers	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	central nervous system depressants	skeletal muscle relaxants	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	central nervous system depressants	antihistamines	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUG2 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	sedatives	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUG2 , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	hypnotics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , other  DRUG2 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	opioids	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	anesthetics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCOC(=O)C1=CC=C(N)C=C1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	barbiturates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	tricyclic antidepressants	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	phenothiazines	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	tranquilizers	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	alcohol	skeletal muscle relaxants	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	alcohol	antihistamines	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUG2 , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	sedatives	hypnotics		
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , other  DRUG2 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	sedatives	opioids		
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , other  DRUGOTHER , general  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	sedatives	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	sedatives	barbiturates		CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	sedatives	tricyclic antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	sedatives	phenothiazines		N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	sedatives	tranquilizers		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	sedatives	skeletal muscle relaxants		
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	sedatives	antihistamines		NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , other  DRUG2 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	hypnotics	opioids		
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , other  DRUGOTHER , general  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	hypnotics	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , other  DRUGOTHER , general  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	hypnotics	barbiturates		CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	hypnotics	tricyclic antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	hypnotics	phenothiazines		N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	hypnotics	tranquilizers		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	hypnotics	skeletal muscle relaxants		
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	hypnotics	antihistamines		NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUG1 , general  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	opioids	anesthetics		CCOC(=O)C1=CC=C(N)C=C1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUG1 , general  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	opioids	barbiturates		CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	opioids	tricyclic antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	opioids	phenothiazines		N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	opioids	tranquilizers		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	opioids	skeletal muscle relaxants		
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUG1 , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	opioids	antihistamines		NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	anesthetics	barbiturates	CCOC(=O)C1=CC=C(N)C=C1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	anesthetics	tricyclic antidepressants	CCOC(=O)C1=CC=C(N)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	anesthetics	phenothiazines	CCOC(=O)C1=CC=C(N)C=C1	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	anesthetics	tranquilizers	CCOC(=O)C1=CC=C(N)C=C1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	anesthetics	skeletal muscle relaxants	CCOC(=O)C1=CC=C(N)C=C1	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	anesthetics	antihistamines	CCOC(=O)C1=CC=C(N)C=C1	NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	barbiturates	tricyclic antidepressants	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	barbiturates	phenothiazines	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	barbiturates	tranquilizers	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	barbiturates	skeletal muscle relaxants	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	barbiturates	antihistamines	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O	NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	tricyclic antidepressants	phenothiazines	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	N1C2=CC=CC=C2SC2=CC=CC=C12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	tricyclic antidepressants	tranquilizers	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	tricyclic antidepressants	skeletal muscle relaxants	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	tricyclic antidepressants	antihistamines	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	phenothiazines	tranquilizers	N1C2=CC=CC=C2SC2=CC=CC=C12	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	phenothiazines	skeletal muscle relaxants	N1C2=CC=CC=C2SC2=CC=CC=C12	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	phenothiazines	antihistamines	N1C2=CC=CC=C2SC2=CC=CC=C12	NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER ) may result in additive central nervous system depressant effects."	tranquilizers	skeletal muscle relaxants	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2 ) may result in additive central nervous system depressant effects."	tranquilizers	antihistamines	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12	NCCC1=CNC=N1
other	"Interactions with Other CNS Agents: Concurrent use of  DRUGOTHER  with all  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2 ) may result in additive central nervous system depressant effects."	skeletal muscle relaxants	antihistamines		NCCC1=CNC=N1
other	"No significant drug interactions have been reported in studies of  DRUG1  given with other drugs such as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	candesartan cilexetil	glyburide	CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"No significant drug interactions have been reported in studies of  DRUG1  given with other drugs such as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	candesartan cilexetil	nifedipine	CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"No significant drug interactions have been reported in studies of  DRUG1  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	candesartan cilexetil	digoxin	CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"No significant drug interactions have been reported in studies of  DRUG1  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	candesartan cilexetil	warfarin	CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No significant drug interactions have been reported in studies of  DRUG1  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	candesartan cilexetil	hydrochlorothiazide	CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"No significant drug interactions have been reported in studies of  DRUG1  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUG2  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	candesartan cilexetil	contraceptives	CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUG1  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUG2  to patients with heart failure (NYHA class II and III)."	candesartan cilexetil	enalapril	CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	glyburide	nifedipine	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	glyburide	digoxin	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	glyburide	warfarin	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	glyburide	hydrochlorothiazide	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUG2  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	glyburide	contraceptives	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUG2  to patients with heart failure (NYHA class II and III)."	glyburide	enalapril	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	nifedipine	digoxin	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	nifedipine	warfarin	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	nifedipine	hydrochlorothiazide	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUG2  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	nifedipine	contraceptives	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUG2  to patients with heart failure (NYHA class II and III)."	nifedipine	enalapril	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	digoxin	warfarin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	digoxin	hydrochlorothiazide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUG2  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	digoxin	contraceptives	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUG2  to patients with heart failure (NYHA class II and III)."	digoxin	enalapril	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	warfarin	hydrochlorothiazide	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and oral  DRUG2  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	warfarin	contraceptives	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUG2  to patients with heart failure (NYHA class II and III)."	warfarin	enalapril	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and oral  DRUG2  in healthy volunteers, or given with  DRUGOTHER  to patients with heart failure (NYHA class II and III)."	hydrochlorothiazide	contraceptives	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and oral  DRUGOTHER  in healthy volunteers, or given with  DRUG2  to patients with heart failure (NYHA class II and III)."	hydrochlorothiazide	enalapril	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"No significant drug interactions have been reported in studies of  DRUGOTHER  given with other drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and oral  DRUG1  in healthy volunteers, or given with  DRUG2  to patients with heart failure (NYHA class II and III)."	contraceptives	enalapril	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	" DRUG1 : The addition of  DRUG2  to patients taking  DRUGOTHER  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	Valproate	tiagabine		NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	" DRUG1 : The addition of  DRUGOTHER  to patients taking  DRUG2  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	Valproate	valproate		
other	" DRUG1 : The addition of  DRUGOTHER  to patients taking  DRUGOTHER  chronically had no effect on  DRUG2  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	Valproate	tiagabine		NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	" DRUG1 : The addition of  DRUGOTHER  to patients taking  DRUGOTHER  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUG2  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	Valproate	valproate		
other	" DRUG1 : The addition of  DRUGOTHER  to patients taking  DRUGOTHER  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUG2  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	Valproate	tiagabine		NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	" DRUGOTHER : The addition of  DRUG1  to patients taking  DRUG2  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	tiagabine	valproate	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	
other	" DRUGOTHER : The addition of  DRUG1  to patients taking  DRUGOTHER  chronically had no effect on  DRUG2  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	tiagabine	tiagabine	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	" DRUGOTHER : The addition of  DRUG1  to patients taking  DRUGOTHER  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUG2  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	tiagabine	valproate	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	
other	" DRUGOTHER : The addition of  DRUG1  to patients taking  DRUGOTHER  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUG2  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	tiagabine	tiagabine	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	" DRUGOTHER : The addition of  DRUGOTHER  to patients taking  DRUG1  chronically had no effect on  DRUG2  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	valproate	tiagabine		NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	" DRUGOTHER : The addition of  DRUGOTHER  to patients taking  DRUG1  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUG2  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	valproate	valproate		
other	" DRUGOTHER : The addition of  DRUGOTHER  to patients taking  DRUG1  chronically had no effect on  DRUGOTHER  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUG2  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	valproate	tiagabine		NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
other	" DRUGOTHER : The addition of  DRUGOTHER  to patients taking  DRUGOTHER  chronically had no effect on  DRUG1  pharmacokinetics, but  DRUG2  significantly decreased  DRUGOTHER  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	tiagabine	valproate	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	
other	" DRUGOTHER : The addition of  DRUGOTHER  to patients taking  DRUGOTHER  chronically had no effect on  DRUG1  pharmacokinetics, but  DRUGOTHER  significantly decreased  DRUG2  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration."	tiagabine	tiagabine	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUG2  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	alcohol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUG2 , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	amiodarone	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	chlordiazepoxide	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	cimetidine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	diazepam	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	dicumarol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	disulfiram	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCN(CC)C(=S)SSC(=S)N(CC)CC
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	estrogens	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	ethosuximide	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(C)CC(=O)NC1=O
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	fluoxetine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
mechanism	"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  DRUG1  concentrations include: acute  DRUGOTHER  intake,  DRUGOTHER , chboramphenicol,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER "	phenytoin	H2-antagonists	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	
mechanism	The half-life of  DRUG1  in plasma and brain was longer in the presence of  DRUG2  than when  DRUGOTHER  was given alone.	ketamine	halothane	CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	"The serum estrogen concentrations of  DRUG1  +  DRUG2 -treated rats decreased by 50%, while those of the  DRUGOTHER -treated rats increased (2- to 5-fold)."	estradiol	endotoxin	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"When  DRUG1  at an increased dose (1000 mg every 8 hours) was given with  DRUGOTHER  (600 mg once daily), the  DRUG2  AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when  DRUGOTHER  (800 mg every 8 hours) was given alone."	indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"When  DRUG1  at an increased dose (1000 mg every 8 hours) was given with  DRUGOTHER  (600 mg once daily), the  DRUGOTHER  AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when  DRUG2  (800 mg every 8 hours) was given alone."	indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"When  DRUGOTHER  at an increased dose (1000 mg every 8 hours) was given with  DRUG1  (600 mg once daily), the  DRUG2  AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when  DRUGOTHER  (800 mg every 8 hours) was given alone."	SUSTIVA	indinavir	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"When  DRUGOTHER  at an increased dose (1000 mg every 8 hours) was given with  DRUG1  (600 mg once daily), the  DRUGOTHER  AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when  DRUG2  (800 mg every 8 hours) was given alone."	SUSTIVA	indinavir	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"When  DRUGOTHER  at an increased dose (1000 mg every 8 hours) was given with  DRUGOTHER  (600 mg once daily), the  DRUG1  AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when  DRUG2  (800 mg every 8 hours) was given alone."	indinavir	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUG2 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	efavirenz	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	aluminum/magnesium hydroxide antacids	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	[OH-].[OH-].[Mg++]
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	azithromycin	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	cetirizine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	famotidine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	fluconazole	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	lamivudine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	OC(=O)CCCCCCCC(O)=O
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	lorazepam	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	SUSTIVA	nelfinavir	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	SUSTIVA	paroxetine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUG1  ( DRUGOTHER ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	SUSTIVA	zidovudine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	efavirenz	aluminum/magnesium hydroxide antacids	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	[OH-].[OH-].[Mg++]
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	efavirenz	azithromycin	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	efavirenz	cetirizine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	efavirenz	famotidine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	efavirenz	fluconazole	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	efavirenz	lamivudine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	OC(=O)CCCCCCCC(O)=O
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	efavirenz	lorazepam	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	efavirenz	nelfinavir	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	efavirenz	paroxetine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUG1 ) is given with the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	efavirenz	zidovudine	FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUGOTHER ) is given with the following:  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aluminum/magnesium hydroxide antacids	azithromycin	[OH-].[OH-].[Mg++]	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUGOTHER ) is given with the following:  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aluminum/magnesium hydroxide antacids	cetirizine	[OH-].[OH-].[Mg++]	CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUGOTHER ) is given with the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aluminum/magnesium hydroxide antacids	famotidine	[OH-].[OH-].[Mg++]	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUGOTHER ) is given with the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aluminum/magnesium hydroxide antacids	fluconazole	[OH-].[OH-].[Mg++]	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUGOTHER ) is given with the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aluminum/magnesium hydroxide antacids	lamivudine	[OH-].[OH-].[Mg++]	OC(=O)CCCCCCCC(O)=O
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUGOTHER ) is given with the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	aluminum/magnesium hydroxide antacids	lorazepam	[OH-].[OH-].[Mg++]	OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
other	"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  DRUGOTHER  ( DRUGOTHER ) is given with the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	aluminum/magnesium hydroxide antacids	nelfinavir	[OH-].[OH-].[Mg++]	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
int	" DRUG1  may interact with  DRUG2 ,  DRUGOTHER s,  DRUGOTHER  (allergy, cold, and sinus medicines), diabetic drugs,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  like  DRUGOTHER  or  DRUGOTHER , and high blood pressure medications."	Benzthiazide	alcohol	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
int	" DRUG1  may interact with  DRUGOTHER ,  DRUG2 s,  DRUGOTHER  (allergy, cold, and sinus medicines), diabetic drugs,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  like  DRUGOTHER  or  DRUGOTHER , and high blood pressure medications."	Benzthiazide	blood thinner	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	
int	" DRUG1  may interact with  DRUGOTHER ,  DRUGOTHER s,  DRUG2  (allergy, cold, and sinus medicines), diabetic drugs,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  like  DRUGOTHER  or  DRUGOTHER , and high blood pressure medications."	Benzthiazide	decongestant drugs	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	
int	" DRUG1  may interact with  DRUGOTHER ,  DRUGOTHER s,  DRUGOTHER  (allergy, cold, and sinus medicines), diabetic drugs,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  like  DRUGOTHER  or  DRUGOTHER , and high blood pressure medications."	Benzthiazide	lithium	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	[Li+]
int	" DRUG1  may interact with  DRUGOTHER ,  DRUGOTHER s,  DRUGOTHER  (allergy, cold, and sinus medicines), diabetic drugs,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  like  DRUGOTHER  or  DRUGOTHER , and high blood pressure medications."	Benzthiazide	norepinephrine	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	CNC[C@H](O)C1=CC(O)=C(O)C=C1
int	" DRUG1  may interact with  DRUGOTHER ,  DRUGOTHER s,  DRUGOTHER  (allergy, cold, and sinus medicines), diabetic drugs,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  like  DRUGOTHER  or  DRUGOTHER , and high blood pressure medications."	Benzthiazide	NSAIDs	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	
int	" DRUG1  may interact with  DRUGOTHER ,  DRUGOTHER s,  DRUGOTHER  (allergy, cold, and sinus medicines), diabetic drugs,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  like  DRUG2  or  DRUGOTHER , and high blood pressure medications."	Benzthiazide	Aleve	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
int	" DRUG1  may interact with  DRUGOTHER ,  DRUGOTHER s,  DRUGOTHER  (allergy, cold, and sinus medicines), diabetic drugs,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  like  DRUGOTHER  or  DRUG2 , and high blood pressure medications."	Benzthiazide	Ibuprofen	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
effect	"Drugs that have been reported to diminish oral  DRUG1  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG2 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	anticoagulant	adrenocortical steroids	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
effect	"Drugs that have been reported to diminish oral  DRUG1  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG2 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	anticoagulant	alcohol	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	"Drugs that have been reported to diminish oral  DRUG1  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	anticoagulant	antacids	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	
effect	"Drugs that have been reported to diminish oral  DRUG1  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	anticoagulant	antihistamines	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	NCCC1=CNC=N1
effect	"Drugs that have been reported to diminish oral  DRUG1  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	anticoagulant	barbiturates	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUG2 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	alcohol	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	antacids	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	antihistamines	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	NCCC1=CNC=N1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	barbiturates	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	carbamazepine	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	chloral hydrate	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUG2 ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	chlordiazepoxide	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUG2 ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	cholestyramine	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	NCCC1=CC=C(O)C=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUG2 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	vitamin K	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUG2 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	diuretics	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	ethchlorvynol	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[H]C(Cl)=CC(O)(CC)C#C
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	glutethimide	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	griseofulvin	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	haloperidol	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	meprobamate	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	contraceptives	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	paraldehyde	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	OCC(O)CO
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	primidone	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	ranitidine	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUG2 ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	adrenocortical steroids	rifampin	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUG2 ; DRUGOTHER  under-dosage."	adrenocortical steroids	vitamin C	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUG1 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUG2  under-dosage."	adrenocortical steroids	warfarin sodium	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	antacids	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	antihistamines	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCCC1=CNC=N1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	barbiturates	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	carbamazepine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	chloral hydrate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUG2 ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	chlordiazepoxide	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUG2 ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	cholestyramine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCCC1=CC=C(O)C=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUG2 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	vitamin K	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CCCCCCCC(O)=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUG2 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	diuretics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	ethchlorvynol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H]C(Cl)=CC(O)(CC)C#C
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	glutethimide	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	griseofulvin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	haloperidol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	meprobamate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	contraceptives	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	paraldehyde	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OCC(O)CO
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	primidone	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	ranitidine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUG2 ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	alcohol	rifampin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUG2 ; DRUGOTHER  under-dosage."	alcohol	vitamin C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUG1 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUG2  under-dosage."	alcohol	warfarin sodium	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	antihistamines		NCCC1=CNC=N1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	barbiturates		CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	carbamazepine		NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	chloral hydrate		CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUG2 ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	chlordiazepoxide		CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUG2 ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	cholestyramine		NCCC1=CC=C(O)C=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUG2 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	vitamin K		OC(=O)CCCCCCCC(O)=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUG2 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	diuretics		COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	ethchlorvynol		[H]C(Cl)=CC(O)(CC)C#C
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	glutethimide		CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	griseofulvin		COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	haloperidol		OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	meprobamate		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	contraceptives		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	paraldehyde		OCC(O)CO
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	primidone		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 *; DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	ranitidine		CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUG2 ;unreliable prothrombin time determinations; DRUGOTHER ; DRUGOTHER  under-dosage."	antacids	rifampin		CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Drugs that have been reported to diminish oral  DRUGOTHER  response, ie, decreased prothrom-bin time response, in man significantly include:  DRUGOTHER ; DRUGOTHER *; DRUG1 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ;diet high in  DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;oral  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ;unreliable prothrombin time determinations; DRUG2 ; DRUGOTHER  under-dosage."	antacids	vitamin C		[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUG2 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	alcohol	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	allopurinol	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	O=C1N=CN=C2NNC=C12
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	aminosalicylic acid	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	NC1=CC(O)=C(C=C1)C(O)=O
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	amiodarone	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	anabolic steroids	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	antibiotics	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	bromelains	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUG2 *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	chloral hydrate	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	chlorpropamide	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	chymotrypsin	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	
effect	"Drugs that reportedly may increase oral  DRUG1  response, ie, increased prothrombin response, in man include: DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUG2 ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;dietary deficiencies; DRUGOTHER ; DRUGOTHER ;drugs affecting blood elements; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;hepatotoxic drugs; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;inhalation  DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ;prolonged hot weather; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER *; DRUGOTHER ; DRUGOTHER ; DRUGOTHER , long acting; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER ; DRUGOTHER / DRUGOTHER ;unreliable prothrombin time determinations; DRUGOTHER  overdosage."	anticoagulant	cimetidine	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
advise	"Therefore, co-administration of  DRUG1  with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain  DRUG2  ( DRUGOTHER  [ DRUGOTHER ], such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ), should be approached with caution."	Duloxetine	antidepressants	CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
int	Caution should be exercised when administering  DRUGOTHER  with  DRUG1  since interactions have been seen with other  DRUG2 .	warfarin	NSAIDs	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
int	" DRUG1  can interact with  DRUG2  or other  DRUGOTHER  (may potentiate the CNS depressant effects of either these medications or  DRUGOTHER ),  DRUGOTHER  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  DRUGOTHER ), and  DRUGOTHER  (concurrent use with  DRUGOTHER  may prolong and intensify the anticholinergic and CNS depressant effects of  DRUGOTHER )."	Dexbrompheniramine	alcohol	CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
int	" DRUG1  can interact with  DRUGOTHER  or other  DRUG2  (may potentiate the CNS depressant effects of either these medications or  DRUGOTHER ),  DRUGOTHER  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  DRUGOTHER ), and  DRUGOTHER  (concurrent use with  DRUGOTHER  may prolong and intensify the anticholinergic and CNS depressant effects of  DRUGOTHER )."	Dexbrompheniramine	CNS depressants	CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
effect	" DRUGOTHER s and  DRUGOTHER : The following adverse events were experienced more commonly in patients receiving concomitant  DRUG1  or  DRUG2  (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%."	antihypertensive medications	vasodilators	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	
advise	"However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between  DRUG1  and  DRUG2 ."	antiretroviral drugs	antineoplastic drugs	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	
int	"When administered concurrently, the following drugs may interact with  DRUG1 :  DRUG2 , general: exaggeration of the hypotension induced by general  DRUGOTHER ."	beta-adrenergic receptor blocking agents	Anesthetics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCOC(=O)C1=CC=C(N)C=C1
mechanism	" DRUG1  diminished the binding of  DRUG2  to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L."	Acetaminophen	theophylline	OC(=O)CCCCCCCC(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
effect	" DRUG1  can interact with  DRUG2  or other  DRUGOTHER  (may potentiate the CNS depressant effects of either these medications or  DRUGOTHER ),  DRUGOTHER  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  DRUGOTHER ), and  DRUGOTHER  (concurrent use with  DRUGOTHER  may prolong and intensify the anticholinergic and CNS depressant effects of  DRUGOTHER )."	Dexbrompheniramine	alcohol	CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	" DRUG1  can interact with  DRUGOTHER  or other  DRUG2  (may potentiate the CNS depressant effects of either these medications or  DRUGOTHER ),  DRUGOTHER  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  DRUGOTHER ), and  DRUGOTHER  (concurrent use with  DRUGOTHER  may prolong and intensify the anticholinergic and CNS depressant effects of  DRUGOTHER )."	Dexbrompheniramine	CNS depressants	CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
effect	" DRUG1  can interact with  DRUGOTHER  or other  DRUGOTHER  (may potentiate the CNS depressant effects of either these medications or  DRUGOTHER ),  DRUG2  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  DRUGOTHER ), and  DRUGOTHER  (concurrent use with  DRUGOTHER  may prolong and intensify the anticholinergic and CNS depressant effects of  DRUGOTHER )."	Dexbrompheniramine	anticholinergics	CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1	C[N+](C)(C)CCO
effect	" DRUG1  can interact with  DRUGOTHER  or other  DRUGOTHER  (may potentiate the CNS depressant effects of either these medications or  DRUGOTHER ),  DRUGOTHER  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  DRUGOTHER ), and  DRUG2  (concurrent use with  DRUGOTHER  may prolong and intensify the anticholinergic and CNS depressant effects of  DRUGOTHER )."	Dexbrompheniramine	monoamine oxidase (MAO) inhibitors	CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1	OC(=O)CCCCCCCC(O)=O
int	Experience with  DRUG1  ( DRUGOTHER ) suggests the potential for interactions with  DRUG2  and  DRUGOTHER .	nonsteroidal anti-inflammatory drugs	furosemide	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
advise	"This interaction, which has not been investigated using higher doses of  DRUGOTHER , may be more pronounced if a 300 mg daily dose is co-administered, particularly since  DRUGOTHER  exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If  DRUG1  is co-administered with  DRUG2  Tablets, the initial  DRUGOTHER  dosage should be at least halved and titration to the lowest effective dose is recommended."	alprazolam	Fluvoxamine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
effect	" DRUGOTHER : The concomitant use of  DRUG1   ( DRUGOTHER  transdermal system) with other  DRUG2 , including but not limited to other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death."	DURAGESIC	central nervous system depressants	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER : The concomitant use of  DRUG1   ( DRUGOTHER  transdermal system) with other  DRUGOTHER , including but not limited to other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death."	DURAGESIC	opioids	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1	
effect	" DRUGOTHER : The concomitant use of  DRUG1   ( DRUGOTHER  transdermal system) with other  DRUGOTHER , including but not limited to other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death."	DURAGESIC	sedatives	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1	
mechanism	"RESULTS: The geometric mean (90% confidence interval) whole blood  DRUG1  area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with  DRUG2  coadministration, whereas the mean elimination half-life of  DRUGOTHER  decreased slightly, from 79 to 67 hours."	sirolimus	diltiazem	[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC	
advise	We report the case of an adolescent with altered consciousness caused by  DRUGOTHER  overdose with a positive  DRUGOTHER  level to alert clinicians to the cross-reactivity of  DRUG1  with a toxicology screen for  DRUG2 .	carbamazepine	tricyclic antidepressants	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
effect	"Aortic rings with intact endothelium from the high-dose (4 mg/kg/day)  DRUG1  group were supersensitive to  DRUG2  compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively)."	estradiol	noradrenaline	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	CNC[C@H](O)C1=CC(O)=C(O)C=C1
advise	"Therefore, co-administration of  DRUG1  with drugs that are metabolized by CYP2D6 isoenzyme including certain  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), and  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."	bupropion	antidepressants	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
advise	"Therefore, co-administration of  DRUG1  with drugs that are metabolized by CYP2D6 isoenzyme including certain  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), and  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."	bupropion	nortriptyline	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
advise	"Therefore, co-administration of  DRUG1  with drugs that are metabolized by CYP2D6 isoenzyme including certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), and  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."	bupropion	imipramine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
advise	"Therefore, co-administration of  DRUG1  with drugs that are metabolized by CYP2D6 isoenzyme including certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ), and  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."	bupropion	desipramine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
